



# Summary Tables by Region, Health Area, Country and Product

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Region**  
**1/2017 - 4/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	9,091	-	-	-	1,680,536	1,700	403,524	21,746	829	118	-	22,997
East Africa	19,152	2	-	-	1,773,262	1,350	462,486	9,716	258	617	-	11,186
Southern Africa	38,663	8	-	1	683,255	287	131,020	1,396	205	627	-	2,245
Americas	821	7	-	189	176,400	16	35,731	-	112	-	-	311
Asia and Eastern Europe	2,825	-	1	1,352	2,379,853	558	653,352	179	83	-	-	2,003
<b>Total</b>	<b>70,551</b>	<b>17</b>	<b>1</b>	<b>1,542</b>	<b>6,693,305</b>	<b>3,911</b>	<b>1,686,113</b>	<b>33,036</b>	<b>1,487</b>	<b>1,362</b>	<b>-</b>	<b>38,742</b>

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Region**  
**Period: 4**  
**Year: 2017**

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,898,503</b>	<b>10,495,927</b>	<b>8,592,982</b>	<b>(18%)</b>		<b>18,924,067</b>	<b>45%</b>
<b>West and Central Africa</b>	<b>661,501</b>	<b>5,101,925</b>	<b>3,167,370</b>	<b>(38)%</b>	<b>100 %</b>	<b>10,124,875</b>	<b>31%</b>
Family Planning	153,054	715,555	883,346	23%	28%	2,434,357	36%
HIV & STIs	52,378	462,063	362,897	(21)%	11%	1,434,900	25%
Malaria	435,029	3,818,856	1,820,041	(52)%	57%	5,926,969	31%
Maternal, Newborn, and Child Health	17,542	59,061	84,355	43%	3%	149,686	56%
Non-communicable diseases	1	146	123	(16)%	0%	326	38%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	3,027	44,160	12,258	(72)%	0%	174,275	7%
WASH	472	2,084	4,350	109%	0%	4,364	100%
<b>East Africa</b>	<b>577,867</b>	<b>2,448,749</b>	<b>2,514,736</b>	<b>3%</b>	<b>100 %</b>	<b>8,579,902</b>	<b>29%</b>
Family Planning	174,587	556,972	842,010	51%	33%	2,436,560	35%
HIV & STIs	202,836	1,099,862	775,455	(29)%	31%	3,150,257	25%
Malaria	146,403	682,538	782,606	15%	31%	1,760,498	44%
Maternal, Newborn, and Child Health	32,307	86,804	76,041	(12)%	3%	866,929	9%
Non-communicable diseases	27	197	90	(54)%	0%	894	10%
Nutrition	20,370	-	20,370	0%	1%	-	0%
Safe Abortion	329	12,625	12,081	(4)%	0%	344,144	4%
Tuberculosis	-	29	-	(100)%	0%	-	0%
WASH	1,009	9,723	6,083	(37)%	0%	20,620	30%
<b>Southern Africa</b>	<b>469,455</b>	<b>2,411,771</b>	<b>2,113,566</b>	<b>(12)%</b>	<b>100 %</b>	<b>-</b>	<b>0%</b>
Family Planning	37,385	206,138	165,869	(20)%	8%	-	0%
HIV & STIs	386,152	2,026,618	1,766,182	(13)%	84%	-	0%
Malaria	17,818	133,024	114,562	(14)%	5%	-	0%
Maternal, Newborn, and Child Health	25,877	36,777	56,253	53%	3%	-	0%
Non-communicable diseases	22	117	110	(6)%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	57	-	241	0%	0%	-	0%
Tuberculosis	7	127	50	(61)%	0%	-	0%
WASH	2,137	8,970	10,300	15%	0%	-	0%
<b>Americas</b>	<b>14,231</b>	<b>45,965</b>	<b>69,979</b>	<b>52%</b>	<b>100 %</b>	<b>219,289</b>	<b>32%</b>
Family Planning	2,254	12,927	11,254	(13)%	16%	53,376	21%
HIV & STIs	6,817	32,989	37,656	14%	54%	114,251	33%
Malaria	-	-	-	0%	0%	2,258	0%
Maternal, Newborn, and Child Health	5,143	-	10,287	7,459,778%	15%	14,123	73%
Nutrition	-	48	16	(67)%	0%	183	9%
Safe Abortion	17	1	121	8,943%	0%	870	14%
Tuberculosis	-	-	10,645	0%	15%	34,228	31%
<b>Asia and Eastern Europe</b>	<b>175,449</b>	<b>487,517</b>	<b>727,331</b>	<b>49%</b>	<b>100 %</b>	<b>-</b>	<b>0%</b>
Family Planning	120,019	267,965	492,932	84%	68%	-	0%
HIV & STIs	30,530	104,357	136,001	30%	19%	-	0%
Malaria	3,692	17,890	16,733	(6)%	2%	-	0%
Maternal, Newborn, and Child Health	(953)	40,760	3,535	(91)%	0%	-	0%
Non-communicable diseases	-	6	183	3,042%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	5,268	14,004	22,117	58%	3%	-	0%
Tuberculosis	16,882	42,504	54,051	27%	7%	-	0%
WASH	10	31	1,780	5,690%	0%	-	0%

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Health Area**  
**Period: 4**  
**Year: 2017**

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,898,503</b>	<b>10,495,927</b>	<b>8,592,982</b>	<b>(18)%</b>		<b>18,924,067</b>	<b>45%</b>
<b>Family Planning</b>	<b>487,298</b>	<b>1,759,556</b>	<b>2,395,410</b>	<b>36%</b>	<b>100%</b>	<b>4,924,293</b>	<b>49 %</b>
West and Central Africa	153,054	715,555	883,346	23%	37 %	2,434,357	36%
East Africa	174,587	556,972	842,010	51%	35 %	2,436,560	35%
Southern Africa	37,385	206,138	165,869	(20)%	7 %	-	0%
Americas	2,254	12,927	11,254	(13)%	0 %	53,376	21%
Asia and Eastern Europe	120,019	267,965	492,932	84%	21 %	-	0%
<b>HIV &amp; STIs</b>	<b>678,712</b>	<b>3,725,890</b>	<b>3,078,192</b>	<b>(17)%</b>	<b>100%</b>	<b>4,699,407</b>	<b>66 %</b>
West and Central Africa	52,378	462,063	362,897	(21)%	12 %	1,434,900	25%
East Africa	202,836	1,099,862	775,455	(29)%	25 %	3,150,257	25%
Southern Africa	386,152	2,026,618	1,766,182	(13)%	57 %	-	0%
Americas	6,817	32,989	37,656	14%	1 %	114,251	33%
Asia and Eastern Europe	30,530	104,357	136,001	30%	4 %	-	0%
<b>Malaria</b>	<b>602,942</b>	<b>4,652,307</b>	<b>2,733,941</b>	<b>(41)%</b>	<b>100%</b>	<b>7,689,725</b>	<b>36 %</b>
West and Central Africa	435,029	3,818,856	1,820,041	(52)%	67 %	5,926,969	31%
East Africa	146,403	682,538	782,606	15%	29 %	1,760,498	44%
Southern Africa	17,818	133,024	114,562	(14)%	4 %	-	0%
Americas	-	-	-	0%	0 %	2,258	0%
Asia and Eastern Europe	3,692	17,890	16,733	(6)%	1 %	-	0%
<b>Maternal, Newborn, and Child Health</b>	<b>79,917</b>	<b>223,402</b>	<b>230,472</b>	<b>3%</b>	<b>100%</b>	<b>1,030,738</b>	<b>22 %</b>
West and Central Africa	17,542	59,061	84,355	43%	37 %	149,686	56%
East Africa	32,307	86,804	76,041	(12)%	33 %	866,929	9%
Southern Africa	25,877	36,777	56,253	53%	24 %	-	0%
Americas	5,143	-	10,287	7,459,778%	4 %	14,123	73%
Asia and Eastern Europe	(953)	40,760	3,535	(91)%	2 %	-	0%
<b>Non-communicable diseases</b>	<b>51</b>	<b>466</b>	<b>506</b>	<b>8%</b>	<b>100%</b>	<b>1,220</b>	<b>41 %</b>
West and Central Africa	1	146	123	(16)%	24 %	326	38%
East Africa	27	197	90	(54)%	18 %	894	10%
Southern Africa	22	117	110	(6)%	22 %	-	0%
Asia and Eastern Europe	-	6	183	3,042%	36 %	-	0%
<b>Nutrition</b>	<b>20,370</b>	<b>48</b>	<b>20,385</b>	<b>42,669%</b>	<b>100%</b>	<b>183</b>	<b>11,131 %</b>
West and Central Africa	-	-	-	0%	0 %	-	0%
East Africa	20,370	-	20,370	0%	100 %	-	0%
Southern Africa	-	-	-	0%	0 %	-	0%
Americas	-	48	16	(67)%	0 %	183	9%
Asia and Eastern Europe	-	-	-	0%	0 %	-	0%
<b>Safe Abortion</b>	<b>8,697</b>	<b>70,791</b>	<b>46,817</b>	<b>(34)%</b>	<b>100%</b>	<b>519,289</b>	<b>9 %</b>
West and Central Africa	3,027	44,160	12,258	(72)%	26 %	174,275	7%
East Africa	329	12,625	12,081	(4)%	26 %	344,144	4%
Southern Africa	57	-	241	0%	1 %	-	0%
Americas	17	1	121	8,943%	0 %	870	14%
Asia and Eastern Europe	5,268	14,004	22,117	58%	47 %	-	0%
<b>Tuberculosis</b>	<b>16,889</b>	<b>42,660</b>	<b>64,745</b>	<b>52%</b>	<b>100%</b>	<b>34,228</b>	<b>189 %</b>
East Africa	-	29	-	(100)%	0 %	-	0%
Southern Africa	7	127	50	(61)%	0 %	-	0%
Americas	-	-	10,645	0%	16 %	34,228	31%
Asia and Eastern Europe	16,882	42,504	54,051	27%	83 %	-	0%

**POPULATION SERVICES INTERNATIONAL**

**Monthly DALY Report by Health Area**

Period: 4

Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>WASH</b>	<b>3,628</b>	<b>20,807</b>	<b>22,513</b>	<b>8%</b>	<b>100%</b>	<b>24,983</b>	<b>90 %</b>
West and Central Africa	472	2,084	4,350	109%	19 %	4,364	100%
East Africa	1,009	9,723	6,083	(37)%	27 %	20,620	30%
Southern Africa	2,137	8,970	10,300	15%	46 %	-	0%
Asia and Eastern Europe	10	31	1,780	5,690%	8 %	-	0%

POPULATION SERVICES INTERNATIONAL  
 Monthly DALY Report by Country  
 Period: 4  
 Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>GRAND TOTAL</b>	<b>1,898,503</b>	<b>10,495,927</b>	<b>8,592,982</b>	<b>(18%)</b>		<b>18,924,067</b>	<b>45%</b>
<b>West and Central Africa</b>	<b>661,501</b>	<b>5,101,925</b>	<b>3,167,370</b>	<b>(38%)</b>		<b>10,124,875</b>	<b>31%</b>
<b>Benin</b>	<b>10,253</b>	<b>53,503</b>	<b>71,079</b>	<b>33 %</b>	100%	<b>252,456</b>	<b>28%</b>
Family Planning	7,580	33,847	56,465	67%	79%	185,959	30 %
HIV & STIs	711	5,454	4,863	(11)%	7%	21,795	22 %
Malaria	9	1,561	63	(96)%	0%	1,027	6 %
Maternal, Newborn, and Child Health	1,103	11,933	6,088	(49)%	9%	33,276	18 %
Non-communicable diseases	1	4	9	131%	0%	-	0 %
Safe Abortion	801	468	3,342	614%	5%	9,355	36 %
WASH	49	237	249	5%	0%	1,044	24 %
<b>Cameroon</b>	<b>24,875</b>	<b>127,095</b>	<b>85,627</b>	<b>(33)%</b>	100%	<b>343,441</b>	<b>25%</b>
Family Planning	11,487	54,715	48,547	(11)%	57%	200,367	24 %
HIV & STIs	251	38,063	17,975	(53)%	21%	59,219	30 %
Malaria	1,646	4,977	2,465	(50)%	3%	15,650	16 %
Maternal, Newborn, and Child Health	10,263	22,301	12,361	(45)%	14%	46,603	27 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	1,225	7,037	4,273	(39)%	5%	21,593	20 %
WASH	3	2	6	254%	0%	10	65 %
<b>Congo-Kinshasa</b>	<b>271,366</b>	<b>1,306,439</b>	<b>904,756</b>	<b>(31)%</b>	100%	<b>4,764,972</b>	<b>19%</b>
Family Planning	36,927	45,344	148,110	227%	16%	288,193	51 %
HIV & STIs	1,503	1,405	4,396	213%	0%	14,133	31 %
Malaria	232,419	1,258,602	729,140	(42)%	81%	4,452,382	16 %
Maternal, Newborn, and Child Health	498	-	23,039	0%	3%	10,012	230 %
WASH	20	1,087	71	(93)%	0%	252	28 %
<b>Cote d'Ivoire</b>	<b>155</b>	<b>1,231</b>	<b>732</b>	<b>(41)%</b>	100%	<b>1,263</b>	<b>58%</b>
Family Planning	67	553	332	(40)%	45%	537	62 %
HIV & STIs	88	678	400	(41)%	55%	726	55 %
<b>Ghana</b>	<b>6,575</b>	<b>-</b>	<b>106,207</b>	<b>- %</b>	100%	<b>72,274</b>	<b>147%</b>
Family Planning	6,435	-	103,193	0%	97%	65,356	158 %
HIV & STIs	139	-	3,014	0%	3%	6,836	44 %
WASH	-	-	-	0%	0%	82	0 %
<b>Guinea</b>	<b>8,259</b>	<b>30,264</b>	<b>42,227</b>	<b>40 %</b>	100%	<b>146,993</b>	<b>29%</b>
Family Planning	2,901	13,948	13,408	(4)%	32%	117,224	11 %
HIV & STIs	735	1,323	3,402	157%	8%	29,768	11 %
Maternal, Newborn, and Child Health	4,437	14,835	22,393	51%	53%	-	0 %
WASH	186	158	3,025	1,820%	7%	-	0 %
<b>Liberia</b>	<b>429</b>	<b>1,442</b>	<b>2,889</b>	<b>100 %</b>	100%	<b>9,880</b>	<b>29%</b>
Family Planning	148	512	974	90%	34%	3,417	29 %
HIV & STIs	265	916	1,745	90%	60%	6,271	28 %
WASH	17	14	169	1,079%	6%	193	88 %
<b>Mali</b>	<b>11,715</b>	<b>1,180,676</b>	<b>767,364</b>	<b>(35)%</b>	100%	<b>1,673,132</b>	<b>46%</b>
Family Planning	11,098	50,157	53,439	7%	7%	224,782	24 %
HIV & STIs	-	385	-	(100)%	0%	570	0 %
Malaria	-	1,130,033	711,493	(37)%	93%	1,443,891	49 %
Non-communicable diseases	-	53	40	(24)%	0%	326	12 %
Safe Abortion	461	48	1,805	3,661%	0%	2,384	76 %
WASH	155	-	586	0%	0%	1,180	50 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 4

Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Niger</b>	<b>1,147</b>	-	<b>3,954</b>	- %	100%	<b>11,647</b>	<b>34%</b>
Family Planning	1,141	-	3,936	0%	100%	10,160	39 %
HIV & STIs	7	-	18	0%	0%	1,252	1 %
Safe Abortion	-	-	-	0%	0%	234	0 %
<b>Nigeria</b>	<b>326,678</b>	<b>2,382,382</b>	<b>1,182,361</b>	<b>(50)%</b>	100%	<b>2,755,660</b>	<b>43%</b>
Family Planning	75,221	510,123	454,770	(11)%	38%	1,309,753	35 %
HIV & STIs	48,679	402,705	327,084	(19)%	28%	1,240,068	26 %
Malaria	200,954	1,422,323	376,877	(74)%	32%	3,814	9,882 %
Maternal, Newborn, and Child Health	1,242	9,991	20,475	105%	2%	59,795	34 %
Non-communicable diseases	-	89	74	(17)%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	539	36,608	2,838	(92)%	0%	140,709	2 %
WASH	42	541	243	(55)%	0%	1,522	16 %
<b>Senegal</b>	<b>49</b>	<b>18,893</b>	<b>175</b>	<b>(99)%</b>	100%	<b>93,157</b>	<b>-%</b>
Family Planning	49	6,355	172	(97)%	98%	28,611	1 %
HIV & STIs	-	11,133	-	(100)%	0%	54,261	0 %
Malaria	-	1,360	3	(100)%	2%	10,205	0 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	-	46	-	(100)%	0%	81	0 %
<b>East Africa</b>	<b>577,867</b>	<b>2,448,749</b>	<b>2,514,736</b>	<b>3%</b>		<b>8,579,902</b>	<b>29%</b>
<b>Burundi</b>	<b>6,091</b>	<b>40,080</b>	<b>38,678</b>	<b>(3)%</b>	100%	<b>162,466</b>	<b>24%</b>
Family Planning	1,730	7,532	5,417	(28)%	14%	28,897	19 %
HIV & STIs	2,431	12,427	8,743	(30)%	23%	36,855	24 %
Malaria	1,906	20,121	24,362	21%	63%	96,590	25 %
Safe Abortion	24	-	156	0%	0%	125	125 %
<b>Ethiopia</b>	<b>845</b>	<b>36,394</b>	<b>3,729</b>	<b>(90)%</b>	100%	<b>205,237</b>	<b>2%</b>
Family Planning	146	7,924	186	(98)%	5%	43,686	0 %
HIV & STIs	540	27,358	1,061	(96)%	28%	151,973	1 %
Tuberculosis	-	29	-	(100)%	0%	-	0 %
WASH	159	1,082	2,481	129%	67%	9,577	26 %
<b>Kenya</b>	<b>117,006</b>	<b>616,357</b>	<b>486,152</b>	<b>(21)%</b>	100%	<b>2,393,098</b>	<b>20%</b>
Family Planning	34,228	178,274	132,694	(26)%	27%	895,469	15 %
HIV & STIs	76,852	415,941	328,381	(21)%	68%	1,385,441	24 %
Malaria	1,539	19,892	13,600	(32)%	3%	80,480	17 %
Maternal, Newborn, and Child Health	4,019	217	9,564	4,301%	2%	26,033	37 %
Non-communicable diseases	6	88	47	(47)%	0%	93	51 %
WASH	363	1,945	1,867	(4)%	0%	5,584	33 %
<b>Malawi</b>	<b>58,803</b>	<b>222,698</b>	<b>318,819</b>	<b>43 %</b>	100%	<b>918,685</b>	<b>35%</b>
Family Planning	20,292	39,065	165,805	324%	52%	265,964	62 %
HIV & STIs	38,204	154,648	142,490	(8)%	45%	646,971	22 %
Malaria	267	22,249	10,253	(54)%	3%	4,573	224 %
Maternal, Newborn, and Child Health	-	6,241	-	(100)%	0%	-	0 %
WASH	40	494	270	(45)%	0%	1,178	23 %
<b>Rwanda</b>	<b>11,481</b>	<b>110,838</b>	<b>57,609</b>	<b>(48)%</b>	100%	<b>219,295</b>	<b>26%</b>
Family Planning	2,026	18,916	10,533	(44)%	18%	36,565	29 %
HIV & STIs	9,410	91,835	46,923	(49)%	81%	182,180	26 %
WASH	45	88	153	75%	0%	551	28 %
<b>Somaliland</b>	<b>1,910</b>	<b>7,122</b>	<b>7,154</b>	- %	100%	<b>32,618</b>	<b>22%</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly DALY Report by Country**  
**Period: 4**  
**Year: 2017**

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Family Planning	40	573	421	(27)%	6%	1,953	22 %
Maternal, Newborn, and Child Health	1,613	6,090	6,099	0%	85%	28,939	21 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	257	458	634	38%	9%	1,726	37 %
<b>South Sudan</b>	<b>186,671</b>	<b>657,919</b>	<b>805,879</b>	<b>22 %</b>	100%	<b>2,218,619</b>	<b>36%</b>
Malaria	139,898	592,031	728,710	23%	90%	1,418,762	51 %
Maternal, Newborn, and Child Health	26,403	65,888	56,799	(14)%	7%	799,857	7 %
Nutrition	20,370	-	20,370	0%	3%	-	0 %
<b>Tanzania</b>	<b>108,824</b>	<b>400,313</b>	<b>540,020</b>	<b>35 %</b>	100%	<b>1,346,068</b>	<b>40%</b>
Family Planning	60,320	209,236	323,542	55%	60%	613,291	53 %
HIV & STIs	45,686	151,853	198,324	31%	37%	590,393	34 %
Malaria	2,478	23,344	5,300	(77)%	1%	114,927	5 %
Maternal, Newborn, and Child Health	-	-	769	0%	0%	-	0 %
Non-communicable diseases	3	53	26	(51)%	0%	90	29 %
Safe Abortion	305	12,564	11,827	(6)%	2%	26,850	44 %
WASH	31	3,263	234	(93)%	0%	517	45 %
<b>Uganda</b>	<b>86,235</b>	<b>357,028</b>	<b>256,697</b>	<b>(28)%</b>	100%	<b>1,083,816</b>	<b>24%</b>
Family Planning	55,804	95,451	203,412	113%	79%	550,735	37 %
HIV & STIs	29,713	245,801	49,533	(80)%	19%	156,444	32 %
Malaria	314	4,900	382	(92)%	0%	45,166	1 %
Maternal, Newborn, and Child Health	273	8,367	2,811	(66)%	1%	12,101	23 %
Non-communicable diseases	17	56	17	(69)%	0%	712	2 %
Safe Abortion	-	61	98	61%	0%	317,170	0 %
WASH	113	2,392	444	(81)%	0%	1,488	30 %
<b>Southern Africa</b>	<b>469,455</b>	<b>2,411,771</b>	<b>2,113,566</b>	<b>(12)%</b>		-	<b>-%</b>
<b>Angola</b>	<b>3,259</b>	<b>126,010</b>	<b>7,980</b>	<b>(94)%</b>	100%	-	<b>-%</b>
Family Planning	694	2	2,426	133,420%	30%	-	0 %
HIV & STIs	1,025	3	3,344	124,506%	42%	-	0 %
Malaria	971	125,961	971	(99)%	12%	-	0 %
WASH	568	45	1,239	2,669%	16%	-	0 %
<b>Botswana</b>	<b>1,935</b>	<b>4,196</b>	<b>6,258</b>	<b>49 %</b>	100%	-	<b>-%</b>
Family Planning	135	294	438	49%	7%	-	0 %
HIV & STIs	1,799	3,902	5,820	49%	93%	-	0 %
<b>Lesotho</b>	<b>21,981</b>	<b>74,980</b>	<b>91,949</b>	<b>23 %</b>	100%	-	<b>-%</b>
Family Planning	1,359	4,549	5,955	31%	6%	-	0 %
HIV & STIs	20,622	70,432	85,978	22%	94%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	16	0%	0%	-	0 %
<b>Madagascar</b>	<b>78,791</b>	<b>143,671</b>	<b>288,597</b>	<b>101 %</b>	100%	-	<b>-%</b>
Family Planning	23,260	91,748	92,487	1%	32%	-	0 %
HIV & STIs	14,123	6,386	38,247	499%	13%	-	0 %
Malaria	14,459	4,563	96,882	2,023%	34%	-	0 %
Maternal, Newborn, and Child Health	25,877	36,777	56,253	53%	19%	-	0 %
Non-communicable diseases	2	-	9	0%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	57	-	241	0%	0%	-	0 %
WASH	1,013	4,197	4,478	7%	2%	-	0 %
<b>Mozambique</b>	<b>25,167</b>	<b>65,146</b>	<b>105,789</b>	<b>62 %</b>	100%	-	<b>-%</b>



## POPULATION SERVICES INTERNATIONAL

## Monthly DALY Report by Country

Period: 4

Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Family Planning	4,283	27,057	16,993	(37)%	16%	-	0 %
HIV & STIs	18,138	32,079	68,162	112%	64%	-	0 %
Malaria	2,388	2,499	16,709	569%	16%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
WASH	357	3,511	3,925	12%	4%	-	0 %
<b>Namibia</b>	<b>195</b>	<b>6,134</b>	<b>195</b>	<b>(97)%</b>	100%	-	<b>-%</b>
Family Planning	16	485	16	(97)%	8%	-	0 %
HIV & STIs	180	5,635	180	(97)%	92%	-	0 %
Tuberculosis	-	14	-	(100)%	0%	-	0 %
<b>South Africa</b>	<b>72,139</b>	<b>882,312</b>	<b>528,328</b>	<b>(40)%</b>	100%	-	<b>-%</b>
Family Planning	2,362	36,552	20,855	(43)%	4%	-	0 %
HIV & STIs	69,777	845,759	507,473	(40)%	96%	-	0 %
<b>Swaziland</b>	<b>76,935</b>	<b>277,945</b>	<b>260,491</b>	<b>(6)%</b>	100%	-	<b>-%</b>
Family Planning	3,225	12,500	11,554	(8)%	4%	-	0 %
HIV & STIs	73,710	265,446	248,937	(6)%	96%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Zambia</b>	<b>99,076</b>	<b>287,718</b>	<b>321,299</b>	<b>12 %</b>	100%	-	<b>-%</b>
Family Planning	731	100	2,792	2,691%	1%	-	0 %
HIV & STIs	98,146	286,520	317,849	11%	99%	-	0 %
WASH	199	1,098	659	(40)%	0%	-	0 %
<b>Zimbabwe</b>	<b>89,978</b>	<b>543,659</b>	<b>502,680</b>	<b>(8)%</b>	100%	-	<b>-%</b>
Family Planning	1,320	32,852	12,354	(62)%	2%	-	0 %
HIV & STIs	88,632	510,459	490,193	(4)%	98%	-	0 %
Non-communicable diseases	20	117	100	(14)%	0%	-	0 %
Tuberculosis	7	112	33	(70)%	0%	-	0 %
WASH	-	120	-	(100)%	0%	-	0 %
<b>Americas</b>	<b>14,231</b>	<b>45,965</b>	<b>69,979</b>	<b>52%</b>		<b>219,289</b>	<b>32%</b>
<b>Belize</b>	-	<b>12</b>	-	<b>(100)%</b>	0%	-	<b>-%</b>
Family Planning	-	-	-	(100)%	0%	-	0 %
HIV & STIs	-	11	-	(100)%	0%	-	0 %
<b>Caribbean</b>	-	<b>29</b>	<b>16</b>	<b>(45)%</b>	100%	-	<b>-%</b>
Family Planning	-	5	3	(45)%	17%	-	0 %
HIV & STIs	-	24	13	(45)%	83%	-	0 %
<b>Costa Rica</b>	<b>138</b>	<b>517</b>	<b>525</b>	<b>1 %</b>	100%	<b>1,607</b>	<b>33%</b>
Family Planning	9	34	35	1%	7%	106	33 %
HIV & STIs	128	483	490	1%	93%	1,501	33 %
<b>Dominican Republic</b>	<b>665</b>	<b>6,710</b>	<b>7,921</b>	<b>18 %</b>	100%	<b>15,810</b>	<b>50%</b>
Family Planning	143	1,478	1,751	18%	22%	3,483	50 %
HIV & STIs	522	5,232	6,171	18%	78%	12,327	50 %
<b>El Salvador</b>	<b>401</b>	<b>9,884</b>	<b>2,566</b>	<b>(74)%</b>	100%	<b>7,913</b>	<b>32%</b>
Family Planning	128	1,427	735	(48)%	29%	3,004	24 %
HIV & STIs	266	8,456	1,815	(79)%	71%	4,772	38 %
Maternal, Newborn, and Child Health	1	-	1	0%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	6	1	14	951%	1%	136	10 %
<b>Guatemala</b>	<b>2,359</b>	<b>10,388</b>	<b>10,481</b>	<b>1 %</b>	100%	<b>31,762</b>	<b>33%</b>

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 4

Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Family Planning	1,550	5,682	6,114	8%	58%	14,766	41 %
HIV & STIs	798	4,707	4,290	(9)%	41%	16,567	26 %
Maternal, Newborn, and Child Health	-	-	2	1,058%	0%	-	0 %
Safe Abortion	10	-	75	0%	1%	428	17 %
<b>Haiti</b>	<b>7,573</b>	<b>87</b>	<b>34,485</b>	<b>39,317 %</b>	<b>100%</b>	<b>94,734</b>	<b>36%</b>
Family Planning	-	87	44	(50)%	0%	17,271	0 %
HIV & STIs	2,431	-	13,511	0%	39%	26,854	50 %
Malaria	-	-	-	0%	0%	2,258	0 %
Maternal, Newborn, and Child Health	5,142	-	10,285	0%	30%	14,123	73 %
Tuberculosis	-	-	10,645	0%	31%	34,228	31 %
<b>Honduras</b>	<b>1,872</b>	<b>5,764</b>	<b>6,527</b>	<b>13 %</b>	<b>100%</b>	<b>17,859</b>	<b>37%</b>
Family Planning	136	419	476	14%	7%	1,306	36 %
HIV & STIs	1,736	5,345	6,051	13%	93%	16,553	37 %
<b>Nicaragua</b>	<b>641</b>	<b>3,853</b>	<b>3,890</b>	<b>1 %</b>	<b>100%</b>	<b>15,056</b>	<b>26%</b>
Family Planning	210	1,673	1,446	(14)%	37%	6,711	22 %
HIV & STIs	431	2,180	2,413	11%	62%	8,040	30 %
Safe Abortion	1	-	32	0%	1%	305	10 %
<b>Panama</b>	<b>582</b>	<b>2,209</b>	<b>2,085</b>	<b>(6)%</b>	<b>100%</b>	<b>7,586</b>	<b>27%</b>
Family Planning	77	293	277	(6)%	13%	1,008	27 %
HIV & STIs	505	1,915	1,808	(6)%	87%	6,578	27 %
<b>Paraguay</b>	<b>-</b>	<b>6,510</b>	<b>1,482</b>	<b>(77)%</b>	<b>100%</b>	<b>26,963</b>	<b>5%</b>
Family Planning	-	1,827	372	(80)%	25%	5,721	7 %
HIV & STIs	-	4,636	1,094	(76)%	74%	21,059	5 %
Nutrition	-	48	16	(67)%	1%	183	9 %
<b>Asia and Eastern Europe</b>	<b>175,449</b>	<b>487,517</b>	<b>727,331</b>	<b>49%</b>		<b>-</b>	<b>-%</b>
<b>Cambodia</b>	<b>13,062</b>	<b>61,574</b>	<b>57,799</b>	<b>(6)%</b>	<b>100%</b>	<b>-</b>	<b>-%</b>
Family Planning	6,586	27,644	28,104	2%	49%	-	0 %
HIV & STIs	4,784	23,149	21,773	(6)%	38%	-	0 %
Malaria	297	2,574	1,046	(59)%	2%	-	0 %
Maternal, Newborn, and Child Health	51	1,004	283	(72)%	0%	-	0 %
Safe Abortion	1,344	7,203	6,592	(8)%	11%	-	0 %
<b>India</b>	<b>10,658</b>	<b>71,749</b>	<b>70,651</b>	<b>(2)%</b>	<b>100%</b>	<b>-</b>	<b>-%</b>
Family Planning	11,011	28,940	63,254	119%	90%	-	0 %
HIV & STIs	-	31,690	(2)	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	(2,848)	6,538	(237)	(104)%	0%	-	0 %
Non-communicable diseases	-	-	182	0%	0%	-	0 %
Safe Abortion	-	4,581	(117)	(103)%	0%	-	0 %
Tuberculosis	2,486	-	5,792	0%	8%	-	0 %
WASH	10	-	1,777	0%	3%	-	0 %
<b>India LLC</b>	<b>37,517</b>	<b>-</b>	<b>144,580</b>	<b>- %</b>	<b>100%</b>	<b>-</b>	<b>-%</b>
Family Planning	19,359	-	74,097	0%	51%	-	0 %
HIV & STIs	13,504	-	56,229	0%	39%	-	0 %
Maternal, Newborn, and Child Health	1,813	-	1,998	0%	1%	-	0 %
Safe Abortion	2,841	-	12,256	0%	8%	-	0 %
<b>Kazakhstan</b>	<b>25</b>	<b>-</b>	<b>215</b>	<b>- %</b>	<b>100%</b>	<b>-</b>	<b>-%</b>
Family Planning	-	-	3	0%	1%	-	0 %
HIV & STIs	25	-	212	0%	99%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 4

Year: 2017

	DALY 4/2017	YTD DALY 2016	YTD DALY 2017	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
<b>Kyrgyzstan</b>	<b>73</b>	-	<b>349</b>	- %	100%	-	-%
HIV & STIs	73	-	349	0%	100%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Laos</b>	<b>1,330</b>	<b>2,997</b>	<b>6,124</b>	<b>104 %</b>	100%	-	-%
Family Planning	1,254	2,954	5,439	84%	89%	-	0 %
HIV & STIs	-	-	215	0%	4%	-	0 %
Safe Abortion	-	43	347	700%	6%	-	0 %
Tuberculosis	76	-	122	0%	2%	-	0 %
<b>Myanmar</b>	<b>21,339</b>	<b>115,160</b>	<b>92,935</b>	<b>(19)%</b>	100%	-	-%
Family Planning	3,608	9,805	17,803	82%	19%	-	0 %
HIV & STIs	7,583	27,452	32,628	19%	35%	-	0 %
Malaria	3,395	14,530	15,686	8%	17%	-	0 %
Maternal, Newborn, and Child Health	29	33,171	838	(97)%	1%	-	0 %
Non-communicable diseases	-	6	-	(95)%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Tuberculosis	6,724	30,189	25,977	(14)%	28%	-	0 %
WASH	-	8	2	(77)%	0%	-	0 %
<b>Nepal</b>	<b>3,414</b>	<b>5,609</b>	<b>11,765</b>	<b>110 %</b>	100%	-	-%
Family Planning	2,457	3,339	8,079	142%	69%	-	0 %
HIV & STIs	-	93	1,183	1,172%	10%	-	0 %
Safe Abortion	957	2,177	2,503	15%	21%	-	0 %
<b>Pakistan</b>	<b>84,425</b>	<b>221,278</b>	<b>326,576</b>	<b>48 %</b>	100%	-	-%
Family Planning	75,628	195,218	295,978	52%	91%	-	0 %
HIV & STIs	1,075	13,726	7,904	(42)%	2%	-	0 %
Safe Abortion	125	-	535	0%	0%	-	0 %
Tuberculosis	7,597	12,315	22,159	80%	7%	-	0 %
WASH	-	19	-	(100)%	0%	-	0 %
<b>Papua New Guinea</b>	<b>301</b>	<b>1,019</b>	<b>1,051</b>	<b>3 %</b>	100%	-	-%
Family Planning	103	65	138	113%	13%	-	0 %
HIV & STIs	196	121	261	116%	25%	-	0 %
Malaria	-	786	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	2	47	651	1,281%	62%	-	0 %
WASH	-	-	-	450%	0%	-	0 %
<b>Tajikistan</b>	<b>628</b>	-	<b>3,188</b>	- %	100%	-	-%
Family Planning	14	-	35	0%	1%	-	0 %
HIV & STIs	615	-	3,153	0%	99%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
<b>Viet Nam</b>	<b>2,678</b>	<b>8,131</b>	<b>12,098</b>	<b>49 %</b>	100%	-	-%
Family Planning	1	-	3	0%	0%	-	0 %
HIV & STIs	2,677	8,127	12,095	49%	100%	-	0 %
Malaria	-	-	-	0%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	-	4	-	(100)%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Acute Malnutrition Screening_CU</b>	61	54	223	-	-	-%	-	223	-
West and Central Africa	61	54	223	-	-	-%	-	223	-
<b>Antiretroviral Treatment</b>	-	-	-	-	-	-%	-	18,119	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	18,119	-
<b>Antiretroviral Treatment (Currentl</b>	30,330	33,288	130,195	14,986	-	-%	12,235	142,430	22,945
East Africa	6,058	2,624	13,929	6,986	-	-%	5,564	19,493	2,913
Southern Africa	8,072	7,383	30,220	-	-	-%	5,010	35,230	5,369
Americas	12,926	20,491	74,400	8,000	-	-%	-	74,400	12,629
Asia and Eastern Europe	3,274	2,791	11,646	-	-	-%	1,661	13,307	2,034
<b>Antiretroviral Treatment (Newly E</b>	1,773	1,665	6,769	-	-	-%	7,226	13,995	-
East Africa	352	230	1,043	-	-	-%	901	1,944	-
Southern Africa	762	918	3,516	-	-	-%	5,283	8,799	-
Americas	445	290	1,315	-	-	-%	-	1,315	-
Asia and Eastern Europe	214	227	895	-	-	-%	1,042	1,937	-
<b>Antiretroviral Treatment (Tablet)</b>	-	-	-	-	-	-%	-	97,980	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	97,980	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	382	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	382	-
<b>ARV Prophylaxis 28 wks (Mother</b>	-	-	-	-	-	-%	-	359	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	359	-
<b>Basic Care Package</b>	-	133	400	-	17,301,754	(100)%	52,637,120	176,452,481	-
East Africa	-	133	400	-	17,301,754	(100)%	52,637,120	176,034,156	-
Southern Africa	-	-	-	-	-	-%	-	418,325	-
<b>CD4 Tests Provided to HIV+ Clie</b>	877	1,680	5,918	-	-	-%	1,193	7,111	-
West and Central Africa	12	17	63	-	-	-%	297	360	-
East Africa	60	61	243	-	-	-%	-	243	-
Southern Africa	692	1,602	5,499	-	-	-%	778	6,277	-
Americas	113	-	113	-	-	-%	118	231	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Cervical Cancer-Pap and Cryothe</b>	-	-	-	-	-	-%	-	35	-
Americas	-	-	-	-	-	-%	-	35	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	1	-	-	-%	1	2	-
Southern Africa	-	-	1	-	-	-%	1	2	-
<b>Cervical Cancer-Pap and Refer to</b>	-	-	-	-	-	-%	7	9	-
Southern Africa	-	-	-	-	-	-%	7	9	-
<b>Cervical Cancer-Pap Smear Scree</b>	-	160	479	-	1,450	(67)%	6,309	7,029	-
West and Central Africa	-	-	-	-	1,450	(100)%	1,450	1,450	-
East Africa	-	58	173	-	-	-%	-	173	-
Southern Africa	-	1	2	-	-	-%	116	118	-
Americas	-	-	-	-	-	-%	-	241	-
Asia and Eastern Europe	-	101	304	-	-	-%	4,743	5,047	-
<b>Cervical Cancer-VIA and Conizati</b>	23	22	90	-	-	-%	10	100	26
Southern Africa	23	22	90	-	-	-%	10	100	26
<b>Cervical Cancer-VIA and Cryothe</b>	139	442	1,466	3,264	1,510	(3)%	9,025	17,333	400
West and Central Africa	3	150	452	719	533	(15)%	2,406	3,467	123
East Africa	86	83	336	2,545	707	(52)%	2,707	5,840	90
Southern Africa	49	70	258	-	249	4%	1,194	3,945	72
Americas	-	-	-	-	-	-%	-	68	-
Asia and Eastern Europe	1	140	420	-	21	1,900%	2,718	4,013	115
<b>Cervical Cancer-VIA and Refer to</b>	1	28	85	-	-	-%	65	381	12
Southern Africa	1	2	6	-	-	-%	17	254	1
Asia and Eastern Europe	-	26	79	-	-	-%	48	127	11
<b>Cervical Cancer-VIA and Refer to</b>	14	15	60	-	302	(80)%	402	1,949	9
Southern Africa	14	15	60	-	302	(80)%	402	1,949	9
<b>Cervical Cancer-VIA and Refer to</b>	-	145	435	102	31	1,303%	479	2,045	59
West and Central Africa	-	-	-	-	-	-%	-	546	-
East Africa	-	-	-	102	-	-%	-	19	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	-	5	16	-	31	(48)%	33	615	2
Asia and Eastern Europe	-	140	419	-	-	-%	446	865	57
<b>Cervical Cancer-VIA/VILI Screenir</b>	<b>15,369</b>	<b>17,253</b>	<b>67,127</b>	<b>-</b>	<b>68,096</b>	<b>(1)%</b>	<b>443,880</b>	<b>674,996</b>	<b>-</b>
West and Central Africa	2,043	8,094	26,324	-	15,935	65%	90,919	162,797	-
East Africa	12,005	5,569	28,713	-	40,196	(29)%	228,181	345,824	-
Southern Africa	1,319	1,736	6,527	-	11,437	(43)%	26,740	58,008	-
Americas	-	-	-	-	-	-%	-	1,079	-
Asia and Eastern Europe	2	1,854	5,563	-	528	954%	98,040	107,288	-
<b>Chlorhexidine</b>	<b>7,395</b>	<b>23,974</b>	<b>79,317</b>	<b>240,000</b>	<b>18,757</b>	<b>323%</b>	<b>293,776</b>	<b>433,018</b>	<b>7,700</b>
West and Central Africa	6,606	21,867	72,206	200,000	-	-%	46,000	118,206	7,265
East Africa	10	334	1,011	40,000	-	-%	6,682	7,693	63
Southern Africa	779	1,774	6,100	-	18,757	(67)%	241,094	307,119	373
<b>Clean Delivery Kit</b>	<b>342</b>	<b>5,310</b>	<b>16,272</b>	<b>15,000</b>	<b>6,197</b>	<b>163%</b>	<b>58,792</b>	<b>1,674,458</b>	<b>1,163</b>
West and Central Africa	-	-	-	15,000	1,800	(100)%	4,400	225,110	-
East Africa	342	5,310	16,272	-	4,097	297%	53,992	451,215	1,163
Asia and Eastern Europe	-	-	-	-	300	(100)%	400	998,133	-
<b>Condom</b>	<b>33,743,696</b>	<b>48,351,247</b>	<b>178,797,438</b>	<b>355,242,828</b>	<b>213,068,031</b>	<b>(16)%</b>	<b>707,434,557</b>	<b>20,528,457,220</b>	<b>1,740,252</b>
West and Central Africa	6,400,654	11,297,453	40,293,014	163,145,833	55,796,908	(28)%	167,432,871	5,471,006,623	444,806
East Africa	7,599,970	11,131,204	40,993,583	147,400,070	44,487,206	(8)%	168,952,588	2,636,087,328	672,994
Southern Africa	4,949,900	5,229,924	20,639,673	-	31,421,580	(34)%	100,081,646	2,356,702,411	425,125
Americas	2,327,274	3,828,773	13,813,594	44,696,925	13,303,872	4%	38,832,417	1,162,917,982	28,212
Other Africa	-	-	-	-	-	-%	-	14,310,880	-
Asia and Eastern Europe	12,465,898	16,863,892	63,057,574	-	68,058,465	(7)%	232,135,035	8,887,431,996	169,114
<b>Condom Provided</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,182,567</b>	<b>(100)%</b>	<b>3,659,226</b>	<b>18,930,351</b>	<b>-</b>
West and Central Africa	-	-	-	-	17,875	(100)%	55,399	83,854	-
East Africa	-	-	-	-	907,314	(100)%	2,231,548	17,065,364	-
Southern Africa	-	-	-	-	227,533	(100)%	842,352	1,079,341	-
Americas	-	-	-	-	26,913	(100)%	466,816	616,702	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	-	-	-	-	2,932	(100)%	63,111	85,090	-
<b>Counseling &amp; Tx for Moderate Ac</b>	155,152	1	155,155	-	-	-%	-	155,155	-
West and Central Africa	5	1	8	-	-	-%	-	8	-
East Africa	155,147	-	155,147	-	-	-%	-	155,147	-
<b>Deworming Tablets</b>	-	-	-	-	-	-%	-	1,095,308	-
East Africa	-	-	-	-	-	-%	-	978,174	-
Southern Africa	-	-	-	-	-	-%	-	117,134	-
<b>Diarrhea Treatment Kit</b>	160,266	236,373	869,384	1,240,671	942,645	(8)%	2,396,570	18,220,587	54,140
West and Central Africa	111,107	193,726	692,286	1,012,000	522,780	32%	1,301,535	8,598,507	44,660
East Africa	14,810	13,913	56,548	188,671	65,377	(14)%	176,147	1,222,688	6,061
Southern Africa	31,132	19,068	88,337	-	184,732	(52)%	479,996	1,959,761	2,230
Americas	-	-	-	40,000	-	-%	-	-	-
Asia and Eastern Europe	3,217	9,665	32,213	-	169,756	(81)%	438,892	6,439,631	1,188
<b>Diarrhea Treatment Kit Provided</b>	7,205	568	8,908	-	-	-%	24,604	33,512	332
West and Central Africa	-	-	-	-	-	-%	2,400	2,400	-
East Africa	6,711	-	6,711	-	-	-%	17,338	24,049	270
Southern Africa	494	568	2,197	-	-	-%	4,866	7,063	62
<b>Early Infant Male Circumcision</b>	-	-	-	-	1	(100)%	5	4,886	-
Southern Africa	-	-	-	-	1	(100)%	5	4,886	-
<b>Emergency Contraception</b>	238,391	371,184	1,351,943	2,545,500	1,645,287	(18)%	4,760,176	38,227,175	10,034
West and Central Africa	178,816	114,955	523,682	2,055,000	626,235	(16)%	1,808,411	13,580,151	6,250
East Africa	1,456	34,813	105,896	154,000	7,846	1,250%	73,906	1,555,178	860
Southern Africa	2,462	15,357	48,532	-	54,408	(11)%	208,155	1,062,408	249
Americas	-	7,735	23,206	336,500	99,707	(77)%	308,976	3,886,753	32
Asia and Eastern Europe	55,657	198,323	650,627	-	857,091	(24)%	2,360,728	18,142,685	2,643
<b>Emergency Contraception Provid</b>	1,004	1,151	4,458	2,000	3,861	15%	11,214	28,037	24
West and Central Africa	18	41	141	-	84	68%	201	663	2
East Africa	141	138	555	2,000	18	2,983%	246	857	4

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	99	91	371	-	120	209%	1,660	2,422	3
Americas	-	-	1	-	-	-%	6	89	-
Asia and Eastern Europe	746	881	3,390	-	3,639	(7)%	9,101	24,006	16
<b>Expanded Clean Delivery Kit</b>	-	-	-	25,000	-	-%	-	-	-
East Africa	-	-	-	25,000	-	-%	-	-	-
<b>Expanded Clean Delivery Kit (+C)</b>	-	-	-	14,000	-	-%	-	-	-
East Africa	-	-	-	14,000	-	-%	-	-	-
<b>Family Planning Counseling</b>	-	-	-	-	436	(100)%	42,161	42,190	-
West and Central Africa	-	-	-	-	173	(100)%	20,577	20,606	-
East Africa	-	-	-	-	263	(100)%	17,574	17,574	-
Southern Africa	-	-	-	-	-	-%	223	223	-
Americas	-	-	-	-	-	-%	3,787	3,787	-
<b>Fecal Sludge Management (House)</b>	44	63	232	-	-	-%	921	1,153	-
Asia and Eastern Europe	44	63	232	-	-	-%	921	1,153	-
<b>Fecal Sludge Management (Liters)</b>	172,000	294,667	1,056,000	-	-	-%	3,021,000	4,077,000	58
Asia and Eastern Europe	172,000	294,667	1,056,000	-	-	-%	3,021,000	4,077,000	58
<b>Female Condom</b>	60,435	181,193	604,015	364,568	1,582,547	(62)%	6,171,177	83,322,532	7,952
West and Central Africa	5,949	23,169	75,455	224,568	647,762	(88)%	2,318,144	25,443,409	381
East Africa	3,880	94,100	286,180	140,000	405,220	(29)%	1,099,340	11,113,516	2,778
Southern Africa	31,380	57,919	205,137	-	495,994	(59)%	2,644,759	39,626,743	4,625
Americas	-	-	-	-	-	-%	-	3,751,762	-
Asia and Eastern Europe	19,226	6,006	37,243	-	33,571	11%	108,934	3,387,102	167
<b>Female Condom Provided</b>	-	-	-	-	27,364	(100)%	83,044	112,394	-
West and Central Africa	-	-	-	-	357	(100)%	2,591	3,027	-
East Africa	-	-	-	-	-	-%	-	9,654	-
Southern Africa	-	-	-	-	27,006	(100)%	80,452	99,712	-
Americas	-	-	-	-	1	(100)%	1	1	-
<b>Fever Cases Attended</b>	61,927	159,199	539,523	-	-	-%	3,637,532	4,177,055	-



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	-	-%	2,927,861	2,927,861	-
East Africa	-	221	664	-	-	-%	26,315	26,979	-
Southern Africa	3,812	93,063	283,001	-	-	-%	24,338	307,339	-
Americas	1,279	8,476	26,707	-	-	-%	1,187	27,894	-
Asia and Eastern Europe	56,836	57,438	229,151	-	-	-%	657,831	886,982	-
<b>Fever Cases Tested with Microsc</b>	<b>6,468</b>	<b>24,841</b>	<b>80,992</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>261,944</b>	<b>342,936</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	247,772	247,772	-
East Africa	-	40	121	-	-	-%	7,353	7,474	-
Southern Africa	468	365	1,563	-	-	-%	1,885	3,448	-
Americas	6,000	24,436	79,308	-	-	-%	4,934	84,242	-
<b>Fever Cases Tested with RDTs</b>	<b>78,199</b>	<b>256,607</b>	<b>848,020</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>3,355,756</b>	<b>4,203,776</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	2,634,426	2,634,426	-
East Africa	-	181	543	-	-	-%	18,608	19,151	-
Southern Africa	3,479	87,041	264,602	-	-	-%	20,935	285,537	-
Americas	17,884	111,947	353,724	-	-	-%	23,956	377,680	-
Asia and Eastern Europe	56,836	57,438	229,151	-	-	-%	657,831	886,982	-
<b>Free Condom</b>	<b>11,545,213</b>	<b>12,559,523</b>	<b>49,223,782</b>	<b>126,841,343</b>	<b>49,152,565</b>	<b>-%</b>	<b>220,640,510</b>	<b>2,283,095,984</b>	<b>814,550</b>
West and Central Africa	1,786,352	3,171,059	11,299,528	62,124,626	3,165,822	257%	32,825,359	181,889,519	72,540
East Africa	5,994,418	2,104,062	12,306,605	57,032,717	9,723,679	27%	85,946,047	638,144,553	175,543
Southern Africa	3,699,813	6,937,457	24,512,183	-	30,786,461	(20)%	93,108,576	1,353,466,647	563,782
Americas	42,000	156,412	511,236	7,684,000	5,434,915	(91)%	8,079,494	62,522,748	871
Asia and Eastern Europe	22,630	190,533	594,230	-	41,688	1,325%	681,034	47,072,517	1,814
<b>Free Female Condom</b>	<b>74,466</b>	<b>73,946</b>	<b>296,303</b>	<b>2,983,945</b>	<b>380,273</b>	<b>(22)%</b>	<b>1,354,037</b>	<b>13,489,957</b>	<b>2,567</b>
West and Central Africa	68,599	40,743	190,827	1,564,945	11,141	1,613%	431,422	2,781,516	679
East Africa	5,381	10,542	37,006	1,419,000	14,328	158%	107,658	2,827,736	549
Southern Africa	486	21,328	64,470	-	236,604	(73)%	626,979	7,446,122	1,335
Americas	-	-	-	-	118,200	(100)%	167,978	258,270	-
Asia and Eastern Europe	-	1,333	4,000	-	-	-%	20,000	176,313	5

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>HAART (Mother and Baby)</b>	-	-	-	-	-	-%	-	256	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	256	-
<b>HAART (Mother Only)</b>	-	-	-	-	-	-%	-	239	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	239	-
<b>HIV Testing Services</b>	190,458	180,144	730,891	565,615	537,985	36%	2,051,470	19,506,289	34,441
West and Central Africa	8,458	8,976	35,387	65,753	44,305	(20)%	201,781	3,658,782	203
East Africa	32,681	37,971	146,593	332,377	183,608	(20)%	450,690	2,787,842	4,407
Southern Africa	104,401	107,576	427,130	-	281,687	52%	973,831	11,799,957	29,183
Americas	36,271	18,369	91,378	167,485	6,225	1,368%	355,059	684,945	609
Asia and Eastern Europe	8,647	7,252	30,403	-	22,160	37%	70,109	574,763	40
<b>Hypertension Diagnosis</b>	212	1,940	6,032	-	-	-%	31,408	37,440	-
East Africa	-	1,930	5,790	-	-	-%	31,404	37,194	-
Southern Africa	62	10	92	-	-	-%	4	96	-
Asia and Eastern Europe	150	-	150	-	-	-%	-	150	-
<b>Hypertension Screening</b>	13,494	89,602	282,300	-	-	-%	142,939	425,239	-
East Africa	-	19,036	57,107	-	-	-%	129,978	187,085	-
Southern Africa	13,324	70,566	225,023	-	-	-%	12,961	237,984	-
Asia and Eastern Europe	170	-	170	-	-	-%	-	170	-
<b>Hypertension_Controlled Conditio</b>	129	1,171	3,643	-	-	-%	25,845	29,488	-
East Africa	-	1,165	3,495	-	-	-%	25,842	29,337	-
Southern Africa	-	6	19	-	-	-%	3	22	-
Asia and Eastern Europe	129	-	129	-	-	-%	-	129	-
<b>Implant 3</b>	(241)	24,520	73,320	339,101	79,704	(8)%	153,491	754,800	90,760
West and Central Africa	1,936	2,101	8,239	7,550	1,514	444%	9,011	8,544	13,515
East Africa	(1,738)	20,492	59,738	331,101	78,514	(24)%	143,202	714,685	76,185
Southern Africa	(510)	(101)	(812)	-	(661)	-%	(1,712)	691	(808)
Americas	-	(19)	(56)	450	138	(141)%	333	576	(14)
Asia and Eastern Europe	71	2,047	6,211	-	199	3,021%	2,657	30,304	1,882

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Implant 3 Insertion</b>	14,932	20,977	77,864	41,561	23,548	231%	165,326	404,670	133,282
West and Central Africa	417	5,415	16,663	20,002	321	5,091%	20,727	48,538	34,756
East Africa	12,696	13,796	54,084	21,248	19,251	181%	127,841	297,930	92,976
Southern Africa	977	859	3,555	-	3,384	5%	11,806	42,134	3,903
Americas	22	51	174	311	189	(8)%	797	4,823	47
Asia and Eastern Europe	820	856	3,388	-	403	741%	4,155	11,245	1,599
<b>Implant 4</b>	176	207	797	-	1,362	(41)%	3,419	30,770	1,867
East Africa	-	-	-	-	-	-%	(369)	(369)	-
Southern Africa	176	207	797	-	1,362	(41)%	3,788	31,839	1,867
Asia and Eastern Europe	-	-	-	-	-	-%	-	(700)	-
<b>Implant 4 Insertion</b>	25	5	39	-	70	(44)%	1,789	10,181	58
West and Central Africa	22	-	22	-	-	-%	-	22	34
East Africa	-	-	-	-	-	-%	1,460	1,460	-
Southern Africa	3	5	17	-	70	(76)%	329	3,357	24
Asia and Eastern Europe	-	-	-	-	-	-%	-	5,342	-
<b>Implant 5</b>	2,455	4,453	15,813	264,836	17,309	(9)%	104,114	467,228	38,469
West and Central Africa	4,796	1,934	10,599	84,157	13,168	(20)%	29,265	199,775	26,219
East Africa	(1,787)	3,547	8,855	180,121	4,285	107%	63,837	155,598	21,386
Southern Africa	(809)	(1,097)	(4,100)	-	(1,988)	-%	(9,930)	32,523	(9,794)
Americas	37	(338)	(977)	558	641	(252)%	(333)	12,455	(473)
Asia and Eastern Europe	218	406	1,436	-	1,203	19%	21,275	66,877	1,131
<b>Implant 5 Insertion</b>	20,867	25,975	98,792	82,539	55,339	79%	251,846	1,379,529	255,173
West and Central Africa	9,255	13,859	50,833	41,399	25,181	102%	106,632	561,412	151,392
East Africa	9,678	9,167	37,178	38,768	17,299	115%	104,800	478,128	84,981
Southern Africa	1,367	2,043	7,497	-	10,875	(31)%	32,406	282,275	16,960
Americas	392	567	2,093	2,372	926	126%	4,862	28,478	1,009
Asia and Eastern Europe	175	339	1,191	-	1,058	13%	3,146	29,236	831
<b>Infant Fortified Food</b>	-	-	-	-	-	-%	-	91,859	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Asia and Eastern Europe	-	-	-	-	-	-%	-	91,859	-
<b>Injectable 1</b>	<b>8,227</b>	<b>10,335</b>	<b>39,233</b>	<b>54,269</b>	<b>37,229</b>	<b>5%</b>	<b>116,015</b>	<b>3,452,836</b>	<b>576</b>
West and Central Africa	-	-	-	-	-	-%	-	224,928	-
Americas	179	3,286	10,038	54,269	13,292	(24)%	30,791	350,765	72
Asia and Eastern Europe	8,048	7,049	29,195	-	23,937	22%	85,224	2,877,143	504
<b>Injectable 1 Provided</b>	<b>4,615</b>	<b>4,702</b>	<b>18,722</b>	<b>42</b>	<b>14,685</b>	<b>27%</b>	<b>41,833</b>	<b>91,290</b>	<b>312</b>
Southern Africa	47	26	124	-	-	-%	135	259	5
Americas	1,416	992	4,393	42	3,822	15%	11,222	21,670	35
Asia and Eastern Europe	3,152	3,684	14,205	-	10,863	31%	30,476	69,361	272
<b>Injectable 2</b>	<b>34,294</b>	<b>137,989</b>	<b>448,262</b>	<b>1,045,150</b>	<b>415,762</b>	<b>8%</b>	<b>1,838,773</b>	<b>22,287,803</b>	<b>35,883</b>
West and Central Africa	36,342	94,018	318,396	1,045,150	321,716	(1)%	1,538,928	15,482,155	31,404
Americas	-	-	-	-	(7)	-%	(7)	22	-
Asia and Eastern Europe	(2,048)	43,971	129,866	-	94,053	38%	299,852	6,805,626	4,480
<b>Injectable 2 Provided</b>	<b>3,377</b>	<b>3,820</b>	<b>14,837</b>	<b>-</b>	<b>14,234</b>	<b>4%</b>	<b>40,856</b>	<b>86,770</b>	<b>659</b>
West and Central Africa	834	1,059	4,012	-	2,984	34%	10,433	14,445	283
Southern Africa	-	32	97	-	-	-%	686	783	7
Americas	495	460	1,874	-	3,383	(45)%	6,869	16,557	30
Asia and Eastern Europe	2,048	2,269	8,854	-	7,867	13%	22,868	54,985	339
<b>Injectable 3</b>	<b>474,619</b>	<b>1,080,019</b>	<b>3,714,677</b>	<b>4,204,067</b>	<b>2,103,028</b>	<b>77%</b>	<b>6,467,982</b>	<b>83,101,863</b>	<b>304,814</b>
West and Central Africa	132,515	524,563	1,706,203	2,252,284	535,088	219%	1,814,801	26,855,699	147,511
East Africa	61,166	284,049	913,314	1,894,283	283,602	222%	857,441	14,133,828	97,824
Southern Africa	139,065	146,546	578,704	-	810,100	(29)%	2,197,761	18,699,513	39,987
Americas	(4)	-	(4)	57,500	(407)	-%	(414)	3,366,882	-
Asia and Eastern Europe	141,877	124,861	516,460	-	474,645	9%	1,598,393	20,045,941	19,491
<b>Injectable 3 Provided</b>	<b>73,578</b>	<b>72,792</b>	<b>291,955</b>	<b>182,898</b>	<b>80,633</b>	<b>262%</b>	<b>364,902</b>	<b>887,044</b>	<b>23,451</b>
West and Central Africa	2,533	2,250	9,282	27,082	6,194	50%	16,028	38,741	1,379
East Africa	14,323	15,838	61,836	155,758	15,755	292%	62,588	156,592	6,411
Southern Africa	17,656	20,570	79,366	-	41,039	93%	209,517	423,807	8,250

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	5,815	3,978	17,748	58	9,495	87%	37,200	83,541	427
Asia and Eastern Europe	33,251	30,157	123,723	-	8,150	1,418%	39,569	184,363	6,984
<b>IPTp2</b>	<b>320</b>	<b>6,070</b>	<b>18,530</b>	<b>836,961</b>	<b>5,302</b>	<b>249%</b>	<b>177,461</b>	<b>224,985</b>	<b>1,078</b>
West and Central Africa	8	13	46	836,961	-	-%	-	46	3
East Africa	312	554	1,974	-	5,302	(63)%	19,006	49,974	97
Southern Africa	-	5,503	16,510	-	-	-%	158,455	174,965	978
<b>Iron Folic Acid Tablet</b>	<b>-</b>	<b>1,200</b>	<b>3,600</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>9,088</b>	<b>48,246,658</b>	<b>-</b>
West and Central Africa	-	1,200	3,600	-	-	-%	14,500	18,100	-
Asia and Eastern Europe	-	-	-	-	-	-%	(5,412)	48,228,558	-
<b>ITN</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>19,397,605</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	891,146	-
East Africa	-	-	-	-	-	-%	-	17,134,604	-
Southern Africa	-	-	-	-	-	-%	-	1,341,567	-
Americas	-	-	-	-	-	-%	-	30,288	-
<b>UD 10</b>	<b>22,176</b>	<b>28,032</b>	<b>106,272</b>	<b>80,433</b>	<b>122,474</b>	<b>(13)%</b>	<b>275,238</b>	<b>2,522,166</b>	<b>212,355</b>
West and Central Africa	3,775	4,870	18,385	95,321	20,977	(12)%	112,075	1,587,521	64,847
East Africa	1,625	8,326	26,604	(17,071)	43,039	(38)%	(6,010)	272,541	72,141
Southern Africa	(388)	(95)	(673)	-	(40)	-%	3,287	24,878	(2,226)
Americas	368	(114)	26	2,183	1,964	(99)%	4,625	203,226	(190)
Asia and Eastern Europe	16,796	15,045	61,930	-	56,534	10%	161,261	434,000	77,783
<b>UD 10 Insertion</b>	<b>43,587</b>	<b>43,748</b>	<b>174,830</b>	<b>325,291</b>	<b>76,921</b>	<b>127%</b>	<b>404,855</b>	<b>2,226,950</b>	<b>437,540</b>
West and Central Africa	8,716	10,207	39,337	57,282	30,590	29%	117,595	580,905	153,787
East Africa	16,613	15,929	64,401	242,836	27,471	134%	195,352	852,506	191,367
Southern Africa	2,106	1,785	7,462	-	6,249	19%	25,159	267,907	16,095
Americas	940	1,780	6,279	25,173	4,512	39%	18,956	173,535	3,434
Asia and Eastern Europe	15,212	14,046	57,351	-	8,099	608%	47,793	352,097	72,858
<b>UD 5</b>	<b>25,069</b>	<b>20,300</b>	<b>85,968</b>	<b>50</b>	<b>6,421</b>	<b>1,239%</b>	<b>35,316</b>	<b>4,217,359</b>	<b>70,999</b>
West and Central Africa	-	-	-	-	-	-%	-	3,726	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
East Africa	(50)	(33)	(148)	-	90	(264)%	477	13,976	(330)
Southern Africa	-	-	-	-	-	-%	-	937	-
Americas	3	24	75	50	-	-%	587	662	28
Asia and Eastern Europe	25,116	20,308	86,041	-	6,331	1,259%	34,252	4,198,058	71,301
<b>IUD 5 Insertion</b>	<b>18,916</b>	<b>16,826</b>	<b>69,393</b>	<b>800</b>	<b>74,233</b>	<b>(7)%</b>	<b>203,272</b>	<b>935,386</b>	<b>71,654</b>
West and Central Africa	7	-	7	-	-	-%	-	52	12
East Africa	50	33	149	-	168	(11)%	691	27,892	369
Southern Africa	-	-	-	-	-	-%	241	3,162	-
Americas	-	-	-	800	-	-%	154	154	-
Asia and Eastern Europe	18,859	16,793	69,237	-	74,065	(7)%	202,186	904,126	71,273
<b>IUS 5</b>	<b>(38)</b>	<b>-</b>	<b>(38)</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>(38)</b>	<b>(46)</b>
Southern Africa	(38)	-	(38)	-	-	-%	-	(38)	(46)
<b>IUS 5 Insertion</b>	<b>38</b>	<b>-</b>	<b>38</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>38</b>	<b>52</b>
Southern Africa	38	-	38	-	-	-%	-	38	52
<b>LifeStraw</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>15,965</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	645	-
East Africa	-	-	-	-	-	-%	-	15,320	-
<b>LLIN</b>	<b>831,434</b>	<b>1,268,687</b>	<b>4,637,494</b>	<b>20,701,042</b>	<b>8,352,554</b>	<b>(44)%</b>	<b>42,829,969</b>	<b>307,190,958</b>	<b>1,079,686</b>
West and Central Africa	100,703	526,999	1,681,700	12,347,682	5,697,137	(70)%	30,675,129	142,354,033	654,024
East Africa	362,184	603,261	2,171,967	7,978,360	1,939,975	12%	9,344,931	89,929,171	379,335
Southern Africa	368,547	138,427	783,827	-	715,442	10%	2,787,629	65,712,997	46,327
Americas	-	-	-	375,000	-	-%	-	3,396,535	-
Other Africa	-	-	-	-	-	-%	-	22,408	-
Asia and Eastern Europe	-	-	-	-	-	-%	22,280	5,775,814	-
<b>Lubricant</b>	<b>383,452</b>	<b>741,439</b>	<b>2,607,770</b>	<b>-</b>	<b>1,035,087</b>	<b>152%</b>	<b>3,223,877</b>	<b>64,120,809</b>	<b>-</b>
West and Central Africa	7,946	417,544	1,260,577	-	84,017	1,400%	349,026	3,616,539	-
East Africa	193,226	71,336	407,235	-	28,510	1,328%	538,215	1,904,947	-
Southern Africa	54,038	102,199	360,635	-	251,972	43%	621,962	4,676,017	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	77,136	70,525	288,712	-	400,531	(28)%	1,002,585	6,720,185	-
Asia and Eastern Europe	51,106	79,835	290,611	-	270,057	8%	712,089	47,203,121	-
<b>Malaria PPT (ACT)</b>	<b>1,509,286</b>	<b>1,200,854</b>	<b>5,111,848</b>	<b>7,407,536</b>	<b>7,304,566</b>	<b>(30)%</b>	<b>17,642,023</b>	<b>117,425,955</b>	<b>1,652,712</b>
West and Central Africa	1,224,799	741,114	3,448,141	4,289,752	5,528,466	(38)%	12,109,484	79,227,088	1,166,013
East Africa	256,728	350,778	1,309,061	3,117,784	1,637,413	(20)%	4,074,406	25,825,286	403,157
Southern Africa	1,400	78,384	236,552	-	11,558	1,947%	991,622	7,154,872	67,257
Asia and Eastern Europe	26,359	30,578	118,094	-	127,129	(7)%	466,511	5,218,709	16,285
<b>Malaria PPT (Non-ACT)</b>	<b>132</b>	<b>128</b>	<b>515</b>	<b>11,000</b>	<b>2,587</b>	<b>(80)%</b>	<b>3,078</b>	<b>13,895,583</b>	<b>72</b>
West and Central Africa	-	-	-	-	-	-%	-	5,009,188	-
Southern Africa	-	-	-	-	-	-%	-	8,462,175	-
Americas	-	-	-	11,000	-	-%	-	318,740	-
Asia and Eastern Europe	132	128	515	-	2,587	(80)%	3,078	105,480	72
<b>Malaria RDK</b>	<b>2,103,711</b>	<b>441,294</b>	<b>3,427,593</b>	<b>9,409,403</b>	<b>4,362,895</b>	<b>(21)%</b>	<b>12,864,534</b>	<b>41,527,074</b>	<b>-</b>
West and Central Africa	197,400	299,401	1,095,602	7,528,315	3,338,109	(67)%	8,902,668	18,035,713	-
East Africa	43,400	-	43,400	1,881,088	42,659	2%	1,596,819	4,238,318	-
Southern Africa	1,758,311	55,047	1,923,451	-	660,730	191%	1,133,756	9,978,576	-
Americas	-	-	-	-	-	-%	-	190	-
Asia and Eastern Europe	104,600	86,847	365,140	-	321,397	14%	1,231,291	9,274,277	-
<b>Male Circumcision (HIV-Positive)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,037</b>	<b>(100)%</b>	<b>3,526</b>	<b>10,836</b>	<b>-</b>
East Africa	-	-	-	-	57	(100)%	287	614	-
Southern Africa	-	-	-	-	980	(100)%	3,239	10,222	-
<b>Manual Vacuum Aspiration for PA</b>	<b>3,312</b>	<b>4,120</b>	<b>15,672</b>	<b>2,939</b>	<b>305</b>	<b>5,038%</b>	<b>46,635</b>	<b>62,378</b>	<b>1,483</b>
West and Central Africa	270	267	1,072	1,909	85	1,161%	7,369	8,512	521
East Africa	83	195	668	250	220	204%	1,253	1,921	138
Southern Africa	163	200	764	-	-	-%	1,457	2,221	229
Americas	352	795	2,736	780	-	-%	5,421	8,157	61
Asia and Eastern Europe	2,444	2,663	10,432	-	-	-%	31,135	41,567	535
<b>Manual Vacuum Aspiration for SA</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>3,249</b>	<b>-</b>

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	-	-%	-	-	-
East Africa	-	-	-	-	-	-%	-	-	-
Southern Africa	-	-	-	-	-	-%	-	-	-
Americas	-	-	-	-	-	-%	-	-	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	3,249	-
<b>Medical Abortion</b>	<b>55,351</b>	<b>59,558</b>	<b>234,026</b>	<b>25,000</b>	<b>160,548</b>	<b>46%</b>	<b>390,819</b>	<b>3,176,585</b>	<b>21,032</b>
West and Central Africa	-	-	-	-	-	-%	(105)	(105)	-
East Africa	-	-	-	25,000	-	-%	-	-	-
Southern Africa	-	-	-	-	-	-%	-	10,451	-
Asia and Eastern Europe	55,351	59,558	234,026	-	160,548	46%	390,924	3,166,239	21,032
<b>Medical Abortion Provided</b>	<b>403</b>	<b>659</b>	<b>2,381</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>105</b>	<b>2,486</b>	<b>203</b>
West and Central Africa	-	-	-	-	-	-%	105	105	-
Asia and Eastern Europe	403	659	2,381	-	-	-%	-	2,381	203
<b>Micronutrient Powder</b>	<b>1,110,161</b>	<b>755,387</b>	<b>3,376,321</b>	<b>1,813,790</b>	<b>1,137,180</b>	<b>197%</b>	<b>4,607,780</b>	<b>28,914,881</b>	<b>-</b>
West and Central Africa	132,141	65,010	327,171	1,713,790	-	-%	85,400	412,571	-
East Africa	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-
Southern Africa	913,950	543,613	2,544,790	-	1,113,220	129%	4,024,990	14,340,100	-
Americas	-	-	-	-	20,460	(100)%	395,910	3,365,323	-
Asia and Eastern Europe	64,070	146,763	504,360	-	-	-%	97,980	9,558,832	-
<b>Misoprostol for PAC (Oral)</b>	<b>30,758</b>	<b>135,731</b>	<b>437,952</b>	<b>1,775,906</b>	<b>582,892</b>	<b>(25)%</b>	<b>2,011,632</b>	<b>6,398,633</b>	<b>22,292</b>
West and Central Africa	22,262	21,750	87,512	906,686	229,140	(62)%	626,258	1,739,485	10,300
East Africa	8,272	106,640	328,191	750,300	350,952	(6)%	1,265,369	4,355,984	11,723
Southern Africa	(864)	(112)	(1,200)	-	-	-%	(6,537)	(7,737)	(108)
Americas	1,088	787	3,449	118,920	300	1,050%	2,042	21,001	29
Asia and Eastern Europe	-	6,667	20,000	-	2,500	700%	124,500	289,900	347
<b>Misoprostol for PAC (oral) Provid</b>	<b>3,507</b>	<b>3,655</b>	<b>14,472</b>	<b>10,720</b>	<b>-</b>	<b>-%</b>	<b>9,129</b>	<b>23,601</b>	<b>1,737</b>
West and Central Africa	2,040	1,934	7,842	10,120	-	-%	2,427	10,269	1,437
East Africa	42	467	1,443	-	-	-%	129	1,572	150



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	864	112	1,200	-	-	-%	6,537	7,737	120
Americas	561	1,142	3,987	600	-	-%	36	4,023	31
<b>Misoprostol for PAC (Sublingual)</b>	<b>30</b>	<b>63</b>	<b>218</b>	<b>2,480,200</b>	<b>-</b>	<b>-%</b>	<b>6,156</b>	<b>6,374</b>	<b>58</b>
East Africa	30	63	218	2,480,200	-	-%	156	374	58
Southern Africa	-	-	-	-	-	-%	6,000	6,000	-
<b>Misoprostol for PAC (sublingual)</b>	<b>6</b>	<b>11</b>	<b>38</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>38</b>	<b>11</b>
East Africa	6	11	38	-	-	-%	-	38	11
<b>Misoprostol for PPH</b>	<b>76,500</b>	<b>204,527</b>	<b>690,080</b>	<b>330,000</b>	<b>379,326</b>	<b>82%</b>	<b>1,714,080</b>	<b>6,915,938</b>	<b>2,393</b>
West and Central Africa	-	-	-	300,000	-	-%	-	373,010	-
East Africa	76,500	204,233	689,200	30,000	379,250	82%	1,634,400	5,651,939	2,391
Southern Africa	-	-	-	-	-	-%	-	684,608	-
Americas	-	293	880	-	76	1,058%	79,680	184,166	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	22,215	-
<b>Multivitamin</b>	<b>-</b>	<b>70,850</b>	<b>212,550</b>	<b>2,476,080</b>	<b>644,400</b>	<b>(67)%</b>	<b>1,789,770</b>	<b>93,514,639</b>	<b>16</b>
West and Central Africa	-	-	-	-	-	-%	-	15,761,378	-
Southern Africa	-	-	-	-	-	-%	-	12,270,645	-
Americas	-	70,850	212,550	2,476,080	644,400	(67)%	1,789,770	51,972,571	16
Asia and Eastern Europe	-	-	-	-	-	-%	-	13,510,045	-
<b>Naloxone</b>	<b>60</b>	<b>-</b>	<b>60</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>62,230</b>	<b>82</b>
Asia and Eastern Europe	60	-	60	-	-	-%	-	62,230	82
<b>Needle &amp; Syringe</b>	<b>486,000</b>	<b>602,970</b>	<b>2,294,911</b>	<b>-</b>	<b>1,240,200</b>	<b>85%</b>	<b>4,903,605</b>	<b>21,932,559</b>	<b>17,706</b>
Americas	-	-	-	-	-	-%	-	1,540,000	-
Asia and Eastern Europe	486,000	602,970	2,294,911	-	1,240,200	85%	4,903,605	20,392,559	17,706
<b>NVP</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>11,442</b>	<b>-</b>
East Africa	-	-	-	-	-	-%	-	235	-
Southern Africa	-	-	-	-	-	-%	-	11,057	-
Americas	-	-	-	-	-	-%	-	150	-
<b>OCs</b>	<b>3,134,856</b>	<b>2,582,365</b>	<b>10,881,952</b>	<b>18,883,554</b>	<b>7,424,643</b>	<b>47%</b>	<b>29,961,954</b>	<b>586,635,764</b>	<b>214,623</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	349,527	729,258	2,537,301	11,612,236	2,623,288	(3)%	9,528,389	161,934,783	88,691
East Africa	1,470,799	341,995	2,496,783	6,170,698	1,397,826	79%	7,878,628	72,843,274	64,764
Southern Africa	214,194	286,415	1,073,440	-	1,016,186	6%	2,534,347	69,696,541	20,368
Americas	7,371	37,708	120,496	1,100,620	340,548	(65)%	901,873	34,972,928	557
Asia and Eastern Europe	1,092,965	1,186,989	4,653,932	-	2,046,795	127%	9,118,717	247,188,238	40,244
<b>OCs Provided</b>	<b>118,713</b>	<b>107,064</b>	<b>439,904</b>	<b>54,384</b>	<b>230,479</b>	<b>91%</b>	<b>757,658</b>	<b>1,807,307</b>	<b>9,245</b>
West and Central Africa	6,140	7,263	27,928	15,000	3,015	826%	28,690	81,055	1,156
East Africa	4,078	5,155	19,543	39,344	9,418	108%	58,379	107,800	589
Southern Africa	28,780	35,687	135,842	-	191,526	(29)%	566,148	1,181,381	3,604
Americas	1,355	1,064	4,546	40	4,229	7%	12,463	34,666	30
Asia and Eastern Europe	78,360	57,895	252,045	-	22,291	1,031%	91,978	402,405	3,867
<b>ORS</b>	<b>4,093</b>	<b>229,865</b>	<b>693,687</b>	<b>1,418,576</b>	<b>837,005</b>	<b>(17)%</b>	<b>1,692,324</b>	<b>435,278,835</b>	<b>23,531</b>
West and Central Africa	-	89,302	267,906	1,965	56,891	371%	70,974	64,179,790	10,440
East Africa	(90,632)	40,796	31,756	1,086,611	432,264	(93)%	752,366	24,045,619	1,045
Southern Africa	-	-	-	-	-	-%	-	1,999,000	-
Americas	150,000	50,000	300,000	330,000	-	-%	300,000	10,047,338	10,285
Other Africa	-	-	-	-	-	-%	-	6,127,779	-
Asia and Eastern Europe	(55,275)	49,767	94,025	-	347,850	(73)%	568,984	328,879,309	1,762
<b>ORS Provided</b>	<b>121,954</b>	<b>-</b>	<b>121,954</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>5,546</b>	<b>127,500</b>	<b>4,427</b>
East Africa	121,954	-	121,954	-	-	-%	5,546	127,500	4,427
<b>Pneumonia PPT</b>	<b>18,239</b>	<b>35,493</b>	<b>124,718</b>	<b>970,330</b>	<b>240,231</b>	<b>(48)%</b>	<b>827,943</b>	<b>5,788,684</b>	<b>32,060</b>
West and Central Africa	14,640	-	14,640	60,000	29,898	(51)%	57,518	807,555	10,029
East Africa	(64,604)	9,552	(35,948)	910,330	69,750	(152)%	266,190	2,113,759	(31,558)
Southern Africa	68,203	25,941	146,026	-	84,386	73%	376,369	1,333,124	53,589
Asia and Eastern Europe	-	-	-	-	56,197	(100)%	127,866	1,534,246	-
<b>Pneumonia PPT Provided</b>	<b>89,387</b>	<b>-</b>	<b>89,387</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>22,354</b>	<b>111,741</b>	<b>84,291</b>
West and Central Africa	-	-	-	-	-	-%	2,500	2,500	-
East Africa	89,387	-	89,387	-	-	-%	19,854	109,241	84,291

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Positive RDTs</b>	2,463	41,308	126,388	-	-	-%	2,068,034	2,194,422	-
West and Central Africa	-	-	-	-	-	-%	2,047,931	2,047,931	-
East Africa	-	37	110	-	-	-%	3,656	3,766	-
Southern Africa	775	32,596	98,562	-	-	-%	2,177	100,739	-
Americas	1,246	7,863	24,834	-	-	-%	1,069	25,903	-
Asia and Eastern Europe	442	813	2,882	-	-	-%	13,201	16,083	-
<b>Positive RDTs Given First Line Tr</b>	428	610	2,259	-	-	-%	2,062,102	2,064,361	-
West and Central Africa	-	-	-	-	-	-%	2,047,743	2,047,743	-
East Africa	-	37	110	-	-	-%	3,489	3,599	-
Asia and Eastern Europe	428	574	2,149	-	-	-%	10,870	13,019	-
<b>Pregnancy Test</b>	-	-	-	-	-	-%	-	930,449	-
West and Central Africa	-	-	-	-	-	-%	-	5,685	-
Americas	-	-	-	-	-	-%	-	129,873	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	794,891	-
<b>PrEP</b>	231	207	852	-	-	-%	403	1,255	28
Southern Africa	231	207	852	-	-	-%	403	1,255	28
<b>PUR</b>	6,174,902	5,427,025	22,455,978	53,861,647	13,940,204	61%	73,371,542	509,554,767	863
West and Central Africa	220,566	169,440	728,886	4,792,000	707,644	3%	5,988,604	44,588,531	67
East Africa	5,949,649	5,234,426	21,652,927	49,069,647	12,912,601	68%	65,302,222	380,699,997	795
Southern Africa	-	-	-	-	-	-%	-	4,694,784	-
Americas	-	-	-	-	-	-%	-	21,231,358	-
Asia and Eastern Europe	4,687	23,159	74,165	-	319,959	(77)%	2,080,716	58,340,097	2
<b>QAACts Provided after Confirma</b>	191	529	1,778	-	-	-%	2,046,155	2,047,933	292
West and Central Africa	-	-	-	-	-	-%	2,034,979	2,034,979	-
East Africa	-	37	110	-	-	-%	3,815	3,925	18
Asia and Eastern Europe	191	492	1,668	-	-	-%	7,361	9,029	274
<b>Referral to Advanced Cervical Cai</b>	2	6	19	-	66	(71)%	142	362	-
Southern Africa	2	6	19	-	66	(71)%	142	362	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Referral to CD4/Clinical Staging</b>	-	-	-	2,596	3,502	(100)%	10,820	34,138	-
West and Central Africa	-	-	-	553	-	-%	-	18	-
East Africa	-	-	-	2,043	950	(100)%	2,210	3,364	-
Southern Africa	-	-	-	-	2,552	(100)%	8,610	30,613	-
Americas	-	-	-	-	-	-%	-	143	-
<b>Referral to Clinical Staging</b>	-	-	-	-	795	(100)%	2,986	18,909	-
East Africa	-	-	-	-	77	(100)%	107	1,893	-
Southern Africa	-	-	-	-	718	(100)%	2,879	17,016	-
<b>Referral to Early Infant Male Circu</b>	-	-	-	-	28	(100)%	36	94	-
Southern Africa	-	-	-	-	28	(100)%	36	94	-
<b>Referral to Emergency Contracep</b>	-	2	5	-	14	(64)%	43	141	-
East Africa	-	2	5	-	14	(64)%	37	133	-
Southern Africa	-	-	-	-	-	-%	6	8	-
<b>Referral to HIV Testing Services</b>	3,040	3,375	13,165	173,445	15,539	(15)%	36,096	254,461	222
West and Central Africa	-	-	-	60,035	5,372	(100)%	5,682	66,105	-
East Africa	386	1,298	4,281	113,410	7,360	(42)%	12,052	122,326	11
Southern Africa	1,880	664	3,872	-	2,807	38%	7,911	30,555	203
Americas	-	-	-	-	-	-%	27	577	-
Asia and Eastern Europe	774	1,413	5,012	-	-	-%	10,424	34,898	7
<b>Referral to Hypertension Manager</b>	5	2	12	-	-	-%	27	39	-
Southern Africa	5	2	12	-	-	-%	27	39	-
<b>Referral to Implant 3 Insertion</b>	-	5	16	8,500	183	(91)%	1,223	16,099	12
West and Central Africa	-	-	-	-	-	-%	-	4,343	-
East Africa	-	5	16	8,500	183	(91)%	586	7,937	12
Southern Africa	-	-	-	-	-	-%	1	1,507	-
Americas	-	-	-	-	-	-%	-	974	-
Asia and Eastern Europe	-	-	-	-	-	-%	636	1,338	-
<b>Referral to Implant 5 Insertion</b>	16	26	95	1,500	62	53%	1,831	19,317	51

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
West and Central Africa	-	-	-	-	-	-%	-	12,941	-
East Africa	-	8	23	1,500	18	28%	1,717	3,702	26
Southern Africa	-	-	-	-	-	-%	-	1,748	-
Americas	-	-	-	-	-	-%	-	260	-
Asia and Eastern Europe	16	19	72	-	44	64%	114	666	25
<b>Referral to Implant Insertion (dura</b>	-	-	-	-	-	-%	-	89	-
East Africa	-	-	-	-	-	-%	-	89	-
<b>Referral to Injectable (duration un</b>	-	-	-	-	-	-%	-	773	-
Southern Africa	-	-	-	-	-	-%	-	110	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	663	-
<b>Referral to Injectable 1</b>	9	-	9	-	-	-%	32	41	-
Southern Africa	9	-	9	-	-	-%	32	41	-
<b>Referral to Injectable 2</b>	-	-	-	-	-	-%	-	1	-
Southern Africa	-	-	-	-	-	-%	-	1	-
<b>Referral to Injectable 3</b>	73	25	147	10,000	591	(75)%	13,305	21,975	6
East Africa	-	11	34	10,000	494	(93)%	12,012	13,710	2
Southern Africa	56	1	59	-	-	-%	45	836	3
Asia and Eastern Europe	17	12	54	-	97	(44)%	1,248	7,429	1
<b>Referral to IUD 10 Insertion</b>	54	68	258	11,200	431	(40)%	2,382	131,882	124
West and Central Africa	-	-	-	-	-	-%	22	20,803	-
East Africa	-	-	-	11,200	6	(100)%	343	24,155	-
Southern Africa	8	6	27	-	2	1,250%	7	14,749	25
Americas	-	-	-	-	-	-%	-	52,430	-
Asia and Eastern Europe	46	62	231	-	423	(45)%	2,010	19,745	99
<b>Referral to IUD 5 Insertion</b>	-	-	-	-	9	(100)%	9	498	-
East Africa	-	-	-	-	9	(100)%	9	49	-
Southern Africa	-	-	-	-	-	-%	-	9	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	440	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Referral to IUD Insertion (duration)</b>	-	-	-	-	-	-%	2	11	-
East Africa	-	-	-	-	-	-%	-	9	-
Southern Africa	-	-	-	-	-	-%	2	2	-
<b>Referral to Linkage to HIV Care</b>	1,349	2,023	7,419	460	-	-%	4,072	11,491	4,692
West and Central Africa	-	-	-	460	-	-%	281	281	-
East Africa	-	55	166	-	-	-%	-	166	84
Southern Africa	1,177	1,721	6,341	-	-	-%	2,624	8,965	3,774
Americas	-	-	-	-	-	-%	333	333	-
Asia and Eastern Europe	172	247	912	-	-	-%	834	1,746	833
<b>Referral to Manual Vacuum Aspir:</b>	-	-	-	-	-	-%	46	46	-
Asia and Eastern Europe	-	-	-	-	-	-%	46	46	-
<b>Referral to Medication Abortion</b>	-	-	-	-	-	-%	24	24	-
Asia and Eastern Europe	-	-	-	-	-	-%	24	24	-
<b>Referral to OCs</b>	39	30	130	1,500	189	(31)%	3,408	8,693	1
East Africa	-	2	7	1,500	148	(95)%	2,049	2,725	-
Southern Africa	31	16	78	-	1	7,700%	79	1,004	1
Asia and Eastern Europe	8	12	45	-	40	13%	1,280	4,964	-
<b>Referral to Opioid Treatment</b>	13	17	63	-	-	-%	136	199	-
Asia and Eastern Europe	13	17	63	-	-	-%	136	199	-
<b>Referral to PAC Service (unknowr</b>	-	-	-	-	-	-%	488	488	-
Asia and Eastern Europe	-	-	-	-	-	-%	488	488	-
<b>Referral to Pre-Exposure Prophyl:</b>	34	18	87	-	-	-%	-	87	1
Southern Africa	34	18	87	-	-	-%	-	87	1
<b>Referral to STI Diagnosis (lab con</b>	13	106	332	-	-	-%	-	332	-
East Africa	13	106	332	-	-	-%	-	332	-
<b>Referral to STI Screening (syndro</b>	561	1,322	4,526	-	-	-%	8	4,534	-
East Africa	554	1,312	4,491	-	-	-%	-	4,491	-
Southern Africa	7	9	35	-	-	-%	8	43	-

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Referral to STI Treatment (unknov</b>	7	5	22	142,281	513	(96)%	957	8,859	-
East Africa	-	-	-	142,281	5	(100)%	5	915	-
Southern Africa	7	5	22	-	508	(96)%	952	5,614	-
Americas	-	-	-	-	-	-%	-	4	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,326	-
<b>Referral to TB Diagnosis</b>	560	411	1,794	-	-	-%	1,446	29,104	-
East Africa	141	72	356	-	-	-%	-	8,054	-
Southern Africa	6	23	74	-	-	-%	11	7,537	-
Asia and Eastern Europe	413	317	1,364	-	-	-%	1,435	13,513	-
<b>Referral to TB DOTS (completion</b>	196	78	431	-	-	-%	773	1,488	722
Southern Africa	-	-	1	-	-	-%	2	17	1
Asia and Eastern Europe	196	78	430	-	-	-%	771	1,471	721
<b>Referral to TB DOTS (completion</b>	339	260	1,119	-	239	368%	1,778	6,638	1,632
East Africa	-	-	-	-	26	(100)%	26	1,617	-
Southern Africa	12	16	59	-	213	(72)%	484	2,512	33
Asia and Eastern Europe	327	244	1,060	-	-	-%	1,268	2,509	1,600
<b>Referral to TB Screening</b>	13,190	9,857	42,762	-	-	-%	35,695	78,457	-
East Africa	634	1,578	5,369	-	-	-%	-	5,369	-
Southern Africa	297	2,638	8,212	-	-	-%	434	8,646	-
Asia and Eastern Europe	12,259	5,641	29,181	-	-	-%	35,261	64,442	-
<b>Referral to Treatment for Cerviciti</b>	-	-	-	-	4	(100)%	4	26	-
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	-	-	-	-	4	(100)%	4	23	-
<b>Referral to Treatment for Genital I</b>	-	-	-	-	-	-%	3	6	-
East Africa	-	-	-	-	-	-%	-	3	-
Southern Africa	-	-	-	-	-	-%	3	3	-
<b>Referral to Treatment for Inguinal</b>	-	9	28	-	-	-%	-	133	-
East Africa	-	9	28	-	-	-%	-	133	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Referral to Treatment for Lower A</b>	-	10	29	-	5	480%	13	125	-
East Africa	-	9	27	-	5	440%	5	100	-
Southern Africa	-	1	2	-	-	-%	8	25	-
<b>Referral to Treatment for Urethral</b>	-	25	74	-	7	957%	32	2,545	-
East Africa	-	25	74	-	-	-%	-	2,489	-
Southern Africa	-	-	-	-	7	(100)%	32	56	-
<b>Referral to Treatment for Vaginitis</b>	-	27	80	-	137	(42)%	143	7,130	1
East Africa	-	27	80	-	136	(41)%	136	7,118	1
Southern Africa	-	-	-	-	1	(100)%	7	12	-
<b>Referral to Tubal Ligation</b>	-	-	1	-	3	(67)%	3	65	2
East Africa	-	-	-	-	3	(100)%	3	3	-
Southern Africa	-	-	1	-	-	-%	-	1	2
Asia and Eastern Europe	-	-	-	-	-	-%	-	61	-
<b>Referral to Tx for Nonherpetic Gei</b>	-	11	32	-	22	45%	35	1,041	2
East Africa	-	11	32	-	22	45%	22	1,019	2
Southern Africa	-	-	-	-	-	-%	13	22	-
<b>Referral to Tx for Urethral Discha</b>	10	17	60	-	138	(57)%	222	2,380	6
East Africa	-	-	-	-	66	(100)%	66	1,921	-
Southern Africa	10	17	60	-	72	(17)%	156	459	6
<b>Referral to Vasectomy</b>	-	-	-	-	-	-%	-	2	-
Southern Africa	-	-	-	-	-	-%	-	2	-
<b>Referral to Voluntary Medical Mal</b>	47	62	233	-	2,044	(89)%	3,891	20,359	1,160
East Africa	-	-	-	-	-	-%	42	42	-
Southern Africa	47	62	233	-	2,044	(89)%	3,849	20,317	1,160
<b>Retreatment</b>	-	-	-	-	-	-%	-	46,984,114	-
West and Central Africa	-	-	-	-	-	-%	-	1,638,283	-
East Africa	-	-	-	-	-	-%	-	40,242,797	-
Southern Africa	-	-	-	-	-	-%	-	543,345	-



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	-	-	-	-	-	-%	-	111,568	-
Other Africa	-	-	-	-	-	-%	-	26,407	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	4,421,714	-
<b>Retreatment IconMaxx</b>	-	-	-	-	-	-%	-	4,873,846	-
East Africa	-	-	-	-	-	-%	-	2,297,300	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,576,546	-
<b>Retreatment KO123</b>	-	-	-	-	-	-%	-	9,124,110	-
West and Central Africa	-	-	-	-	-	-%	-	4,082	-
East Africa	-	-	-	-	-	-%	-	8,813,436	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	306,592	-
<b>Retreatment KO123 net</b>	-	-	-	-	-	-%	-	10,259,477	-
East Africa	-	-	-	-	-	-%	-	10,259,477	-
<b>Safe Injection Kit</b>	-	-	-	-	-	-%	-	5	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	5	-
<b>Safe Water Solution</b>	444,622	945,904	3,282,333	4,439,239	2,573,284	28%	9,075,837	153,337,942	16,233
West and Central Africa	46,315	209,772	675,631	200,000	101,092	568%	160,999	13,202,382	3,434
East Africa	131,496	335,785	1,138,852	4,239,239	887,171	28%	4,616,248	61,908,189	4,023
Southern Africa	266,811	400,346	1,467,850	-	1,580,021	(7)%	4,291,617	71,598,886	8,776
Americas	-	-	-	-	-	-%	-	449,298	-
Asia and Eastern Europe	-	-	-	-	5,000	(100)%	6,973	6,179,187	-
<b>SD NVP w/o Baby ARV Prophylax</b>	-	-	-	-	-	-%	-	271	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	271	-
<b>SD NVP with Baby ARV Prophyla</b>	-	-	-	-	-	-%	-	235	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	235	-
<b>SDM (Cycle Beads)</b>	2,810	363	3,900	18,256	10,562	(63)%	31,571	582,274	4,236
West and Central Africa	2,185	177	2,716	18,256	5,208	(48)%	20,227	361,738	3,435
East Africa	-	-	-	-	-	-%	5	8,591	-
Southern Africa	625	186	1,184	-	5,356	(78)%	11,341	209,451	802

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	-	-	-	-	(2)	-%	(2)	(2)	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	2,496	-
<b>SDM (Cycle Beads) Provided</b>	<b>583</b>	<b>785</b>	<b>2,937</b>	<b>-</b>	<b>358</b>	<b>720%</b>	<b>5,027</b>	<b>9,726</b>	<b>3,551</b>
West and Central Africa	356	568	2,061	-	343	501%	2,812	5,745	2,897
East Africa	-	-	-	-	-	-%	-	134	-
Southern Africa	225	214	866	-	-	-%	2,176	3,731	652
Americas	2	3	10	-	15	(33)%	39	116	2
<b>Skilled Birth Attendance</b>	<b>7,615</b>	<b>3,028</b>	<b>16,699</b>	<b>16,237</b>	<b>6,088</b>	<b>174%</b>	<b>28,307</b>	<b>79,282</b>	<b>6,409</b>
West and Central Africa	6,554	833	9,054	-	-	-%	-	9,054	-
East Africa	1,061	2,195	7,645	16,237	6,088	26%	28,307	70,228	6,409
<b>STI Kit</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>691,263</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	-	1,796	-
East Africa	-	-	-	-	-	-%	-	438,695	-
Asia and Eastern Europe	-	-	-	-	-	-%	-	250,772	-
<b>STI Kit (Non-Ulcerative)</b>	<b>383</b>	<b>309</b>	<b>1,309</b>	<b>9,070</b>	<b>30,544</b>	<b>(96)%</b>	<b>62,324</b>	<b>4,007,230</b>	<b>108</b>
West and Central Africa	-	-	-	-	-	-%	-	7,704	-
East Africa	320	250	1,070	9,070	7,280	(85)%	18,139	851,012	65
Southern Africa	63	59	239	-	156	53%	797	2,057,805	43
Asia and Eastern Europe	-	-	-	-	23,108	(100)%	43,388	1,090,709	-
<b>STI Kit (Ulcerative)</b>	<b>7</b>	<b>11</b>	<b>40</b>	<b>1,121</b>	<b>2,522</b>	<b>(98)%</b>	<b>7,179</b>	<b>1,853,502</b>	<b>16</b>
West and Central Africa	-	-	-	-	-	-%	-	480	-
East Africa	-	-	-	1,121	1,174	(100)%	3,373	71,528	-
Southern Africa	7	11	40	-	12	233%	127	1,721,021	16
Asia and Eastern Europe	-	-	-	-	1,336	(100)%	3,679	60,473	-
<b>STI Screening</b>	<b>32,125</b>	<b>34,948</b>	<b>136,969</b>	<b>3,000</b>	<b>166,754</b>	<b>(18)%</b>	<b>443,197</b>	<b>738,428</b>	<b>-</b>
West and Central Africa	367	574	2,090	-	2,469	(15)%	19,906	25,688	-
East Africa	5,645	11,739	40,863	3,000	77,926	(48)%	153,790	331,691	-
Southern Africa	5,995	6,096	24,283	-	11,049	120%	47,096	85,635	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Americas	17,560	13,625	58,436	-	75,310	(22)%	222,184	283,313	-
Asia and Eastern Europe	2,558	2,913	11,297	-	-	-%	221	12,101	-
<b>TB Diagnosis</b>	<b>6,478</b>	<b>5,983</b>	<b>24,427</b>	<b>-</b>	<b>9,380</b>	<b>160%</b>	<b>62,507</b>	<b>111,631</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	10,219	10,219	-
East Africa	-	-	-	-	-	-%	-	615	-
Southern Africa	30	31	123	-	121	2%	336	858	-
Americas	-	1,135	3,405	-	-	-%	11,406	14,811	-
Asia and Eastern Europe	6,448	4,817	20,899	-	9,259	126%	40,546	85,128	-
<b>TB DOTS</b>	<b>3,350</b>	<b>3,335</b>	<b>13,354</b>	<b>10,000</b>	<b>7,561</b>	<b>77%</b>	<b>39,561</b>	<b>291,189</b>	<b>62,391</b>
West and Central Africa	-	-	-	-	-	-%	5,763	5,763	-
Southern Africa	-	1	2	-	3	(33)%	11	44	16
Americas	-	1,037	3,110	10,000	-	-%	9,997	13,107	10,645
Asia and Eastern Europe	3,350	2,297	10,242	-	7,558	36%	23,790	272,275	51,730
<b>TB Screening</b>	<b>48,624</b>	<b>60,128</b>	<b>229,009</b>	<b>-</b>	<b>198,297</b>	<b>15%</b>	<b>556,967</b>	<b>1,307,070</b>	<b>-</b>
West and Central Africa	-	-	-	-	-	-%	7,139	7,139	-
East Africa	4,840	10,579	36,578	-	75,688	(52)%	143,594	388,187	-
Southern Africa	22,321	30,016	112,368	-	104,913	7%	284,453	645,172	-
Americas	-	1,188	3,564	-	-	-%	12,026	15,590	-
Asia and Eastern Europe	21,463	18,345	76,499	-	17,696	332%	109,755	250,982	-
<b>Toilets Constructed</b>	<b>571</b>	<b>4,799</b>	<b>14,969</b>	<b>3,000</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>14,969</b>	<b>2,298</b>
West and Central Africa	571	532	2,167	3,000	-	-%	-	2,167	579
Asia and Eastern Europe	-	4,267	12,802	-	-	-%	-	12,802	1,719
<b>Toilets Sold</b>	<b>40,865</b>	<b>15,795</b>	<b>88,249</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>75,880</b>	<b>164,129</b>	<b>-</b>
West and Central Africa	571	530	2,162	-	-	-%	2,598	4,760	-
Asia and Eastern Europe	40,294	15,264	86,087	-	-	-%	73,282	159,369	-
<b>Treatment for Cervicitis</b>	<b>27</b>	<b>49</b>	<b>175</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>20</b>	<b>195</b>	<b>16</b>
East Africa	-	2	5	-	-	-%	-	5	-
Southern Africa	27	48	170	-	-	-%	20	190	16

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
<b>Treatment for Genital Herpes</b>	7	9	33	300	-	-%	7	40	1
East Africa	-	-	-	300	-	-%	2	2	-
Southern Africa	7	9	33	-	-	-%	5	38	1
<b>Treatment for Inguinal Bubo</b>	15	12	51	-	-	-%	8	59	-
East Africa	6	-	7	-	-	-%	-	7	-
Southern Africa	9	12	44	-	-	-%	8	52	-
<b>Treatment for Lower Abdominal P</b>	141	140	562	400	-	-%	106	668	-
East Africa	23	16	70	400	-	-%	4	74	-
Southern Africa	118	125	492	-	-	-%	102	594	-
<b>Treatment for Nonherpetic Genita</b>	752	725	2,928	300	-	-%	1,466	4,394	493
East Africa	72	28	157	300	-	-%	14	171	23
Southern Africa	160	214	803	-	-	-%	162	965	141
Americas	520	483	1,968	-	-	-%	1,290	3,258	328
<b>Treatment for Pre-Eclampsia (witl</b>	5	13	43	39	-	-%	28	71	29
East Africa	5	13	43	39	-	-%	28	71	29
<b>Treatment for Severe Acute Maln</b>	16,205	-	16,206	-	-	-%	25,444	41,650	20,370
West and Central Africa	3	-	4	-	-	-%	-	4	-
East Africa	16,202	-	16,202	-	-	-%	25,444	41,646	20,370
<b>Treatment for Urethral Discharge</b>	799	790	3,168	700	-	-%	698	3,866	44
West and Central Africa	-	-	-	-	-	-%	116	116	-
East Africa	125	24	198	700	-	-%	1	199	2
Southern Africa	674	765	2,970	-	-	-%	581	3,551	42
<b>Treatment for Urethral Discharge</b>	222	166	720	900	-	-%	224	944	94
West and Central Africa	-	-	-	-	-	-%	138	138	-
East Africa	119	44	252	900	-	-%	2	254	8
Southern Africa	103	122	468	-	-	-%	84	552	86
<b>Treatment for Vaginitis</b>	763	810	3,193	-	-	-%	671	3,864	76
East Africa	68	68	271	-	-	-%	67	338	6

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Product**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	695	742	2,922	-	-	-%	604	3,526	71
<b>Tubal Ligation</b>	<b>3,756</b>	<b>5,161</b>	<b>19,239</b>	<b>5,500</b>	<b>1,515</b>	<b>1,170%</b>	<b>24,786</b>	<b>274,161</b>	<b>75,212</b>
West and Central Africa	5	1	8	-	-	-%	-	8	57
East Africa	1,094	678	3,129	5,500	508	516%	4,523	8,191	18,401
Southern Africa	5	10	34	-	-	-%	-	34	116
Americas	246	176	775	-	358	116%	1,982	11,385	1,215
Asia and Eastern Europe	2,406	4,296	15,293	-	649	2,256%	18,281	254,543	55,423
<b>Type 2 Diabetes Screening</b>	<b>159</b>	<b>370</b>	<b>1,270</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>1,270</b>	<b>-</b>
Southern Africa	159	370	1,270	-	-	-%	-	1,270	-
<b>Type 2 Diabetes_Controlled Cond</b>	<b>-</b>	<b>-</b>	<b>1</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>1</b>	<b>-</b>
Southern Africa	-	-	1	-	-	-%	-	1	-
<b>Vasectomy</b>	<b>180</b>	<b>310</b>	<b>1,109</b>	<b>-</b>	<b>5</b>	<b>22,080%</b>	<b>1,886</b>	<b>3,254</b>	<b>4,154</b>
West and Central Africa	-	-	1	-	-	-%	-	1	7
East Africa	-	2	7	-	1	600%	2	11	43
Americas	4	3	12	-	4	200%	14	283	19
Asia and Eastern Europe	176	304	1,089	-	-	-%	1,870	2,959	4,084
<b>Vivax Treatment after Confir</b>	<b>129</b>	<b>162</b>	<b>615</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>3,796</b>	<b>4,411</b>	<b>101</b>
Asia and Eastern Europe	129	162	615	-	-	-%	3,796	4,411	101
<b>Voluntary Medical Male Circumcis</b>	<b>32,473</b>	<b>29,052</b>	<b>119,629</b>	<b>68,253</b>	<b>91,882</b>	<b>30%</b>	<b>279,911</b>	<b>1,764,562</b>	<b>826,920</b>
East Africa	4,157	1,395	8,341	68,253	8,975	(7)%	30,631	100,337	30,066
Southern Africa	28,316	27,657	111,288	-	82,907	34%	249,280	1,664,225	796,854
<b>Water Treatment Tablets</b>	<b>4,513,780</b>	<b>4,116,178</b>	<b>16,862,314</b>	<b>37,503,520</b>	<b>41,373,723</b>	<b>(59)%</b>	<b>92,147,698</b>	<b>741,283,225</b>	<b>3,060</b>
West and Central Africa	392,800	515,207	1,938,422	14,097,521	8,408,223	(77)%	23,980,058	171,902,023	270
East Africa	1,650,800	2,190,313	8,221,740	23,405,999	29,451,650	(72)%	47,341,850	381,210,852	1,265
Southern Africa	2,467,480	1,409,724	6,696,652	-	3,271,350	105%	20,557,660	172,598,160	1,525
Americas	-	-	-	-	-	-%	-	4,918,000	-
Asia and Eastern Europe	2,700	933	5,500	-	242,500	(98)%	268,130	10,654,190	-
<b>Woman Condom</b>	<b>1,152</b>	<b>1,320</b>	<b>5,112</b>	<b>-</b>	<b>336</b>	<b>1,421%</b>	<b>9,600</b>	<b>14,712</b>	<b>96</b>

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY 2017
Southern Africa	1,152	1,320	5,112	-	336	1,421%	9,600	14,712	96
<b>Zika Prevention Kit</b>	63	-	63	-	-	-%	112,890	112,953	1
Americas	63	-	63	-	-	-%	112,890	112,953	1
<b>Zinc</b>	(13,474)	365,937	1,084,336	347,677	52,108	1,981%	143,544	5,443,565	13,596
West and Central Africa	1,601	300,593	903,381	34,685	18,402	4,809%	42,892	1,538,125	11,962
East Africa	(15,075)	37,043	96,055	312,992	31,206	208%	53,910	2,175,191	1,049
Asia and Eastern Europe	-	28,300	84,900	-	2,500	3,296%	46,742	1,730,249	585
<b>Zinc Provided</b>	33,075	-	33,075	-	-	-%	-	33,075	401
East Africa	33,075	-	33,075	-	-	-%	-	33,075	401



# West & Central Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 4/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
West and Central Africa	9,091	-	-	-	1,680,536	1,700	403,524	21,746	829	118	-	22,997
Benin	120	-	-	-	111,947	89	33,532	1	73	-	-	134
Cameroon	425	-	-	-	89,995	91	24,508	30	27	118	-	251
Congo-Kinshasa	100	-	-	-	202,474	266	62,457	8,632	260	-	-	8,892
Cote d'Ivoire	10	-	-	-	1,287	1	182	-	-	-	-	-
Ghana	74	-	-	-	375,484	191	84,144	-	-	-	-	-
Guinea	86	-	-	-	40,545	28	5,800	-	299	-	-	299
Liberia	37	-	-	-	3,802	3	545	-	2	-	-	2
Mali	-	-	-	-	62,396	79	20,022	8,683	13	-	-	8,728
Niger	-	-	-	-	4,621	5	1,501	-	-	-	-	-
Nigeria	8,239	-	-	-	787,631	946	170,712	4,400	155	-	-	4,691
Senegal	-	-	-	-	355	-	122	-	-	-	-	-

\* Using USAID CYP conversion factors



POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>									<b>362,897</b>	<b>2,804,473</b>	<b>3,167,370</b>
Acute Malnutrition Screen	61	54	223	-	-	-%	-	223	-	-	-
CD4 Tests Provided to HIV	12	17	63	-	-	-%	297	360	-	-	-
Cervical Cancer-Pap Sme:	-	-	-	-	1,450	(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and C	3	150	452	719	533	(15)%	2,406	3,467	-	123	123
Cervical Cancer-VIA/VILI §	2,043	8,094	26,324	-	15,935	65%	90,919	153,443	-	-	-
Chlorhexidine	6,606	21,867	72,206	200,000	-	-%	46,000	118,206	-	7,265	7,265
Clean Delivery Kit	-	-	-	15,000	1,800	(100)%	4,400	43,750	-	-	-
Condom	6,400,654	11,297,453	40,293,014	163,145,833	55,807,484	(28)%	167,463,624	3,895,971,866	322,483	122,322	444,806
Condom Provided	-	-	-	-	17,875	(100)%	55,399	83,854	-	-	-
Counseling & Tx for Mode	5	1	8	-	-	-%	-	8	-	-	-
Diarrhea Treatment Kit	111,107	193,726	692,286	1,012,000	522,780	32%	1,303,935	7,784,824	-	44,660	44,660
Diarrhea Treatment Kit Pri	-	-	-	-	-	-%	2,400	2,400	-	-	-
Emergency Contraception	178,816	114,955	523,682	2,055,000	626,235	(16)%	1,808,411	12,578,228	-	6,250	6,250
Emergency Contraception	18	41	141	-	84	68%	201	663	-	2	2
Family Planning Counseli	-	-	-	-	173	(100)%	20,577	20,606	-	-	-
Female Condom	5,949	23,169	75,455	224,568	647,788	(88)%	2,318,459	22,260,126	232	149	381
Female Condom Provided	-	-	-	-	357	(100)%	2,591	3,027	-	-	-
Fever Cases Attended	-	-	-	-	-	-%	2,927,861	2,927,861	-	-	-
Fever Cases Tested with I	-	-	-	-	-	-%	247,772	247,772	-	-	-
Fever Cases Tested with F	-	-	-	-	-	-%	2,634,426	2,634,426	-	-	-
Free Condom	1,786,352	3,171,059	11,299,528	62,124,626	3,165,822	257%	32,825,359	149,577,656	39,713	32,827	72,540

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	68,599	40,743	190,827	1,564,945	11,141	1,613%	431,422	1,966,713	266	414	679
HIV Testing Services	8,458	8,976	35,387	65,753	44,305	(20)%	201,781	2,708,618	203	-	203
Implant 3	1,936	2,101	8,239	7,550	1,533	437%	9,211	17,162	-	13,515	13,515
Implant 3 Insertion	417	5,415	16,663	20,002	321	5,091%	20,727	40,876	-	34,756	34,756
Implant 4 Insertion	22	-	22	-	-	-%	-	22	-	34	34
Implant 5	4,796	1,934	10,599	84,157	15,800	(33)%	32,153	271,622	-	26,219	26,219
Implant 5 Insertion	9,255	13,859	50,833	41,399	25,181	102%	106,632	497,814	-	151,392	151,392
Injectable 2	36,342	94,018	318,396	1,045,150	321,716	(1)%	1,538,928	15,482,155	-	31,404	31,404
Injectable 2 Provided	834	1,059	4,012	-	2,984	34%	10,433	14,445	-	283	283
Injectable 3	132,515	524,563	1,706,203	2,252,284	536,248	218%	1,815,961	24,449,467	-	147,511	147,511
Injectable 3 Provided	2,533	2,250	9,282	27,082	6,194	50%	16,028	38,741	-	1,379	1,379
IPTp2	8	13	46	836,961	-	-%	-	46	-	3	3
Iron Folic Acid Tablet	-	1,200	3,600	-	-	-%	14,500	18,100	-	-	-
IUD 10	3,775	4,870	18,385	95,321	27,367	(33)%	115,968	1,675,892	-	64,847	64,847
IUD 10 Insertion	8,716	10,207	39,337	57,282	30,590	29%	117,595	566,665	-	153,787	153,787
IUD 5 Insertion	7	-	7	-	-	-%	-	7	-	12	12
LLIN	100,703	526,999	1,681,700	12,347,682	5,697,137	(70)%	30,675,129	107,791,407	-	654,024	654,024
Lubricant	7,946	417,544	1,260,577	-	84,017	1,400%	349,026	3,140,728	-	-	-
Malaria PPT (ACT)	1,224,799	741,114	3,448,141	4,289,752	5,528,466	(38)%	14,144,463	58,908,042	-	1,166,013	1,166,013
Malaria RDK	197,400	299,401	1,095,602	7,528,315	3,338,109	(67)%	8,902,668	16,265,188	-	-	-
Manual Vacuum Aspiratio	270	267	1,072	1,909	85	1,161%	7,369	8,512	-	521	521
Medical Abortion Provider	-	-	-	-	-	-%	105	105	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Micronutrient Powder	132,141	65,010	327,171	1,713,790	-	-%	85,400	412,571	-	-	-
Misoprostol for PAC (Oral	22,262	21,750	87,512	906,686	229,140	(62)%	626,258	1,739,485	-	10,300	10,300
Misoprostol for PAC (oral)	2,040	1,934	7,842	10,120	-	-%	2,427	10,269	-	1,437	1,437
Misoprostol for PPH	-	-	-	300,000	-	-%	-	349,630	-	-	-
OCs	349,527	729,258	2,537,301	11,612,236	2,623,288	(3)%	9,528,389	65,055,090	-	88,691	88,691
OCs Provided	6,140	7,263	27,928	15,000	3,015	826%	28,690	81,055	-	1,156	1,156
ORS	-	89,302	267,906	1,965	56,891	371%	70,974	3,826,920	-	10,440	10,440
Pneumonia PPT	14,640	-	14,640	60,000	29,898	(51)%	60,018	404,818	-	10,029	10,029
Pneumonia PPT Provided	-	-	-	-	-	-%	2,500	2,500	-	-	-
Positive RDTs	-	-	-	-	-	-%	2,047,931	2,047,931	-	-	-
Positive RDTs Given First	-	-	-	-	-	-%	2,047,743	2,047,743	-	-	-
PUR	220,566	169,440	728,886	4,792,000	707,644	3%	5,988,604	19,597,652	-	67	67
QAACTs Provided after C	-	-	-	-	-	-%	2,034,979	2,034,979	-	-	-
Referral to CD4/Clinical St	-	-	-	553	-	-%	-	18	-	-	-
Referral to HIV Testing Se	-	-	-	60,035	5,372	(100)%	5,682	7,471	-	-	-
Referral to IUD 10 Insertio	-	-	-	-	-	-%	22	22	-	-	-
Referral to Linkage to HIV	-	-	-	460	-	-%	281	281	-	-	-
Safe Water Solution	46,315	209,772	675,631	200,000	101,092	568%	160,999	12,794,415	-	3,434	3,434
SDM (Cycle Beads)	2,185	177	2,716	18,256	5,208	(48)%	20,227	318,989	-	3,435	3,435
SDM (Cycle Beads) Provic	356	568	2,061	-	343	501%	2,812	5,745	-	2,897	2,897
Skilled Birth Attendance	6,554	833	9,054	-	-	-%	-	9,054	-	-	-
STI Screening	367	574	2,090	-	2,469	(15)%	19,906	25,688	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>TB Diagnosis</b>	-	-	-	-	-	-%	<b>10,219</b>	<b>10,219</b>	-	-	-
<b>TB DOTS</b>	-	-	-	-	-	-%	<b>5,763</b>	<b>5,763</b>	-	-	-
<b>TB Screening</b>	-	-	-	-	-	-%	<b>7,139</b>	<b>7,139</b>	-	-	-
<b>Toilets Constructed</b>	<b>571</b>	<b>532</b>	<b>2,167</b>	<b>3,000</b>	-	-%	-	<b>2,167</b>	-	<b>579</b>	<b>579</b>
<b>Toilets Sold</b>	<b>571</b>	<b>530</b>	<b>2,162</b>	-	-	-%	<b>2,598</b>	<b>4,760</b>	-	-	-
<b>Treatment for Severe Acu</b>	<b>3</b>	-	<b>4</b>	-	-	-%	-	<b>4</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	-	-%	<b>116</b>	<b>116</b>	-	-	-
<b>Treatment for Urethral Dis</b>	-	-	-	-	-	-%	<b>138</b>	<b>138</b>	-	-	-
<b>Tubal Ligation</b>	<b>5</b>	<b>1</b>	<b>8</b>	-	-	-%	-	<b>8</b>	-	<b>57</b>	<b>57</b>
<b>Vasectomy</b>	-	-	<b>1</b>	-	-	-%	-	<b>1</b>	-	<b>7</b>	<b>7</b>
<b>Water Treatment Tablets</b>	<b>392,800</b>	<b>515,207</b>	<b>1,938,422</b>	<b>14,097,521</b>	<b>8,408,223</b>	<b>(77)%</b>	<b>23,980,058</b>	<b>162,973,573</b>	-	<b>270</b>	<b>270</b>
<b>Zinc</b>	<b>1,601</b>	<b>300,593</b>	<b>903,381</b>	<b>34,685</b>	<b>18,402</b>	<b>4,809%</b>	<b>42,892</b>	<b>1,158,335</b>	-	<b>11,962</b>	<b>11,962</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>West and Central Africa - All</b>										<b>362,897</b>	<b>2,804,473</b>	<b>3,167,370</b>
<b>Benin</b>										<b>4,863</b>	<b>66,216</b>	<b>71,079</b>
Cervical Cancer-VIA and Cryotherapy	3	9	30	-	13		131%	155	261	-	9	9
Cervical Cancer-VIA and Cryotherapy	3	9	30	-	13	2/13	131%	155	261	-	9	9
Cervical Cancer-VIA/VILI Screening	1,996	3,853	13,556	-	7,135		90%	41,466	68,168	-	-	-
Cervical Cancer-VIA/VILI Screening	1,996	3,853	13,556	-	7,135		90%	41,466	68,168	-	-	-
Condom	282,948	515,676	1,829,976	9,000,000	2,194,941		(17)%	6,861,921	67,166,792	4,393	3,694	8,086
PSI Condom Distributed Provided	-	-	-	-	(9,636)		-%	(28,048)	(49,532)	-	-	-
Kool	88,476	156,768	558,780	2,000,000	502,332	2/10	11%	1,872,356	15,420,467	1,341	1,128	2,469
Prudence Plus	194,472	358,908	1,271,196	7,000,000	1,702,245	1/08	(25)%	5,017,613	51,795,857	3,051	2,566	5,617
Condom Provided	-	-	-	-	9,704		(100)%	28,116	49,600	-	-	-
PSI Condom Provided	-	-	-	-	9,636		(100)%	28,048	49,532	-	-	-
Non-PSI Condom Provided	-	-	-	-	68		(100)%	68	68	-	-	-
Diarrhea Treatment Kit	11,599	17,477	64,029	350,000	125,515		(49)%	450,468	2,861,392	-	6,088	6,088
Orasel Zinc DTK	11,599	17,477	64,029	350,000	125,515	4/08	(49)%	450,468	2,861,392	-	6,088	6,088
Family Planning Counseling	-	-	-	-	-		0%	19,918	19,918	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	19,918	19,918	-	-	-
Female Condom	-	7,807	23,421	5,000	572		3995%	21,399	128,399	56	36	93
Cupid	-	4,639	13,917	-	304	3/14	4,478%	5,698	23,646	33	22	55
Femidom	-	3,168	9,504	5,000	268	6/08	3,446%	15,701	104,753	23	15	38
Free Condom	-	36,255	108,764	-	-		0%	247,097	1,004,715	261	220	481
No Logo	-	36,255	108,764	-	-	1/12	-%	247,097	1,004,715	261	220	481
HIV Testing Services	5,938	7,683	28,986	34,058	29,813		(3)%	83,163	532,233	153	-	153
VCT Concordant Couple (HIV-Negative)	-	-	-	-	6	1/10	(100)%	30	8,527	-	-	-
VCT Individual (HIV-Negative)	5,863	7,581	28,607	34,058	29,517	1/10	(3)%	82,139	517,605	151	-	151

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	75	101	379	-	290	1/10	31%	994	6,101	2	-	2
Implant 5	(52)	1,408	4,173	20,501	(377)		0%	437	31,516	-	8,183	8,183
PSI Implant 5 Distributed Inserted (	(572)	(625)	(2,447)	(19,499)	(4,685)		-%	(31,168)	(117,668)	-	(4,798)	(4,798)
Implant 5 (insertion)	520	2,033	6,620	-	4,308	12/09	54%	31,605	61,978	-	12,981	12,981
Jadelle	-	-	-	40,000	-	9/09	-%	-	87,206	-	-	-
Implant 5 Insertion	1,214	3,194	10,795	19,499	5,366		101%	31,849	126,697	-	23,520	23,520
PSI Implant 5 Inserted	572	625	2,447	19,499	4,685		(48)%	31,168	117,668	-	5,331	5,331
Non-PSI Implant 5 Inserted	642	2,569	8,348	-	681		1,126%	681	9,029	-	18,188	18,188
Injectable 2	3,736	2,951	12,590	45,150	14,716		(14)%	30,602	203,655	-	798	798
PSI Injectable 2 Distributed Provide	(471)	(507)	(1,992)	-	(2,348)		-%	(9,797)	(11,789)	-	(126)	(126)
Noristerat	4,207	3,458	14,582	45,150	17,064	1/12	(15)%	40,399	215,444	-	925	925
Injectable 2 Provided	834	1,059	4,012	-	2,984		34%	10,433	14,445	-	283	283
PSI Injectable 2 Provided	471	507	1,992	-	2,348		(15)%	9,797	11,789	-	140	140
Non-PSI Injectable 2 Provided	363	552	2,020	-	636		218%	636	2,656	-	142	142
Injectable 3	-	-	-	-	(1,160)		0%	(1,160)	(6,968)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(1,160)		-%	(1,160)	(6,968)	-	-	-
Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
PSI Injectable 3 Provided	-	-	-	-	1,160		(100)%	1,160	6,968	-	-	-
IUD 10	263	303	1,172	13,000	1,299		(10)%	9,115	43,568	-	2,841	2,841
PSI IUD 10 Distributed Inserted (1)	(979)	(1,010)	(4,008)	(16,000)	(4,123)		-%	(19,392)	(82,067)	-	(9,716)	(9,716)
IUD (insertion)	680	-	680	-	-	12/09	-%	-	1,390	-	1,648	1,648
IUD Copper-T TCU 380A	562	1,313	4,500	29,000	5,422	9/09	(17)%	28,507	124,245	-	10,909	10,909
IUD 10 Insertion	1,096	1,460	5,475	16,000	4,280		28%	19,549	83,703	-	14,747	14,747
PSI IUD 10 Inserted	979	1,010	4,008	16,000	4,123		(3)%	19,392	82,067	-	10,796	10,796
Non-PSI IUD 10 Inserted	117	450	1,467	-	157		834%	157	1,636	-	3,951	3,951

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>LLIN</b>	<b>70</b>	<b>137</b>	<b>482</b>	<b>7,800</b>	<b>11,850</b>		<b>(96)%</b>	<b>18,304</b>	<b>747,173</b>	-	<b>63</b>	<b>63</b>
Moustiquaires Peace Corps	-	-	-	-	<b>7,000</b>	3/13	(100)%	<b>10,000</b>	<b>20,000</b>	-	-	-
Super Moustiquaire Longue Durée	<b>70</b>	<b>104</b>	<b>381</b>	<b>7,800</b>	<b>3,960</b>	5/06	(90)%	<b>6,209</b>	<b>721,308</b>	-	<b>50</b>	<b>50</b>
SuperMoustiquaire (blanche 1 place	-	<b>31</b>	<b>93</b>	-	<b>587</b>	9/15	(84)%	<b>1,404</b>	<b>2,887</b>	-	<b>12</b>	<b>12</b>
SuperMoustiquaire (blanche 3 place	-	<b>3</b>	<b>8</b>	-	<b>303</b>	9/15	(97)%	<b>691</b>	<b>2,978</b>	-	<b>1</b>	<b>1</b>
<b>Lubricant</b>	-	<b>23,680</b>	<b>71,040</b>	-	-		<b>0%</b>	<b>106,260</b>	<b>177,300</b>	-	-	-
Gel Lubricant 5 mL	-	<b>23,680</b>	<b>71,040</b>	-	-	12/16	-%	<b>106,260</b>	<b>177,300</b>	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	<b>87</b>	<b>82</b>	<b>333</b>	-	-		<b>0%</b>	<b>689</b>	<b>1,022</b>	-	<b>104</b>	<b>104</b>
MVA for PAC	<b>87</b>	<b>82</b>	<b>333</b>	-	-	10/16	-%	<b>689</b>	<b>1,022</b>	-	<b>104</b>	<b>104</b>
<b>Medical Abortion</b>	-	-	-	-	-		<b>0%</b>	<b>(105)</b>	<b>(105)</b>	-	-	-
PSI Medical Abortion Distributed Pr	-	-	-	-	-		-%	<b>(105)</b>	<b>(105)</b>	-	-	-
<b>Medical Abortion Provided</b>	-	-	-	-	-		<b>0%</b>	<b>105</b>	<b>105</b>	-	-	-
PSI Medical Abortion Provided	-	-	-	-	-		-%	<b>105</b>	<b>105</b>	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>8,122</b>	<b>8,657</b>	<b>34,092</b>	<b>100,000</b>	<b>5,000</b>		<b>582%</b>	<b>113,461</b>	<b>317,441</b>	-	<b>3,189</b>	<b>3,189</b>
PSI Misoprostol for PAC Oral Dist F	<b>(138)</b>	<b>(110)</b>	<b>(468)</b>	-	-		-%	<b>(111)</b>	<b>(579)</b>	-	<b>(44)</b>	<b>(44)</b>
Misoprostol for PAC (oral)	<b>8,260</b>	<b>8,767</b>	<b>34,560</b>	<b>100,000</b>	<b>5,000</b>	1/13	591%	<b>113,572</b>	<b>318,020</b>	-	<b>3,233</b>	<b>3,233</b>
<b>Misoprostol for PAC (oral) Provided</b>	<b>138</b>	<b>110</b>	<b>468</b>	-	-		<b>0%</b>	<b>111</b>	<b>579</b>	-	<b>49</b>	<b>49</b>
PSI Misoprostol for PAC (oral) Prov	<b>138</b>	<b>110</b>	<b>468</b>	-	-		-%	<b>111</b>	<b>579</b>	-	<b>49</b>	<b>49</b>
<b>OCs</b>	<b>22,148</b>	<b>17,610</b>	<b>74,979</b>	<b>208,635</b>	<b>86,926</b>		<b>(14)%</b>	<b>209,829</b>	<b>931,064</b>	-	<b>1,931</b>	<b>1,931</b>
PSI OCs Distributed Provided	<b>(253)</b>	<b>(235)</b>	<b>(957)</b>	-	<b>(991)</b>		-%	<b>(3,299)</b>	<b>(22,911)</b>	-	<b>(25)</b>	<b>(25)</b>
Laafia Pilule	<b>22,401</b>	<b>17,845</b>	<b>75,936</b>	<b>208,635</b>	<b>87,917</b>	6/12	(14)%	<b>213,125</b>	<b>953,972</b>	-	<b>1,955</b>	<b>1,955</b>
Microgynon	-	-	-	-	-	9/15	-%	<b>3</b>	<b>3</b>	-	-	-
<b>OCs Provided</b>	<b>319</b>	<b>332</b>	<b>1,316</b>	-	<b>1,065</b>		<b>24%</b>	<b>3,373</b>	<b>23,344</b>	-	<b>38</b>	<b>38</b>
PSI OCs Provided	<b>253</b>	<b>235</b>	<b>957</b>	-	<b>991</b>		(3)%	<b>3,299</b>	<b>22,911</b>	-	<b>27</b>	<b>27</b>
Non-PSI OCs Provided	<b>66</b>	<b>98</b>	<b>359</b>	-	<b>74</b>		385%	<b>74</b>	<b>433</b>	-	<b>10</b>	<b>10</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
SDM (Cycle Beads)	(6)	57	166	2,500	361		(54)%	3,196	34,539	-	150	150
PSI SDM (Cycle Beads) Distributed	(6)	(7)	(26)	-	(15)		-%	(48)	(104)	-	(23)	(23)
CycleBeads	-	64	192	2,500	376	12/04	(49)%	3,244	34,643	-	173	173
SDM (Cycle Beads) Provided	6	7	26	-	15		73%	48	104	-	26	26
PSI SDM (Cycle Beads) Provided	6	7	26	-	15		73%	48	104	-	26	26
Skilled Birth Attendance	6,554	833	9,054	-	-		0%	-	9,054	-	-	-
Skilled Birth Attendance	6,554	833	9,054	-	-		-%	-	9,054	-	-	-
STI Screening	367	574	2,090	-	2,469		(15)%	6,499	12,281	-	-	-
STI Screening	367	574	2,090	-	2,469		(15)%	6,499	12,281	-	-	-
Toilets Constructed	-	2	5	-	-		0%	-	5	-	-	-
Toilet Type 1	-	2	5	-	-		-%	-	5	-	-	-
Treatment for Urethral Discharge (Mer	-	-	-	-	-		0%	116	116	-	-	-
Treatment for Urethral Discharge (M	-	-	-	-	-		-%	116	116	-	-	-
Treatment for Urethral Discharge (Wor	-	-	-	-	-		0%	138	138	-	-	-
Treatment for Urethral Discharge (W	-	-	-	-	-		-%	138	138	-	-	-
Water Treatment Tablets	353,400	483,067	1,802,600	7,560,000	1,713,430		5%	7,464,550	60,374,070	-	249	249
Aquatab	353,400	483,067	1,802,600	7,560,000	1,713,430	1/08	5%	7,464,550	60,374,070	-	249	249
<b>Cameroon</b>										17,975	67,652	85,627
CD4 Tests Provided to HIV+ Clients	-	-	-	-	-		0%	297	297	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	-		-%	297	297	-	-	-
Condom	32,612	830,479	2,524,048	8,250,000	5,025,722		(50)%	20,438,811	185,950,378	17,863	6,003	23,866
Lovers Plus	-	(42,600)	(127,800)	-	828,144	1/15	(115)%	2,169,288	3,241,836	(904)	(304)	(1,208)
Préservatif Masculin Aromatisé UNF	-	-	-	50,000	-	12/15	-%	144	144	-	-	-
Préservatif Masculin UNFPA	500	9,691	29,572	1,200,000	2,680	12/15	1,003%	61,016	90,588	209	70	280
Prudence Plus	-	-	-	-	2,718	8/06	(100)%	2,718	141,675,005	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Prudence Plus Nouveau	32,112	863,388	2,622,276	7,000,000	4,192,180	1/15	(37)%	18,205,645	40,942,805	18,558	6,237	24,794
Diarrhea Treatment Kit	3,714	11,295	37,598	87,000	-		0%	16,065	699,460	-	2,164	2,164
PSI Diarrhea Treatment Kit Distribu	-	-	-	-	-		-%	(2,400)	(2,400)	-	-	-
Orasel Zinc	3,714	11,295	37,598	87,000	-	10/09	-%	18,465	701,860	-	2,164	2,164
Diarrhea Treatment Kit Provided	-	-	-	-	-		0%	2,400	2,400	-	-	-
PSI Diarrhea Treatment Kit Provide	-	-	-	-	-		-%	2,400	2,400	-	-	-
Emergency Contraception	2,208	2,251	8,962	15,000	1,649		443%	10,842	19,804	-	80	80
PSI Emergency Contraception Distr	-	(11)	(32)	-	(39)		-%	(65)	(97)	-	-	-
Norlevo	2,208	2,262	8,994	15,000	1,688	11/15	433%	10,907	19,901	-	81	81
Emergency Contraception Provided	-	11	32	-	39		(18)%	65	97	-	-	-
PSI Emergency Contraception Prov	-	11	32	-	39		(18)%	65	97	-	-	-
Female Condom	2,055	1,491	6,528	19,568	337,062		(98)%	1,531,414	7,993,974	46	12	58
Préservatif Féminin CUPID	25	25	100	10,000	-	7/14	-%	488,548	611,770	1	-	1
Préservatif Féminins UNFPA	2,030	1,133	5,428	-	130,720	3/15	(96)%	504,712	790,044	38	10	48
Protectiv	-	-	-	6,437	-	11/02	-%	-	4,184,561	-	-	-
Protectiv Plus	-	333	1,000	-	1,560	4/14	(36)%	19,116	958,157	7	2	9
Securite Plus Female Condom	-	-	-	3,131	204,782	11/13	(100)%	519,038	1,449,442	-	-	-
Fever Cases Attended	-	-	-	-	-		0%	12,764	12,764	-	-	-
Fever Cases Attended	-	-	-	-	-		-%	12,764	12,764	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		0%	13,416	13,416	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		-%	13,416	13,416	-	-	-
Free Condom	780	2,681	8,824	-	-		0%	735,220	744,044	62	21	83
Generic MC	780	2,681	8,824	-	-	11/16	-%	735,220	744,044	62	21	83
Free Female Condom	-	-	-	-	-		0%	1,000	1,000	-	-	-
Generic FC	-	-	-	-	-	1/08	-%	1,000	1,000	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
HIV Testing Services	-	50	149	10,035	4,769		(97)%	11,896	58,648	3	-	3
VCT Individual (HIV-Negative)	-	47	141	9,523	4,544	1/10	(97)%	11,335	55,360	3	-	3
VCT Individual (HIV-Positive)	-	3	8	512	225	1/10	(96)%	561	3,288	-	-	-
Implant 3	1,413	1,642	6,338	-	1,333		375%	9,165	15,503	-	9,946	9,946
PSI Implant 3 Distributed Inserted (	(13)	(256)	(781)	-	(302)	3/16	-%	(4,594)	(5,375)	-	(1,226)	(1,226)
Implanon NXT	1,426	1,898	7,119	-	1,635	12/15	335%	13,759	20,878	-	11,171	11,171
Implant 3 Insertion	13	256	782	-	302		159%	4,594	5,376	-	1,363	1,363
PSI Implant 3 Inserted	13	256	781	-	302	3/16	159%	4,594	5,375	-	1,362	1,362
Non-PSI Implant 3 Inserted	-	-	1	-	-		-%	-	1	-	2	2
Implant 5	668	342	1,693	5,000	2,812		(40)%	8,625	2,935	-	3,903	3,903
PSI Implant 5 Distributed Inserted (	(172)	(372)	(1,287)	-	(300)		-%	(3,134)	(25,470)	-	(2,967)	(2,967)
Jadelle UNFPA	840	713	2,980	5,000	3,112	3/15	(4)%	11,759	28,405	-	6,870	6,870
Implant 5 Insertion	172	392	1,348	-	300		349%	3,170	26,273	-	3,453	3,453
PSI Implant 5 Inserted	172	372	1,287	-	300		329%	3,134	25,470	-	3,297	3,297
Non-PSI Implant 5 Inserted	-	20	61	-	-		-%	36	803	-	156	156
Injectable 3	6,881	5,173	22,399	198,650	7,370		204%	52,057	122,476	-	2,510	2,510
PSI Injectable 3 Distributed Provide	-	(387)	(1,161)	-	(2,207)		-%	(4,794)	(5,955)	-	(130)	(130)
Depo-Provera UNFPA	3,375	516	4,924	37,650	9,577	3/15	(49)%	42,529	95,473	-	552	552
Equilibre	3,506	5,043	18,636	161,000	-	5/16	-%	14,322	32,958	-	2,088	2,088
Injectable 3 Provided	-	387	1,161	-	2,207		(47)%	4,794	5,955	-	145	145
PSI Injectable 3 Provided	-	387	1,161	-	2,207		(47)%	4,794	5,955	-	145	145
IUD 10	1,265	605	3,081	-	9,783		(69)%	29,990	82,848	-	8,768	8,768
PSI IUD 10 Distributed Inserted (1)	(785)	(894)	(3,466)	-	(769)		-%	(11,279)	(59,775)	-	(9,863)	(9,863)
DIU UNFPA	-	200	600	-	6,902	3/15	(91)%	17,643	22,043	-	1,707	1,707
IUD	1,750	933	4,550	-	3,650	9/09	25%	12,250	107,807	-	12,948	12,948

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD Copper T 380A	300	366	1,397	-	-	2/16	-%	11,376	12,773	-	3,976	3,976
IUD 10 Insertion	786	894	3,469	-	769		351%	11,303	60,408	-	10,969	10,969
PSI IUD 10 Inserted	785	894	3,466	-	769		351%	11,279	59,775	-	10,959	10,959
Non-PSI IUD 10 Inserted	1	1	3	-	-		-%	24	633	-	9	9
LLIN	2,394	1,067	5,596	40,000	8,715		(36)%	39,178	7,980,719	-	1,223	1,223
Super Moustiquaire	2,394	1,067	5,596	40,000	8,715	1/09	(36)%	39,178	7,980,719	-	1,223	1,223
Lubricant	107	1,778	5,441	-	1,705		219%	11,891	17,652	-	-	-
Lubricant 60 mL bottle	107	95	391	-	1,705	12/15	(77)%	7,266	7,977	-	-	-
Water-based Lubricant, 4 mL sachet	-	1,683	5,050	-	-	12/16	-%	4,625	9,675	-	-	-
Malaria PPT (ACT)	4,065	143	4,495	25,000	11,119		(60)%	29,363	76,057	-	1,242	1,242
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablet)	-	-	-	1,000	-	2/15	-%	5,100	5,100	-	-	-
ACT 2 (ASAQ 50 / 135.5 mg, 3 table	2,450	-	2,450	15,000	6,800	2/15	(64)%	15,000	47,524	-	677	677
ACT 3 (ASAQ 100 / 270 mg, 3 table	700	75	925	4,500	1,959	2/15	(53)%	4,493	11,918	-	256	256
ACT 4 (ASAQ 100 / 270 mg, 6 table	915	68	1,120	4,500	2,360	2/15	(53)%	4,770	11,515	-	309	309
Malaria RDK	4,975	208	5,600	25,000	13,001		(57)%	25,569	180,877	-	-	-
Malaria Ag Pf/Pan_PA	4,975	208	5,600	25,000	13,001	12/12	(57)%	25,569	180,877	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	314	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	314	-		-%	-	-	-	-	-
Micronutrient Powder	132,141	65,010	327,171	1,713,790	-		0%	85,400	412,571	-	-	-
Super Bebe	132,141	65,010	327,171	1,713,790	-	9/16	-%	85,400	412,571	-	-	-
Misoprostol for PAC (Oral)	11,840	9,827	41,320	207,500	68,040		(39)%	107,297	409,494	-	4,273	4,273
PSI Misoprostol for PAC Oral Dist F	-	-	-	105,500	-		-%	(1,383)	(1,383)	-	-	-
Misoprostol for PAC (oral)	11,840	9,827	41,320	102,000	68,040	1/13	(39)%	108,680	410,877	-	4,273	4,273
Misoprostol for PAC (oral) Provided	-	-	-	2,120	-		0%	1,383	1,383	-	-	-
PSI Misoprostol for PAC (oral) Prov	-	-	-	2,120	-		-%	1,383	1,383	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>OCs</b>	<b>10,126</b>	<b>11,136</b>	<b>43,535</b>	<b>159,000</b>	<b>28,504</b>		<b>53%</b>	<b>88,610</b>	<b>574,246</b>	-	<b>1,321</b>	<b>1,321</b>
PSI OCs Distributed Provided	-	(525)	(1,576)	-	(698)		-%	(2,500)	(4,076)	-	(48)	(48)
Microgynon Ed Fe	4,770	1,190	8,340	15,000	29,202	7/14	(71)%	67,958	443,463	-	253	253
Novelle Duo	5,356	10,472	36,771	144,000	-	1/08	-%	23,152	134,859	-	1,116	1,116
<b>OCs Provided</b>	-	<b>525</b>	<b>1,576</b>	-	<b>698</b>		<b>126%</b>	<b>2,567</b>	<b>4,143</b>	-	<b>53</b>	<b>53</b>
PSI OCs Provided	-	525	1,576	-	698		126%	2,500	4,076	-	53	53
Non-PSI OCs Provided	-	-	-	-	-		-%	67	67	-	-	-
<b>ORS</b>	-	<b>150</b>	<b>450</b>	<b>1,965</b>	<b>56,891</b>		<b>(99)%</b>	<b>70,974</b>	<b>3,559,464</b>	-	<b>13</b>	<b>13</b>
Orasel	-	150	450	1,965	56,891	9/98	(99)%	70,974	3,559,464	-	13	13
<b>Pneumonia PPT</b>	<b>14,640</b>	-	<b>14,640</b>	<b>60,000</b>	<b>29,898</b>		<b>(51)%</b>	<b>57,518</b>	<b>402,318</b>	-	<b>10,029</b>	<b>10,029</b>
PSI Pneumonia PPT Distributed Pr	-	-	-	-	-		-%	(2,500)	(2,500)	-	-	-
Amoxicillin 500mg x 15's -- Children	14,640	-	14,640	2,400	28,569	1/13	(49)%	57,600	256,302	-	10,029	10,029
Amoxicillin 500mg x 7's - Children 2-	-	-	-	57,600	1,329	1/13	(100)%	2,418	148,516	-	-	-
<b>Pneumonia PPT Provided</b>	-	-	-	-	-		<b>0%</b>	<b>2,500</b>	<b>2,500</b>	-	-	-
PSI Pneumonia PPT Provided	-	-	-	-	-		-%	2,500	2,500	-	-	-
<b>Positive RDTs</b>	-	-	-	-	-		<b>0%</b>	<b>12,952</b>	<b>12,952</b>	-	-	-
Positive RDTs	-	-	-	-	-		-%	12,952	12,952	-	-	-
<b>Positive RDTs Given First Line Treatm</b>	-	-	-	-	-		<b>0%</b>	<b>12,764</b>	<b>12,764</b>	-	-	-
Positive RDTs Given First Line Trea	-	-	-	-	-		-%	12,764	12,764	-	-	-
<b>Referral to HIV Testing Services</b>	-	-	-	<b>10,035</b>	-		<b>0%</b>	<b>281</b>	<b>1,285</b>	-	-	-
Referral to HIV Testing & Counselin	-	-	-	10,035	-	12/13	-%	281	1,285	-	-	-
<b>Referral to Linkage to HIV Care</b>	-	-	-	<b>460</b>	-		<b>0%</b>	<b>281</b>	<b>281</b>	-	-	-
Referral to Linkage to HIV Care	-	-	-	460	-		-%	281	281	-	-	-
<b>Water Treatment Tablets</b>	<b>26,600</b>	<b>7,893</b>	<b>50,280</b>	<b>76,791</b>	<b>14,209</b>		<b>254%</b>	<b>76,459</b>	<b>126,739</b>	-	<b>6</b>	<b>6</b>
Aquatabs 67 mg (20 L)	26,600	7,893	50,280	76,791	14,209	12/15	254%	76,459	126,739	-	6	6

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Zinc	1,601	3,560	12,281	34,685	18,402		(33)%	42,892	267,235	-	155	155
Zinc	1,601	3,560	12,281	34,685	18,402	7/09	(33)%	42,892	267,235	-	155	155
<b>Congo-Kinshasa</b>										4,396	900,360	904,756
Condom	342,868	93,711	624,000	9,000,000	193,704		222%	5,295,269	490,138,000	842	1,776	2,618
PSI Condom Distributed Provided	-	-	-	-	(940)		-%	(2,705)	(6,043)	-	-	-
Prudence	81,216	52,264	238,008	9,000,000	20,604	11/87	1,055%	4,679,032	473,180,680	321	677	998
Prudence Sensuel	261,652	41,447	385,992	-	174,040	12/12	122%	618,942	16,963,363	521	1,099	1,619
Condom Provided	-	-	-	-	8,165		(100)%	17,042	23,943	-	-	-
PSI Condom Provided	-	-	-	-	940		(100)%	2,705	6,043	-	-	-
Non-PSI Condom Provided	-	-	-	-	7,225		(100)%	14,337	17,900	-	-	-
Diarrhea Treatment Kit	6,214	1,282	10,059	125,000	-		0%	20,537	427,261	-	806	806
ORA-ZINC	6,214	1,282	10,059	125,000	-	11/13	-%	20,537	427,261	-	806	806
Emergency Contraception	2,650	2,112	8,986	40,000	50		17872%	7,209	36,019	-	96	96
PSI Emergency Contraception Distr	(2)	(10)	(33)	-	(26)		-%	(67)	(352)	-	-	-
Norlevo	2,652	2,122	9,019	40,000	76	10/14	11,767%	7,276	36,371	-	97	97
Emergency Contraception Provided	18	30	109	-	45		142%	136	566	-	1	1
PSI Emergency Contraception Prov	2	10	33	-	26		27%	67	352	-	-	-
Non-PSI Emergency Contraception I	16	20	76	-	19		300%	69	214	-	1	1
Female Condom	-	41	124	-	107,688		(100)%	309,955	7,631,419	-	-	-
PSI Female Condom Distributed Pr	-	-	-	-	(26)		-%	(315)	(374)	-	-	-
Prudence Femme	-	41	124	-	107,714	8/04	(100)%	310,270	7,631,793	-	-	-
Female Condom Provided	-	-	-	-	357		(100)%	2,591	3,027	-	-	-
PSI Female Condom Provided	-	-	-	-	26		(100)%	315	374	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	331		(100)%	2,276	2,653	-	-	-
Fever Cases Attended	-	-	-	-	-		0%	2,915,097	2,915,097	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fever Cases Attended	-	-	-	-	-		-%	2,915,097	2,915,097	-	-	-
Fever Cases Tested with Microscopy	-	-	-	-	-		0%	247,772	247,772	-	-	-
Fever Cases Tested with Microscopy	-	-	-	-	-		-%	247,772	247,772	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		0%	2,621,010	2,621,010	-	-	-
Fever Cases Tested with RDTs	-	-	-	-	-		-%	2,621,010	2,621,010	-	-	-
Free Condom	706,980	581,533	2,451,580	859,750	731,000		235%	5,115,000	35,221,465	3,307	6,978	10,284
Generic MC	706,980	581,533	2,451,580	859,750	731,000	3/09	235%	5,115,000	35,221,465	3,307	6,978	10,284
Free Female Condom	64,200	39,667	183,200	617,960	-		0%	420,000	1,906,800	247	401	648
Generic FC	64,200	39,667	183,200	617,960	-	3/09	-%	420,000	1,906,800	247	401	648
Implant 3	523	459	1,901	938	-		0%	(154)	1,459	-	3,569	3,569
PSI Implant 3 Distributed Inserted (	-	(7)	(21)	-	-		-%	(14,530)	(14,839)	-	(39)	(39)
Implanon	523	466	1,922	938	-	6/16	-%	14,376	16,298	-	3,609	3,609
Implant 3 Insertion	-	4,843	14,530	-	-		0%	14,530	29,348	-	30,313	30,313
PSI Implant 3 Inserted	-	7	21	-	-		-%	14,530	14,839	-	44	44
Non-PSI Implant 3 Inserted	-	4,836	14,509	-	-		-%	-	14,509	-	30,269	30,269
Implant 5	3,880	(776)	1,553	46,656	7,485		(79)%	3,351	14,899	-	4,283	4,283
PSI Implant 5 Distributed Inserted (	(3,457)	(2,647)	(11,397)	-	(3,471)		-%	(18,068)	(83,113)	-	(31,435)	(31,435)
Jadelle	7,337	1,871	12,950	46,656	10,956	9/09	18%	21,419	98,012	-	35,718	35,718
Implant 5 Insertion	3,741	6,501	23,243	-	3,752		519%	19,994	100,631	-	71,232	71,232
PSI Implant 5 Inserted	3,457	2,647	11,397	-	3,471		228%	18,068	83,113	-	34,928	34,928
Non-PSI Implant 5 Inserted	284	3,854	11,846	-	281		4,116%	1,926	17,518	-	36,304	36,304
Injectable 3	7,553	2,348	14,597	422,467	14,559		0%	126,833	1,830,792	-	1,957	1,957
PSI Injectable 3 Distributed Provide	(1,656)	(1,373)	(5,775)	-	(2,319)		-%	(7,886)	(19,775)	-	(774)	(774)
Confiance Depo-Provera	1,440	3,121	10,803	272,467	12,344	9/03	(12)%	129,721	1,835,998	-	1,449	1,449
Sayana Press	7,769	600	9,569	150,000	4,534	10/15	111%	4,998	14,569	-	1,283	1,283

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Injectable 3 Provided</b>	<b>1,864</b>	<b>1,528</b>	<b>6,449</b>	-	<b>2,504</b>		<b>158%</b>	<b>8,514</b>	<b>21,307</b>	-	<b>961</b>	<b>961</b>
PSI Injectable 3 Provided	<b>1,656</b>	<b>1,373</b>	<b>5,775</b>	-	<b>2,319</b>		149%	<b>7,886</b>	<b>19,775</b>	-	<b>860</b>	<b>860</b>
Non-PSI Injectable 3 Provided	<b>208</b>	<b>155</b>	<b>674</b>	-	<b>185</b>		264%	<b>628</b>	<b>1,532</b>	-	<b>100</b>	<b>100</b>
<b>IPTp2</b>	-	-	-	<b>836,961</b>	-		<b>0%</b>	-	-	-	-	-
IPTp2	-	-	-	<b>836,961</b>	-		-%	-	-	-	-	-
<b>IUD 10</b>	<b>1,141</b>	<b>335</b>	<b>2,146</b>	<b>5,203</b>	<b>615</b>		<b>249%</b>	<b>2,590</b>	<b>30,402</b>	-	<b>7,305</b>	<b>7,305</b>
PSI IUD 10 Distributed Inserted (1)	<b>(150)</b>	<b>(264)</b>	<b>(943)</b>	-	<b>(680)</b>		-%	<b>(2,334)</b>	<b>(9,703)</b>	-	<b>(3,210)</b>	<b>(3,210)</b>
Confiance	<b>1,291</b>	<b>599</b>	<b>3,089</b>	<b>5,203</b>	<b>1,295</b>	9/03	139%	<b>4,924</b>	<b>40,105</b>	-	<b>10,515</b>	<b>10,515</b>
<b>IUD 10 Insertion</b>	<b>162</b>	<b>902</b>	<b>2,867</b>	-	<b>681</b>		<b>321%</b>	<b>2,538</b>	<b>11,991</b>	-	<b>10,844</b>	<b>10,844</b>
PSI IUD 10 Inserted	<b>150</b>	<b>264</b>	<b>943</b>	-	<b>680</b>		39%	<b>2,334</b>	<b>9,703</b>	-	<b>3,567</b>	<b>3,567</b>
Non-PSI IUD 10 Inserted	<b>12</b>	<b>637</b>	<b>1,924</b>	-	<b>1</b>		192,300%	<b>204</b>	<b>2,288</b>	-	<b>7,277</b>	<b>7,277</b>
<b>LLIN</b>	<b>98,224</b>	<b>65,717</b>	<b>295,376</b>	<b>8,769,882</b>	<b>2,574,333</b>		<b>(89)%</b>	<b>22,968,572</b>	<b>67,421,190</b>	-	<b>107,933</b>	<b>107,933</b>
Dawa Plus Large Rectangular Mosc	-	-	-	<b>8,037,600</b>	-	11/15	-%	<b>7,782,222</b>	<b>8,666,468</b>	-	-	-
Dawa Plus Rectangular Mosquito Net	-	-	-	-	<b>369,892</b>	11/15	(100)%	<b>11,733,728</b>	<b>13,740,547</b>	-	-	-
Olyset 160X180X150 cm	-	-	-	-	-	7/14	-%	<b>13,803</b>	<b>3,680,169</b>	-	-	-
PermaNet	<b>98,224</b>	<b>65,717</b>	<b>295,376</b>	-	<b>427,832</b>	9/06	(31)%	<b>1,662,210</b>	<b>37,549,104</b>	-	<b>107,933</b>	<b>107,933</b>
Yorkool Rectangular Mosquito Net	-	-	-	<b>732,282</b>	<b>1,776,609</b>	11/15	(100)%	<b>1,776,609</b>	<b>3,784,902</b>	-	-	-
<b>Lubricant</b>	<b>6,000</b>	<b>4,350</b>	<b>19,050</b>	-	-		<b>0%</b>	-	<b>38,450</b>	-	-	-
Personal Lubricant 4.5 g	<b>6,000</b>	<b>4,350</b>	<b>19,050</b>	-	-	7/13	-%	-	<b>38,450</b>	-	-	-
<b>Malaria PPT (ACT)</b>	<b>655,276</b>	<b>472,001</b>	<b>2,071,279</b>	<b>3,944,752</b>	<b>1,060,039</b>		<b>95%</b>	<b>2,805,565</b>	<b>13,373,534</b>	-	<b>621,207</b>	<b>621,207</b>
PSI QAACTs Distributed Provided	-	-	-	-	-		-%	<b>(2,034,979)</b>	<b>(2,034,979)</b>	-	-	-
ACT 1 (2 to 11 months)	<b>58,126</b>	<b>34,299</b>	<b>161,022</b>	<b>3,944,752</b>	<b>148,048</b>	4/11	9%	<b>445,352</b>	<b>1,336,328</b>	-	<b>48,293</b>	<b>48,293</b>
ACT 2 (1 to 5 years)	<b>182,811</b>	<b>120,649</b>	<b>544,757</b>	-	<b>291,476</b>	4/11	87%	<b>1,210,730</b>	<b>4,983,371</b>	-	<b>163,381</b>	<b>163,381</b>
ACT 3 (6 to 13 years)	<b>152,934</b>	<b>155,490</b>	<b>619,403</b>	-	<b>245,708</b>	12/13	152%	<b>1,268,434</b>	<b>4,068,495</b>	-	<b>185,768</b>	<b>185,768</b>
ACT 4 (over 13 years)	<b>261,405</b>	<b>161,564</b>	<b>746,097</b>	-	<b>374,807</b>	12/13	99%	<b>1,916,028</b>	<b>5,020,319</b>	-	<b>223,765</b>	<b>223,765</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Malaria RDK	192,425	273,558	1,013,100	7,503,315	1,744,933		(42)%	3,773,657	9,572,644	-	-	-
SD Bioline	192,425	273,558	1,013,100	7,503,315	1,744,933	12/13	(42)%	3,773,657	9,572,644	-	-	-
OCs	39,777	6,805	60,191	1,273,200	12,571		379%	739,882	4,417,844	-	2,186	2,186
PSI OCs Distributed Provided	(2,724)	(2,615)	(10,568)	-	(714)		-%	(9,528)	(25,316)	-	(384)	(384)
Combination 3	32,295	7,858	55,870	1,102,500	13,285	11/11	321%	749,410	4,428,271	-	2,029	2,029
Microgynon	1,140	-	1,140	-	-	8/16	-%	-	1,140	-	41	41
Microlut	9,066	1,561	13,749	170,700	-	2/17	-%	-	13,749	-	499	499
OCs Provided	3,015	3,046	12,152	-	1,157		950%	10,744	28,436	-	490	490
PSI OCs Provided	2,724	2,615	10,568	-	714		1,380%	9,528	25,316	-	426	426
Non-PSI OCs Provided	291	431	1,584	-	443		258%	1,216	3,120	-	64	64
ORS	-	89,152	267,456	-	-		0%	-	267,456	-	10,427	10,427
ORS	-	89,152	267,456	-	-	10/16	-%	-	267,456	-	10,427	10,427
Positive RDTs	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
Positive RDTs	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Treatm	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
Positive RDTs Given First Line Trea	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
PUR	220,320	155,520	686,880	1,292,000	324,364		112%	929,884	3,871,961	-	63	63
P&G Purifiant	-	-	-	-	26,204	12/13	(100)%	26,204	907,200	-	-	-
P&G Purifiant Water	220,320	155,520	686,880	1,292,000	298,160	3/14	130%	903,680	2,964,761	-	63	63
QAACTs Provided after Confirmatory I	-	-	-	-	-		0%	2,034,979	2,034,979	-	-	-
PSI QAACTs Provided after Confirm	-	-	-	-	-		-%	2,034,979	2,034,979	-	-	-
SDM (Cycle Beads)	2,185	20	2,244	5,756	1,847		21%	4,731	84,003	-	2,849	2,849
PSI SDM (Cycle Beads) Distributed	(300)	(473)	(1,719)	-	(295)		-%	(2,561)	(5,071)	-	(2,183)	(2,183)
CycleBeads	2,485	493	3,963	5,756	2,142	9/04	85%	7,292	89,074	-	5,032	5,032
SDM (Cycle Beads) Provided	350	561	2,033	-	328		520%	2,763	5,631	-	2,868	2,868

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI SDM (Cycle Beads) Provided	300	473	1,719	-	295		483%	2,561	5,071	-	2,425	2,425
Non-PSI SDM (Cycle Beads) Provid	50	88	314	-	33		852%	202	560	-	443	443
Water Treatment Tablets	-	14,647	43,942	725,000	5,750,524		(99)%	13,584,989	53,594,478	-	8	8
Aquatab	-	14,647	43,942	725,000	5,750,524	7/08	(99)%	13,584,989	53,594,478	-	8	8
Zinc	-	297,033	891,100	-	-		0%	-	891,100	-	11,806	11,806
Zinc Sulfate 20 mg	-	297,033	891,100	-	-	10/16	-%	-	891,100	-	11,806	11,806
<b>Cote d'Ivoire</b>										400	332	732
CD4 Tests Provided to HIV+ Clients	12	17	63	-	-		0%	-	63	-	-	-
CD4 Tests Provided to HIV+ Clients	12	17	63	-	-		-%	-	63	-	-	-
Free Condom	27,392	39,789	146,760	238,320	245,822		(40)%	469,778	4,960,511	355	319	674
Free Distribution	27,392	39,789	146,760	238,320	245,822	1/08	(40)%	469,778	4,960,511	355	319	674
Free Female Condom	4,399	1,076	7,627	11,000	10,991		(31)%	10,272	58,763	18	13	31
Female Condom Free	4,399	1,076	7,627	11,000	10,991	8/12	(31)%	10,272	58,763	18	13	31
HIV Testing Services	1,572	738	3,787	17,260	5,372		(30)%	11,043	99,895	27	-	27
VCT Individual (HIV-Negative)	1,503	692	3,579	16,569	5,290	1/10	(32)%	10,827	95,279	26	-	26
VCT Individual (HIV-Positive)	69	46	208	691	82	1/10	154%	216	4,616	1	-	1
Lubricant	574	1,076	3,802	-	30,353		(87)%	28,568	61,449	-	-	-
Gel Lubricant 4.5 g	574	1,076	3,802	-	30,353	9/12	(87)%	28,568	61,449	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		0%	-	18	-	-	-
Referral to CD4/Clinical Staging	-	-	-	553	-		-%	-	18	-	-	-
Referral to HIV Testing Services	-	-	-	-	5,372		(100)%	5,401	6,185	-	-	-
Referral to HIV Testing & Counselin	-	-	-	-	5,372		(100)%	5,401	6,185	-	-	-
<b>Ghana</b>										3,014	103,193	106,207
Condom	32,080	220,412	693,316	1,572,430	-		0%	73,612	766,928	3,014	1,015	4,029
Protector	32,080	220,412	693,316	1,572,430	-		-%	73,612	766,928	3,014	1,015	4,029

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Injectable 3	74,375	417,009	1,325,401	427,249	-		0%	4,771	1,330,172	-	91,431	91,431
Famplan	74,375	417,009	1,325,401	427,249	-		-%	4,771	1,330,172	-	91,431	91,431
OCs	67,320	169,340	575,340	1,797,801	-		0%	174,665	750,005	-	10,747	10,747
Secure	67,320	169,340	575,340	1,797,801	-		-%	174,665	750,005	-	10,747	10,747
Water Treatment Tablets	-	-	-	1,761,730	-		0%	-	-	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	1,761,730	-		-%	-	-	-	-	-
<b>Guinea</b>										3,402	38,825	42,227
Condom	-	-	-	-	1,891,965		(100)%	2,535,165	49,102,734	-	-	-
Prudence Plus	-	-	-	-	1,891,965	1/08	(100)%	2,535,165	49,102,734	-	-	-
Diarrhea Treatment Kit	82,380	111,140	415,800	-	275,465		51%	426,665	2,697,986	-	22,393	22,393
Orasel Zinc DTK	82,380	111,140	415,800	-	275,465	9/12	51%	426,665	2,697,986	-	22,393	22,393
Female Condom	-	11,000	33,000	-	-		0%	-	33,000	23	70	93
Condom Feminin	-	11,000	33,000	-	-	5/16	-%	-	33,000	23	70	93
Free Condom	1,051,200	1,260,400	4,832,400	42,136,556	-		0%	864,000	5,696,400	3,379	13,338	16,717
Condom Combo	-	22,000	66,000	-	-	11/16	-%	-	66,000	46	182	228
Generic Combo Pack	-	-	-	1,086,696	-		-%	-	-	-	-	-
Generic Condom	1,051,200	1,238,400	4,766,400	-	-	11/16	-%	864,000	5,630,400	3,333	13,155	16,488
Generic Male Condom	-	-	-	41,049,860	-		-%	-	-	-	-	-
Free Female Condom	-	-	-	435,985	-		0%	-	-	-	-	-
Generic Female Condom	-	-	-	435,985	-		-%	-	-	-	-	-
Injectable 3	-	-	-	-	40,255		(100)%	60,259	1,438,474	-	-	-
Equilibre	-	-	-	-	40,255	9/07	(100)%	60,259	1,438,474	-	-	-
Lubricant	-	384,000	1,152,000	-	-		0%	-	1,152,000	-	-	-
Vanilla Scented Lubricant Sachet, 3.	-	384,000	1,152,000	-	-	10/16	-%	-	1,152,000	-	-	-
OCs	-	-	-	-	99,163		(100)%	218,035	6,447,369	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Planyl	-	-	-	-	99,163	12/95	(100)%	218,035	6,447,369	-	-	-
Safe Water Solution	36,901	188,028	600,985	-	31,296		1820%	46,632	3,986,759	-	3,025	3,025
Sur Eau	36,901	188,028	600,985	-	31,296	7/06	1,820%	46,632	3,986,759	-	3,025	3,025
TB Diagnosis	-	-	-	-	-		0%	10,219	10,219	-	-	-
TB Diagnosis	-	-	-	-	-		-%	10,219	10,219	-	-	-
TB DOTS	-	-	-	-	-		0%	5,763	5,763	-	-	-
TB DOTS	-	-	-	-	-		-%	5,763	5,763	-	-	-
TB Screening	-	-	-	-	-		0%	7,139	7,139	-	-	-
TB Screening	-	-	-	-	-		-%	7,139	7,139	-	-	-
<b>Liberia</b>										1,745	1,143	2,889
Condom	69,120	129,024	456,192	1,100,000	239,616		90%	1,014,608	4,766,818	1,745	974	2,719
STAR	69,120	129,024	456,192	1,100,000	239,616	7/09	90%	1,014,608	4,766,818	1,745	974	2,719
Free Condom	-	-	-	500,000	-		0%	-	47,208	-	-	-
Free Condom	-	-	-	500,000	-	11/13	-%	-	47,208	-	-	-
HIV Testing Services	90	20	151	-	-		0%	-	1,956	1	-	1
VCT Individual (HIV-Negative)	76	15	121	-	-	5/14	-%	-	1,908	1	-	1
VCT Individual (HIV-Positive)	14	5	30	-	-	5/14	-%	-	48	-	-	-
Implant 5	-	-	-	-	-		0%	3,030	4,745	-	-	-
Jadelle	-	-	-	-	-	11/13	-%	3,030	4,745	-	-	-
Referral to HIV Testing Services	-	-	-	50,000	-		0%	-	1	-	-	-
Referral to HIV Testing & Counseling	-	-	-	50,000	-	12/13	-%	-	1	-	-	-
Safe Water Solution	4,320	13,184	43,872	50,000	3,720		1079%	13,272	697,210	-	169	169
WaterGuard	4,320	13,184	43,872	50,000	3,720	7/09	1,079%	13,272	697,210	-	169	169
<b>Mali</b>										-	767,364	767,364
Cervical Cancer-VIA and Cryotherapy	-	30	89	719	117		(24)%	599	818	-	40	40

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Cervical Cancer-VIA and Cryotherapy	-	30	89	719	117	12/13	(24)%	599	818	-	40	40
Cervical Cancer-VIA/VILI Screening	47	2,149	6,494	-	3,597		81%	23,345	36,364	-	-	-
Cervical Cancer-VIA/VILI Screening	47	2,149	6,494	-	3,597		81%	23,345	36,364	-	-	-
Condom Provided	-	-	-	-	6		(100)%	18	88	-	-	-
Non-PSI Condom Provided	-	-	-	-	6		(100)%	18	88	-	-	-
Family Planning Counseling	-	-	-	-	173		(100)%	659	688	-	-	-
Family Planning Counseling	-	-	-	-	173		(100)%	659	688	-	-	-
Free Condom	-	-	-	110,000	72,200		(100)%	204,200	916,360	-	-	-
Protector Free	-	-	-	110,000	-	1/08	-%	-	72,000	-	-	-
Protector Plus Free	-	-	-	-	72,200	4/14	(100)%	204,200	844,360	-	-	-
Free Female Condom	-	-	-	-	150		(100)%	150	150	-	-	-
Protectiv Free	-	-	-	-	150	1/08	(100)%	150	150	-	-	-
HIV Testing Services	-	-	-	-	4,351		(100)%	4,351	128,136	-	-	-
VCT Concordant Couple (HIV-Nega	-	-	-	-	6	1/10	(100)%	6	611	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	4,230	1/10	(100)%	4,230	124,942	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	115	1/10	(100)%	115	2,583	-	-	-
Implant 3	-	-	-	-	181		(100)%	-	(3,198)	-	-	-
PSI Implant 3 Distributed Inserted (	-	-	-	-	(19)		-%	(200)	(3,398)	-	-	-
Implanon NXT	-	-	-	-	200	2/16	(100)%	200	200	-	-	-
Implant 3 Insertion	112	133	510	10,000	19		2584%	796	4,504	-	1,197	1,197
PSI Implant 3 Inserted	-	-	-	-	19		(100)%	200	3,398	-	-	-
Non-PSI Implant 3 Inserted	112	133	510	10,000	-		-%	596	1,106	-	1,197	1,197
Implant 5	-	-	-	-	(522)		0%	(30)	(1,060)	-	-	-
PSI Implant 5 Distributed Inserted (	-	-	-	-	(2,632)		-%	(2,340)	(108,214)	-	-	-
Jadelle	-	-	-	-	2,110	7/09	(100)%	2,310	107,154	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	1,776	1,563	6,466	21,000	8,827		(27)%	28,286	151,648	-	22,330	22,330
PSI Implant 5 Inserted	-	-	-	-	2,632		(100)%	2,340	108,214	-	-	-
Non-PSI Implant 5 Inserted	1,776	1,563	6,466	21,000	6,195		4%	25,946	43,434	-	22,330	22,330
Injectable 3	-	-	-	-	33,264		(100)%	95,040	4,053,900	-	-	-
Confiance Injectable	-	-	-	-	33,264	5/03	(100)%	95,040	4,053,900	-	-	-
Injectable 3 Provided	79	53	238	-	323		(26)%	739	2,256	-	40	40
Non-PSI Injectable 3 Provided	79	53	238	-	323		(26)%	739	2,256	-	40	40
IUD 10	200	207	820	6,000	(3,740)		0%	1,783	(48,583)	-	3,154	3,154
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(6,390)		-%	(2,650)	(67,117)	-	-	-
IUD Copper T 380A	200	207	820	6,000	2,650	12/13	(69)%	4,433	18,534	-	3,154	3,154
IUD 10 Insertion	917	1,226	4,594	23,000	6,390		(28)%	21,400	90,584	-	19,631	19,631
PSI IUD 10 Inserted	-	-	-	-	6,390		(100)%	2,650	67,117	-	-	-
Non-PSI IUD 10 Inserted	917	1,226	4,594	23,000	-		-%	18,750	23,467	-	19,631	19,631
LLIN	-	455,025	1,365,076	3,210,000	161,041		748%	2,275,809	11,962,946	-	541,912	541,912
MILD - (G)	-	453,500	1,360,500	3,210,000	-	10/14	-%	549,100	6,547,319	-	540,096	540,096
MILD - (O)	-	-	-	-	-	9/16	-%	336,140	336,140	-	-	-
MILD - (U)	-	1,525	4,576	-	161,041	12/14	(97)%	1,390,569	5,079,487	-	1,817	1,817
Lubricant	-	-	-	-	19		(100)%	19	19	-	-	-
Lubricant	-	-	-	-	19		(100)%	19	19	-	-	-
Malaria PPT (ACT)	-	106,670	320,010	320,000	2,011,813		(84)%	2,256,073	6,062,584	-	169,580	169,580
Coartem 12 tabs	-	32,000	96,000	96,000	405,755	5/10	(76)%	464,105	1,556,315	-	50,872	50,872
Coartem 24 tabs	-	-	-	-	1,005,793	10/14	(100)%	1,005,793	1,876,259	-	-	-
Coartem 6 tabs	-	74,670	224,010	224,000	600,265	5/10	(63)%	786,175	2,630,010	-	118,708	118,708
Manual Vacuum Aspiration for PAC	183	185	739	1,555	85		769%	1,384	2,194	-	417	417
MVA for PAC	183	185	739	1,555	85	7/15	769%	1,384	2,194	-	417	417

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Misoprostol for PAC (Oral)	-	-	-	-	-		0%	2,400	2,400	-	-	-
Misoprostol for PAC (oral)	-	-	-	-	-	9/16	-%	2,400	2,400	-	-	-
Misoprostol for PAC (oral) Provided	1,902	1,824	7,374	8,000	-		0%	933	8,307	-	1,388	1,388
Non-PSI Misoprostol for PAC (oral) I	1,902	1,824	7,374	8,000	-		-%	933	8,307	-	1,388	1,388
OCs	-	57,867	173,600	173,600	64,960		167%	197,680	14,158,129	-	7,077	7,077
Pilplan	-	57,867	173,600	173,600	64,960	5/03	167%	197,680	14,158,129	-	7,077	7,077
OCs Provided	23	44	154	-	95		62%	262	658	-	7	7
Non-PSI OCs Provided	23	44	154	-	95		62%	262	658	-	7	7
SDM (Cycle Beads) Provided	-	1	2	-	-		0%	1	10	-	3	3
Non-PSI SDM (Cycle Beads) Provid	-	1	2	-	-		-%	1	10	-	3	3
Toilets Constructed	571	530	2,162	3,000	-		0%	-	2,162	-	579	579
Toilet Type 1	571	530	2,162	3,000	-	10/16	-%	-	2,162	-	579	579
Toilets Sold	571	530	2,162	-	-		0%	2,598	4,760	-	-	-
Toilet Type 1, Direct Sales	571	530	2,162	-	-		-%	2,598	4,760	-	-	-
Water Treatment Tablets	12,800	9,600	41,600	2,324,000	-		0%	176,000	42,186,870	-	7	7
Aquatab	12,800	9,600	41,600	2,324,000	-	2/09	-%	176,000	42,186,870	-	7	7
<b>Niger</b>										18	3,936	3,954
Condom Provided	-	-	-	-	-		0%	10,223	10,223	-	-	-
Non-PSI Condom Provided	-	-	-	-	-		-%	10,223	10,223	-	-	-
Free Condom	-	-	-	280,000	-		0%	465,120	465,120	-	-	-
Generic Condom	-	-	-	280,000	-	6/16	-%	465,120	465,120	-	-	-
HIV Testing Services	842	474	2,264	4,400	-		0%	9,319	11,583	18	-	18
VCT Concordant Couple (HIV-Nega)	-	-	-	-	-		-%	127	127	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	-		-%	6	6	-	-	-
VCT Individual (HIV-Negative)	827	470	2,236	4,385	-		-%	8,639	10,875	18	-	18

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	15	4	28	15	-		-%	547	575	-	-	-
Implant 3 Insertion	292	165	788	1,614	-		0%	807	1,595	-	1,818	1,818
Non-PSI Implant 3 Inserted	292	165	788	1,614	-		-%	807	1,595	-	1,818	1,818
Implant 5 Insertion	9	-	9	900	-		0%	430	439	-	30	30
Non-PSI Implant 5 Inserted	9	-	9	900	-		-%	430	439	-	30	30
Injectable 3 Provided	576	277	1,406	1,000	-		0%	821	2,227	-	232	232
Non-PSI Injectable 3 Provided	576	277	1,406	1,000	-		-%	821	2,227	-	232	232
IUD 10 Insertion	52	85	308	400	-		0%	198	506	-	1,288	1,288
Non-PSI IUD 10 Inserted	52	85	308	400	-		-%	198	506	-	1,288	1,288
Manual Vacuum Aspiration for PAC	-	-	-	40	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	40	-	1/16	-%	-	-	-	-	-
Misoprostol for PAC (Oral)	-	-	-	1,306	-		0%	-	-	-	-	-
Misoprostol for PAC (oral)	-	-	-	1,306	-		-%	-	-	-	-	-
OCs Provided	2,783	3,316	12,730	15,000	-		0%	11,744	24,474	-	568	568
Non-PSI OCs Provided	2,783	3,316	12,730	15,000	-		-%	11,744	24,474	-	568	568
Referral to IUD 10 Insertion	-	-	-	-	-		0%	22	22	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-		-%	22	22	-	-	-
<b>Nigeria</b>										327,084	855,277	1,182,361
Cervical Cancer-Pap Smear Screening	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	1,450		(100)%	1,450	1,450	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	111	333	-	403		(17)%	1,652	2,388	-	74	74
Cervical Cancer-VIA and Cryotherap	-	111	333	-	403	3/16	(17)%	1,652	2,388	-	74	74
Cervical Cancer-VIA/VILI Screening	-	2,091	6,274	-	5,203		21%	26,108	48,911	-	-	-
Cervical Cancer-VIA/VILI Screening	-	2,091	6,274	-	5,203		21%	26,108	48,911	-	-	-
Chlorhexidine	6,606	21,867	72,206	200,000	-		0%	46,000	118,206	-	7,265	7,265

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Chlorxy-G Gel 25 gm tube	6,606	21,867	72,206	200,000	-	11/16	-%	46,000	118,206	-	7,265	7,265
Clean Delivery Kit	-	-	-	15,000	1,800		(100)%	4,400	43,750	-	-	-
Clean Delivery Kit	-	-	-	15,000	1,800	9/10	(100)%	4,400	43,750	-	-	-
Condom	5,641,026	9,508,152	34,165,482	125,100,000	44,379,024		(23)%	126,960,705	3,074,811,188	294,628	108,860	403,488
Gold Circle	5,382,240	9,183,360	32,932,320	120,000,000	43,031,616	3/90	(23)%	122,269,932	3,059,607,956	283,994	104,931	388,925
Gold Circle Flex	230,922	292,608	1,108,746	4,500,000	1,158,192	5/14	(4)%	4,119,660	8,283,978	9,561	3,533	13,094
Lifestyle - Flavours	7,128	9,936	36,936	120,000	50,544	10/06	(27)%	160,281	1,636,086	319	118	436
Lifestyle - Original Small Cartons	5,832	3,240	15,552	120,000	34,992	10/06	(56)%	102,384	1,505,172	134	50	184
Lifestyle - Ribbed	7,128	10,584	38,880	180,000	48,600	10/06	(20)%	153,576	1,902,189	335	124	459
Lifestyle - Ultra Thin	7,776	8,424	33,048	180,000	55,080	10/06	(40)%	154,872	1,875,807	285	105	390
Diarrhea Treatment Kit	7,200	52,533	164,800	450,000	121,800		35%	387,800	1,096,325	-	13,210	13,210
Pediatric Zinc Sulphate Tabs/ORS C	7,200	52,533	164,800	450,000	121,800	2/14	35%	387,800	1,096,325	-	13,210	13,210
Emergency Contraception	173,958	110,592	505,734	2,000,000	624,536		(19)%	1,790,360	12,522,405	-	6,074	6,074
Postinor II	173,958	110,592	505,734	2,000,000	624,536	4/99	(19)%	1,790,360	12,522,405	-	6,074	6,074
Female Condom	3,894	2,829	12,382	200,000	202,440		(94)%	455,376	6,472,960	107	30	137
Female Condom	3,894	2,829	12,382	200,000	202,440	7/09	(94)%	455,376	6,472,960	107	30	137
Free Condom	-	1,250,400	3,751,200	18,000,000	2,116,800		77%	24,724,944	100,521,833	32,349	11,952	44,301
Condom Sample	-	384,000	1,152,000	-	2,030,400	12/05	(43)%	10,821,744	84,019,433	9,934	3,671	13,605
GF HIV Condom	-	866,400	2,599,200	18,000,000	86,400	1/16	2,908%	13,903,200	16,502,400	22,414	8,282	30,696
Free Female Condom	-	-	-	500,000	-		0%	-	-	-	-	-
Free Female Condoms	-	-	-	500,000	-		-%	-	-	-	-	-
HIV Testing Services	-	-	-	-	-		0%	82,009	1,876,117	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	-	12/09	-%	78,516	1,738,272	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	-	12/09	-%	3,493	137,845	-	-	-
Implant 5	300	960	3,180	12,000	3,770		(16)%	13,852	91,543	-	9,850	9,850

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Distributed Inserted (	-	-	-	-	-		-%	(548)	(18,830)	-	-	-
Jadelle	300	960	3,180	12,000	3,770	9/07	(16)%	14,400	110,373	-	9,850	9,850
Implant 5 Insertion	2,342	2,199	8,940	-	6,936		29%	22,903	92,094	-	30,768	30,768
PSI Implant 5 Inserted	-	-	-	-	-		-%	548	18,830	-	-	-
Non-PSI Implant 5 Inserted	2,342	2,199	8,940	-	6,936	3/16	29%	22,355	73,264	-	30,768	30,768
Injectable 2	32,606	91,067	305,806	1,000,000	307,000		0%	1,508,326	15,278,500	-	30,605	30,605
Noristerat	32,606	91,067	305,806	1,000,000	307,000	12/95	-%	1,508,326	15,278,500	-	30,605	30,605
Injectable 3	43,706	100,033	343,806	1,200,000	440,800		(22)%	1,476,701	15,631,047	-	51,613	51,613
Depo-Provera	43,706	100,033	343,806	1,200,000	440,800	12/95	(22)%	1,476,701	15,631,047	-	51,613	51,613
Iron Folic Acid Tablet	-	1,200	3,600	-	-		0%	14,500	18,100	-	-	-
Folic Acid 5 mg	-	1,200	3,600	-	-	11/16	-%	14,500	18,100	-	-	-
IUD 10	906	3,420	11,166	50,000	13,020		(14)%	68,597	1,404,963	-	42,779	42,779
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	-		-%	(1,243)	(95,577)	-	-	-
Copper T 380	-	-	-	50,000	-	9/12	-%	-	21,250	-	-	-
IUD	906	3,420	11,166	-	13,020	5/93	(14)%	69,840	1,479,290	-	42,779	42,779
IUD 10 Insertion	5,703	5,640	22,624	-	18,470		22%	62,607	319,473	-	96,308	96,308
PSI IUD 10 Inserted	-	-	-	-	-		-%	1,243	95,577	-	-	-
Non-PSI IUD 10 Inserted	5,703	5,640	22,624	-	18,470	3/16	22%	61,364	223,896	-	96,308	96,308
LLIN	15	5,052	15,170	20,000	2,901,215		(99)%	5,218,177	19,013,648	-	2,893	2,893
GF Rectangular Net	-	-	-	-	2,897,480	11/13	(100)%	5,204,770	16,582,137	-	-	-
PermaNet	15	767	2,315	20,000	1,380	11/04	68%	3,795	2,157,436	-	441	441
Permanet Rectangular (220 x210x 1	-	4,260	12,780	-	1,905	1/16	571%	8,662	21,442	-	2,437	2,437
PermaNet Student	-	25	75	-	450	9/06	(83)%	950	252,633	-	14	14
Lubricant	1,265	2,660	9,244	-	51,940		(82)%	202,288	1,693,858	-	-	-
Lubrica	1,265	2,555	8,930	-	51,940	12/03	(83)%	118,895	1,610,151	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant 30 ml Sachet	-	105	314	-	-	1/16	-%	83,393	83,707	-	-	-
<b>Malaria PPT (ACT)</b>	<b>565,458</b>	<b>162,300</b>	<b>1,052,357</b>	-	<b>2,445,495</b>		<b>(57)%</b>	<b>7,018,483</b>	<b>37,360,888</b>	-	<b>373,984</b>	<b>373,984</b>
ACT 1 (Lumartem 6's)	8,646	9,480	37,086	-	480	1/16	7,626%	8,280	45,366	-	13,180	13,180
ACT 1 (Yellow)	94,500	27,537	177,111	-	731,500	9/12	(76)%	2,202,000	9,875,998	-	62,941	62,941
ACT 2 (Blue)	143,700	20,962	206,586	-	622,500	9/12	(67)%	1,853,860	9,521,550	-	73,416	73,416
ACT 2 (Lumartem 12's)	32,766	35,160	138,246	-	1,860	1/16	7,333%	142,920	281,166	-	49,130	49,130
ACT 3 (Lumartem 18's)	7,560	10,320	38,520	-	80	1/16	48,050%	3,600	42,120	-	13,689	13,689
ACT 3 (Orange)	35,280	2	35,286	-	360,900	9/12	(90)%	556,560	6,597,284	-	12,540	12,540
ACT 4 (Green)	204,480	20,679	266,516	-	727,740	9/12	(63)%	2,156,943	10,750,078	-	94,714	94,714
ACT 4 (Lumartem 24's)	38,526	38,160	153,006	-	435	1/16	35,074%	94,320	247,326	-	54,375	54,375
<b>Malaria RDK</b>	-	<b>25,634</b>	<b>76,902</b>	-	<b>1,580,175</b>		<b>(95)%</b>	<b>5,103,442</b>	<b>6,511,667</b>	-	-	-
GF Malaria Test Kit (Access Bio by :)	-	2,700	8,100	-	1,580,175	1/16	(99)%	4,882,275	4,890,375	-	-	-
Rapid Diagnostic Test (RDT) Kit	-	22,934	68,802	-	-	9/10	-%	221,167	1,621,292	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	-	-	-	-	-		<b>0%</b>	<b>5,296</b>	<b>5,296</b>	-	-	-
MVA for PAC	-	-	-	-	-	11/16	-%	5,296	5,296	-	-	-
<b>Misoprostol for PAC (Oral)</b>	<b>2,300</b>	<b>3,267</b>	<b>12,100</b>	<b>600,000</b>	<b>156,100</b>		<b>(92)%</b>	<b>403,100</b>	<b>1,010,150</b>	-	<b>2,838</b>	<b>2,838</b>
Misoprostol for PAC (oral)	2,300	3,267	12,100	600,000	156,100	3/15	(92)%	403,100	1,010,150	-	2,838	2,838
<b>Misoprostol for PPH</b>	-	-	-	<b>300,000</b>	-		<b>0%</b>	-	<b>349,630</b>	-	-	-
Misoprostol	-	-	-	300,000	-	7/11	-%	-	349,630	-	-	-
<b>OCs</b>	<b>210,156</b>	<b>466,500</b>	<b>1,609,656</b>	<b>7,500,000</b>	<b>2,183,400</b>		<b>(26)%</b>	<b>7,389,890</b>	<b>35,472,848</b>	-	<b>65,430</b>	<b>65,430</b>
Combination 3	210,156	466,500	1,609,656	7,500,000	2,183,400	10/11	(26)%	7,389,890	35,472,848	-	65,430	65,430
<b>PUR</b>	<b>246</b>	<b>13,920</b>	<b>42,006</b>	<b>3,500,000</b>	<b>383,280</b>		<b>(89)%</b>	<b>5,058,720</b>	<b>15,725,691</b>	-	<b>3</b>	<b>3</b>
PuR	246	13,920	42,006	3,500,000	383,280	1/08	(89)%	5,058,720	15,725,691	-	3	3
<b>Safe Water Solution</b>	<b>5,094</b>	<b>8,560</b>	<b>30,774</b>	<b>150,000</b>	<b>66,076</b>		<b>(53)%</b>	<b>101,095</b>	<b>8,110,446</b>	-	<b>240</b>	<b>240</b>
WaterGuard	-	8,560	25,680	-	66,076	11/04	(61)%	101,095	8,105,352	-	198	198

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
WaterGuard Plus (1000L)	5,094	-	5,094	150,000	-	4/17	-%	-	5,094	-	42	42
SDM (Cycle Beads)	6	100	306	10,000	3,000		(90)%	12,300	200,447	-	436	436
CycleBeads	6	100	306	10,000	3,000	7/06	(90)%	12,300	200,447	-	436	436
STI Screening	-	-	-	-	-		0%	13,407	13,407	-	-	-
STI Screening	-	-	-	-	-		-%	13,407	13,407	-	-	-
Tubal Ligation	5	1	8	-	-		0%	-	8	-	57	57
Tubal Ligation	5	1	8	-	-		-%	-	8	-	57	57
Vasectomy	-	-	1	-	-		0%	-	1	-	7	7
Vasectomy	-	-	1	-	-		-%	-	1	-	7	7
<b>Senegal</b>										-	175	175
Acute Malnutrition Screening_CU5	61	54	223	-	-		0%	-	223	-	-	-
Acute Malnutrition Screening_CU5	61	54	223	-	-		-%	-	223	-	-	-
Condom	-	-	-	9,123,403	1,871,936		(100)%	4,252,780	23,213,453	-	-	-
Fagaru	-	-	-	1,876,597	777,680	11/12	(100)%	1,443,536	7,903,016	-	-	-
Protec	-	-	-	3,623,403	-	11/12	-%	-	1,160,433	-	-	-
Protec Fraise	-	-	-	655,380	209,088	1/13	(100)%	524,304	2,817,860	-	-	-
Protec Naturel	-	-	-	2,742,231	874,368	1/13	(100)%	2,108,540	10,576,852	-	-	-
Protec Vanille	-	-	-	225,792	10,800	1/13	(100)%	176,400	755,292	-	-	-
Counseling & Tx for Moderate Acute M	5	1	8	-	-		0%	-	8	-	-	-
Counseling & Tx for Moderate Acute	5	1	8	-	-		-%	-	8	-	-	-
HIV Testing Services	16	11	50	-	-		0%	-	50	-	-	-
VCT Individual (HIV-Negative)	16	10	47	-	-		-%	-	47	-	-	-
VCT Individual (HIV-Positive)	-	1	3	-	-		-%	-	3	-	-	-
Implant 3 Insertion	-	18	53	-	-		0%	-	53	-	66	66
Non-PSI Implant 3 Inserted	-	18	53	-	-		-%	-	53	-	66	66

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 4 Insertion	22	-	22	-	-		0%	-	22	-	34	34
Non-PSI Implant 4 Inserted	22	-	22	-	-		-%	-	22	-	34	34
Implant 5 Insertion	1	10	32	-	-		0%	-	32	-	58	58
Non-PSI Implant 5 Inserted	1	10	32	-	-		-%	-	32	-	58	58
Injectable 3	-	-	-	30,000	-		0%	300	42,606	-	-	-
Depo-Provera	-	-	-	-	-	11/12	-%	300	42,606	-	-	-
Securil Press	-	-	-	30,000	-		-%	-	-	-	-	-
Injectable 3 Provided	14	5	28	-	-		0%	-	28	-	2	2
Non-PSI Injectable 3 Provided	14	5	28	-	-		-%	-	28	-	2	2
IPTp2	8	13	46	-	-		0%	-	46	-	3	3
IPTp2	8	13	46	-	-		-%	-	46	-	3	3
IUD 5 Insertion	7	-	7	-	-		0%	-	7	-	12	12
Non-PSI IUD 5 Inserted	7	-	7	-	-		-%	-	7	-	12	12
LLIN	-	-	-	300,000	39,983		(100)%	155,089	665,731	-	-	-
MILDA	-	-	-	300,000	39,983	8/13	(100)%	155,089	665,731	-	-	-
OCs	-	-	-	500,000	147,764		(100)%	509,798	2,303,585	-	-	-
Securil	-	-	-	500,000	147,764	11/12	(100)%	509,798	2,303,585	-	-	-
Treatment for Severe Acute Malnutritic	3	-	4	-	-		0%	-	4	-	-	-
Treatment for Severe Acute Malnutri	3	-	4	-	-		-%	-	4	-	-	-
Water Treatment Tablets	-	-	-	1,650,000	930,060		(100)%	2,678,060	6,691,416	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	1,650,000	930,060	11/12	(100)%	2,678,060	6,691,416	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>West and Central Africa</b>															
<b>Benin</b>							\$27,850		\$31,344	\$36,724	0.85				
<b>Other Revenues</b>															
Amour et Vie +	04/2017	9,500	900	0	10,400	9%	\$771	0%	\$0	\$2,194	NA	51,961	28,233	1.84	
<b>Condom</b>															
Kool	04/2017	85,608	2,868	0	88,476	3%	\$4,038	19%	\$787	\$6,608	0.12	1,814,873	142,292	12.75	
Prudence Plus	04/2017	192,960	1,512	0	194,472	1%	\$3,790	0%	\$1,385	\$6,481	0.21	6,106,486	335,345	18.21	
<b>Female Condom</b>															
Cupid	04/2017	0	0	0	0	NA	\$0	NA	\$1	\$31	0.03	24	4,616	0.01	
Femidom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,807	3,168	2.46	
<b>LLIN</b>															
Super Moustiquaire Longue Durée	04/2017	70	0	0	70	0%	\$283	42%	\$406	\$369	1.10	7,150	91	78.57	
SuperMoustiquaire (blanche 1 plac	04/2017	0	0	0	0	NA	\$0	NA	\$173	\$87	1.99	2,157	24	88.64	
SuperMoustiquaire (blanche 3 plac	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$9	NA	43	2	21.50	
<b>Retreatment</b>															
Alafia	04/2017	0	0	0	0	NA	\$0	NA	\$2,212	\$0	NA	0	0	NA	
<b>Diarrhea Treatment Kit</b>															
Orasel Zinc DTK	04/2017	11,599	0	0	11,599	0%	\$5,566	55%	\$6,258	\$6,573	0.95	59,991	13,977	4.29	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	04/2017	8,260	0	0	8,260	0%	\$1,341	19%	\$386	\$1,434	0.27	141,856	8,853	16.02	
<b>ORS</b>															
Orasel	04/2017	0	0	0	0	NA	\$0	NA	\$1,218	\$0	NA	0	0	NA	
<b>Water Treatment Tablets</b>															
Aquatab	04/2017	352,200	1,200	0	353,400	0%	\$4,707	45%	\$2,695	\$5,520	0.49	5,396,360	416,533	12.96	
<b>Implant 5</b>															
Implant 5 (insertion)	04/2017	440	80	0	520	15%	\$215	0%	\$10	\$205	0.05	27,949	2,113	13.23	
<b>Injectable 2</b>															
Noristerat	04/2017	3,727	480	1	4,208	11%	\$2,504	72%	\$2,428	\$2,085	1.16	77,636	3,276	23.70	
<b>Injectable 3</b>															
Equilibre	04/2017	0	0	0	0	NA	\$0	NA	\$1,944	\$0	NA	0	0	NA	
<b>IUD 10</b>															
IUD (insertion)	04/2017	100	580	0	680	85%	\$16	0%	\$0	NA	NA	14,320	NA	NA	
IUD Copper-T TCU 380A	04/2017	562	0	0	562	0%	\$92	0%	\$33	\$95	0.34	50,422	1,383	36.45	
<b>OCs</b>															
Harmonie	04/2017	0	0	0	0	NA	\$0	NA	\$1,480	\$0	NA	0	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Benin</b>							\$27,850		\$31,344	\$36,724	0.85				
<b>OCs</b>															
Laafia Pilule	04/2017	22,320	81	0	22,401	0%	\$4,528	88%	\$9,929	\$5,008	1.98	9,400	24,912	0.38	
Microgynon	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	148,551	0	NA	
<b>SDM (Cycle Beads)</b>															
CycleBeads	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$19	NA	5,915	46	128.59	
<b>Cameroon</b>							\$35,592		\$67,340	\$47,774	1.41				
<b>HIV Test Kit</b>															
HIV Determine Test	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	13,000	0	NA	
HIV ORAQUICK	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	14	0	NA	
<b>Medicines &amp; Supplies</b>															
MEDBAR AMIU KIT	04/2017	38	0	0	38	0%	\$929	5%	\$42	\$399	0.10	384	16	23.51	
<b>Other Revenues</b>															
100% Jeune	04/2017	-64	0	0	-64	0%	-\$16	100%	-\$20	\$38	-0.54	38,333	246	155.83	
<b>Condom</b>															
Lovers Plus	04/2017	0	0	-4,572	-4,572	NA	\$0	NA	\$2,561	\$165	15.52	175,000	-42,600	-4.11	
Préservatif Masculin Aromatisé UN	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50,256	0	NA	
Préservatif Masculin UNFPA	04/2017	0	500	0	500	100%	\$0	NA	\$0	\$0	NA	2,242,212	7,457	300.67	
Prudence Plus	04/2017	0	0	0	0	NA	\$0	NA	\$738	\$0	NA	0	0	NA	
Prudence Plus Nouveau	04/2017	31,320	792	0	32,112	2%	\$827	15%	\$91	\$17,615	0.01	32,313,133	756,012	42.74	
<b>Female Condom</b>															
Préservatif Féminin CUPID	04/2017	0	25	-2,100	-2,075	100%	\$0	NA	\$2,211	\$0	NA	513,252	33	15,397.56	
Préservatif Féminins UNFPA	04/2017	1,440	590	0	2,030	29%	\$53	0%	-\$1,213	\$28	-43.74	653,920	1,729	378.13	
Protectiv Plus	04/2017	0	0	0	0	NA	\$0	NA	\$7	\$0	NA	675,884	333	2,027.65	
Securite Plus Female Condom	04/2017	0	0	0	0	NA	\$0	NA	-\$514	\$0	NA	1,483,460	0	NA	
<b>Free Condom</b>															
Generic MC	04/2017	0	780	0	780	100%	\$0	NA	\$0	\$0	NA	607,116	1,075	564.93	
<b>Free Female Condom</b>															
Generic FC	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	117,500	0	NA	
<b>Lubricant A</b>															
Water-based Lubricant, 4 mL sach	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	11,325	750	15.10	
<b>Lubricant E</b>															
Lubricant 60 mL bottle	04/2017	92	15	0	107	14%	\$67	0%	-\$8	\$65	-0.13	8,438	99	85.23	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$35,592		\$67,340	\$47,774	1.41				
<u>LLIN</u>															
Super Moustiquaire	04/2017	2,394	0	0	2,394	0%	\$16,151	22%	\$12,109	\$9,428	1.28	29,753	1,406	21.17	
Super Moustiquaire Interceptor	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	7,570	0	NA	
<u>Malaria PPT (ACT)</u>															
ACT 2 (ASAQ 50 / 135.5 mg, 3 tab)	04/2017	0	2,450	0	2,450	100%	\$0	NA	\$0	\$0	NA	12,550	817	15.37	
ACT 3 (ASAQ 100 / 270 mg, 3 tabl)	04/2017	0	700	0	700	100%	\$0	NA	\$0	\$0	NA	4,557	308	14.78	
ACT 4 (ASAQ 100 / 270 mg, 6 tabl)	04/2017	0	915	0	915	100%	\$0	NA	\$0	\$0	NA	4,085	373	10.94	
<u>Malaria RDK</u>															
Malaria Ag Pf/Pan_PA	04/2017	0	4,975	0	4,975	100%	\$0	NA	\$0	\$0	NA	19,400	1,867	10.39	
<u>Diarrhea Treatment Kit</u>															
Orasel Zinc	04/2017	2,730	984	0	3,714	26%	\$1,676	68%	\$11,164	\$5,543	2.01	52,947	9,868	5.37	
<u>Micronutrient Powder</u>															
Super Bebe	04/2017	131,991	150	0	132,141	0%	\$2,555	53%	\$2,831	\$1,921	1.47	1,386,499	107,027	12.95	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	04/2017	11,760	80	0	11,840	1%	\$2,671	19%	\$15,324	\$2,654	5.77	249,840	11,987	20.84	
<u>ORS</u>															
Orasel	04/2017	0	0	0	0	NA	\$0	NA	\$2,619	\$0	NA	1,515	0	NA	
<u>Safe Water Solution</u>															
Sur'Eau Water Guard	04/2017	0	0	0	0	NA	\$0	NA	\$314	NA	NA	0	NA	NA	
<u>Water Treatment Tablets</u>															
Aquatabs 67 mg (20 L)	04/2017	26,550	50	0	26,600	0%	\$4,912	80%	\$6,343	\$2,903	2.18	26,511	16,000	1.66	
<u>Zinc</u>															
Zinc	04/2017	1,581	20	0	1,601	1%	\$260	0%	-\$15	\$432	-0.03	22,404	2,634	8.51	
<u>Emergency Contraception</u>															
Norlevo	04/2017	2,163	45	0	2,208	2%	\$2,641	50%	\$6,053	\$2,978	2.03	104,079	2,529	41.15	
<u>Implant 3</u>															
Implanon NXT	04/2017	1,380	46	0	1,426	3%	\$1,138	80%	\$3,298	\$1,696	1.94	29,075	2,136	13.61	
<u>Implant 5</u>															
Jadelle UNFPA	04/2017	720	120	0	840	14%	\$665	8%	-\$110	\$645	-0.17	6,011	817	7.36	
<u>Injectable 3</u>															
Depo-Provera UNFPA	04/2017	3,300	75	0	3,375	2%	\$306	2%	-\$366	\$83	-4.40	56,465	1,466	38.51	
Equilibre	04/2017	3,411	95	0	3,506	3%	\$324	76%	\$3,029	\$556	5.45	449,391	6,119	73.44	
<u>IUD 10</u>															
DIU UNFPA	04/2017	0	0	0	0	NA	\$0	NA	\$12	\$0	NA	2,727	200	13.64	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Cameroon</b>							\$35,592		\$67,340	\$47,774	1.41				
<u>IUD 10</u>															
IUD	04/2017	1,500	250	0	1,750	14%	\$61	23%	\$25	\$56	0.46	80,847	1,450	55.76	
IUD Copper T 380A	04/2017	150	150	0	300	50%	\$6	29%	\$11	\$9	1.18	19,023	403	47.20	
<u>OCs</u>															
Microgynon Ed Fe	04/2017	4,740	30	0	4,770	1%	\$155	15%	\$105	\$87	1.20	14,460	2,700	5.36	
Novelle Duo	04/2017	5,236	120	0	5,356	2%	\$210	73%	\$700	\$473	1.48	438,926	12,140	36.15	
<u>Pneumonia PPT</u>															
Amoxicillin 500mg x 15's -- Childre	04/2017	0	14,640	0	14,640	100%	\$0	NA	\$0	\$0	NA	42,960	4,880	8.80	
Amoxicillin 500mg x 7's - Children	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,400	0	NA	
<b>Congo-Kinshasa</b>							\$26,197		\$0	\$20,422	NA				
<u>HIV Test Kit</u>															
Determine	04/2017	0	900	0	900	100%	\$0	NA	\$0	\$0	NA	10,500	400	26.25	
Uni Gold Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	840	13	63.00	
<u>Medicines &amp; Supplies</u>															
Amoxicillin 250 mg	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	328,524	16,688	19.69	
Artésunate 200mg Suppositoire	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	21,577	766	28.16	
Artesunate 60 mg Injectable	04/2017	0	16,588	0	16,588	100%	\$0	NA	\$0	\$0	NA	0	11,639	NA	
COTRIMOXAZOLE Comprimés de	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	363,000	0	NA	
COTRIMOXAZOLE Suspension fla	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,225	0	NA	
La Sulfadoxine-Pyriméthamine	04/2017	0	485,151	315,000	800,151	100%	\$0	NA	\$0	\$0	NA	487,849	412,050	1.18	
Mebendazole 100 mg	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,135,000	30,000	37.83	
MEBENDAZOLE Comprimés de 5	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	33,000	0	NA	
MULTIVITAMINE en Comprimés	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,000	0	NA	
NEVIRAPINE Comprimés de 200	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	16,800	0	NA	
NEVIRAPINE ORAL flacon de 240	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15	0	NA	
Quinine HCl/Sulf 300 mg base tabl	04/2017	0	0	2,000	2,000	NA	\$0	NA	\$0	\$0	NA	0	19,000	NA	
Quinine Injectable 600 mg / 2ml	04/2017	0	0	530	530	NA	\$0	NA	\$0	\$0	NA	1	2,800	0.00	
ZIDOVUDINE Comprimés de 300	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,000	0	NA	
<u>Other Revenues</u>															
100% Jeune	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5,476	0	NA	



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$26,197		\$0	\$20,422	NA				
<b>Condom</b>															
Prudence	04/2017	81,024	192	0	81,216	0%	\$3,428	0%	\$0	\$2,596	NA	29,492,514	64,728	455.64	
Prudence Sensuel	04/2017	255,072	6,580	45,120	306,772	3%	\$8,833	0%	\$0	\$4,452	NA	31,537,719	120,584	261.54	
<b>Female Condom</b>															
Prudence Femme	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	107,751	41	2,606.88	
<b>Free Condom</b>															
Generic MC	04/2017	0	706,980	2,673	709,653	100%	\$0	NA	\$0	\$0	NA	8,047,747	777,193	10.35	
<b>Free Female Condom</b>															
Generic FC	04/2017	0	64,200	0	64,200	100%	\$0	NA	\$0	\$0	NA	833,800	61,067	13.65	
<b>Lubricant A</b>															
Personal Lubricant 4.5 g	04/2017	0	6,000	0	6,000	100%	\$0	NA	\$0	\$0	NA	30,949	6,350	4.87	
<b>LLIN</b>															
Dawa Plus Rectangular Mosquito	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	16	0	NA	
PermaNet-Rectangular	04/2017	0	98,224	0	98,224	100%	\$0	NA	\$0	\$0	NA	95,635	94,544	1.01	
Yorkool Rectangular Mosquito Net	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2	0	NA	
<b>Malaria PPT (ACT)</b>															
ACT 1 (2 to 11 months)	04/2017	0	58,126	82,574	140,700	100%	\$0	NA	\$0	\$0	NA	167,452	43,241	3.87	
ACT 2 (1 to 5 years)	04/2017	0	182,811	412,540	595,351	100%	\$0	NA	\$0	\$0	NA	661,385	172,506	3.83	
ACT 3 (6 to 13 years)	04/2017	0	152,934	362,494	515,428	100%	\$0	NA	\$0	\$0	NA	697,088	206,468	3.38	
ACT 4 (over 13 years)	04/2017	0	261,405	241,750	503,155	100%	\$0	NA	\$0	\$0	NA	793,594	248,699	3.19	
<b>Malaria RDK</b>															
SD Bioline	04/2017	0	192,425	287,289	479,714	100%	\$0	NA	\$0	\$0	NA	614,500	323,817	1.90	
<b>Diarrhea Treatment Kit</b>															
ORA-ZINC	04/2017	92	6,122	0	6,214	99%	\$62	0%	\$0	\$152	NA	156,811	2,814	55.73	
<b>ORS</b>															
ORS	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	232,999	89,152	2.61	
<b>PUR</b>															
P&G Purifiant Water	04/2017	219,840	480	42,000	262,320	0%	\$11,780	0%	\$0	\$9,789	NA	1,887,250	204,880	9.21	
<b>Zinc</b>															
Zinc Sulfate 20 mg	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,312,900	297,033	4.42	
<b>Emergency Contraception</b>															
Norlevo	04/2017	1,440	1,212	0	2,652	46%	\$928	0%	\$0	\$1,472	NA	3,780	2,798	1.35	
<b>Implant 3</b>															
Implanon	04/2017	11	512	0	523	98%	\$21	0%	\$0	\$587	NA	3,702	641	5.78	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Congo-Kinshasa</b>							\$26,197		\$0	\$20,422	NA				
<u>Implant 5</u>															
Jadelle	04/2017	0	7,337	0	7,337	100%	\$0	NA	\$0	\$304	NA	39,181	4,317	9.08	
<u>Injectable 3</u>															
Confiance Depo-Provera	04/2017	0	1,440	0	1,440	100%	\$0	NA	\$0	\$300	NA	353,551	3,004	117.68	
Sayana Press	04/2017	381	7,388	248	8,017	95%	\$219	0%	\$0	\$128	NA	50,430	3,190	15.81	
<u>IUD 10</u>															
Confiance	04/2017	15	1,276	0	1,291	99%	\$6	0%	\$0	\$57	NA	4,775	1,029	4.64	
<u>OCs</u>															
Combination 3	04/2017	8,340	23,955	0	32,295	74%	\$575	0%	\$0	\$357	NA	1,267,994	17,833	71.10	
Microgynon	04/2017	0	1,140	0	1,140	100%	\$0	NA	\$0	\$0	NA	65,790	380	173.13	
Microlut	04/2017	4,570	4,496	1,800	10,866	50%	\$316	0%	\$0	\$153	NA	99,250	4,583	21.66	
<u>SDM (Cycle Beads)</u>															
CycleBeads	04/2017	85	2,400	0	2,485	97%	\$29	0%	\$0	\$74	NA	25,992	1,304	19.93	
<b>Cote d'Ivoire</b>							\$0		\$776	\$0	NA				
<u>Free Condom</u>															
Free Distribution	04/2017	0	27,392	0	27,392	100%	\$0	NA	\$0	\$0	NA	460,302	48,920	9.41	
<u>Free Female Condom</u>															
Female Condom Free	04/2017	0	4,399	0	4,399	100%	\$0	NA	\$0	\$0	NA	4,236	2,542	1.67	
<u>Lubricant A</u>															
Gel Lubricant 4.5 g	04/2017	0	574	0	574	100%	\$0	NA	\$0	\$0	NA	30,000	1,267	23.67	
<u>LifeStraw</u>															
Life Straw - PLWHIV	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	5	NA	NA	
<u>Water Treatment Tablets</u>															
Aquatab	04/2017	0	0	0	0	NA	\$0	NA	\$776	\$0	NA	0	0	NA	
<b>Ghana</b>							\$14,231		\$55,442	\$48,400	1.15				
<u>Condom</u>															
Protector	04/2017	32,080	0	0	32,080	0%	\$1,860	11%	\$24,468	\$10,206	2.40	2,945,472	228,972	12.86	
<u>Injectable 3</u>															
Famplan	04/2017	74,375	0	0	74,375	0%	\$3,494	0%	\$9,094	\$18,023	0.50	1,086,556	384,417	2.83	
<u>OCs</u>															
Secure	04/2017	67,320	0	0	67,320	0%	\$8,877	4%	\$21,880	\$20,171	1.08	4,503,997	180,900	24.90	
<b>Guinea</b>							\$0		\$5,306	\$0	NA				
<u>Condom</u>															
Prudence Plus	04/2017	0	0	324,667	324,667	NA	\$0	NA	\$0	\$0	NA	7,973,743	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guinea</b>							\$0		\$5,306	\$0	NA				
<u>Female Condom</u>															
Condom Feminin	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	244,848	11,000	22.26	
<u>Free Condom</u>															
Condom Combo	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	180,500	22,000	8.20	
Generic Condom	04/2017	0	1,051,200	0	1,051,200	100%	\$0	NA	\$0	\$0	NA	19,630,320	931,200	21.08	
<u>Lubricant A</u>															
Vanilla Scented Lubricant Sachet,	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	9,047,494	360,000	25.13	
<u>Diarrhea Treatment Kit</u>															
Orasel Zinc DTK	04/2017	0	82,380	0	82,380	100%	\$0	NA	\$4,347	\$0	NA	54,981	138,600	0.40	
<u>Safe Water Solution</u>															
Sur Eau	04/2017	0	36,901	0	36,901	100%	\$0	NA	\$0	\$0	NA	7,325	200,328	0.04	
<u>Injectable 3</u>															
Equilibre	04/2017	0	0	0	0	NA	\$0	NA	\$959	\$0	NA	394,780	0	NA	
<u>OCs</u>															
Planyl	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	227,895	0	NA	
<b>Liberia</b>							\$4,104		\$460	\$3,788	0.12				
<u>Condom</u>															
STAR	04/2017	69,120	0	0	69,120	0%	\$3,037	0%	\$460	\$2,971	0.15	970,378	67,584	14.36	
<u>Safe Water Solution</u>															
WaterGuard	04/2017	4,320	0	2,664	6,984	0%	\$1,067	0%	\$0	\$816	NA	12,576	3,736	3.37	
<b>Nigeria</b>							\$349,034		\$0	\$428,532	NA				
<u>HIV Test Kit</u>															
Determine	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	227,320	31,867	7.13	
Stat Pak	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,760	207	23.03	
Uni Gold Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	690	66	10.51	
<u>Medicines &amp; Supplies</u>															
Fersolate (Iron 200 mg)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	33,425	3,068	10.89	
Sulfadoxine 500mg/ Pyrimethamin	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,041,526	0	NA	
<u>Condom</u>															
Gold Circle	04/2017	5,382,144	96	0	5,382,240	0%	\$112,447	0%	\$0	\$169,483	NA	43,376,016	8,125,472	5.34	
Gold Circle Flex	04/2017	230,904	18	0	230,922	0%	\$15,437	0%	\$0	\$20,817	NA	1,716,093	311,622	5.51	
Lifestyle - Flavours	04/2017	7,128	0	0	7,128	0%	\$935	0%	\$0	\$1,331	NA	95,955	10,152	9.45	
Lifestyle - Original Small Cartons	04/2017	5,832	0	0	5,832	0%	\$765	0%	\$0	\$566	NA	48,660	4,320	11.26	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$349,034		\$0	\$428,532	NA				
<b>Condom</b>															
Lifestyle - Ribbed	04/2017	7,128	0	0	7,128	0%	\$935	0%	\$0	\$1,331	NA	183,150	10,152	18.04	
Lifestyle - Ultra Thin	04/2017	7,776	0	0	7,776	0%	\$1,020	0%	\$0	\$1,161	NA	182,298	8,856	20.58	
<b>Female Condom</b>															
Female Condom	04/2017	3,888	6	0	3,894	0%	\$125	0%	\$0	\$115	NA	1,478,739	3,602	410.53	
<b>Free Condom</b>															
Condom Sample	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	173,468	384,000	0.45	
GF HIV Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	9,861,179	453,600	21.74	
<b>Lubricant C</b>															
Lubricant 30 ml Sachet	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	94	80	1.18	
<b>Lubricant E</b>															
Lubrica	04/2017	1,260	5	0	1,265	0%	\$2,224	0%	\$0	\$1,762	NA	131,722	1,483	88.80	
<b>LLIN</b>															
GF Rectangular Net	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	887,336	0	NA	
PermaNet-Conical	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$35	NA	425	7	63.75	
PermaNet-Rectangular	04/2017	15	0	0	15	0%	\$101	0%	\$0	\$4,402	NA	9,520	665	14.32	
Permanet Rectangular (220 x210x	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$5,262	NA	769,132	813	945.65	
PermaNet Student	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$59	NA	283	17	16.98	
<b>Malaria PPT (ACT)</b>															
ACT 1 (Lumartem 6's)	04/2017	8,640	6	0	8,646	0%	\$832	0%	\$0	\$1,185	NA	46,290	12,362	3.74	
ACT 1 (Yellow)	04/2017	94,500	0	0	94,500	0%	\$1,516	0%	\$0	\$945	NA	169,665	59,037	2.87	
ACT 2 (Blue)	04/2017	143,700	0	0	143,700	0%	\$4,611	0%	\$0	\$2,206	NA	1,543,090	68,862	22.41	
ACT 2 (Lumartem 12's)	04/2017	32,760	6	0	32,766	0%	\$4,731	0%	\$0	\$6,562	NA	90,366	45,602	1.98	
ACT 3 (Lumartem 18's)	04/2017	7,560	0	0	7,560	0%	\$1,383	0%	\$0	\$2,340	NA	49,720	12,840	3.87	
ACT 3 (Orange)	04/2017	35,280	0	0	35,280	0%	\$4,529	0%	\$0	\$1,510	NA	105,300	11,762	8.95	
ACT 4 (Green)	04/2017	204,480	0	0	204,480	0%	\$13,124	0%	\$0	\$5,695	NA	428,513	88,839	4.82	
ACT 4 (Lumartem 24's)	04/2017	38,520	6	0	38,526	0%	\$8,653	0%	\$0	\$11,417	NA	116,406	51,002	2.28	
<b>Malaria RDK</b>															
GF Malaria Test Kit (Access Bio by	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,825,225	2,700	1,787.12	
Rapid Diagnostic Test (RDT) Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	322,531	22,934	14.06	
<b>Chlorhexidine</b>															
Chloroxy-G Gel 25 gm tube	04/2017	6,600	6	0	6,606	0%	\$3,558	0%	\$0	\$10,226	NA	541,794	23,135	23.42	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nigeria</b>							\$349,034		\$0	\$428,532	NA				
<u>Clean Delivery Kit</u>															
Clean Delivery Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,045	0	NA	
<u>Diarrhea Treatment Kit</u>															
Pediatric Zinc Sulphate Tabs/ORS	04/2017	7,200	0	0	7,200	0%	\$2,888	0%	\$0	\$14,775	NA	66,843	44,733	1.49	
<u>Iron Folic Acid Tablet</u>															
Folic Acid 5 mg	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	63,275	1,200	52.73	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	04/2017	2,300	0	0	2,300	0%	\$443	0%	\$0	\$603	NA	71,400	3,033	23.54	
<u>PUR</u>															
PuR	04/2017	240	6	0	246	2%	\$12	0%	\$0	\$491	NA	3,762,103	13,362	281.55	
<u>Safe Water Solution</u>															
WaterGuard	04/2017	0	0	21,502	21,502	NA	\$0	NA	\$0	\$6,856	NA	0	8,552	NA	
WaterGuard Plus (1000L)	04/2017	5,088	6	0	5,094	0%	\$3,889	0%	\$0	NA	NA	22,552	NA	NA	
<u>Emergency Contraception</u>															
Postinor II	04/2017	173,952	6	0	173,958	0%	\$128,392	0%	\$0	\$91,712	NA	720,346	131,394	5.48	
<u>Implant 5</u>															
Jadelle	04/2017	300	0	0	300	0%	\$366	0%	\$0	\$934	NA	39,403	767	51.40	
<u>Injectable 2</u>															
Noristerat	04/2017	32,600	6	0	32,606	0%	\$8,369	0%	\$0	\$14,489	NA	1,659,065	62,969	26.35	
<u>Injectable 3</u>															
Depo-Provera	04/2017	43,700	6	0	43,706	0%	\$12,621	0%	\$0	\$22,508	NA	2,581,479	85,969	30.03	
<u>IUD 10</u>															
IUD	04/2017	900	6	0	906	1%	\$289	0%	\$0	\$899	NA	166,231	2,802	59.33	
<u>OCs</u>															
Combination 3	04/2017	210,150	6	0	210,156	0%	\$14,837	0%	\$0	\$25,535	NA	6,685,306	391,202	17.09	
<u>SDM (Cycle Beads)</u>															
CycleBeads	04/2017	0	6	0	6	100%	\$0	NA	\$0	\$22	NA	7,424	102	72.78	
<b>Senegal</b>							\$0		\$0	\$0	NA				
<u>Condom</u>															
Fagaru	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,490,350	0	NA	
Protec Fraise	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	776,929	0	NA	
Protec Naturel	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,570,928	0	NA	
Protec Vanille	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	371,208	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Senegal</b>							\$0		\$0	\$0	NA				
<u>LLIN</u>															
MILDA	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,306	0	NA	
<u>Water Treatment Tablets</u>															
Aquatabs 67 mg (20 L)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,402,200	0	NA	
<u>Injectable 3</u>															
Depo-Provera	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	-300	0	NA	
<u>OCs</u>															
Securil	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	528,278	0	NA	



# East Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 4/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
East Africa	19,152	2	-	-	1,773,262	1,350	462,486	9,716	258	617	-	11,186
Burundi	222	-	-	-	12,713	11	2,308	316	-	-	-	319
Ethiopia	23	2	-	-	643	-	105	-	44	-	-	46
Kenya	7,547	-	-	-	340,242	306	86,588	177	37	33	-	331
Malawi	3,594	-	-	-	363,846	404	87,525	133	5	-	-	138
Rwanda	1,227	-	-	-	37,247	11	5,776	-	3	-	-	3
Somaliland	-	-	-	-	716	1	196	-	80	-	-	81
South Sudan	-	-	-	-	-	-	-	9,017	78	584	-	9,914
Tanzania	5,361	-	-	-	708,033	417	182,275	69	4	-	-	292
Uganda	1,179	-	-	-	309,821	200	97,713	4	8	-	-	63

\* Using USAID CYP conversion factors



POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>									<b>775,347</b>	<b>1,739,389</b>	<b>2,514,736</b>
Antiretroviral Treatment (C	6,058	2,624	13,929	6,986	-	-%	5,564	19,493	2,913	-	2,913
Antiretroviral Treatment (I	352	230	1,043	-	-	-%	901	1,944	-	-	-
Basic Care Package	-	133	400	-	17,301,754	(100)%	52,637,120	172,110,122	-	-	-
CD4 Tests Provided to HIV	60	61	243	-	-	-%	-	243	-	-	-
Cervical Cancer-Pap Sme:	-	58	173	-	-	-%	-	173	-	-	-
Cervical Cancer-VIA and C	86	83	336	2,545	707	(52)%	2,707	5,840	-	90	90
Cervical Cancer-VIA and F	-	-	-	102	-	-%	-	19	-	-	-
Cervical Cancer-VIA/VILI §	12,005	5,569	28,713	-	40,196	(29)%	228,181	345,824	-	-	-
Chlorhexidine	10	334	1,011	40,000	-	-%	6,682	7,693	-	63	63
Clean Delivery Kit	342	5,310	16,272	-	4,097	297%	53,992	451,215	-	1,163	1,163
Condom	7,599,970	11,131,204	40,993,583	147,400,070	44,491,378	(8)%	168,965,758	2,105,560,704	587,917	85,077	672,994
Condom Provided	-	-	-	-	907,314	(100)%	2,231,548	2,283,254	-	-	-
Counseling & Tx for Mode	155,147	-	155,147	-	-	-%	-	155,147	-	-	-
Diarrhea Treatment Kit	14,810	13,913	56,548	188,671	65,377	(14)%	176,147	896,925	-	6,061	6,061
Diarrhea Treatment Kit Pri	6,711	-	6,711	-	-	-%	17,338	24,049	-	270	270
Emergency Contraception	1,456	34,813	105,896	154,000	7,846	1,250%	73,906	382,527	-	860	860
Emergency Contraception	141	138	555	2,000	18	2,983%	246	803	-	4	4
Expanded Clean Delivery	-	-	-	25,000	-	-%	-	-	-	-	-
Expanded Clean Delivery	-	-	-	14,000	-	-%	-	-	-	-	-
Family Planning Counseli	-	-	-	-	263	(100)%	17,574	17,574	-	-	-
Female Condom	3,880	94,100	286,180	140,000	405,220	(29)%	1,099,340	11,082,912	2,306	472	2,778

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fever Cases Attended	-	221	664	-	-	-%	26,315	26,979	-	-	-
Fever Cases Tested with I	-	40	121	-	-	-%	7,353	7,474	-	-	-
Fever Cases Tested with F	-	181	543	-	-	-%	18,608	19,151	-	-	-
Free Condom	5,994,418	2,104,062	12,306,605	57,032,717	9,723,679	27%	85,946,047	508,921,551	147,164	28,378	175,543
Free Female Condom	5,381	10,542	37,006	1,419,000	14,328	158%	107,658	2,320,540	478	71	549
HIV Testing Services	32,681	37,971	146,593	332,377	183,608	(20)%	450,690	2,340,459	4,407	-	4,407
Hypertension Diagnosis	-	1,930	5,790	-	-	-%	31,404	37,194	-	-	-
Hypertension Screening	-	19,036	57,107	-	-	-%	129,978	187,085	-	-	-
Hypertension_Controlled	-	1,165	3,495	-	-	-%	25,842	29,337	-	-	-
Implant 3	(1,738)	20,492	59,738	331,101	78,514	(24)%	143,202	711,004	-	76,185	76,185
Implant 3 Insertion	12,696	13,796	54,084	21,248	19,251	181%	127,841	297,622	-	92,976	92,976
Implant 4 Insertion	-	-	-	-	-	-%	1,460	1,460	-	-	-
Implant 5	(1,787)	3,547	8,855	180,121	4,285	107%	63,837	149,548	-	21,386	21,386
Implant 5 Insertion	9,678	9,167	37,178	38,768	17,299	115%	104,800	477,846	-	84,981	84,981
Injectable 3	61,166	284,049	913,314	1,894,283	283,602	222%	857,441	8,385,131	-	97,824	97,824
Injectable 3 Provided	14,323	15,838	61,836	155,758	15,755	292%	62,588	142,531	-	6,411	6,411
IPTp2	312	554	1,974	-	5,302	(63)%	19,006	49,974	-	97	97
IUD 10	1,625	8,326	26,604	(17,071)	43,039	(38)%	(6,010)	158,873	-	72,141	72,141
IUD 10 Insertion	16,613	15,929	64,401	242,836	27,471	134%	195,352	852,483	-	191,367	191,367
IUD 5	(50)	(33)	(148)	-	90	(264)%	484	(3,841)	-	(330)	(330)
IUD 5 Insertion	50	33	149	-	168	(11)%	691	27,892	-	369	369
LLIN	362,184	603,261	2,171,967	7,978,360	1,939,975	12%	9,344,931	65,881,804	-	379,335	379,335

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	193,226	71,336	407,235	-	28,510	1,328%	538,215	1,806,947	-	-	-
Malaria PPT (ACT)	256,728	350,778	1,309,061	3,117,784	1,637,413	(20)%	4,074,406	10,949,796	-	403,157	403,157
Malaria RDK	43,400	-	43,400	1,881,088	42,659	2%	1,596,819	4,190,143	-	-	-
Male Circumcision (HIV-Pi	-	-	-	-	57	(100)%	287	607	-	-	-
Manual Vacuum Aspiratio	83	195	668	250	220	204%	1,253	1,921	-	138	138
Medical Abortion	-	-	-	25,000	-	-%	-	-	-	-	-
Micronutrient Powder	-	-	-	100,000	3,500	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PAC (Oral	8,272	106,640	328,191	750,300	350,952	(6)%	1,265,369	4,355,984	-	11,723	11,723
Misoprostol for PAC (oral)	42	467	1,443	-	-	-%	129	1,572	-	150	150
Misoprostol for PAC (Subl	30	63	218	2,480,200	-	-%	156	374	-	58	58
Misoprostol for PAC (subl	6	11	38	-	-	-%	-	38	-	11	11
Misoprostol for PPH	76,500	204,233	689,200	30,000	379,250	82%	1,634,400	5,010,739	-	2,391	2,391
OCs	1,470,799	341,995	2,496,783	6,170,698	1,397,826	79%	7,878,628	55,237,654	-	64,764	64,764
OCs Provided	4,078	5,155	19,543	39,344	9,418	108%	58,379	90,609	-	589	589
ORS	(90,632)	40,796	31,756	1,086,611	432,264	(93)%	752,366	19,820,737	-	1,045	1,045
ORS Provided	121,954	-	121,954	-	-	-%	5,546	127,500	-	4,427	4,427
Pneumonia PPT	(64,604)	9,552	(35,948)	910,330	69,750	(152)%	266,190	1,153,403	-	(31,558)	(31,558)
Pneumonia PPT Provided	89,387	-	89,387	-	-	-%	19,854	109,241	-	84,291	84,291
Positive RDTs	-	37	110	-	-	-%	3,656	3,766	-	-	-
Positive RDTs Given First	-	37	110	-	-	-%	3,489	3,599	-	-	-
PUR	5,949,649	5,234,426	21,652,927	49,069,647	12,912,601	68%	65,302,222	264,030,636	-	795	795
QAACs Provided after C	-	37	110	-	-	-%	3,815	3,925	-	18	18

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to CD4/Clinical St	-	-	-	2,043	950	(100)%	2,210	3,364	-	-	-
Referral to Clinical Stagin	-	-	-	-	77	(100)%	107	1,893	-	-	-
Referral to Emergency Co	-	2	5	-	14	(64)%	37	133	-	-	-
Referral to HIV Testing Se	386	1,298	4,281	113,410	7,360	(42)%	12,052	109,882	11	-	11
Referral to Implant 3 Inser	-	5	16	8,500	183	(91)%	586	1,600	-	12	12
Referral to Implant 5 Inser	-	8	23	1,500	18	28%	1,717	1,997	-	26	26
Referral to Injectable 3	-	11	34	10,000	494	(93)%	12,012	13,710	-	2	2
Referral to IUD 10 Insertio	-	-	-	11,200	6	(100)%	343	704	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	(100)%	9	49	-	-	-
Referral to Linkage to HIV	-	55	166	-	-	-%	-	166	84	-	84
Referral to OCs	-	2	7	1,500	148	(95)%	2,049	2,725	-	-	-
Referral to STI Diagnosis	13	106	332	-	-	-%	-	332	-	-	-
Referral to STI Screening	554	1,312	4,491	-	-	-%	-	4,491	-	-	-
Referral to STI Treatment	-	-	-	142,281	5	(100)%	5	663	-	-	-
Referral to TB Diagnosis	141	72	356	-	-	-%	-	8,054	-	-	-
Referral to TB DOTS (com	-	-	-	-	26	(100)%	26	1,617	-	-	-
Referral to TB Screening	634	1,578	5,369	-	-	-%	-	5,369	-	-	-
Referral to Treatment for I	-	9	28	-	-	-%	-	133	-	-	-
Referral to Treatment for I	-	9	27	-	5	440%	5	100	-	-	-
Referral to Treatment for I	-	25	74	-	-	-%	-	2,489	-	-	-
Referral to Treatment for \	-	27	80	-	136	(41)%	136	7,118	-	1	1
Referral to Tubal Ligation	-	-	-	-	3	(100)%	3	3	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Tx for Nonherp	-	11	32	-	22	45%	22	994	-	2	2
Referral to Tx for Urethral	-	-	-	-	66	(100)%	66	724	-	-	-
Referral to Voluntary Medi	-	-	-	-	-	-%	42	42	-	-	-
Safe Water Solution	131,496	335,785	1,138,852	4,239,239	887,171	28%	4,616,248	54,202,572	-	4,023	4,023
SDM (Cycle Beads)	-	-	-	-	-	-%	5	418	-	-	-
Skilled Birth Attendance	1,061	2,195	7,645	16,237	6,088	26%	28,307	70,228	-	6,409	6,409
STI Kit (Non-Ulcerative)	320	250	1,070	9,070	7,280	(85)%	18,139	820,306	-	65	65
STI Kit (Ulcerative)	-	-	-	1,121	1,174	(100)%	3,373	71,528	-	-	-
STI Screening	5,645	11,739	40,863	3,000	77,926	(48)%	153,790	331,691	-	-	-
TB Screening	4,840	10,579	36,578	-	75,688	(52)%	143,594	314,148	-	-	-
Treatment for Cervicitis	-	2	5	-	-	-%	-	5	-	-	-
Treatment for Genital Herp	-	-	-	300	-	-%	2	2	-	-	-
Treatment for Inguinal Bul	6	-	7	-	-	-%	-	7	-	-	-
Treatment for Lower Abdc	23	16	70	400	-	-%	4	74	-	-	-
Treatment for Nonherpetic	72	28	157	300	-	-%	14	171	-	23	23
Treatment for Pre-Eclamp	5	13	43	39	-	-%	28	71	-	29	29
Treatment for Severe Acu	16,202	-	16,202	-	-	-%	25,444	41,646	-	20,370	20,370
Treatment for Urethral Dis	125	24	198	700	-	-%	1	199	-	2	2
Treatment for Urethral Dis	119	44	252	900	-	-%	2	254	-	8	8
Treatment for Vaginitis	68	68	271	-	-	-%	67	338	-	6	6
Tubal Ligation	1,094	678	3,129	5,500	508	516%	4,523	8,191	-	18,401	18,401
Vasectomy	-	2	7	-	1	600%	2	11	-	43	43

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Voluntary Medical Male Ci</b>	<b>4,157</b>	<b>1,395</b>	<b>8,341</b>	<b>68,253</b>	<b>8,975</b>	<b>(7)%</b>	<b>30,631</b>	<b>97,375</b>	<b>30,066</b>	<b>-</b>	<b>30,066</b>
<b>Water Treatment Tablets</b>	<b>1,650,800</b>	<b>2,190,313</b>	<b>8,221,740</b>	<b>23,405,999</b>	<b>29,451,650</b>	<b>(72)%</b>	<b>47,341,850</b>	<b>198,654,863</b>	<b>-</b>	<b>1,265</b>	<b>1,265</b>
<b>Zinc</b>	<b>(15,075)</b>	<b>37,043</b>	<b>96,055</b>	<b>312,992</b>	<b>31,206</b>	<b>208%</b>	<b>53,910</b>	<b>1,169,668</b>	<b>-</b>	<b>1,049</b>	<b>1,049</b>
<b>Zinc Provided</b>	<b>33,075</b>	<b>-</b>	<b>33,075</b>	<b>-</b>	<b>-</b>	<b>-%</b>	<b>-</b>	<b>33,075</b>	<b>-</b>	<b>401</b>	<b>401</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>East Africa - All</b>										<b>775,347</b>	<b>1,739,389</b>	<b>2,514,736</b>
<b>Burundi</b>										<b>8,713</b>	<b>29,965</b>	<b>38,678</b>
Antiretroviral Treatment (Currently Enr	466	420	1,727	-	-		0%	-	1,727	324	-	324
Antiretroviral Treatment (Currently E	466	420	1,727	-	-		-%	-	1,727	324	-	324
Antiretroviral Treatment (Newly Enrolle	25	38	139	-	-		0%	-	139	-	-	-
Antiretroviral Treatment (Newly Enrc	25	38	139	-	-		-%	-	139	-	-	-
CD4 Tests Provided to HIV+ Clients	58	61	241	-	-		0%	-	241	-	-	-
CD4 Tests Provided to HIV+ Clients	58	61	241	-	-		-%	-	241	-	-	-
Condom	243,090	150,570	694,800	3,500,000	1,301,701		(47)%	4,273,233	21,137,122	5,082	1,951	7,033
PSI Condom Distributed Provided	-	-	-	-	(1,982)		-%	(7,020)	(9,371)	-	-	-
Prudence Class	243,090	150,570	694,800	3,500,000	1,303,683	12/09	(47)%	4,280,253	21,146,493	5,082	1,951	7,033
Condom Provided	-	-	-	-	1,982		(100)%	7,020	9,371	-	-	-
PSI Condom Provided	-	-	-	-	1,982		(100)%	7,020	9,371	-	-	-
Family Planning Counseling	-	-	-	-	-		0%	1,692	1,692	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	1,692	1,692	-	-	-
Free Condom	72,000	120,000	432,000	1,500,000	391,360		10%	1,591,736	7,204,016	3,160	1,213	4,373
Free Male Condoms	72,000	120,000	432,000	1,500,000	391,360	5/11	10%	1,591,736	7,204,016	3,160	1,213	4,373
Free Female Condom	2,000	3,333	12,000	8,000	-		0%	46,000	113,930	88	26	114
Free Female Condoms	2,000	3,333	12,000	8,000	-	5/11	-%	46,000	113,930	88	26	114
HIV Testing Services	1,309	2,523	8,877	20,300	4,114		116%	20,909	93,356	59	-	59
VCT Concordant Couple (HIV-Nega	-	-	-	-	328	12/09	(100)%	971	3,253	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	7	5/15	(100)%	13	15	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	7	2/12	(100)%	20	26	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	7	2/12	(100)%	20	26	-	-	-
VCT Individual (HIV-Negative)	1,282	2,481	8,725	20,000	3,720	12/09	135%	19,658	88,978	58	-	58

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Individual (HIV-Positive)	27	42	152	300	46	12/09	230%	227	1,058	1	-	1
Implant 5	16	(8)	(8)	600	74		(111)%	(97)	717	-	(22)	(22)
PSI Implant 5 Distributed Inserted (	(87)	(56)	(256)	(1,400)	(297)		-%	(1,062)	(2,305)	-	(697)	(697)
Jadelle	103	48	248	2,000	371	2/14	(33)%	965	3,022	-	675	675
Implant 5 Insertion	87	56	256	1,400	297		(14)%	1,062	2,305	-	774	774
PSI Implant 5 Inserted	87	56	256	1,400	297		(14)%	1,062	2,305	-	774	774
Injectable 3	27	53	187	5,000	1,775		(89)%	3,701	6,534	-	25	25
PSI Injectable 3 Distributed Provide (1,186)	(1,186)	(1,261)	(4,969)	(12,000)	(2,947)		-%	(11,094)	(22,626)	-	(657)	(657)
DMPA 3-month Injectable	1,213	1,314	5,156	17,000	4,722	2/14	9%	14,795	29,160	-	682	682
Injectable 3 Provided	1,186	1,261	4,969	12,000	2,947		69%	11,094	22,626	-	731	731
PSI Injectable 3 Provided	1,186	1,261	4,969	12,000	2,947		69%	11,094	22,626	-	731	731
IUD 10	82	(1)	79	200	135		(41)%	240	944	-	265	265
PSI IUD 10 Distributed Inserted (1)	(16)	(23)	(84)	(500)	(108)		-%	(409)	(763)	-	(282)	(282)
Copper-T 380-A IUD	98	22	163	700	243	2/14	(33)%	649	1,707	-	547	547
IUD 10 Insertion	16	23	84	500	108		(22)%	409	763	-	313	313
PSI IUD 10 Inserted	16	23	84	500	108		(22)%	409	763	-	313	313
LLIN	21,000	82,450	268,350	1,063,950	221,632		21%	604,482	6,674,958	-	24,362	24,362
MII Permanet Free	21,000	82,450	268,350	1,063,950	220,350	4/10	22%	603,200	6,624,958	-	24,362	24,362
Supanet (LLIN)	-	-	-	-	1,282	9/13	(100)%	1,282	50,000	-	-	-
Manual Vacuum Aspiration for PAC	6	6	24	30	-		0%	19	43	-	14	14
MVA for PAC	6	6	24	30	-	6/16	-%	19	43	-	14	14
Misoprostol for PAC (Oral)	15	66	213	300	-		0%	234	447	-	38	38
PSI Misoprostol for PAC Oral Dist F	(39)	(44)	(171)	-	-		-%	-	(171)	-	(30)	(30)
Misoprostol for PAC (oral)	54	110	384	300	-	7/16	-%	234	618	-	68	68
Misoprostol for PAC (oral) Provided	39	44	171	-	-		0%	-	171	-	34	34

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Misoprostol for PAC (oral) Prov	39	44	171	-	-		-%	-	171	-	34	34
Misoprostol for PAC (Sublingual)	30	63	218	200	-		0%	156	374	-	58	58
PSI Misoprostol for PAC Sublingual	(6)	(11)	(38)	-	-		-%	-	(38)	-	(10)	(10)
Misoprostol for PAC (Sublingual)	36	73	256	200	-	7/16	-%	156	412	-	68	68
Misoprostol for PAC (sublingual) Provi	6	11	38	-	-		0%	-	38	-	11	11
PSI Misoprostol for PAC (sublingua	6	11	38	-	-		-%	-	38	-	11	11
OCs	(190)	407	1,030	8,000	2,195		(53)%	4,992	10,490	-	37	37
PSI OCs Distributed Provided	(706)	(631)	(2,600)	(8,000)	(1,732)		-%	(6,795)	(14,461)	-	(93)	(93)
Confiance OC	516	1,038	3,630	16,000	3,927	2/14	(8)%	11,787	24,951	-	130	130
OCs Provided	706	631	2,600	8,000	1,732		50%	6,795	14,461	-	104	104
PSI OCs Provided	706	631	2,600	8,000	1,732		50%	6,795	14,461	-	104	104
Referral to Implant 5 Insertion	-	-	-	1,500	-		0%	1,100	1,100	-	-	-
Referral to Implant 5 Insertion	-	-	-	1,500	-		-%	1,100	1,100	-	-	-
Referral to Injectable 3	-	-	-	10,000	-		0%	8,547	8,547	-	-	-
Referral to Injectable 3	-	-	-	10,000	-		-%	8,547	8,547	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	-		0%	192	192	-	-	-
Referral to IUD 10 Insertion	-	-	-	200	-		-%	192	192	-	-	-
Referral to OCs	-	-	-	1,500	-		0%	1,381	1,381	-	-	-
Referral to OCs	-	-	-	1,500	-		-%	1,381	1,381	-	-	-
Referral to STI Treatment (unknown)	-	-	-	60	-		0%	-	-	-	-	-
Referral to STI Treatment (unknown	-	-	-	60	-		-%	-	-	-	-	-
STI Screening	331	299	1,228	3,000	-		0%	2,374	3,602	-	-	-
STI Screening	331	299	1,228	3,000	-		-%	2,374	3,602	-	-	-
Treatment for Cervicitis	-	2	5	-	-		0%	-	5	-	-	-
Treatment for Cervicitis	-	2	5	-	-		-%	-	5	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Genital Herpes	-	-	-	300	-		0%	-	-	-	-	-
Treatment for Genital Herpes	-	-	-	300	-		-%	-	-	-	-	-
Treatment for Inguinal Bubo	6	-	7	-	-		0%	-	7	-	-	-
Treatment for Inguinal Bubo	6	-	7	-	-		-%	-	7	-	-	-
Treatment for Lower Abdominal Pain	22	13	60	400	-		0%	-	60	-	-	-
Treatment for Lower Abdominal Pair	22	13	60	400	-		-%	-	60	-	-	-
Treatment for Nonherpetic Genital Ulc	67	24	138	300	-		0%	-	138	-	21	21
Treatment for Nonherpetic Genital U	67	24	138	300	-		-%	-	138	-	21	21
Treatment for Urethral Discharge (Mer	118	22	183	700	-		0%	-	183	-	2	2
Treatment for Urethral Discharge (M	118	22	183	700	-		-%	-	183	-	2	2
Treatment for Urethral Discharge (Wor	118	39	236	900	-		0%	-	236	-	8	8
Treatment for Urethral Discharge (W	118	39	236	900	-		-%	-	236	-	8	8
Treatment for Vaginitis	-	1	3	-	-		0%	-	3	-	-	-
Treatment for Vaginitis	-	1	3	-	-		-%	-	3	-	-	-
<b>Ethiopia</b>										983	2,746	3,729
Antiretroviral Treatment (Currently Enr	-	383	1,149	900	-		0%	211	1,360	184	-	184
Antiretroviral Treatment (Currently E	-	383	1,149	900	-		-%	211	1,360	184	-	184
Antiretroviral Treatment (Newly Enrolle	-	77	231	-	-		0%	76	307	-	-	-
Antiretroviral Treatment (Newly Encr	-	77	231	-	-		-%	76	307	-	-	-
CD4 Tests Provided to HIV+ Clients	2	-	2	-	-		0%	-	2	-	-	-
CD4 Tests Provided to HIV+ Clients	2	-	2	-	-		-%	-	2	-	-	-
Free Condom	69,000	-	69,000	19,678,921	3,639,400		(98)%	31,422,325	118,794,037	495	146	641
Generic Male Condom	-	-	-	-	-	8/16	-%	1,439,620	1,439,620	-	-	-
Protector Plus	69,000	-	69,000	19,678,921	3,639,400	12/12	(98)%	29,982,705	117,354,417	495	146	641
Free Female Condom	-	-	-	1,241,000	-		0%	24,500	58,602	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condoms	-	-	-	<b>1,241,000</b>	-	10/13	-%	<b>24,500</b>	<b>58,602</b>	-	-	-
HIV Testing Services	<b>4,575</b>	<b>11,550</b>	<b>39,225</b>	<b>129,100</b>	<b>98,062</b>		<b>(60)%</b>	<b>167,787</b>	<b>893,464</b>	<b>209</b>	-	<b>209</b>
VCT Concordant Couple (HIV-Negati	-	-	-	-	<b>104</b>	4/13	(100)%	<b>269</b>	<b>1,373</b>	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	<b>4</b>	4/13	(100)%	<b>26</b>	<b>150</b>	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	<b>6</b>	5/13	(100)%	<b>13</b>	<b>26</b>	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	<b>6</b>	5/13	(100)%	<b>13</b>	<b>26</b>	-	-	-
VCT Individual (HIV-Negative)	<b>4,438</b>	<b>11,221</b>	<b>38,102</b>	<b>129,100</b>	<b>96,591</b>	3/13	(61)%	<b>163,986</b>	<b>873,005</b>	<b>203</b>	-	<b>203</b>
VCT Individual (HIV-Positive)	<b>137</b>	<b>329</b>	<b>1,123</b>	-	<b>1,351</b>	3/13	(17)%	<b>3,480</b>	<b>18,884</b>	<b>6</b>	-	<b>6</b>
Implant 3	-	-	-	-	-		<b>0%</b>	<b>3</b>	<b>1,088</b>	-	-	-
Implanon	-	-	-	-	-	7/14	-%	<b>3</b>	<b>1,088</b>	-	-	-
Injectable 3	-	-	-	-	-		<b>0%</b>	<b>83</b>	<b>16,400</b>	-	-	-
Depo-Provera	-	-	-	-	-	7/14	-%	<b>83</b>	<b>16,400</b>	-	-	-
PUR	<b>3,468,040</b>	<b>2,532,080</b>	<b>11,064,280</b>	<b>22,469,647</b>	<b>3,285,451</b>		<b>237%</b>	<b>31,608,878</b>	<b>48,251,944</b>	-	<b>425</b>	<b>425</b>
P&G Purifier of Water	<b>3,468,040</b>	<b>2,532,080</b>	<b>11,064,280</b>	<b>22,469,647</b>	<b>3,285,451</b>	11/15	237%	<b>31,608,878</b>	<b>48,251,944</b>	-	<b>425</b>	<b>425</b>
Referral to CD4/Clinical Staging	-	-	-	<b>2,043</b>	<b>56</b>		<b>(100)%</b>	<b>164</b>	<b>1,205</b>	-	-	-
Referral to CD4/Clinical Staging	-	-	-	<b>2,043</b>	<b>56</b>	12/14	(100)%	<b>164</b>	<b>1,205</b>	-	-	-
Referral to Clinical Staging	-	-	-	-	<b>77</b>		<b>(100)%</b>	<b>107</b>	<b>1,893</b>	-	-	-
Referral to Clinical Staging	-	-	-	-	<b>77</b>	12/14	(100)%	<b>107</b>	<b>1,893</b>	-	-	-
Referral to Emergency Contraception	-	<b>2</b>	<b>5</b>	-	<b>14</b>		<b>(64)%</b>	<b>37</b>	<b>133</b>	-	-	-
Referral to Emergency Contraceptio	-	<b>2</b>	<b>5</b>	-	<b>14</b>	2/15	(64)%	<b>37</b>	<b>133</b>	-	-	-
Referral to HIV Testing Services	<b>386</b>	<b>1,298</b>	<b>4,281</b>	<b>113,230</b>	<b>7,360</b>		<b>(42)%</b>	<b>11,934</b>	<b>109,764</b>	<b>11</b>	-	<b>11</b>
Referral to HIV Testing & Counselinç	<b>386</b>	<b>1,298</b>	<b>4,281</b>	<b>113,230</b>	<b>7,360</b>	12/13	(42)%	<b>11,934</b>	<b>109,764</b>	<b>11</b>	-	<b>11</b>
Referral to Implant 3 Insertion	-	<b>5</b>	<b>16</b>	-	<b>183</b>		<b>(91)%</b>	<b>277</b>	<b>1,134</b>	-	<b>12</b>	<b>12</b>
Referral to Implant 3 Insertion	-	<b>5</b>	<b>16</b>	-	<b>183</b>	12/14	(91)%	<b>277</b>	<b>1,134</b>	-	<b>12</b>	<b>12</b>
Referral to Implant 5 Insertion	-	<b>8</b>	<b>23</b>	-	<b>18</b>		<b>28%</b>	<b>24</b>	<b>304</b>	-	<b>26</b>	<b>26</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Implant 5 Insertion	-	8	23	-	18	12/14	28%	24	304	-	26	26
Referral to Injectable 3	-	11	34	-	494		(93)%	711	2,409	-	2	2
Referral to Injectable 3	-	11	34	-	494	1/15	(93)%	711	2,409	-	2	2
Referral to IUD 10 Insertion	-	-	-	-	6		(100)%	9	139	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	6	12/14	(100)%	9	139	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9		(100)%	9	49	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	9	12/14	(100)%	9	49	-	-	-
Referral to Linkage to HIV Care	-	55	166	-	-		0%	-	166	84	-	84
Referral to Linkage to HIV Care	-	55	166	-	-		-%	-	166	84	-	84
Referral to OCs	-	2	7	-	148		(95)%	214	890	-	-	-
Referral to OCs	-	2	7	-	148	1/15	(95)%	214	890	-	-	-
Referral to STI Diagnosis (lab confirme	13	106	332	-	-		0%	-	332	-	-	-
Referrals to STI Diagnosis (lab confi	13	106	332	-	-		-%	-	332	-	-	-
Referral to STI Screening (syndromic)	554	1,312	4,491	-	-		0%	-	4,491	-	-	-
Referrals to STI Screening (syndron	554	1,312	4,491	-	-		-%	-	4,491	-	-	-
Referral to STI Treatment (unknown)	-	-	-	142,221	5		(100)%	5	663	-	-	-
Referral to STI Treatment (unknown	-	-	-	142,221	5	12/14	(100)%	5	663	-	-	-
Referral to TB Diagnosis	141	72	356	-	-		0%	-	8,054	-	-	-
Referral to TB Diagnosis	141	72	356	-	-	12/14	-%	-	8,054	-	-	-
Referral to TB DOTS (completion unkr	-	-	-	-	26		(100)%	26	1,617	-	-	-
Referral to TB DOTS (completion un	-	-	-	-	26	12/13	(100)%	26	1,617	-	-	-
Referral to TB Screening	634	1,578	5,369	-	-		0%	-	5,369	-	-	-
Referrals to TB Screening	634	1,578	5,369	-	-		-%	-	5,369	-	-	-
Referral to Treatment for Inguinal Bub	-	9	28	-	-		0%	-	133	-	-	-
Referral to Treatment for Inguinal Bu	-	9	28	-	-	12/14	-%	-	133	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Treatment for Lower Abdon	-	9	27	-	5		440%	5	100	-	-	-
Referral to Treatment for Lower Abd	-	9	27	-	5	12/14	440%	5	100	-	-	-
Referral to Treatment for Urethral Disc	-	25	74	-	-		0%	-	2,489	-	-	-
Referral to Treatment for Urethral Di	-	25	74	-	-	12/14	-%	-	2,489	-	-	-
Referral to Treatment for Vaginitis	-	27	80	-	136		(41)%	136	7,118	-	1	1
Referral to Treatment for Vaginitis	-	27	80	-	136	12/14	(41)%	136	7,118	-	1	1
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	3		(100)%	3	3	-	-	-
Referral to Tx for Nonherpetic Genital I	-	11	32	-	22		45%	22	994	-	2	2
Referral to Tx for Nonherpetic Genit	-	11	32	-	22	12/14	45%	22	994	-	2	2
Referral to Tx for Urethral Discharge (I	-	-	-	-	66		(100)%	66	724	-	-	-
Referral to Tx for Urethral Discharge	-	-	-	-	66	12/14	(100)%	66	724	-	-	-
Safe Water Solution	6,600	176,205	535,215	2,267,989	248,871		115%	2,928,090	22,879,810	-	2,056	2,056
Wuha Agar	6,600	176,205	535,215	2,267,989	248,871	2/06	115%	2,928,090	22,879,810	-	2,056	2,056
STI Kit (Non-Ulcerative)	320	250	1,070	9,070	7,280		(85)%	18,139	820,306	-	65	65
STI kit for Urethral Discharge	320	140	740	4,280	2,980	11/10	(75)%	7,053	444,382	-	41	41
STI Kit for Vaginal Discharge	-	110	330	4,790	4,300	11/10	(92)%	11,086	375,924	-	25	25
STI Kit (Ulcerative)	-	-	-	1,121	1,174		(100)%	3,373	71,528	-	-	-
STI Kit for Genital Ulcer	-	-	-	1,121	1,174	11/10	(100)%	3,373	71,528	-	-	-
STI Screening	5,314	11,440	39,635	-	77,926		(49)%	151,416	328,089	-	-	-
STI Screening	5,314	11,440	39,635	-	77,926		(49)%	151,416	328,089	-	-	-
TB Screening	4,840	10,579	36,578	-	75,688		(52)%	143,594	314,148	-	-	-
TB Screening	4,840	10,579	36,578	-	75,688		(52)%	143,594	314,148	-	-	-
Treatment for Genital Herpes	-	-	-	-	-		0%	2	2	-	-	-
Treatment for Genital Herpes	-	-	-	-	-		-%	2	2	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Lower Abdominal Pain	1	3	10	-	-		0%	4	14	-	-	-
Treatment for Lower Abdominal Pair	1	3	10	-	-		-%	4	14	-	-	-
Treatment for Nonherpetic Genital Ulc	5	5	19	-	-		0%	14	33	-	3	3
Treatment for Nonherpetic Genital U	5	5	19	-	-		-%	14	33	-	3	3
Treatment for Urethral Discharge (Mer	7	3	15	-	-		0%	1	16	-	-	-
Treatment for Urethral Discharge (M	7	3	15	-	-		-%	1	16	-	-	-
Treatment for Urethral Discharge (Wor	1	5	16	-	-		0%	2	18	-	1	1
Treatment for Urethral Discharge (W	1	5	16	-	-		-%	2	18	-	1	1
Treatment for Vaginitis	68	67	268	-	-		0%	67	335	-	5	5
Treatment for Vaginitis	68	67	268	-	-		-%	67	335	-	5	5
<b>Kenya</b>										<b>328,381</b>	<b>157,772</b>	<b>486,152</b>
Antiretroviral Treatment (Currently Enr	5,592	1,820	11,053	6,086	-		0%	5,353	16,406	2,405	-	2,405
Antiretroviral Treatment (Currently E	5,592	1,820	11,053	6,086	-		-%	5,353	16,406	2,405	-	2,405
Antiretroviral Treatment (Newly Enrolle	327	115	673	-	-		0%	825	1,498	-	-	-
Antiretroviral Treatment (Newly Enrc	327	115	673	-	-		-%	825	1,498	-	-	-
Cervical Cancer-VIA and Cryotherapy	30	64	221	384	415		(47)%	1,634	2,834	-	47	47
Cervical Cancer-VIA and Cryotherap	30	64	221	384	415	7/13	(47)%	1,634	2,834	-	47	47
Cervical Cancer-VIA and Refer to Cryc	-	-	-	102	-		0%	-	19	-	-	-
Cervical Cancer-VIA and Refer to Ci	-	-	-	102	-	12/14	-%	-	19	-	-	-
Cervical Cancer-VIA/VILI Screening	5,955	5,004	20,967	-	23,786		(12)%	161,217	213,377	-	-	-
Cervical Cancer-VIA/VILI Screening	5,955	5,004	20,967	-	23,786		(12)%	161,217	213,377	-	-	-
Condom	2,836,380	3,128,976	12,223,308	31,966,695	10,317,973		18%	31,610,311	519,626,669	323,233	22,477	345,710
Mid-tier condom	-	-	-	963,413	-		-%	-	-	-	-	-
Trust	2,127,672	2,452,200	9,484,272	23,500,000	8,462,718	10/93	12%	25,384,554	468,883,337	250,802	17,440	268,242
Trust Ribbed	58,008	32,832	156,504	806,046	183,456	5/14	(15)%	762,510	2,241,175	4,139	288	4,426

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Trust Scented	31,104	144,000	463,104	842,747	112,968	5/14	310%	609,834	2,318,959	12,246	852	13,098
Trust Studded	619,596	499,944	2,119,428	5,854,489	1,558,831	1/08	36%	4,853,413	46,183,198	56,046	3,897	59,944
Diarrhea Treatment Kit	-	-	-	18,744	6,000		(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit	-	-	-	18,744	6,000	12/15	(100)%	6,000	48,678	-	-	-
Diarrhea Treatment Kit Provided	6,711	-	6,711	-	-		0%	17,338	24,049	-	270	270
Non-PSI Diarrhea Treatment Kit Pro	6,711	-	6,711	-	-		-%	17,338	24,049	-	270	270
Emergency Contraception	(132)	(130)	(523)	-	-		0%	(136)	(659)	-	(4)	(4)
PSI Emergency Contraception Distr	(132)	(130)	(523)	-	-		-%	(136)	(659)	-	(4)	(4)
Emergency Contraception Provided	132	130	523	2,000	-		0%	136	659	-	4	4
PSI Emergency Contraception Prov	132	130	523	-	-		-%	136	659	-	4	4
Non-PSI Emergency Contraception I	-	-	-	2,000	-		-%	-	-	-	-	-
Fever Cases Attended	-	221	664	-	-		0%	26,315	26,979	-	-	-
Fever Cases Attended	-	221	664	-	-		-%	26,315	26,979	-	-	-
Fever Cases Tested with Microscopy	-	40	121	-	-		0%	7,353	7,474	-	-	-
Fever Cases Tested with Microscopy	-	40	121	-	-		-%	7,353	7,474	-	-	-
Fever Cases Tested with RDTs	-	181	543	-	-		0%	18,608	19,151	-	-	-
Fever Cases Tested with RDTs	-	181	543	-	-		-%	18,608	19,151	-	-	-
Free Condom	-	-	-	20,070,796	5,324,360		(100)%	8,237,600	206,310,814	-	-	-
Free Male Condom - GOK	-	-	-	-	5,324,360	2/14	(100)%	7,085,600	80,771,600	-	-	-
Free Male Condom - NASCOP	-	-	-	20,070,796	-	5/11	-%	-	42,955,117	-	-	-
Free Male Condom - UNFPA	-	-	-	-	-	5/11	-%	1,152,000	82,584,097	-	-	-
HIV Testing Services	15,077	16,862	65,662	99,135	54,666		20%	184,245	994,755	2,743	-	2,743
VCT Concordant Couple (HIV-Negati	-	-	-	-	9,926	9/11	(100)%	28,529	129,685	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	158	9/11	(100)%	282	3,656	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	72	9/11	(100)%	231	1,690	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Discordant Couple (HIV-Positiv	-	-	-	-	72	9/11	(100)%	231	1,690	-	-	-
VCT Individual (HIV-Negative)	14,767	16,536	64,376	96,039	43,236	9/11	49%	151,408	828,964	2,689	-	2,689
VCT Individual (HIV-Positive)	310	325	1,286	3,096	1,202	9/11	7%	3,565	29,070	54	-	54
Hypertension Diagnosis	-	1,930	5,790	-	-		0%	31,404	37,194	-	-	-
Hypertension Diagnosis	-	1,930	5,790	-	-		-%	31,404	37,194	-	-	-
Hypertension Screening	-	19,036	57,107	-	-		0%	129,978	187,085	-	-	-
Hypertension Screening	-	19,036	57,107	-	-		-%	129,978	187,085	-	-	-
Hypertension_Controlled Condition	-	1,165	3,495	-	-		0%	25,842	29,337	-	-	-
Hypertension_Controlled Condition	-	1,165	3,495	-	-		-%	25,842	29,337	-	-	-
Implant 3	-	15,949	47,848	279,025	73,312		(35)%	140,306	587,356	-	57,934	57,934
Implanon	-	15,949	47,848	279,025	73,312	3/14	(35)%	140,306	587,356	-	57,934	57,934
Implant 5	(725)	(850)	(3,274)	132,137	(770)		0%	51,185	43,848	-	(5,813)	(5,813)
PSI Implant 5 Distributed Inserted (	(732)	(860)	(3,313)	(9,180)	(1,099)		-%	(11,324)	(102,707)	-	(5,883)	(5,883)
Jadelle	7	11	39	13,317	329	1/09	(88)%	62,509	146,555	-	69	69
Jadelle - GOK	-	-	-	128,000	-		-%	-	-	-	-	-
Implant 5 Insertion	2,748	2,794	11,130	27,000	6,440		73%	32,830	216,914	-	21,958	21,958
PSI Implant 5 Inserted	732	860	3,313	9,180	1,099		201%	11,324	102,707	-	6,536	6,536
Non-PSI Implant 5 Inserted	2,016	1,934	7,817	17,820	5,341		46%	21,506	114,207	-	15,422	15,422
Injectable 3	(9,920)	(10,943)	(42,748)	325,875	227,572		(119)%	447,968	5,378,224	-	(3,704)	(3,704)
PSI Injectable 3 Distributed Provid	(10,508)	(11,510)	(45,037)	-	-		-%	(11,680)	(56,717)	-	(3,902)	(3,902)
Femiplan Injectable	588	567	2,289	320,000	227,572	3/00	(99)%	459,648	5,434,941	-	198	198
GOK Injectable	-	-	-	5,875	-		-%	-	-	-	-	-
Injectable 3 Provided	10,508	11,510	45,037	141,166	-		0%	11,680	56,717	-	4,336	4,336
PSI Injectable 3 Provided	10,508	11,510	45,037	-	-		-%	11,680	56,717	-	4,336	4,336
Non-PSI Injectable 3 Provided	-	-	-	141,166	-		-%	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IPTp2	312	440	1,631	-	-		0%	3,595	5,226	-	81	81
IPTp2	312	440	1,631	-	-		-%	3,595	5,226	-	81	81
IUD 10	(202)	(21)	(265)	5,540	(536)		0%	(1,578)	2,740	-	(579)	(579)
PSI IUD 10 Distributed Inserted (1)	(472)	(568)	(2,175)	(4,900)	(1,076)		-%	(6,273)	(74,591)	-	(4,754)	(4,754)
CU 380A (Copper T)	270	547	1,910	10,440	540	3/09	254%	4,695	77,331	-	4,175	4,175
IUD 10 Insertion	1,306	1,438	5,620	14,000	3,638		54%	17,920	151,184	-	13,649	13,649
PSI IUD 10 Inserted	472	568	2,175	4,900	1,076		102%	6,273	74,591	-	5,282	5,282
Non-PSI IUD 10 Inserted	834	870	3,445	9,100	2,562		34%	11,647	76,593	-	8,366	8,366
LLIN	47,486	124,434	420,787	1,877,333	618,566		(32)%	2,272,960	35,043,182	-	13,501	13,501
ANC LLIN	-	-	-	1,716,333	486,810	7/08	(100)%	2,111,533	19,189,925	-	-	-
Mass LLIN	-	187	560	-	488	4/11	15%	28,440	6,481,520	-	18	18
Social Marketed LLIN	-	-	-	-	131,268	8/08	(100)%	131,268	4,692,664	-	-	-
Supanet Conical	503	236	1,210	90,500	-	10/16	-%	874	2,084	-	39	39
Supanet Rectangular	503	225	1,177	70,500	-	10/16	-%	845	2,022	-	38	38
Supanet Xtra Power (Olyset)	-	43,140	129,420	-	-	4/05	-%	-	4,386,547	-	4,153	4,153
Supanet XtraPower BL PNET USAII	46,480	80,647	288,420	-	-	3/14	-%	-	288,420	-	9,254	9,254
Malaria PPT (ACT)	-	-	-	147,378	330		(100)%	330	23,010	-	-	-
Artemether 200mg x 12 (15-24 KG)	-	-	-	113,381	-	3/15	-%	-	9,000	-	-	-
Artemether 200mg x 24 (> 34 KG)	-	-	-	-	330	3/15	(100)%	330	11,010	-	-	-
Artemether 200mg x 6 (5-14 KG)	-	-	-	33,997	-	3/15	-%	-	3,000	-	-	-
Malaria RDK	-	-	-	-	40		(100)%	40	499,905	-	-	-
Malaria Rapid Diagnostic Kit	-	-	-	-	40	11/13	(100)%	40	499,905	-	-	-
OCs	935,613	4,091	947,885	3,638,290	938,880		1%	5,417,505	32,623,397	-	22,237	22,237
PSI OCs Distributed Provided	(1,791)	(1,957)	(7,663)	-	-		-%	(2,096)	(9,759)	-	(180)	(180)
Femi Girl Oral Pills	360	536	1,968	208,000	-	11/16	-%	4,512	6,480	-	46	46

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Femiplan Pill	937,044	5,512	953,580	3,430,290	938,880	3/00	2%	5,415,089	32,626,676	-	22,370	22,370
OCs Provided	1,791	1,957	7,663	28,752	-		0%	2,096	9,759	-	200	200
PSI OCs Provided	1,791	1,957	7,663	-	-		-%	2,096	9,759	-	200	200
Non-PSI OCs Provided	-	-	-	28,752	-		-%	-	-	-	-	-
ORS Provided	1,822	-	1,822	-	-		0%	5,546	7,368	-	36	36
Non-PSI ORS Provided	1,822	-	1,822	-	-		-%	5,546	7,368	-	36	36
Pneumonia PPT	-	-	-	27,065	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	27,065	-		-%	-	-	-	-	-
Pneumonia PPT Provided	5,863	-	5,863	-	-		0%	19,854	25,717	-	2,820	2,820
Non-PSI Pneumonia PPT Provided	5,863	-	5,863	-	-		-%	19,854	25,717	-	2,820	2,820
Positive RDTs	-	37	110	-	-		0%	3,656	3,766	-	-	-
Positive RDTs	-	37	110	-	-		-%	3,656	3,766	-	-	-
Positive RDTs Given First Line Treatm	-	37	110	-	-		0%	3,489	3,599	-	-	-
Positive RDTs Given First Line Trea	-	37	110	-	-		-%	3,489	3,599	-	-	-
PUR	1,408,560	2,505,296	8,924,448	15,600,000	9,909,840		(10)%	25,634,046	105,991,924	-	283	283
PuR	1,408,560	2,505,296	8,924,448	15,600,000	9,909,840	2/06	(10)%	25,634,046	105,991,924	-	283	283
QAACTs Provided after Confirmatory I	-	37	110	-	-		0%	3,815	3,925	-	18	18
Non-PSI QAACTs Provided after Co	-	37	110	-	-		-%	3,815	3,925	-	18	18
Safe Water Solution	100,188	132,928	498,972	1,601,250	512,442		(3)%	1,401,214	19,338,193	-	1,581	1,581
WaterGuard	100,188	132,928	498,972	1,601,250	512,442	5/03	(3)%	1,401,214	19,338,193	-	1,581	1,581
Skilled Birth Attendance	1,061	2,195	7,645	16,237	-		0%	12,016	19,661	-	6,409	6,409
Skilled Birth Attendance	1,061	2,195	7,645	16,237	-		-%	12,016	19,661	-	6,409	6,409
Treatment for Pre-Eclampsia (with Mg'	5	13	43	39	-		0%	28	71	-	29	29
Treatment for Pre-Eclampsia (with M	5	13	43	39	-		-%	28	71	-	29	29
Voluntary Medical Male Circumcision	-	-	-	700	2		(100)%	2	734	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Male Circumcision (HIV-Negative)	-	-	-	-	2	3/12	(100)%	2	734	-	-	-
Voluntary Medical Male Circumcision	-	-	-	700	-		-%	-	-	-	-	-
Water Treatment Tablets	10,800	13,680	51,840	239,280	110,210		(53)%	840,790	5,178,840	-	3	3
Aquatab	10,800	13,680	51,840	239,280	110,210	3/09	(53)%	840,790	5,178,840	-	3	3
<b>Malawi</b>										142,490	176,329	318,819
Condom	500,640	836,040	3,008,760	19,000,000	6,941,480		(57)%	22,203,160	192,951,902	49,755	6,805	56,560
Chishango	500,640	836,040	3,008,760	19,000,000	6,941,480	10/94	(57)%	22,203,160	192,951,902	49,755	6,805	56,560
Emergency Contraception	694	1,272	4,509	40,000	7,858		(43)%	34,107	91,501	-	38	38
PSI Emergency Contraception Distr	-	(8)	(23)	-	-		-%	-	(23)	-	-	-
NORLEVO (Norlevo 1.5mg)	694	1,279	4,532	40,000	7,858	2/14	(42)%	34,107	91,524	-	39	39
Emergency Contraception Provided	-	8	23	-	-		0%	-	23	-	-	-
PSI Emergency Contraception Prov	-	8	23	-	-		-%	-	23	-	-	-
Female Condom	2,080	3,367	12,180	55,000	22,900		(47)%	55,100	686,006	201	21	223
Care	2,080	2,973	11,000	45,000	22,900	1/08	(52)%	54,148	683,874	182	19	201
Whisper Female Condom	-	393	1,180	10,000	-	11/16	-%	952	2,132	20	2	22
Free Condom	869,978	934,825	3,674,454	5,045,000	354,039		938%	4,015,632	9,145,569	60,764	8,310	69,074
Free Male Condoms	3,280	480	4,720	-	319,189	2/14	(99)%	322,289	1,657,292	78	11	89
Key Population Male Condom	814,858	528,316	2,399,805	3,000,000	-	7/16	-%	2,271,734	4,671,539	39,685	5,428	45,113
One Community Male Condom	51,840	391,278	1,225,674	2,000,000	-	7/16	-%	1,044,215	2,269,889	20,269	2,772	23,041
VMMC Male Condom	-	14,752	44,255	45,000	34,850	1/15	27%	377,394	546,849	732	100	832
Free Female Condom	1,261	5,752	18,516	100,000	13,328		39%	36,158	140,883	306	32	338
Free Female Condoms	1,261	5,752	18,516	100,000	13,328	2/14	39%	36,158	140,883	306	32	338
HIV Testing Services	11,720	7,036	32,829	77,000	24,899		32%	69,431	111,584	1,396	-	1,396
VCT Individual (HIV-Negative)	11,354	6,716	31,501	73,261	24,899	12/14	27%	69,379	110,163	1,340	-	1,340
VCT Individual (HIV-Positive)	366	321	1,328	3,739	-	12/14	-%	52	1,421	56	-	56

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 3	(319)	163	171	17,000	133		29%	5,225	20,923	-	256	256
PSI Implant 3 Distributed Inserted (1)	(2,603)	(1,866)	(8,200)	-	(3,054)		-%	(13,019)	(29,467)	-	(12,274)	(12,274)
Implanon	2,284	2,029	8,371	17,000	3,187	10/12	163%	18,244	50,390	-	12,530	12,530
Implant 3 Insertion	2,603	1,866	8,200	-	3,054		169%	13,019	29,467	-	13,637	13,637
PSI Implant 3 Inserted	2,603	1,866	8,200	-	3,054		169%	13,019	29,467	-	13,637	13,637
Implant 5	(1,109)	189	(542)	24,000	50		(1184)%	9,934	22,491	-	(1,195)	(1,195)
PSI Implant 5 Distributed Inserted (1)	(3,057)	(2,540)	(10,678)	-	(3,604)	3/16	-%	(17,447)	(37,568)	-	(23,547)	(23,547)
Jadelle	1,948	2,729	10,136	24,000	3,654	10/12	177%	27,381	60,059	-	22,352	22,352
Implant 5 Insertion	3,057	2,540	10,678	-	3,604		196%	17,447	37,568	-	26,163	26,163
PSI Implant 5 Inserted	3,057	2,540	10,678	-	3,604	3/16	196%	17,447	37,568	-	26,163	26,163
Injectable 3	6,312	275,883	833,961	890,500	27,123		2975%	216,611	1,650,058	-	88,865	88,865
PSI Injectable 3 Distributed Provide	-	(1,034)	(3,103)	-	-		-%	-	(3,103)	-	(331)	(331)
SafePlan Inj3	6,312	276,917	837,064	890,500	27,123	1/08	2,986%	216,611	1,653,161	-	89,196	89,196
Injectable 3 Provided	-	1,034	3,103	-	-		0%	-	3,103	-	367	367
PSI Injectable 3 Provided	-	1,034	3,103	-	-		-%	-	3,103	-	367	367
IUD 10	30	75	254	1,600	60		323%	532	4,242	-	694	694
PSI IUD 10 Distributed Inserted (1)	(185)	(136)	(592)	-	(308)	3/16	-%	(1,356)	(3,071)	-	(1,618)	(1,618)
IUD Copper T 380A	215	210	846	1,600	368	10/12	130%	1,888	7,313	-	2,312	2,312
IUD 10 Insertion	185	136	592	-	308		92%	1,356	3,071	-	1,798	1,798
PSI IUD 10 Inserted	185	136	592	-	308	3/16	92%	1,356	3,071	-	1,798	1,798
LLIN	2,628	32,756	100,897	45,000	218,941		(54)%	979,679	8,798,874	-	10,253	10,253
PMI Permanets	-	29,617	88,852	-	202,368	4/07	(56)%	944,049	8,429,422	-	9,029	9,029
Super Chitetezo Net	2,628	3,139	12,045	45,000	16,573	2/11	(27)%	35,630	369,452	-	1,224	1,224
Lubricant	193,226	71,336	407,235	-	10		4072250%	509,715	1,406,947	-	-	-
Personal Lubricant Water 4.5 g	193,226	71,336	407,235	-	10	12/12	4,072,250%	509,715	1,406,947	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Male Circumcision (HIV-Positive)	-	-	-	-	57		(100)%	287	607	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	57		(100)%	287	607	-	-	-
<b>OCs</b>	<b>18,629</b>	<b>12,670</b>	<b>56,638</b>	<b>35,000</b>	<b>44,023</b>		<b>29%</b>	<b>104,659</b>	<b>462,454</b>	-	<b>1,634</b>	<b>1,634</b>
PSI OCs Distributed Provided	-	(762)	(2,287)	-	-		-%	-	(2,287)	-	(66)	(66)
Microgynon	18,629	13,432	58,925	35,000	44,023	11/11	34%	104,659	464,741	-	1,700	1,700
<b>OCs Provided</b>	-	<b>762</b>	<b>2,287</b>	-	-		<b>0%</b>	-	<b>2,287</b>	-	<b>73</b>	<b>73</b>
PSI OCs Provided	-	762	2,287	-	-		-%	-	2,287	-	73	73
<b>ORS</b>	-	-	-	-	<b>208,492</b>		<b>(100)%</b>	<b>208,492</b>	<b>16,373,449</b>	-	-	-
Thanzi	-	-	-	-	208,492	5/99	(100)%	208,492	16,373,449	-	-	-
<b>PUR</b>	<b>100,000</b>	<b>183,757</b>	<b>651,270</b>	<b>6,500,000</b>	<b>1,440</b>		<b>45127%</b>	<b>3,060,140</b>	<b>49,237,880</b>	-	<b>36</b>	<b>36</b>
PuR WaterGuard Waufa	100,000	183,757	651,270	6,500,000	1,440	3/06	45,127%	3,060,140	49,237,880	-	36	36
Referral to CD4/Clinical Staging	-	-	-	-	894		(100)%	2,046	2,159	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	894		(100)%	2,046	2,159	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		0%	309	309	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		-%	309	309	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	-		0%	593	593	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	-		-%	593	593	-	-	-
Referral to Injectable 3	-	-	-	-	-		0%	2,754	2,754	-	-	-
Referral to Injectable 3	-	-	-	-	-		-%	2,754	2,754	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-		0%	142	142	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-		-%	142	142	-	-	-
Referral to OCs	-	-	-	-	-		0%	454	454	-	-	-
Referral to OCs	-	-	-	-	-		-%	454	454	-	-	-
<b>Safe Water Solution</b>	<b>6,324</b>	<b>12,151</b>	<b>42,778</b>	<b>150,000</b>	<b>90,213</b>		<b>(53)%</b>	<b>153,179</b>	<b>8,242,733</b>	-	<b>234</b>	<b>234</b>
WaterGuard	6,324	12,151	42,778	150,000	90,213	12/02	(53)%	153,179	8,242,733	-	234	234

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Tubal Ligation	1,094	672	3,110	5,500	503		518%	4,500	8,091	-	18,280	18,280
Tubal Ligation	1,094	672	3,110	5,500	503	1/15	518%	4,500	8,091	-	18,280	18,280
Vasectomy	-	1	4	-	-		0%	-	5	-	24	24
Vasectomy	-	1	4	-	-		-%	-	5	-	24	24
Voluntary Medical Male Circumcision	4,157	1,395	8,341	67,553	8,973		(7)%	30,629	96,641	30,066	-	30,066
Male Circumcision (HIV-Negative)	-	-	-	-	8,973	3/13	(100)%	30,240	87,911	-	-	-
Voluntary Medical Male Circumcision	4,157	1,395	8,341	67,553	-		-%	389	8,730	30,066	-	30,066
<b>Rwanda</b>										46,923	10,686	57,609
Condom	771,004	931,933	3,566,804	13,567,226	6,519,872		(45)%	14,307,089	179,302,687	43,532	7,765	51,297
Plaisir	26,880	49,847	176,420	1,067,226	384,800	1/08	(54)%	1,707,579	14,245,273	2,153	384	2,537
Prudence Plus	744,124	882,087	3,390,384	12,500,000	6,135,072	3/93	(45)%	12,599,510	165,057,414	41,379	7,381	48,760
Condom Provided	-	-	-	-	901,712		(100)%	2,207,978	2,208,125	-	-	-
Non-PSI Condom Provided	-	-	-	-	901,712		(100)%	2,207,978	2,208,125	-	-	-
Free Condom	-	92,627	277,881	1,350,000	120		231468%	993,900	3,669,986	3,391	605	3,996
Military Condom	-	92,627	277,881	1,350,000	120	11/13	231,468%	993,900	3,669,986	3,391	605	3,996
HIV Testing Services	-	-	-	6,842	1,867		(100)%	8,318	247,300	-	-	-
VCT Concordant Couple (HIV-Negative)	-	-	-	-	6	1/10	(100)%	6	22,320	-	-	-
VCT Individual (HIV-Negative)	-	-	-	6,586	1,670	1/10	(100)%	7,511	212,258	-	-	-
VCT Individual (HIV-Positive)	-	-	-	256	191	1/10	(100)%	801	12,722	-	-	-
Injectable 3	1,440	960	4,320	22,000	8,160		(47)%	17,328	163,773	-	443	443
Confiance Depo-Provera	1,440	960	4,320	-	7,680	1/08	(44)%	16,802	21,122	-	443	443
Depo-Provera (3 Month)	-	-	-	22,000	480	1/06	(100)%	526	142,651	-	-	-
Injectable 3 Provided	-	-	-	-	6,720		(100)%	11,566	11,728	-	-	-
Non-PSI Injectable 3 Provided	-	-	-	-	6,720	3/16	(100)%	11,566	11,728	-	-	-
OCs	7,200	18,240	61,920	66,000	27,360		126%	95,109	297,368	-	1,720	1,720

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Confiance Duofem	-	-	-	-	27,360	1/08	(100)%	28,320	168,656	-	-	-
Microgynon	7,200	18,240	61,920	66,000	-		-%	66,789	128,712	-	1,720	1,720
OCs Provided	-	-	-	-	5,760		(100)%	34,593	34,782	-	-	-
Non-PSI OCs Provided	-	-	-	-	5,760		(100)%	34,593	34,782	-	-	-
PUR	15,349	13,130	54,739	500,000	10,320		430%	224,214	11,125,156	-	1	1
PuR	15,349	13,130	54,739	500,000	10,320	1/11	430%	224,214	11,125,156	-	1	1
Referral to HIV Testing Services	-	-	-	180	-		0%	118	118	-	-	-
Referral to HIV Testing & Counseling	-	-	-	180	-	12/14	-%	118	118	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-		0%	42	42	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-		-%	42	42	-	-	-
Safe Water Solution	18,384	14,501	61,887	220,000	35,645		74%	133,765	3,741,836	-	151	151
Sur Eau	18,384	14,501	61,887	220,000	35,645	8/02	74%	133,765	3,741,836	-	151	151
SDM (Cycle Beads)	-	-	-	-	-		0%	5	418	-	-	-
Collier	-	-	-	-	-	1/08	-%	5	418	-	-	-
<b>Somaliiland</b>										-	7,154	7,154
Diarrhea Treatment Kit	14,810	13,913	56,548	161,500	53,856		5%	161,568	835,738	-	6,061	6,061
SD OFLV-DTK	14,810	13,913	56,548	-	53,856	9/11	5%	161,568	690,217	-	6,061	6,061
Shuban Daweeye_DTK	-	-	-	161,500	-	6/11	-%	-	145,521	-	-	-
Implant 3	(18)	9	10	-	(13)		0%	197	292	-	17	17
PSI Implant 3 Distributed Inserted (DALYs)	(18)	(24)	(90)	(360)	(20)		-%	(66)	(156)	-	(152)	(152)
Nasiye Implant (Implanon)	-	33	100	360	7	12/15	1,329%	263	448	-	169	169
Implant 3 Insertion	18	27	100	360	20		400%	87	187	-	188	188
PSI Implant 3 Inserted	18	24	90	360	20		350%	66	156	-	169	169
Non-PSI Implant 3 Inserted	-	3	10	-	-		-%	21	31	-	19	19
Injectable 3	100	157	570	3,500	2,017		(72)%	4,464	22,059	-	69	69

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Nasiye - Inj 3	100	157	570	3,500	2,017	6/11	(72)%	4,464	22,059	-	69	69
Micronutrient Powder	-	-	-	100,000	3,500		(100)%	3,500	1,238,055	-	-	-
Super Fariid	-	-	-	100,000	3,500	11/14	(100)%	3,500	1,238,055	-	-	-
Misoprostol for PPH	4,000	667	6,000	30,000	2,950		103%	17,750	146,108	-	38	38
Ummul-gargaar	4,000	667	6,000	30,000	2,950	3/10	103%	17,750	146,108	-	38	38
OCs	750	1,240	4,470	26,000	9,570		(53)%	27,705	118,686	-	146	146
Nasiye - OC	750	1,240	4,470	26,000	9,570	3/12	(53)%	27,705	118,686	-	146	146
ORS	-	-	-	-	5,750		(100)%	5,750	5,755	-	-	-
Shuban Daweeye_ORs	-	-	-	-	5,750	6/11	(100)%	5,750	5,755	-	-	-
Pneumonia PPT	-	-	-	11,000	-		0%	11,050	30,819	-	-	-
Pneomox 125mg tablet (Amoxicillin)	-	-	-	2,500	-	11/14	-%	2,220	6,180	-	-	-
Pneomox 250mg tablet (Amoxicillin)	-	-	-	8,500	-	11/14	-%	8,830	24,639	-	-	-
Water Treatment Tablets	624,000	304,920	1,538,760	4,188,000	1,112,400		38%	3,330,000	65,948,062	-	634	634
Aquatab	-	-	-	864,000	-	9/10	-%	-	34,936,790	-	-	-
Biyosifeeye	624,000	304,920	1,538,760	3,324,000	1,112,400	7/08	38%	3,330,000	31,011,272	-	634	634
<b>South Sudan</b>										-	805,879	805,879
Counseling & Tx for Moderate Acute	55,147	-	155,147	-	-		0%	-	155,147	-	-	-
Counseling & Tx for Moderate Acute	55,147	-	155,147	-	-		-%	-	155,147	-	-	-
LLIN	238,590	343,701	1,269,693	1,979,109	354,113		259%	2,778,617	4,395,530	-	325,918	325,918
Mass LLIN - WES	238,590	343,701	1,269,693	1,979,109	354,113	6/14	259%	2,778,617	4,395,530	-	325,918	325,918
Malaria PPT (ACT)	255,300	350,700	1,307,400	2,956,134	1,626,602		(20)%	4,047,867	10,829,134	-	402,792	402,792
ACT Adult - CAIPA	-	-	-	-	758,119	12/15	(100)%	758,119	799,369	-	-	-
ACT Child - CAIPA	-	-	-	-	424,500	12/15	(100)%	424,500	424,500	-	-	-
ACT Infant - CAIPA	-	-	-	-	399,000	12/15	(100)%	399,000	423,000	-	-	-
ACTs for Adult (14+ years)	63,600	75,242	289,325	725,465	1,000	2/13	28,833%	572,600	1,906,980	-	89,137	89,137

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
ACTs for Child (6-14 years)	37,200	31,033	130,300	458,173	5,675	2/13	2,196%	247,425	1,010,156	-	40,144	40,144
ACTs for Infant (2-12 months)	89,100	117,025	440,175	736,237	19,043	2/13	2,211%	685,249	2,488,776	-	135,612	135,612
ACTs for Toddler (1-5 years)	65,400	127,400	447,600	1,036,259	19,265	2/13	2,223%	960,974	3,776,353	-	137,899	137,899
Malaria RDK	43,400	-	43,400	1,881,088	42,619		2%	1,596,694	3,475,153	-	-	-
Malaria Rapid Diagnostic Kit	43,400	-	43,400	1,881,088	39,544	9/14	10%	1,588,269	3,466,728	-	-	-
mRDT Test Kits - CAIPA	-	-	-	-	3,075	12/15	(100)%	8,425	8,425	-	-	-
ORS	(90,632)	40,796	31,756	1,068,611	218,022		(85)%	538,124	3,366,352	-	1,045	1,045
PSI ORS Distributed Provided	(120,132)	-	(120,132)	-	-		-%	-	(120,132)	-	(3,952)	(3,952)
ORS	29,500	40,796	151,888	1,068,611	218,022	9/08	(30)%	538,124	3,486,484	-	4,997	4,997
ORS Provided	120,132	-	120,132	-	-		0%	-	120,132	-	4,391	4,391
PSI ORS Provided	120,132	-	120,132	-	-		-%	-	120,132	-	4,391	4,391
Pneumonia PPT	(64,604)	9,552	(35,948)	867,265	66,496		(154)%	251,497	1,095,573	-	(31,558)	(31,558)
PSI Pneumonia PPT Distributed Provided	(83,524)	-	(83,524)	-	-		-%	-	(83,524)	-	(73,323)	(73,323)
Amoxicillin for Children (1-5 years)	17,520	6,582	37,266	715,056	51,098	10/12	(27)%	161,804	804,024	-	32,715	32,715
Amoxicillin for Infant (2-12 months)	1,400	2,970	10,310	152,209	15,398	10/12	(33)%	89,693	375,073	-	9,051	9,051
Pneumonia PPT Provided	83,524	-	83,524	-	-		0%	-	83,524	-	81,470	81,470
PSI Pneumonia PPT Provided	83,524	-	83,524	-	-		-%	-	83,524	-	81,470	81,470
PUR	-	-	-	-	-		0%	1,099,046	13,499,706	-	-	-
PuR	-	-	-	-	-	1/09	-%	1,099,046	13,499,706	-	-	-
Treatment for Severe Acute Malnutrition	16,202	-	16,202	-	-		0%	25,444	41,646	-	20,370	20,370
Treatment for Severe Acute Malnutrition	16,202	-	16,202	-	-		-%	25,444	41,646	-	20,370	20,370
Zinc	(15,075)	37,043	96,055	307,202	31,206		208%	53,910	1,140,763	-	1,049	1,049
PSI Zinc Distributed Provided	(33,075)	-	(33,075)	-	-		-%	-	(33,075)	-	(361)	(361)
Zinc	18,000	37,043	129,130	307,202	31,206	1/08	314%	53,910	1,173,838	-	1,411	1,411
Zinc Provided	33,075	-	33,075	-	-		0%	-	33,075	-	401	401

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Zinc Provided	33,075	-	33,075	-	-		-%	-	33,075	-	401	401
<b>Tanzania</b>										198,324	341,696	540,020
Cervical Cancer-VIA and Cryotherapy	9	20	68	237	140		(51)%	445	1,228	-	26	26
Cervical Cancer-VIA and Cryotherapy	9	20	68	237	140	12/13	(51)%	445	1,228	-	26	26
Cervical Cancer-VIA/VILI Screening	267	565	1,963	-	4,041		(51)%	12,039	16,635	-	-	-
Cervical Cancer-VIA/VILI Screening	267	565	1,963	-	4,041		(51)%	12,039	16,635	-	-	-
Clean Delivery Kit	-	3,472	10,415	-	-		0%	19,430	32,892	-	769	769
Clean Delivery Pack-CDP	-	3,472	10,415	-	-	9/13	-%	19,430	32,892	-	769	769
Condom	3,231,792	6,016,269	21,280,599	76,774,149	19,367,912		10%	95,295,423	1,146,004,605	163,467	45,530	208,997
PSI Condom Distributed Provided	-	-	-	-	(2,190)		-%	(6,150)	(29,510)	-	-	-
Dume Condom	-	673,056	2,019,168	2,019,168	2,408,400	8/11	(16)%	22,103,107	86,748,019	15,510	4,320	19,830
Familia	-	-	-	4,985,280	-	10/07	-%	-	40,194,688	-	-	-
Salama	-	-	-	-	-	12/93	-%	72	448,294,760	-	-	-
Salama Halisi	2,455,920	4,181,328	14,999,904	50,286,682	10,737,792	2/11	40%	48,705,408	315,375,984	115,222	32,093	147,314
Salama Scented	343,008	843,501	2,873,511	13,053,563	3,034,022	8/06	(5)%	13,642,802	128,410,000	22,073	6,148	28,221
Salama Studded	432,864	318,384	1,388,016	6,429,456	3,189,888	6/04	(56)%	10,850,184	127,010,664	10,662	2,970	13,632
Condom Provided	-	-	-	-	3,620		(100)%	16,550	65,758	-	-	-
PSI Condom Provided	-	-	-	-	2,190		(100)%	6,150	29,510	-	-	-
Non-PSI Condom Provided	-	-	-	-	1,430		(100)%	10,400	36,248	-	-	-
Emergency Contraception	(6)	33,187	99,556	99,000	(12)		0%	39,769	289,165	-	803	803
PSI Emergency Contraception Distr	(6)	-	(6)	-	(12)		-%	(32)	(38)	-	-	-
Emergency Contraception	-	33,187	99,562	99,000	-	7/12	-%	39,801	289,203	-	803	803
Emergency Contraception Provided	9	-	9	-	18		(50)%	110	121	-	-	-
PSI Emergency Contraception Prov	6	-	6	-	12		(50)%	32	38	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI Emergency Contraception I	3	-	3	-	6		(50)%	78	83	-	-	-
Female Condom	1,800	90,733	274,000	85,000	382,320		(28)%	1,044,240	10,396,906	2,105	451	2,556
Care	1,800	-	1,800	85,000	244,800	11/98	(99)%	602,670	5,962,356	14	3	17
Lady Pepeta	-	90,733	272,200	-	137,520	11/11	98%	441,570	4,434,550	2,091	448	2,539
Free Condom	2,714,000	516,600	4,263,800	-	14,400		29510%	38,368,944	103,462,706	32,752	9,123	41,875
Free Familia	2,714,000	516,600	4,263,800	-	14,400	7/10	29,510%	17,455,680	82,549,442	32,752	9,123	41,875
Zana Male Condom	-	-	-	-	-	5/16	-%	20,913,264	20,913,264	-	-	-
Implant 3	(2,446)	2,674	5,577	35,076	2,475		125%	(18,057)	6,695	-	7,855	7,855
PSI Implant 3 Distributed Inserted (	(2,446)	(2,207)	(9,068)	-	(1,237)		-%	(28,041)	(44,302)	-	(12,771)	(12,771)
Implanon	-	4,882	14,645	35,076	3,712	1/09	295%	9,984	50,997	-	20,626	20,626
Implant 3 Insertion	4,508	4,476	17,936	-	4,249		322%	54,069	102,507	-	28,068	28,068
PSI Implant 3 Inserted	2,446	2,207	9,068	-	1,237		633%	28,041	44,302	-	14,190	14,190
Non-PSI Implant 3 Inserted	2,062	2,269	8,868	-	3,012		194%	26,028	58,205	-	13,877	13,877
Implant 4	-	-	-	-	-		0%	(369)	(369)	-	-	-
PSI Implant 4 Distributed Inserted (	-	-	-	-	-		-%	(369)	(369)	-	-	-
Implant 4 Insertion	-	-	-	-	-		0%	1,460	1,460	-	-	-
PSI Implant 4 Inserted	-	-	-	-	-		-%	369	369	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	1,091	1,091	-	-	-
Implant 5	(2,023)	2,835	6,482	23,384	1,063		510%	(27,478)	(3,290)	-	13,385	13,385
PSI Implant 5 Distributed Inserted (	(2,173)	(2,078)	(8,408)	-	(2,857)		-%	(31,398)	(75,440)	-	(17,362)	(17,362)
Jadelle	150	4,913	14,890	23,384	3,920	11/09	280%	3,920	72,150	-	30,746	30,746
Implant 5 Insertion	2,768	2,944	11,599	-	4,904		137%	43,975	121,974	-	26,612	26,612
PSI Implant 5 Inserted	2,173	2,078	8,408	-	2,857		194%	31,398	75,440	-	19,291	19,291
Non-PSI Implant 5 Inserted	595	865	3,191	-	2,047		56%	12,577	46,534	-	7,321	7,321
Injectable 3	63,207	11,516	97,754	647,408	(1,005)		0%	70,933	920,485	-	9,854	9,854

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Distributed Provide	(193)	(231)	(886)	(2,592)	(1,005)		-%	(4,367)	(6,626)	-	(89)	(89)
Familia Injectable 3 Kit	63,400	11,747	98,640	650,000	-	1/10	-%	75,300	927,111	-	9,943	9,943
<b>Injectable 3 Provided</b>	<b>2,629</b>	<b>2,033</b>	<b>8,727</b>	<b>2,592</b>	<b>6,088</b>		<b>43%</b>	<b>28,248</b>	<b>48,357</b>	-	<b>977</b>	<b>977</b>
PSI Injectable 3 Provided	193	231	886	2,592	1,005		(12)%	4,367	6,626	-	99	99
Non-PSI Injectable 3 Provided	2,436	1,802	7,841	-	5,083		54%	23,881	41,731	-	878	878
<b>IUD 10</b>	<b>(1,130)</b>	<b>6,035</b>	<b>16,974</b>	<b>(33,328)</b>	<b>36,367</b>		<b>(53)%</b>	<b>(51,103)</b>	<b>(19,998)</b>	-	<b>43,130</b>	<b>43,130</b>
PSI IUD 10 Distributed Inserted (1)	(6,402)	(6,528)	(25,986)	(39,828)	(11,394)		-%	(107,414)	(269,608)	-	(66,030)	(66,030)
Familia IUD Kit	280	9,535	28,886	6,500	47,761	11/09	(40)%	56,311	235,536	-	73,398	73,398
Pregna IUD (no safe load)	4,992	3,027	14,074	-	-	3/17	-%	-	14,074	-	35,762	35,762
<b>IUD 10 Insertion</b>	<b>8,537</b>	<b>8,871</b>	<b>35,149</b>	<b>99,828</b>	<b>14,322</b>		<b>145%</b>	<b>124,475</b>	<b>387,350</b>	-	<b>99,236</b>	<b>99,236</b>
PSI IUD 10 Inserted	6,402	6,528	25,986	39,828	11,394		128%	107,414	269,608	-	73,366	73,366
Non-PSI IUD 10 Inserted	2,135	2,343	9,163	60,000	2,928		213%	17,061	117,742	-	25,870	25,870
<b>IUD 5</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>(7)</b>	<b>(7)</b>	-	<b>-</b>	<b>-</b>
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	-		-%	(7)	(7)	-	-	-
<b>IUD 5 Insertion</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>8</b>	<b>8</b>	-	<b>-</b>	<b>-</b>
PSI IUD 5 Inserted	-	-	-	-	-		-%	7	7	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
<b>LLIN</b>	<b>52,480</b>	<b>19,920</b>	<b>112,240</b>	<b>2,434,025</b>	<b>494,407</b>		<b>(77)%</b>	<b>2,075,002</b>	<b>2,187,242</b>	-	<b>5,300</b>	<b>5,300</b>
"New Brand" (School Net Program)	-	-	-	2,434,025	-		-%	-	-	-	-	-
Permanet (180x160x180 CM) SI	52,480	19,920	112,240	-	494,407	2/16	(77)%	2,075,002	2,187,242	-	5,300	5,300
<b>Lubricant</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>28,500</b>		<b>(100)%</b>	<b>28,500</b>	<b>400,000</b>	-	<b>-</b>	<b>-</b>
SHOSTI Lubricant 5mL Sachet	-	-	-	-	28,500	12/14	(100)%	28,500	400,000	-	-	-
<b>Malaria RDK</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>85</b>	<b>215,085</b>	-	<b>-</b>	<b>-</b>
Malaria Rapid Diagnostic Kit	-	-	-	-	-	2/14	-%	85	215,085	-	-	-
<b>Manual Vacuum Aspiration for PAC</b>	<b>77</b>	<b>90</b>	<b>347</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>347</b>	-	<b>41</b>	<b>41</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
MVA for PAC	77	90	347	-	-		-%	-	347	-	41	41
Misoprostol for PAC (Oral)	8,257	106,972	329,172	750,000	350,952		(6)%	1,265,264	4,356,860	-	11,784	11,784
PSI Misoprostol for PAC Oral Dist F	(3)	(7)	(24)	-	-		-%	-	(24)	-	(1)	(1)
Misoprostol for PAC (oral)	8,260	106,979	329,196	750,000	350,952	9/12	(6)%	1,265,264	4,356,884	-	11,785	11,785
Misoprostol for PAC (oral) Provided	3	7	24	-	-		0%	-	24	-	1	1
PSI Misoprostol for PAC (oral) Prov	3	7	24	-	-		-%	-	24	-	1	1
OCs	508,077	298,437	1,403,387	2,397,408	368,784		281%	2,184,870	21,373,611	-	38,305	38,305
PSI OCs Distributed Provided	(243)	(326)	(1,221)	(2,592)	(576)		-%	(5,226)	(9,209)	-	(33)	(33)
Familia [OC]	508,320	298,619	1,404,176	2,400,000	-	2/08	-%	309,168	8,534,276	-	38,327	38,327
Flexi P	-	144	432	-	369,360	11/11	(100)%	1,880,928	12,848,544	-	12	12
OCs Provided	1,581	1,804	6,993	2,592	1,926		263%	14,895	29,320	-	212	212
PSI OCs Provided	243	326	1,221	2,592	576		112%	5,226	9,209	-	37	37
Non-PSI OCs Provided	1,338	1,478	5,772	-	1,350		328%	9,669	20,111	-	175	175
Referral to Implant 3 Insertion	-	-	-	8,500	-		0%	-	157	-	-	-
Referral to Implant 3 Insertion	-	-	-	8,500	-	12/12	-%	-	157	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-		0%	-	231	-	-	-
Referral to IUD 10 Insertion	-	-	-	11,000	-	12/12	-%	-	231	-	-	-
Water Treatment Tablets	408,000	815,047	2,853,140	6,700,000	5,124,000		(44)%	18,015,300	42,288,440	-	234	234
Aquatab Tubs 8.68g	-	480	1,440	-	300,000	3/16	(100)%	444,000	445,440	-	14	14
WaterGuard Tablet ENF	408,000	814,567	2,851,700	6,700,000	4,824,000	7/12	(41)%	17,571,300	41,843,000	-	220	220
<b>Uganda</b>										49,533	207,163	256,697
Basic Care Package	-	133	400	-	17,301,754		(100)%	52,637,120	172,110,122	-	-	-
PLP Condom Resupply	-	-	-	-	11,360,172	10/11	(100)%	22,375,504	92,567,418	-	-	-
PLP Female Condom	-	-	-	-	127,003	2/12	(100)%	133,580	2,188,513	-	-	-
PLP Kit - FB (with WaterGuard Tab)	-	-	-	-	9,052	11/11	(100)%	11,132	60,803	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PLP Kit - NFB (with Female Condor	-	-	-	-	<b>3,806</b>	5/12	(100)%	<b>4,371</b>	<b>9,411</b>	-	-	-
PLP Kit - NFB (with WaterGuard Tat	-	-	-	-	<b>57,121</b>	11/11	(100)%	<b>78,698</b>	<b>588,754</b>	-	-	-
PLP LLIN Resupply	-	-	-	-	<b>4,600</b>	10/11	(100)%	<b>18,235</b>	<b>55,623</b>	-	-	-
PLP Waterguard Tablet (67mg) Res	-	<b>133</b>	<b>400</b>	-	<b>5,740,000</b>	10/11	(100)%	<b>30,015,600</b>	<b>76,639,600</b>	-	-	-
Cervical Cancer-Pap Smear Screeningç	-	<b>58</b>	<b>173</b>	-	-		<b>0%</b>	-	<b>173</b>	-	-	-
Cervical Cancer-Pap Smear Screeni	-	<b>58</b>	<b>173</b>	-	-		-%	-	<b>173</b>	-	-	-
Cervical Cancer-VIA and Cryotherapy	<b>47</b>	-	<b>47</b>	<b>1,924</b>	<b>152</b>		<b>(69)%</b>	<b>628</b>	<b>1,778</b>	-	<b>17</b>	<b>17</b>
Cervical Cancer-VIA and Cryotheraç	<b>47</b>	-	<b>47</b>	<b>1,924</b>	<b>152</b>	11/13	(69)%	<b>628</b>	<b>1,778</b>	-	<b>17</b>	<b>17</b>
Cervical Cancer-VIA/VILI Screening	<b>5,783</b>	-	<b>5,783</b>	-	<b>12,369</b>		<b>(53)%</b>	<b>54,925</b>	<b>115,812</b>	-	-	-
Cervical Cancer-VIA/VILI Screening	<b>5,783</b>	-	<b>5,783</b>	-	<b>12,369</b>		(53)%	<b>54,925</b>	<b>115,812</b>	-	-	-
Chlorhexidine	<b>10</b>	<b>334</b>	<b>1,011</b>	<b>40,000</b>	-		<b>0%</b>	<b>6,682</b>	<b>7,693</b>	-	<b>63</b>	<b>63</b>
Chlorhexidine Gel, 5 g tube	<b>10</b>	<b>334</b>	<b>1,011</b>	<b>40,000</b>	-	11/16	-%	<b>6,682</b>	<b>7,693</b>	-	<b>63</b>	<b>63</b>
Clean Delivery Kit	<b>342</b>	<b>1,838</b>	<b>5,857</b>	-	<b>4,097</b>		<b>43%</b>	<b>34,562</b>	<b>418,323</b>	-	<b>394</b>	<b>394</b>
Maama Kit	<b>10</b>	<b>95</b>	<b>296</b>	-	<b>1,194</b>	11/01	(75)%	<b>2,356</b>	<b>253,015</b>	-	<b>20</b>	<b>20</b>
Maama Kit Extra Clean Delivery	<b>332</b>	<b>1,743</b>	<b>5,561</b>	-	<b>2,903</b>	8/10	92%	<b>32,206</b>	<b>165,308</b>	-	<b>374</b>	<b>374</b>
Condom	<b>17,064</b>	<b>67,416</b>	<b>219,312</b>	<b>2,592,000</b>	<b>38,268</b>		<b>473%</b>	<b>1,263,372</b>	<b>46,498,838</b>	<b>2,847</b>	<b>549</b>	<b>3,396</b>
Trust	-	-	-	<b>2,592,000</b>	<b>14,580</b>	6/06	(100)%	<b>417,228</b>	<b>45,166,550</b>	-	-	-
Trust Ribbed	<b>5,832</b>	<b>27,360</b>	<b>87,912</b>	-	<b>6,552</b>	11/15	1,242%	<b>227,736</b>	<b>410,760</b>	<b>1,141</b>	<b>220</b>	<b>1,361</b>
Trust Scented	<b>72</b>	<b>13,152</b>	<b>39,528</b>	-	<b>10,728</b>	11/15	268%	<b>359,280</b>	<b>484,344</b>	<b>513</b>	<b>99</b>	<b>612</b>
Trust Studded	<b>11,160</b>	<b>26,904</b>	<b>91,872</b>	-	<b>6,408</b>	11/15	1,334%	<b>259,128</b>	<b>437,184</b>	<b>1,193</b>	<b>230</b>	<b>1,423</b>
Diarrhea Treatment Kit	-	-	-	<b>8,427</b>	<b>5,521</b>		<b>(100)%</b>	<b>8,579</b>	<b>12,509</b>	-	-	-
A2L Diarrhea Pack	-	-	-	<b>8,427</b>	<b>5,521</b>	7/15	(100)%	<b>8,579</b>	<b>12,509</b>	-	-	-
Emergency Contraception	<b>900</b>	<b>485</b>	<b>2,354</b>	<b>15,000</b>	-		<b>0%</b>	<b>166</b>	<b>2,520</b>	-	<b>22</b>	<b>22</b>
ECP	<b>900</b>	<b>485</b>	<b>2,354</b>	<b>15,000</b>	-	6/16	-%	<b>166</b>	<b>2,520</b>	-	<b>22</b>	<b>22</b>
Expanded Clean Delivery Kit	-	-	-	<b>25,000</b>	-		<b>0%</b>	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Mama Kit Expanded(Chlorhexidine 4	-	-	-	25,000	-		-%	-	-	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	14,000	-		0%	-	-	-	-	-
Expanded Clean Delivery Kit (+CHX	-	-	-	14,000	-		-%	-	-	-	-	-
Family Planning Counseling	-	-	-	-	263		(100)%	15,882	15,882	-	-	-
Family Planning Counseling	-	-	-	-	263		(100)%	15,882	15,882	-	-	-
Free Condom	2,269,440	440,010	3,589,470	9,388,000	-		0%	1,315,910	60,334,423	46,602	8,981	55,583
Generic	2,269,440	440,010	3,589,470	9,388,000	-	1/99	-%	1,315,910	60,334,423	46,602	8,981	55,583
Free Female Condom	2,120	1,457	6,490	70,000	1,000		549%	1,000	2,007,125	84	12	97
Female Condom Free	2,120	1,457	6,490	70,000	1,000	11/09	549%	1,000	2,007,125	84	12	97
Implant 3	1,045	1,696	6,132	-	2,607		135%	15,528	94,650	-	10,123	10,123
PSI Implant 3 Distributed Inserted (	(2,035)	(1,674)	(7,056)	(10,368)	(3,522)		-%	(23,353)	(64,867)	-	(11,649)	(11,649)
Implanon	3,080	3,369	13,188	10,368	6,129	12/08	115%	38,881	159,517	-	21,772	21,772
Implant 3 Insertion	5,567	7,427	27,848	20,888	11,928		133%	60,666	165,461	-	51,082	51,082
PSI Implant 3 Inserted	2,035	1,674	7,056	10,368	3,522		100%	23,353	64,867	-	12,943	12,943
Non-PSI Implant 3 Inserted	3,532	5,753	20,792	10,520	8,406		147%	37,313	100,594	-	38,139	38,139
Implant 5	2,054	1,381	6,197	-	3,868		60%	30,293	85,782	-	15,031	15,031
PSI Implant 5 Distributed Inserted (	(988)	(809)	(3,415)	(10,368)	(1,932)		-%	(9,209)	(70,414)	-	(8,283)	(8,283)
Jadelle	3,042	2,190	9,612	10,368	5,800	12/08	66%	39,502	156,196	-	23,314	23,314
Implant 5 Insertion	1,018	832	3,515	10,368	2,054		71%	9,486	99,085	-	9,473	9,473
PSI Implant 5 Inserted	988	809	3,415	10,368	1,932		77%	9,209	70,414	-	9,204	9,204
Non-PSI Implant 5 Inserted	30	23	100	-	122		(18)%	277	28,671	-	270	270
Injectable 3	-	6,423	19,270	-	17,960		7%	96,353	227,598	-	2,272	2,272
Depo-Provera	-	6,423	19,270	-	17,960	11/11	7%	96,353	227,598	-	2,272	2,272
IPTp2	-	114	343	-	5,302		(94)%	15,411	44,748	-	16	16
IPTp2	-	114	343	-	5,302	1/13	(94)%	15,411	44,748	-	16	16

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	2,845	2,239	9,562	8,917	7,013		36%	45,899	170,945	-	28,630	28,630
PSI IUD 10 Distributed Inserted (1)	(4,335)	(2,931)	(13,127)	(53,083)	(5,875)		-%	(36,427)	(182,876)	-	(39,304)	(39,304)
Copper T 380	5,500	2,450	12,849	62,000	1,698	12/08	657%	44,580	145,246	-	38,472	38,472
IUD PACK CU T380A	1,680	2,720	9,840	-	11,190	4/11	(12)%	37,746	208,575	-	29,463	29,463
IUD 10 Insertion	6,569	5,462	22,956	128,508	9,095		152%	51,192	310,115	-	76,371	76,371
PSI IUD 10 Inserted	4,335	2,931	13,127	53,083	5,875		123%	36,427	182,876	-	43,672	43,672
Non-PSI IUD 10 Inserted	2,234	2,532	9,829	75,425	3,220		205%	14,765	127,240	-	32,700	32,700
IUD 5	(50)	(33)	(148)	-	90		(264)%	484	(3,841)	-	(330)	(330)
PSI IUD 5 Distributed Inserted (1)	(50)	(33)	(148)	-	(160)		-%	(626)	(16,878)	-	(330)	(330)
Multiload CU T375	-	-	-	-	250	8/10	(100)%	1,110	13,037	-	-	-
IUD 5 Insertion	50	33	149	-	168		(11)%	683	27,884	-	369	369
PSI IUD 5 Inserted	50	33	148	-	160		(8)%	626	16,878	-	367	367
Non-PSI IUD 5 Inserted	-	-	1	-	8		(88)%	57	11,005	-	2	2
LLIN	-	-	-	578,943	32,316		(100)%	634,191	8,782,018	-	-	-
LLIN - Global Fund (SI)	-	-	-	578,943	32,316	12/10	(100)%	634,191	8,782,018	-	-	-
Malaria PPT (ACT)	1,428	78	1,661	14,272	10,481		(84)%	26,209	97,652	-	366	366
5 & A Malaria Pack-Child	-	-	-	-	4,995	4/11	(100)%	4,995	33,668	-	-	-
5 & A Malaria Pack-Infant	-	-	-	-	4,999	5/11	(100)%	4,999	33,863	-	-	-
ACT, Lumartem (12 Tabs)	1,428	78	1,661	14,272	43	7/15	3,763%	15,771	21,031	-	366	366
ACT, Lumartem (6 Tabs)	-	-	-	-	444	7/15	(100)%	444	9,090	-	-	-
Manual Vacuum Aspiration for PAC	-	99	297	220	220		35%	1,234	1,531	-	82	82
MVA for PAC	-	99	297	220	220	3/16	35%	1,234	1,531	-	82	82
Medical Abortion	-	-	-	25,000	-		0%	-	-	-	-	-
Miso - Mifeprestone pack	-	-	-	25,000	-		-%	-	-	-	-	-
Misoprostol for PAC (Oral)	-	(398)	(1,194)	-	-		0%	(129)	(1,323)	-	(99)	(99)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Misoprostol for PAC Oral Dist F	-	(398)	(1,194)	-	-		-%	(129)	(1,323)	-	(99)	(99)
Misoprostol for PAC (oral) Provided	-	416	1,248	-	-		0%	129	1,377	-	115	115
PSI Misoprostol for PAC (oral) Prov	-	398	1,194	-	-		-%	129	1,323	-	110	110
Non-PSI Misoprostol for PAC (oral) I	-	18	54	-	-		-%	-	54	-	5	5
Misoprostol for PAC (Sublingual)	-	-	-	2,480,000	-		0%	-	-	-	-	-
Misoprostol for PAC (Sublingual)	-	-	-	2,480,000	-		-%	-	-	-	-	-
Misoprostol for PPH	72,500	203,567	683,200	-	376,300		82%	1,616,650	4,864,631	-	2,354	2,354
Misoprostol Tablet	72,500	203,567	683,200	-	376,300	7/09	82%	1,616,650	4,864,631	-	2,354	2,354
OCs	720	6,911	21,453	-	7,014		206%	43,788	351,648	-	685	685
Family Planning Pills	630	5,880	18,270	-	2,430	11/11	652%	32,118	325,176	-	583	583
Microlut - Oral Contraceptive	90	1,031	3,183	-	4,584	6/14	(31)%	11,670	26,472	-	102	102
ORS	-	-	-	18,000	-		0%	-	75,181	-	-	-
ORS	-	-	-	18,000	-	12/10	-%	-	75,181	-	-	-
Pneumonia PPT	-	-	-	5,000	3,254		(100)%	3,643	27,011	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	2,500	-	6/11	-%	-	11,299	-	-	-
5 & A Pneumonia Pack-Infant	-	-	-	2,500	-	6/11	-%	-	7,332	-	-	-
A2L Pneumonia Pack, Child	-	-	-	-	1,921	7/15	(100)%	2,142	5,993	-	-	-
A2L Pneumonia Pack, Infant	-	-	-	-	1,333	8/15	(100)%	1,501	2,387	-	-	-
PUR	957,700	163	958,190	4,000,000	(294,450)		0%	3,675,898	35,924,026	-	50	50
PuR	957,700	163	958,190	4,000,000	(294,450)	10/04	-%	3,675,898	35,924,026	-	50	50
Skilled Birth Attendance	-	-	-	-	6,088		(100)%	16,291	50,567	-	-	-
Skilled Birth Attendance	-	-	-	-	6,088	1/13	(100)%	16,291	50,567	-	-	-
Tubal Ligation	-	6	19	-	5		280%	23	100	-	121	121
Tubal Ligation	-	6	19	-	5		280%	23	100	-	121	121
Vasectomy	-	1	3	-	1		200%	2	6	-	19	19

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vasectomy	-	1	3	-	1		200%	2	6	-	19	19
Water Treatment Tablets	608,000	1,056,667	3,778,000	12,278,719	23,105,040		(84)%	25,155,760	85,239,521	-	394	394
WaterGuard Tablets	608,000	1,056,667	3,778,000	12,278,719	23,105,040	12/06	(84)%	25,155,760	85,239,521	-	394	394
Zinc	-	-	-	5,790	-		0%	-	28,905	-	-	-
Zinc 20 mg	-	-	-	5,790	-	12/10	-%	-	28,905	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>East Africa</b>														
<b>Burundi</b>							\$5,197		\$560	\$4,260	0.13			
<b>Condom</b>														
Prudence Class	04/2017	243,090	0	0	243,090	0%	\$4,765	6%	\$494	\$3,771	0.13	1,383,366	191,670	7.22
<b>Free Condom</b>														
Free Male Condoms	04/2017	0	72,000	0	72,000	100%	\$0	NA	\$0	\$0	NA	568,800	45,600	12.47
<b>Free Female Condom</b>														
Free Female Condoms	04/2017	0	2,000	0	2,000	100%	\$0	NA	\$0	\$0	NA	22,000	1,667	13.20
<b>LLIN</b>														
MII Permanet Free	04/2017	0	21,000	0	21,000	100%	\$0	NA	\$0	\$0	NA	517,250	38,600	13.40
<b>Misoprostol for PAC (Oral)</b>														
Misoprostol for PAC (oral)	04/2017	0	54	0	54	100%	\$0	NA	\$0	\$0	NA	582	128	4.55
<b>Misoprostol for PAC (Sublingual)</b>														
Misoprostol for PAC (Sublingual)	04/2017	0	36	0	36	100%	\$0	NA	\$0	\$0	NA	388	85	4.55
<b>Implant 5</b>														
Jadelle	04/2017	45	58	0	103	56%	\$40	33%	\$13	\$32	0.41	2,098	73	28.61
<b>Injectable 3</b>														
DPMA 3-month Injectable	04/2017	1,185	28	0	1,213	2%	\$348	13%	\$44	\$395	0.11	3,917	1,348	2.91
<b>IUD 10</b>														
Copper-T 380-A IUD	04/2017	0	98	0	98	100%	\$0	NA	\$0	\$7	NA	5,163	50	102.58
<b>OCs</b>														
Confiance OC	04/2017	450	66	0	516	13%	\$44	20%	\$9	\$55	0.16	42,775	918	46.60
<b>Ethiopia</b>							\$163,375		\$755,696	\$173,513	4.36			
<b>HIV Test Kit</b>														
Diagnostic kit for HIV(1+2) Antibod	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,350	0	NA
First Response, HIV-1/2	04/2017	0	4,050	1,280	5,330	100%	\$0	NA	\$0	\$0	NA	7,410	1,350	5.49
<b>Medicines &amp; Supplies</b>														
Isoniazid 300mg Tablet	04/2017	0	0	1,344	1,344	NA	\$0	NA	\$0	\$0	NA	0	0	NA
Lamivudine150mg+Nevirapine200	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	600	0	NA
<b>Water Vessel</b>														
Water Vessel for PCP Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	197	0	NA
<b>Free Condom</b>														
Blue Denim	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	426	0	NA
Protector Plus	04/2017	0	69,000	0	69,000	100%	\$0	NA	\$0	\$0	NA	17,418,902	23,000	757.34

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Ethiopia</b>							\$163,375		\$755,696	\$173,513	4.36				
<b><u>Free Female Condom</u></b>															
Free Female Condoms	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	576,298	0	NA	
<b><u>STI Kit (Non-Ulcerative)</u></b>															
STI kit for Urethral Discharge	04/2017	0	320	0	320	100%	\$0	NA	\$0	\$0	NA	6,318	247	25.61	
STI Kit for Vaginal Discharge	04/2017	0	0	350	350	NA	\$0	NA	\$0	\$0	NA	5,051	110	45.92	
<b><u>STI Kit (Ulcerative)</u></b>															
STI Kit for Genital Ulcer	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	821	0	NA	
<b><u>LLIN</u></b>															
PermaNet NGO Bag-Light Blue	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15	0	NA	
<b><u>PUR</u></b>															
P&G Purifier of Water	04/2017	3,468,040	0	0	3,468,040	0%	\$162,173	90%	\$506,417	\$152,871	3.31	3,966,777	3,321,427	1.19	
<b><u>Safe Water Solution</u></b>															
Wuha Agar	04/2017	6,600	0	0	6,600	0%	\$1,201	0%	\$249,279	\$20,642	12.08	-71,975	104,085	-0.69	
<b><u>OCs</u></b>															
Microgynon	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6	0	NA	
<b>Kenya</b>							\$543,508		\$376,391	\$522,313	0.72				
<b><u>Condom</u></b>															
Trust	04/2017	2,127,672	0	0	2,127,672	0%	\$73,888	100%	\$73,694	NA	NA	500,328	NA	NA	
Trust Ribbed	04/2017	58,008	0	0	58,008	0%	\$5,490	98%	\$5,404	NA	NA	333,028	NA	NA	
Trust Scented	04/2017	31,104	0	0	31,104	0%	\$2,904	100%	\$2,904	NA	NA	-92,016	NA	NA	
Trust Studded	04/2017	619,596	0	0	619,596	0%	\$58,169	100%	\$58,092	NA	NA	1,733,868	NA	NA	
<b><u>LLIN</u></b>															
Supanet Conical	04/2017	503	0	0	503	0%	\$2,887	99%	\$2,870	NA	NA	97,916	NA	NA	
Supanet Rectangular	04/2017	503	0	0	503	0%	\$2,887	99%	\$2,870	NA	NA	47,978	NA	NA	
Supanet XtraPower BL PNET USA	04/2017	46,480	0	0	46,480	0%	\$0	NA	\$0	NA	NA	256,058	NA	NA	
<b><u>Olyset</u></b>															
Supanet Xtra Power (Olyset)-Coni	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	173,118	NA	NA	
<b><u>PUR</u></b>															
PuR	04/2017	1,408,560	0	24,261,628	25,670,188	0%	\$119,396	99%	\$118,514	NA	NA	7,267,171	NA	NA	
<b><u>Safe Water Solution</u></b>															
WaterGuard	04/2017	100,188	0	193,818	294,006	0%	\$13,563	100%	\$13,561	NA	NA	526,348	NA	NA	
<b><u>Water Treatment Tablets</u></b>															
Aquatab	04/2017	10,800	0	63,730	74,530	0%	\$214	100%	\$214	NA	NA	61,570	NA	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Kenya</b>							\$543,508		\$376,391	\$522,313	0.72				
<b>Implant 3</b>															
Implanon	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	231,177	NA	NA	
<b>Implant 5</b>															
Jadelle	04/2017	7	0	0	7	0%	\$68	0%	\$0	NA	NA	6,787	NA	NA	
<b>Injectable 3</b>															
Femiplan Injectable	04/2017	588	0	27,427	28,015	0%	\$15,061	100%	\$15,061	NA	NA	2,395	NA	NA	
<b>IUD 10</b>															
CU 380A (Copper T)	04/2017	230	40	0	270	15%	\$1	0%	\$0	NA	NA	22,615	NA	NA	
<b>OCs</b>															
Femi Girl Oral Pills	04/2017	360	0	166,320	166,680	0%	\$417	100%	\$417	NA	NA	1,665,480	NA	NA	
Femiplan Pill	04/2017	1,728	756	45,530	48,014	30%	\$248	100%	\$248	NA	NA	1,547,196	NA	NA	
Femiplan Pill-1 cycle	04/2017	535,680	0	0	535,680	0%	\$159,134	100%	\$49,088	NA	NA	581,319	NA	NA	
Femiplan Pill-3 cycles	04/2017	398,880	0	0	398,880	0%	\$89,182	100%	\$33,455	NA	NA	305,919	NA	NA	
<b>Malawi</b>							\$35,645		\$52,363	\$46,498	1.13				
<b>Condom</b>															
Chishango	04/2017	498,720	1,920	0	500,640	0%	\$5,179	19%	\$4,512	\$2,994	1.51	14,663,760	296,933	49.38	
<b>Female Condom</b>															
Care	04/2017	2,080	0	0	2,080	0%	\$57	0%	\$36	\$69	0.53	786	2,500	0.31	
Whisper Female Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,597	357	43.65	
<b>Free Condom</b>															
Free Male Condoms	04/2017	0	3,280	0	3,280	100%	\$0	NA	\$0	\$0	NA	15,723	1,573	9.99	
Key Population Male Condom	04/2017	0	814,858	0	814,858	100%	\$0	NA	\$0	\$0	NA	1,827,699	799,935	2.28	
One Community Male Condom	04/2017	0	51,840	0	51,840	100%	\$0	NA	\$0	\$0	NA	1,966,982	367,644	5.35	
<b>Free Female Condom</b>															
Free Female Condoms	04/2017	0	1,261	0	1,261	100%	\$0	NA	\$0	\$0	NA	51,579	4,280	12.05	
<b>Lubricant A</b>															
Personal Lubricant Water 4.5 g	04/2017	0	193,226	0	193,226	100%	\$0	NA	\$0	\$0	NA	903,057	135,745	6.65	
<b>LLIN</b>															
Super Chitetezo Net	04/2017	2,628	0	0	2,628	0%	\$16,206	79%	\$37,176	\$22,387	1.66	131,100	3,614	36.28	
<b>PUR</b>															
PuR WaterGuard Waufa	04/2017	100,000	0	0	100,000	0%	\$6,022	0%	\$0	\$12,958	NA	6,328,753	214,690	29.48	
<b>Safe Water Solution</b>															
WaterGuard	04/2017	6,324	0	0	6,324	0%	\$2,836	35%	\$6,338	\$4,735	1.34	17,969	10,571	1.70	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Malawi</b>							\$35,645		\$52,363	\$46,498	1.13				
<u>Emergency Contraception</u>															
NORLEVO (Norlevo 1.5mg)	04/2017	694	0	0	694	0%	\$479	0%	\$1,073	\$542	1.98	35,146	796	44.17	
<u>Implant 3</u>															
Implanon	04/2017	60	2,224	0	2,284	97%	\$41	0%	\$0	\$57	NA	4,027	2,150	1.87	
<u>Implant 5</u>															
Jadelle	04/2017	90	1,858	0	1,948	95%	\$62	0%	\$0	\$57	NA	5,559	2,584	2.15	
<u>Injectable 3</u>															
SafePlan Inj3	04/2017	3,860	2,452	20	6,332	39%	\$1,634	91%	\$1,501	\$1,034	1.45	43,645	7,940	5.50	
<u>IUD 10</u>															
IUD Copper T 380A	04/2017	20	195	0	215	91%	\$7	0%	\$0	\$24	NA	28,719	201	143.12	
<u>OCs</u>															
Microgynon	04/2017	8,590	10,039	0	18,629	54%	\$3,122	55%	\$1,725	\$1,642	1.05	206,961	13,742	15.06	
<b>SFH Rwanda</b>							\$17,264		\$1,683	\$22,174	0.08				
<u>Condom</u>															
Plaisir	04/2017	26,880	0	0	26,880	0%	\$1,462	0%	\$0	\$2,817	NA	216,866	52,220	4.15	
Prudence Plus	04/2017	726,624	17,500	0	744,124	2%	\$8,863	0%	\$0	\$11,040	NA	11,909,350	976,576	12.20	
<u>Free Condom</u>															
Military Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	36,008	92,327	0.39	
<u>PUR</u>															
PuR	04/2017	2,149	13,200	0	15,349	86%	\$125	0%	\$0	\$149	NA	1,735,484	18,156	95.59	
<u>Safe Water Solution</u>															
Sur Eau	04/2017	18,384	0	0	18,384	0%	\$6,117	28%	\$1,683	\$6,652	0.25	39,770	20,340	1.96	
<u>Injectable 3</u>															
Confiance Depo-Provera	04/2017	1,440	0	0	1,440	0%	\$261	0%	\$0	\$262	NA	87,078	1,440	60.47	
<u>OCs</u>															
Microgynon	04/2017	7,200	0	0	7,200	0%	\$435	0%	\$0	\$1,254	NA	189,528	20,640	9.18	
<u>SDM (Cycle Beads)</u>															
Collier	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	10	0	NA	
<b>Somaliland</b>							\$5,922		\$0	\$5,017	NA				
<u>Diarrhea Treatment Kit</u>															
SD OFLV-DTK	04/2017	14,810	0	0	14,810	0%	\$1,503	0%	\$0	\$1,519	NA	778	14,361	0.05	
<u>Micronutrient Powder</u>															
Super Fariid	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,633,745	0	NA	
<u>Misoprostol for PPH</u>															
Ummul-gargaar	04/2017	4,000	0	0	4,000	0%	\$216	0%	\$0	\$112	NA	9,200	2,000	4.60	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Somaliland</b>							\$5,922		\$0	\$5,017	NA				
<b>ORS</b>															
SD OFLV-ORS	04/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	9,380	0	NA	
<b>Water Treatment Tablets</b>															
Aquatab	04/2017	0	0	288,000	288,000	NA	\$0	NA	\$0	\$0	NA	357,602	0	NA	
Biyosifeeye	04/2017	624,000	0	0	624,000	0%	\$3,895	0%	\$0	\$2,678	NA	983,678	420,520	2.34	
<b>Zinc</b>															
Shuban Daweeye_Zinc	04/2017	0	0	150,000	150,000	NA	\$0	NA	\$0	\$0	NA	632,190	0	NA	
<b>Implant 3</b>															
Nasiye Implant (Implanon)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$321	NA	1,566	33	46.98	
<b>Injectable 3</b>															
Nasiye - Inj 3	04/2017	100	0	0	100	0%	\$60	0%	\$0	\$42	NA	2,088	67	31.32	
<b>OCs</b>															
Nasiye - OC	04/2017	750	0	0	750	0%	\$247	0%	\$0	\$346	NA	8,281	1,000	8.28	
OC	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	16	0	NA	
<b>Pneumonia PPT</b>															
Pneomox 125mg tablet (Amoxicilli)	04/2017	0	0	1,386	1,386	NA	\$0	NA	\$0	\$0	NA	1,159	0	NA	
Pneomox 250mg tablet (Amoxicilli)	04/2017	0	0	5,258	5,258	NA	\$0	NA	\$0	\$0	NA	4,637	0	NA	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<b>Medicines &amp; Supplies</b>															
Artesunate 60 mg vial	04/2017	0	8,900	1	8,901	100%	\$0	NA	\$0	\$0	NA	96,029	2,967	32.37	
Falcistat Tablet (SP 500/25 mg)	04/2017	0	7,000	0	7,000	100%	\$0	NA	\$0	\$0	NA	2,000	2,333	0.86	
<b>LLIN</b>															
Mass LLIN - WES-Green Rectang	04/2017	0	238,590	0	238,590	100%	\$0	NA	\$0	\$0	NA	3,176,706	423,231	7.51	
<b>Malaria PPT (ACT)</b>															
ACTs for Adult (14+ years)	04/2017	0	63,600	0	63,600	100%	\$0	NA	\$0	\$0	NA	287,125	85,400	3.36	
ACTs for Child (6-14 years)	04/2017	0	37,200	0	37,200	100%	\$0	NA	\$0	\$0	NA	214,225	37,400	5.73	
ACTs for Infant (2-12 months)	04/2017	0	89,100	0	89,100	100%	\$0	NA	\$0	\$0	NA	27,275	122,425	0.22	
ACTs for Toddler (1-5 years)	04/2017	0	65,400	0	65,400	100%	\$0	NA	\$0	\$0	NA	309,550	124,167	2.49	
<b>Malaria RDK</b>															
Malaria Rapid Diagnostic Kit	04/2017	0	43,400	2	43,402	100%	\$0	NA	\$0	\$0	NA	1,837,698	14,467	127.03	
<b>ORS</b>															
ORS	04/2017	0	29,500	0	29,500	100%	\$0	NA	\$0	\$0	NA	178,668	30,813	5.80	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>South Sudan</b>							\$0		\$0	\$0	NA				
<u>Zinc</u>															
Zinc	04/2017	0	18,000	0	18,000	100%	\$0	NA	\$0	\$0	NA	144,954	22,960	6.31	
<u>Pneumonia PPT</u>															
Amoxicillin for Children (1-5 years)	04/2017	0	17,520	0	17,520	100%	\$0	NA	\$0	\$0	NA	159,517	10,286	15.51	
Amoxicillin for Infant (2-12 months)	04/2017	0	1,400	0	1,400	100%	\$0	NA	\$0	\$0	NA	14,611	1,768	8.26	





# Southern Africa

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 4/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Southern Africa	38,663	8	-	1	683,255	287	131,020	1,396	205	627	-	2,245
Angola	93	-	-	-	6,949	3	1,034	13	18	-	-	30
Botswana	154	-	-	-	3,657	-	524	-	-	-	-	-
Lesotho	2,558	-	-	-	24,277	12	3,601	-	-	-	-	-
Madagascar	730	2	-	-	317,991	166	72,733	1,166	105	627	-	1,909
Mozambique	1,791	-	-	-	40,720	22	7,142	217	70	-	-	287
Namibia	5	-	-	-	115	-	17	-	-	-	-	-
South Africa	13,391	-	-	-	190,493	28	27,275	-	-	-	-	-
Swaziland	6,130	3	-	-	45,558	19	6,539	-	-	-	-	3
Zambia	7,653	-	-	-	4,234	2	1,346	-	12	-	-	12
Zimbabwe	6,159	3	-	-	49,261	35	10,811	-	-	-	-	4

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 4  
Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>									<b>1,765,762</b>	<b>347,804</b>	<b>2,113,566</b>
Antiretroviral Treatment (C	8,072	7,383	30,220	-	-	-%	5,010	35,230	5,369	-	5,369
Antiretroviral Treatment (I	762	918	3,516	-	-	-%	5,283	8,799	-	-	-
CD4 Tests Provided to HIV	692	1,602	5,499	-	-	-%	778	6,277	-	-	-
Cervical Cancer-Pap and I	-	-	1	-	-	-%	1	2	-	-	-
Cervical Cancer-Pap and I	-	-	-	-	-	-%	7	9	-	-	-
Cervical Cancer-Pap Sme:	-	1	2	-	-	-%	116	118	-	-	-
Cervical Cancer-VIA and C	23	22	90	-	-	-%	10	100	-	26	26
Cervical Cancer-VIA and C	49	70	258	-	249	4%	1,194	3,329	-	72	72
Cervical Cancer-VIA and F	1	2	6	-	-	-%	17	254	-	1	1
Cervical Cancer-VIA and F	14	15	60	-	302	(80)%	402	1,927	-	9	9
Cervical Cancer-VIA and F	-	5	16	-	31	(48)%	33	449	-	2	2
Cervical Cancer-VIA/VILI §	1,319	1,736	6,527	-	11,437	(43)%	26,740	58,008	-	-	-
Chlorhexidine	779	1,774	6,100	-	18,757	(67)%	241,094	307,119	-	373	373
Condom	4,949,900	5,229,924	20,639,673	-	31,536,782	(35)%	100,683,376	1,319,694,516	392,946	32,179	425,125
Condom Provided	-	-	-	-	227,533	(100)%	842,352	1,075,691	-	-	-
Diarrhea Treatment Kit	31,132	19,068	88,337	-	184,732	(52)%	479,996	1,932,337	-	2,230	2,230
Diarrhea Treatment Kit Pri	494	568	2,197	-	-	-%	4,866	7,063	-	62	62
Early Infant Male Circumc	-	-	-	-	1	(100)%	5	5	-	-	-
Emergency Contraception	2,462	15,357	48,532	-	54,408	(11)%	208,155	799,267	-	249	249
Emergency Contraception	99	91	371	-	120	209%	1,660	2,422	-	3	3
Family Planning Counseli	-	-	-	-	-	-%	223	223	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Female Condom	31,380	57,919	205,137	-	519,083	(60)%	2,709,105	33,504,808	4,407	218	4,625
Female Condom Provided	-	-	-	-	27,006	(100)%	80,452	99,712	-	-	-
Fever Cases Attended	3,812	93,063	283,001	-	-	-%	24,338	307,339	-	-	-
Fever Cases Tested with I	468	365	1,563	-	-	-%	1,885	3,448	-	-	-
Fever Cases Tested with F	3,479	87,041	264,602	-	-	-%	20,935	285,537	-	-	-
Free Condom	3,699,813	6,937,457	24,512,183	-	30,786,461	(20)%	93,108,576	1,257,396,757	530,468	33,314	563,782
Free Female Condom	486	21,328	64,470	-	236,604	(73)%	626,979	4,932,392	1,285	50	1,335
HIV Testing Services	104,401	107,576	427,130	-	281,687	52%	973,831	7,622,242	29,183	-	29,183
Hypertension Diagnosis	62	10	92	-	-	-%	4	96	-	-	-
Hypertension Screening	13,324	70,566	225,023	-	-	-%	12,961	237,984	-	-	-
Hypertension_Controlled	-	6	19	-	-	-%	3	22	-	-	-
Implant 3	(510)	(101)	(812)	-	(661)	-%	(1,712)	691	-	(808)	(808)
Implant 3 Insertion	977	859	3,555	-	3,384	5%	11,806	39,158	-	3,903	3,903
Implant 4	176	207	797	-	1,362	(41)%	3,788	16,113	-	1,867	1,867
Implant 4 Insertion	3	5	17	-	70	(76)%	329	2,646	-	24	24
Implant 5	(809)	(1,097)	(4,100)	-	(1,678)	-%	(9,620)	(45,749)	-	(9,794)	(9,794)
Implant 5 Insertion	1,367	2,043	7,497	-	10,875	(31)%	32,406	282,275	-	16,960	16,960
Injectable 1 Provided	47	26	124	-	-	-%	135	259	-	5	5
Injectable 2 Provided	-	32	97	-	-	-%	686	783	-	7	7
Injectable 3	139,065	146,546	578,704	-	810,100	(29)%	2,197,761	18,688,608	-	39,987	39,987
Injectable 3 Provided	17,656	20,570	79,366	-	41,039	93%	209,517	423,807	-	8,250	8,250
IPTp2	-	5,503	16,510	-	-	-%	158,455	174,965	-	978	978

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10	(388)	(95)	(673)	-	9	(7,578)%	3,336	20,395	-	(2,226)	(2,226)
IUD 10 Insertion	2,106	1,785	7,462	-	6,249	19%	25,159	267,907	-	16,095	16,095
IUD 5 Insertion	-	-	-	-	-	-%	241	241	-	-	-
IUS 5	(38)	-	(38)	-	-	-%	-	(38)	-	(46)	(46)
IUS 5 Insertion	38	-	38	-	-	-%	-	38	-	52	52
LLIN	368,547	138,427	783,827	-	715,442	10%	2,787,629	31,077,192	-	46,327	46,327
Lubricant	54,038	102,199	360,635	-	251,972	43%	621,962	3,868,825	-	-	-
Malaria PPT (ACT)	1,400	78,384	236,552	-	11,558	1,947%	991,622	5,530,729	-	67,257	67,257
Malaria RDK	1,758,311	55,047	1,923,451	-	660,730	191%	1,133,756	9,978,576	-	-	-
Male Circumcision (HIV-Pi	-	-	-	-	980	(100)%	3,239	10,222	-	-	-
Manual Vacuum Aspiratio	163	200	764	-	-	-%	1,457	2,221	-	229	229
Micronutrient Powder	913,950	543,613	2,544,790	-	1,111,820	129%	4,044,450	11,649,760	-	-	-
Misoprostol for PAC (Oral	(864)	(112)	(1,200)	-	-	-%	(6,537)	(7,737)	-	(108)	(108)
Misoprostol for PAC (oral)	864	112	1,200	-	-	-%	6,537	7,737	-	120	120
Misoprostol for PAC (Subl	-	-	-	-	-	-%	6,000	6,000	-	-	-
OCs	214,194	286,415	1,073,440	-	1,016,186	6%	2,534,347	40,006,378	-	20,368	20,368
OCs Provided	28,780	35,687	135,842	-	191,526	(29)%	566,148	1,181,381	-	3,604	3,604
Pneumonia PPT	68,203	25,941	146,026	-	84,386	73%	376,369	977,924	-	53,589	53,589
Positive RDTs	775	32,596	98,562	-	-	-%	2,177	100,739	-	-	-
PrEP	231	207	852	-	-	-%	403	1,255	28	-	28
Referral to Advanced Cer	2	6	19	-	66	(71)%	142	362	-	-	-
Referral to CD4/Clinical St	-	-	-	-	2,552	(100)%	8,610	14,178	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Clinical Staging	-	-	-	-	718	(100)%	2,879	5,010	-	-	-
Referral to Early Infant Maternal	-	-	-	-	28	(100)%	36	94	-	-	-
Referral to Emergency Contraception	-	-	-	-	-	-%	6	8	-	-	-
Referral to HIV Testing Services	1,880	664	3,872	-	2,807	38%	7,911	20,769	203	-	203
Referral to Hypertension Management	5	2	12	-	-	-%	27	39	-	-	-
Referral to Implant 3 Insertions	-	-	-	-	-	-%	1	1	-	-	-
Referral to Injectable 1	9	-	9	-	-	-%	32	41	-	-	-
Referral to Injectable 3	56	1	59	-	-	-%	45	104	-	3	3
Referral to IUD 10 Insertions	8	6	27	-	2	1,250%	7	191	-	25	25
Referral to IUD Insertion (Other)	-	-	-	-	-	-%	2	2	-	-	-
Referral to Linkage to HIV	1,177	1,721	6,341	-	-	-%	2,624	8,965	3,774	-	3,774
Referral to OCs	31	16	78	-	1	7,700%	79	1,004	-	1	1
Referral to Pre-Exposure Prophylaxis	34	18	87	-	-	-%	-	87	1	-	1
Referral to STI Screening	7	9	35	-	-	-%	8	43	-	-	-
Referral to STI Treatment	7	5	22	-	508	(96)%	952	4,502	-	-	-
Referral to TB Diagnosis	6	23	74	-	-	-%	11	3,705	-	-	-
Referral to TB DOTS (com)	-	-	1	-	-	-%	2	17	-	1	1
Referral to TB DOTS (com)	12	16	59	-	213	(72)%	484	2,512	-	33	33
Referral to TB Screening	297	2,638	8,212	-	-	-%	434	8,646	-	-	-
Referral to Treatment for (Other)	-	-	-	-	4	(100)%	4	23	-	-	-
Referral to Treatment for (Other)	-	-	-	-	-	-%	3	3	-	-	-
Referral to Treatment for (Other)	-	1	2	-	-	-%	8	25	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Treatment for l	-	-	-	-	7	(100)%	32	56	-	-	-
Referral to Treatment for \	-	-	-	-	1	(100)%	7	12	-	-	-
Referral to Tubal Ligation	-	-	1	-	-	-%	-	1	-	2	2
Referral to Tx for Nonherp	-	-	-	-	-	-%	13	22	-	-	-
Referral to Tx for Urethral	10	17	60	-	72	(17)%	156	459	-	6	6
Referral to Voluntary Medi	47	62	233	-	2,044	(89)%	3,849	20,277	1,160	-	1,160
Safe Water Solution	266,811	400,346	1,467,850	-	1,580,021	(7)%	4,291,617	62,385,730	-	8,776	8,776
SDM (Cycle Beads)	625	186	1,184	-	5,356	(78)%	11,341	119,191	-	802	802
SDM (Cycle Beads) Provic	225	214	866	-	-	-%	2,176	3,731	-	652	652
STI Kit (Non-Ulcerative)	63	59	239	-	156	53%	797	4,051	-	43	43
STI Kit (Ulcerative)	7	11	40	-	12	233%	127	492	-	16	16
STI Screening	5,995	6,096	24,283	-	11,049	120%	47,096	85,635	-	-	-
TB Diagnosis	30	31	123	-	121	2%	336	858	-	-	-
TB DOTS	-	1	2	-	3	(33)%	11	44	-	16	16
TB Screening	22,321	30,016	112,368	-	104,913	7%	284,453	645,172	-	-	-
Treatment for Cervicitis	27	48	170	-	-	-%	20	190	-	16	16
Treatment for Genital Herp	7	9	33	-	-	-%	5	38	-	1	1
Treatment for Inguinal Bul	9	12	44	-	-	-%	8	52	-	-	-
Treatment for Lower Abdc	118	125	492	-	-	-%	102	594	-	-	-
Treatment for Nonherpetic	160	214	803	-	-	-%	162	965	-	141	141
Treatment for Urethral Dis	674	765	2,970	-	-	-%	581	3,551	-	42	42
Treatment for Urethral Dis	103	122	468	-	-	-%	84	552	-	86	86

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Treatment for Vaginitis</b>	<b>695</b>	<b>742</b>	<b>2,922</b>	-	-	-%	<b>604</b>	<b>3,526</b>	-	<b>71</b>	<b>71</b>
<b>Tubal Ligation</b>	<b>5</b>	<b>10</b>	<b>34</b>	-	-	-%	-	<b>34</b>	-	<b>116</b>	<b>116</b>
<b>Type 2 Diabetes Screenin</b>	<b>159</b>	<b>370</b>	<b>1,270</b>	-	-	-%	-	<b>1,270</b>	-	-	-
<b>Type 2 Diabetes_Controlle</b>	-	-	<b>1</b>	-	-	-%	-	<b>1</b>	-	-	-
<b>Voluntary Medical Male Ci</b>	<b>28,316</b>	<b>27,657</b>	<b>111,288</b>	-	<b>82,907</b>	<b>34%</b>	<b>249,280</b>	<b>1,595,088</b>	<b>796,854</b>	-	<b>796,854</b>
<b>Water Treatment Tablets</b>	<b>2,467,480</b>	<b>1,409,724</b>	<b>6,696,652</b>	-	<b>3,271,350</b>	<b>105%</b>	<b>20,557,660</b>	<b>71,884,642</b>	-	<b>1,525</b>	<b>1,525</b>
<b>Woman Condom</b>	<b>1,152</b>	<b>1,320</b>	<b>5,112</b>	-	<b>336</b>	<b>1,421%</b>	<b>9,600</b>	<b>14,712</b>	<b>86</b>	<b>10</b>	<b>96</b>



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Southern Africa - All</b>										<b>1,765,762</b>	<b>347,804</b>	<b>2,113,566</b>
<b>Angola</b>										<b>3,344</b>	<b>4,636</b>	<b>7,980</b>
Condom	247,572	186,624	807,444	-	648		124506%	6,252,912	99,492,291	3,344	2,264	5,608
Legal	-	-	-	-	-	6/01	-%	1,724,552	85,409,357	-	-	-
Sensual Chocolate	44,028	54,264	206,820	-	-	12/12	-%	142,380	2,288,256	857	580	1,436
Sensual Maracuja	75,672	45,528	212,256	-	-		-%	-	212,256	879	595	1,474
Sensual Menta	80,640	46,020	218,700	-	-	12/12	-%	848,476	3,006,172	906	613	1,519
Sensual Morango	47,232	40,812	169,668	-	-	12/12	-%	716,544	3,021,147	703	476	1,178
Sensual Saliências	-	-	-	-	-	11/13	-%	2,106,980	3,593,643	-	-	-
Sensual Sensitive	-	-	-	-	648	11/13	(100)%	713,980	1,961,460	-	-	-
Family Planning Counseling	-	-	-	-	-		0%	223	223	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	223	223	-	-	-
Implant 5 Insertion	-	-	-	-	-		0%	47	47	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	-		-%	47	47	-	-	-
IUD 10	-	15	46	-	-		0%	1,272	1,318	-	155	155
PSI IUD 10 Distributed Inserted (1)	-	(1)	(2)	-	-		-%	(46)	(48)	-	(7)	(7)
Coper T 380 A – ENOVA	-	16	48	-	-		-%	1,318	1,366	-	161	161
IUD 10 Insertion	-	1	2	-	-		0%	105	107	-	7	7
PSI IUD 10 Inserted	-	1	2	-	-		-%	46	48	-	7	7
Non-PSI IUD 10 Inserted	-	-	-	-	-		-%	59	59	-	-	-
LLIN	5,205	-	5,205	-	675,046		(99)%	1,362,451	5,062,693	-	971	971
Generic LLINs	-	-	-	-	663,896	4/11	(100)%	1,316,525	4,744,897	-	-	-
Joia	5,205	-	5,205	-	11,150	11/04	(53)%	45,926	317,796	-	971	971
Malaria RDK	34,625	36,658	144,600	-	25		578300%	127,550	573,275	-	-	-
Bioline (RDT)	34,625	36,658	144,600	-	25	2/14	578,300%	127,550	573,275	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Manual Vacuum Aspiration for PAC	-	-	-	-	-		0%	223	223	-	-	-
MVA for PAC	-	-	-	-	-	11/16	-%	223	223	-	-	-
Misoprostol for PAC (Sublingual)	-	-	-	-	-		0%	6,000	6,000	-	-	-
ACE Miso (Misoprostol 200mcg tabl	-	-	-	-	-		-%	6,000	6,000	-	-	-
Water Treatment Tablets	1,371,800	539,737	2,991,012	-	108,000		2669%	10,098,200	54,605,462	-	1,239	1,239
Certeza Water Tabs	1,371,800	539,737	2,991,012	-	108,000	4/11	2,669%	10,098,200	54,605,462	-	1,239	1,239
<b>Botswana</b>										5,820	438	6,258
Condom	135,648	101,064	438,840	-	294,192		49%	1,028,592	65,961,917	5,820	438	6,258
Lovers Plus	10,368	13,824	51,840	-	51,840	6/93	-%	139,968	52,388,742	688	52	739
Lovers Plus C&F	25,920	13,800	67,320	-	41,472	8/06	62%	133,056	7,807,846	893	67	960
Lovers Plus Extra Play	15,552	13,824	57,024	-	20,736	3/16	175%	82,944	399,168	756	57	813
Lovers Plus R&S	5,184	13,824	46,656	-	31,104	10/13	50%	108,864	651,744	619	47	665
Trust	37,152	28,512	122,688	-	66,096	6/07	86%	268,272	3,217,969	1,627	123	1,750
Trust Studded	41,472	17,280	93,312	-	82,944	11/12	13%	295,488	1,496,448	1,238	93	1,331
<b>Lesotho</b>										85,978	5,971	91,949
Antiretroviral Treatment (Currently Enr	1,606	1,607	6,426	-	-		0%	-	6,426	1,217	-	1,217
Antiretroviral Treatment (Currently E	1,606	1,607	6,426	-	-		-%	-	6,426	1,217	-	1,217
Antiretroviral Treatment (Newly Enrolle	8	12	44	-	-		0%	-	44	-	-	-
Antiretroviral Treatment (Newly Enrc	8	12	44	-	-		-%	-	44	-	-	-
Condom	276,480	112,896	615,168	-	369,530		66%	530,654	30,514,255	16,224	1,215	17,439
PSI Condom Distributed Provided	-	-	-	-	(81,478)	3/16	-%	(461,218)	(520,647)	-	-	-
Lovers Plus	-	5,760	17,280	-	5,184	3/99	233%	13,824	2,741,269	456	34	490
Lovers Plus C&F	-	7,488	22,464	-	8,640	1/05	160%	32,832	693,880	592	44	637
Lovers Plus Extra Play	-	6,912	20,736	-	3,456	3/16	500%	12,096	36,288	547	41	588

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lovers Plus R&S	-	<b>6,336</b>	<b>19,008</b>	-	<b>5,184</b>	11/12	267%	<b>20,736</b>	<b>129,672</b>	<b>501</b>	<b>38</b>	<b>539</b>
Trust	-	-	-	-	<b>13,824</b>	5/01	(100)%	<b>31,104</b>	<b>12,827,594</b>	-	-	-
Trust Studed	<b>276,480</b>	<b>86,400</b>	<b>535,680</b>	-	<b>414,720</b>	1/05	29%	<b>881,280</b>	<b>14,606,199</b>	<b>14,127</b>	<b>1,058</b>	<b>15,185</b>
Condom Provided	-	-	-	-	<b>81,478</b>		<b>(100)%</b>	<b>496,850</b>	<b>556,279</b>	-	-	-
PSI Condom Provided	-	-	-	-	<b>81,478</b>	3/16	(100)%	<b>461,218</b>	<b>520,647</b>	-	-	-
Non-PSI Condom Provided	-	-	-	-	-		-%	<b>35,632</b>	<b>35,632</b>	-	-	-
Emergency Contraception Provided	-	-	-	-	-		<b>0%</b>	<b>21</b>	<b>21</b>	-	-	-
Non-PSI Emergency Contraception I	-	-	-	-	-		-%	<b>21</b>	<b>21</b>	-	-	-
Female Condom	-	<b>1</b>	<b>3</b>	-	<b>100,024</b>		<b>(100)%</b>	<b>1,505,148</b>	<b>7,646,989</b>	-	-	-
PSI Female Condom Distributed Pr	-	-	-	-	<b>(16,576)</b>	3/16	-%	<b>(49,852)</b>	<b>(52,530)</b>	-	-	-
Female Condom	-	-	-	-	<b>95,000</b>	7/06	(100)%	<b>1,555,000</b>	<b>5,306,236</b>	-	-	-
Generic	-	<b>1</b>	<b>3</b>	-	<b>21,600</b>	1/08	(100)%	-	<b>2,393,283</b>	-	-	-
Female Condom Provided	-	-	-	-	<b>16,576</b>		<b>(100)%</b>	<b>54,540</b>	<b>57,218</b>	-	-	-
PSI Female Condom Provided	-	-	-	-	<b>16,576</b>	3/16	(100)%	<b>49,852</b>	<b>52,530</b>	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	-		-%	<b>4,688</b>	<b>4,688</b>	-	-	-
Free Condom	<b>411,741</b>	<b>593,196</b>	<b>2,191,328</b>	-	<b>1,752,000</b>		<b>25%</b>	<b>11,861,420</b>	<b>102,617,564</b>	<b>57,792</b>	<b>4,328</b>	<b>62,120</b>
Blue & Gold Workplace	-	-	-	-	<b>1,194,000</b>	1/08	(100)%	<b>4,413,000</b>	<b>66,291,000</b>	-	-	-
Camouflage Free	<b>60,000</b>	<b>188,000</b>	<b>624,000</b>	-	<b>558,000</b>	1/16	12%	<b>1,113,000</b>	<b>1,737,000</b>	<b>16,457</b>	<b>1,232</b>	<b>17,689</b>
Generic	-	-	-	-	-	4/05	-%	<b>2,292,480</b>	<b>21,971,296</b>	-	-	-
Vibe Condom	<b>351,741</b>	<b>405,196</b>	<b>1,567,328</b>	-	-	9/14	-%	<b>4,042,940</b>	<b>12,618,268</b>	<b>41,335</b>	<b>3,095</b>	<b>44,431</b>
HIV Testing Services	<b>16,316</b>	<b>21,235</b>	<b>80,022</b>	-	<b>56,812</b>		<b>41%</b>	<b>258,501</b>	<b>753,079</b>	<b>8,383</b>	-	<b>8,383</b>
VCT Concordant Couple (HIV-Nega	-	-	-	-	<b>1,470</b>	12/09	(100)%	<b>3,178</b>	<b>12,206</b>	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	<b>74</b>	12/09	(100)%	<b>164</b>	<b>1,346</b>	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	<b>25</b>	12/09	(100)%	<b>67</b>	<b>666</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Discordant Couple (HIV-Positiv	-	-	-	-	25	12/09	(100)%	67	666	-	-	-
VCT Individual (HIV-Negative)	15,690	20,504	77,202	-	52,791	12/09	46%	243,601	684,616	8,088	-	8,088
VCT Individual (HIV-Positive)	626	731	2,820	-	2,427	12/09	16%	11,424	53,579	295	-	295
Hypertension Screening	1,287	1,524	5,860	-	-		0%	-	5,860	-	-	-
Hypertension Screening	1,287	1,524	5,860	-	-		-%	-	5,860	-	-	-
Implant 3 Insertion	-	1	2	-	-		0%	828	830	-	3	3
Non-PSI Implant 3 Inserted	-	1	2	-	-		-%	828	830	-	3	3
Implant 4 Insertion	-	-	-	-	-		0%	24	24	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	24	24	-	-	-
Implant 5 Insertion	-	26	77	-	-		0%	16	93	-	163	163
Non-PSI Implant 5 Inserted	-	26	77	-	-		-%	16	93	-	163	163
Injectable 1 Provided	-	2	6	-	-		0%	-	6	-	-	-
Non-PSI Injectable 1 Provided	-	2	6	-	-		-%	-	6	-	-	-
Injectable 2 Provided	-	32	97	-	-		0%	686	783	-	7	7
Non-PSI Injectable 2 Provided	-	32	97	-	-		-%	686	783	-	7	7
Injectable 3 Provided	-	520	1,560	-	-		0%	3,255	4,815	-	161	161
Non-PSI Injectable 3 Provided	-	520	1,560	-	-		-%	3,255	4,815	-	161	161
IUD 10 Insertion	-	-	-	-	-		0%	78	78	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	-		-%	78	78	-	-	-
Lubricant	-	-	-	-	-		0%	48	144	-	-	-
Lovers Plus Lube Natural (100mL)	-	-	-	-	-		-%	48	144	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	40		(100)%	231	363	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	40	3/16	(100)%	231	363	-	-	-
OCs Provided	-	925	2,775	-	-		0%	8,616	11,391	-	78	78
Non-PSI OCs Provided	-	925	2,775	-	-		-%	8,616	11,391	-	78	78

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to CD4/Clinical Staging	-	-	-	-	1,422		(100)%	4,277	6,355	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	1,422	3/16	(100)%	4,277	6,355	-	-	-
Referral to Clinical Staging	-	-	-	-	-		0%	422	975	-	-	-
Referral to Clinical Staging	-	-	-	-	-	3/16	-%	422	975	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	28		(100)%	28	28	-	-	-
Referral to HIV Testing Services	1,880	664	3,872	-	-		0%	1,256	5,149	203	-	203
Referral to HIV Testing & Counselin	1,880	664	3,872	-	-	3/16	-%	1,256	5,149	203	-	203
Referral to Linkage to HIV Care	338	629	2,224	-	-		0%	112	2,336	1,337	-	1,337
Referral to Linkage to HIV Care	338	629	2,224	-	-		-%	112	2,336	1,337	-	1,337
Referral to STI Treatment (unknown)	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	17		(100)%	17	17	-	-	-
Referral to Voluntary Medical Male Cir	-	-	-	-	174		(100)%	174	1,711	-	-	-
Referral to Voluntary Medical Male C	-	-	-	-	174	3/16	(100)%	174	1,711	-	-	-
SDM (Cycle Beads) Provided	-	-	-	-	-		0%	10	10	-	-	-
Non-PSI SDM (Cycle Beads) Provid	-	-	-	-	-		-%	10	10	-	-	-
TB Diagnosis	1	3	11	-	-		0%	-	11	-	-	-
TB Diagnosis	1	3	11	-	-		-%	-	11	-	-	-
TB DOTS	-	1	2	-	-		0%	-	2	-	16	16
TB DOTS	-	1	2	-	-		-%	-	2	-	16	16
TB Screening	390	702	2,495	-	-		0%	-	2,495	-	-	-
TB Screening	390	702	2,495	-	-		-%	-	2,495	-	-	-
Voluntary Medical Male Circumcision	12	17	63	-	130		(52)%	4,930	12,857	823	-	823
Male Circumcision (HIV-Negative)	-	-	-	-	129	9/12	(100)%	4,867	12,718	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	1	10/12	(100)%	45	58	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Voluntary Medical Male Circumcisi	12	17	63	-	-		-%	18	81	823	-	823
<b>Madagascar</b>										<b>38,139</b>	<b>250,458</b>	<b>288,597</b>
Cervical Cancer-VIA and Cryotherapy	8	8	32	-	-		0%	13	45	-	9	9
Cervical Cancer-VIA and Cryothera	8	8	32	-	-		-%	13	45	-	9	9
Cervical Cancer-VIA/VILI Screening	104	122	469	-	-		0%	146	615	-	-	-
Cervical Cancer-VIA/VILI Screening	104	122	469	-	-		-%	146	615	-	-	-
Chlorhexidine	779	1,774	6,100	-	18,757		(67)%	241,094	307,119	-	373	373
Arofoitra	779	1,774	6,100	-	18,757	9/15	(67)%	241,094	307,119	-	373	373
Condom	221,010	201,000	824,010	-	927,384		(11)%	5,892,786	58,351,898	5,266	1,254	6,520
Protector Plus	480	47,240	142,200	-	824,304	1/08	(83)%	4,995,576	56,315,618	909	216	1,125
YES	220,530	153,760	681,810	-	103,080	9/14	561%	897,210	2,036,280	4,357	1,038	5,395
Diarrhea Treatment Kit	31,132	19,068	88,337	-	184,732		(52)%	479,996	1,932,337	-	2,230	2,230
PSI Diarrhea Treatment Kit Distribu	(494)	(568)	(2,197)	-	-		-%	(4,866)	(7,063)	-	(55)	(55)
Hydrazinc	-	2,823	8,470	-	120,952	1/10	(93)%	166,308	593,054	-	214	214
ORS-Zinc	-	-	-	-	37,585	8/14	(100)%	187,651	400,662	-	-	-
Viasur	31,626	16,813	82,064	-	26,195	1/10	213%	130,903	945,684	-	2,072	2,072
Diarrhea Treatment Kit Provided	494	568	2,197	-	-		0%	4,866	7,063	-	62	62
PSI Diarrhea Treatment Kit Provide	494	568	2,197	-	-		-%	4,866	7,063	-	62	62
Emergency Contraception	(73)	(50)	(222)	-	-		0%	11,536	24,124	-	(1)	(1)
PSI Emergency Contraception Distr	(73)	(50)	(222)	-	-		-%	(344)	(734)	-	(1)	(1)
Norlevo	-	-	-	-	-	1/14	-%	11,880	24,858	-	-	-
Emergency Contraception Provided	73	50	222	-	-		0%	344	734	-	1	1
PSI Emergency Contraception Prov	73	50	222	-	-		-%	344	734	-	1	1
Female Condom	600	578	2,334	-	8,703		(73)%	20,721	358,529	15	3	18
Feeling	600	578	2,334	-	8,703	10/07	(73)%	20,721	358,529	15	3	18

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Fever Cases Attended	3,812	93,063	283,001	-	-		0%	24,338	307,339	-	-	-
Fever Cases Attended	3,812	93,063	283,001	-	-		-%	24,338	307,339	-	-	-
Fever Cases Tested with Microscopy	468	365	1,563	-	-		0%	1,885	3,448	-	-	-
Fever Cases Tested with Microscopy	468	365	1,563	-	-		-%	1,885	3,448	-	-	-
Fever Cases Tested with RDTs	3,479	87,041	264,602	-	-		0%	20,935	285,537	-	-	-
Fever Cases Tested with RDTs	3,479	87,041	264,602	-	-		-%	20,935	285,537	-	-	-
Free Condom	1,974,072	1,043,594	5,104,855	-	56,500		8935%	344,547	50,832,900	32,621	7,770	40,391
Generic	4,600	4,784	18,951	-	56,500	1/02	(66)%	152,700	45,555,149	121	29	150
Generic Condom	1,969,472	1,038,811	5,085,904	-	-	10/16	-%	191,847	5,277,751	32,500	7,742	40,241
HIV Testing Services	20,524	16,697	70,615	-	12,688		457%	55,027	217,211	238	-	238
VCT Individual (HIV-Negative)	20,472	16,642	70,398	-	12,688	12/09	455%	54,869	216,727	237	-	237
VCT Individual (HIV-Positive)	52	55	217	-	-	12/09	-%	158	484	1	-	1
Implant 3	(481)	(92)	(758)	-	(907)		0%	(1,590)	372	-	(759)	(759)
PSI Implant 3 Distributed Inserted (	(903)	(716)	(3,052)	-	(1,822)		-%	(7,497)	(30,229)	-	(3,058)	(3,058)
Implanon	422	624	2,294	-	915	7/06	151%	5,907	30,601	-	2,298	2,298
Implant 3 Insertion	903	716	3,052	-	1,822		68%	7,497	30,229	-	3,398	3,398
PSI Implant 3 Inserted	903	716	3,052	-	1,822		68%	7,497	30,229	-	3,398	3,398
Implant 4	(3)	1	-	-	(40)		0%	(83)	3,830	-	-	-
PSI Implant 4 Distributed Inserted (	(3)	(5)	(17)	-	(70)		-%	(189)	(2,506)	-	(21)	(21)
Implant Zarin	-	6	17	-	30	7/11	(43)%	106	6,336	-	21	21
Implant 4 Insertion	3	5	17	-	70		(76)%	189	2,506	-	24	24
PSI Implant 4 Inserted	3	5	17	-	70		(76)%	189	2,506	-	24	24
Implant 5	(18)	2	(12)	-	110		(111)%	492	1,692	-	(18)	(18)
PSI Implant 5 Distributed Inserted (	(28)	(34)	(130)	-	(196)		-%	(1,093)	(1,699)	-	(191)	(191)
Jadelle	10	36	118	-	306	7/14	(61)%	1,585	3,391	-	173	173

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	28	34	130	-	196		(34)%	1,093	1,699	-	212	212
PSI Implant 5 Inserted	28	34	130	-	196		(34)%	1,093	1,699	-	212	212
Injectable 3	144,843	151,479	599,280	-	803,258		(25)%	2,221,330	17,870,333	-	42,978	42,978
PSI Injectable 3 Distributed Provide (6,665)		(6,718)	(26,820)	-	-		-%	(66,475)	(127,979)	-	(1,923)	(1,923)
Confiance Injectable	126,760	133,045	525,896	-	623,405	10/98	(16)%	1,966,049	17,534,473	-	37,716	37,716
Sayana Press	24,748	25,152	100,204	-	179,853	9/15	(44)%	321,756	463,839	-	7,186	7,186
Injectable 3 Provided	6,665	6,718	26,820	-	-		0%	66,475	127,979	-	2,137	2,137
PSI Injectable 3 Provided	6,665	6,718	26,820	-	-		-%	66,475	127,979	-	2,137	2,137
IPTp2	-	5,503	16,510	-	-		0%	158,455	174,965	-	978	978
IPTp2	-	5,503	16,510	-	-		-%	158,455	174,965	-	978	978
IUD 10	(169)	(20)	(230)	-	(424)		0%	2,663	17,195	-	(416)	(416)
PSI IUD 10 Distributed Inserted (1) (1,880)		(1,453)	(6,240)	-	(4,118)		-%	(19,846)	(176,590)	-	(11,279)	(11,279)
Copper T	1,586	1,430	5,875	-	3,489	5/06	68%	21,749	190,065	-	10,619	10,619
IUD 1 x 5	125	3	135	-	205	8/11	(34)%	760	3,720	-	244	244
IUD 10 Insertion	1,880	1,453	6,240	-	4,118		52%	19,858	177,682	-	12,532	12,532
PSI IUD 10 Inserted	1,880	1,453	6,240	-	4,118		52%	19,846	176,590	-	12,532	12,532
Non-PSI IUD 10 Inserted	-	-	-	-	-		-%	12	1,092	-	-	-
LLIN	355,610	122,971	724,523	-	32,304		2143%	494,582	20,504,058	-	28,647	28,647
Generic net "PERMANET WHITE" 110,300		115,051	455,452	-	161	5/15	282,789%	151,204	8,690,206	-	18,008	18,008
Interceptor White	-	-	-	-	1	5/09	(100)%	1	1,099,951	-	-	-
Net Protect	-	167	502	-	1	12/13	50,100%	20,851	2,702,750	-	20	20
Olyset Net Blue	-	-	-	-	-	5/12	-%	360	675,553	-	-	-
Olyset Net White	-	-	-	-	480	5/12	(100)%	930	1,387,454	-	-	-
PermaNet	141,755	6,551	161,407	-	2,000	3/07	7,970%	7,228	1,986,516	-	6,382	6,382
Permanet Blue	103,555	-	103,555	-	-	2/17	-%	-	103,555	-	4,094	4,094

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Super Moustiquaire	-	1,202	3,605	-	29,651	9/01	(88)%	313,988	2,792,251	-	143	143
Yorkool Blue (Generic Net)	-	1	2	-	10	7/15	(80)%	20	1,065,822	-	-	-
Lubricant	900	38,005	114,916	-	-		0%	4,000	318,866	-	-	-
Gel Lubricant 5 mL	900	38,003	114,910	-	-	12/16	-%	4,000	118,910	-	-	-
Lubricant	-	2	6	-	-	8/11	-%	-	199,956	-	-	-
Malaria PPT (ACT)	1,400	78,384	236,552	-	11,558		1947%	991,622	5,530,729	-	67,257	67,257
ACT 100 mg (1x3's)	-	-	-	-	2,161	7/15	(100)%	34,235	181,157	-	-	-
ACT 100 mg (1x6's)	-	-	-	-	-	7/15	-%	7,701	163,575	-	-	-
ACT 25 mg (1x3's)	1,400	1,808	6,825	-	1,821	7/15	275%	46,499	72,049	-	1,940	1,940
ACT 50 mg (1x3's)	-	-	-	-	3,951	7/15	(100)%	17,218	32,123	-	-	-
AL for Adolescent, 20/120mg, 18's	-	957	2,871	-	-	7/16	-%	27,955	30,826	-	816	816
AL for Adult, 20/120mg, 24's	-	1,910	5,729	-	-	7/16	-%	46,381	52,110	-	1,629	1,629
AL for Infant, 20/120mg, 6's	-	839	2,517	-	-	7/16	-%	19,191	21,708	-	716	716
AL for Toddler, 20/120mg, 12's	-	1,367	4,100	-	-	7/16	-%	37,668	41,768	-	1,166	1,166
Artesunate Amodiaquine 25 mg	-	-	-	-	1,425	10/10	(100)%	16,425	1,390,827	-	-	-
Artesunate Amodiaquine combo 50 mg	-	-	-	-	2,200	10/10	(100)%	25,975	2,617,702	-	-	-
ASAQ for Adolescent, 100/270mg, 3	-	18,617	55,850	-	-	7/16	-%	180,281	236,131	-	15,879	15,879
ASAQ for Adult, 100/270mg, 6's	-	21,781	65,344	-	-	7/16	-%	203,531	268,875	-	18,579	18,579
ASAQ for Infant, 25/67.5mg, 3's	-	5,724	17,173	-	-	7/16	-%	93,944	111,117	-	4,883	4,883
ASAQ for Toddler, 50/135mg, 3's	-	25,381	76,143	-	-	7/16	-%	234,618	310,761	-	21,649	21,649
Malaria RDK	1,723,673	18,384	1,778,825	-	660,604		169%	1,005,988	9,400,363	-	-	-
RDT Malaria	1,723,673	18,384	1,778,825	-	660,604	8/11	169%	1,005,988	9,400,363	-	-	-
Manual Vacuum Aspiration for PAC	163	200	764	-	-		0%	1,234	1,998	-	229	229
MVA for PAC	163	200	764	-	-	12/16	-%	1,234	1,998	-	229	229

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Micronutrient Powder	900,390	391,760	2,075,670	-	840,120		147%	2,466,510	9,602,220	-	-	-
ZAZATOMADY (ZZT)	900,390	391,760	2,075,670	-	840,120	2/13	147%	2,466,510	9,602,220	-	-	-
Misoprostol for PAC (Oral)	(864)	(112)	(1,200)	-	-		0%	(6,537)	(7,737)	-	(108)	(108)
PSI Misoprostol for PAC Oral Dist F	(864)	(112)	(1,200)	-	-		-%	(6,537)	(7,737)	-	(108)	(108)
Misoprostol for PAC (oral) Provided	864	112	1,200	-	-		0%	6,537	7,737	-	120	120
PSI Misoprostol for PAC (oral) Prov	864	112	1,200	-	-		-%	6,537	7,737	-	120	120
OCs	220,780	295,252	1,106,535	-	1,022,417		8%	2,594,303	36,384,129	-	21,487	21,487
PSI OCs Distributed Provided	(4,122)	(3,481)	(14,566)	-	-		-%	(37,201)	(62,001)	-	(283)	(283)
Pilplan	224,902	298,733	1,121,101	-	1,022,417	10/98	10%	2,631,504	36,446,130	-	21,770	21,770
OCs Provided	4,122	3,481	14,566	-	-		0%	37,201	62,001	-	314	314
PSI OCs Provided	4,122	3,481	14,566	-	-		-%	37,201	62,001	-	314	314
Pneumonia PPT	68,203	25,941	146,026	-	84,386		73%	376,369	977,924	-	53,589	53,589
PneumoStop Tablet (6 x 480 mg)	-	24	71	-	84,386	8/14	(100)%	141,896	597,496	-	26	26
Pneumox 250 (10's) for Children un	68,203	25,917	145,955	-	-	7/16	-%	234,473	380,428	-	53,563	53,563
Positive RDTs	775	32,596	98,562	-	-		0%	2,177	100,739	-	-	-
Positive RDTs	775	32,596	98,562	-	-		-%	2,177	100,739	-	-	-
Safe Water Solution	167,085	195,855	754,649	-	794,835		(5)%	2,482,324	22,975,428	-	4,192	4,192
Sur Eau 40 mL	-	-	-	-	114,746	12/11	(100)%	327,383	2,361,465	-	-	-
Sur Eau Vaovao	167,085	195,855	754,649	-	680,089	9/04	11%	2,154,941	20,613,963	-	4,192	4,192
SDM (Cycle Beads)	625	186	1,184	-	5,356		(78)%	11,341	119,191	-	802	802
PSI SDM (Cycle Beads) Distributed	(225)	(214)	(866)	-	-		-%	(2,166)	(3,721)	-	(586)	(586)
Rojo	850	400	2,050	-	5,356	3/12	(62)%	13,507	122,912	-	1,388	1,388
SDM (Cycle Beads) Provided	225	214	866	-	-		0%	2,166	3,721	-	652	652
PSI SDM (Cycle Beads) Provided	225	214	866	-	-		-%	2,166	3,721	-	652	652
STI Screening	1,548	1,730	6,739	-	9,862		(32)%	33,852	53,081	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
STI Screening	1,548	1,730	6,739	-	9,862		(32)%	33,852	53,081	-	-	-
Treatment for Inguinal Bubo	9	11	42	-	-		0%	3	45	-	-	-
Treatment for Inguinal Bubo	9	11	42	-	-		-%	3	45	-	-	-
Treatment for Lower Abdominal Pain	116	124	488	-	-		0%	99	587	-	-	-
Treatment for Lower Abdominal Pair	116	124	488	-	-		-%	99	587	-	-	-
Treatment for Nonherpetic Genital Ulc	124	159	600	-	-		0%	111	711	-	67	67
Treatment for Nonherpetic Genital U	124	159	600	-	-		-%	111	711	-	67	67
Treatment for Urethral Discharge (Mer	631	715	2,775	-	-		0%	531	3,306	-	16	16
Treatment for Urethral Discharge (M	631	715	2,775	-	-		-%	531	3,306	-	16	16
Treatment for Vaginitis	650	699	2,746	-	-		0%	581	3,327	-	24	24
Treatment for Vaginitis	650	699	2,746	-	-		-%	581	3,327	-	24	24
Tubal Ligation	5	10	34	-	-		0%	-	34	-	116	116
Tubal Ligation	5	10	34	-	-		-%	-	34	-	116	116
Water Treatment Tablets	1,095,680	869,987	3,705,640	-	3,130,220		18%	10,315,940	15,818,810	-	286	286
SUR'EAU PILINA (67mg tablet)	1,095,680	869,987	3,705,640	-	3,130,220	10/14	18%	10,315,940	15,818,810	-	286	286
<b>Mozambique</b>										68,162	37,627	105,789
Condom	1,165,104	1,069,340	4,373,124	-	1,936,273		126%	9,175,026	75,299,609	68,051	12,440	80,491
PSI Condom Distributed Provided	-	-	-	-	(2,195)	3/16	-%	(96,814)	(203,159)	-	-	-
J1	450,648	451,472	1,805,064	-	580,464	10/12	211%	4,469,256	37,301,160	28,089	5,135	33,224
J14	-	-	-	-	1,152	4/14	(100)%	2,232	135,288	-	-	-
J2	335,160	197,256	926,928	-	300,240	10/12	209%	1,365,120	14,320,296	14,424	2,637	17,061
J3	288,000	297,696	1,181,088	-	436,392	10/12	171%	2,065,680	14,746,320	18,379	3,360	21,739
Jeito 4	89,352	100,704	391,464	-	134,856	11/13	190%	649,440	3,160,440	6,092	1,114	7,205
Jeito 5	1,944	22,212	68,580	-	97,524	1/14	(30)%	314,352	1,337,904	1,067	195	1,262
Jzero	-	-	-	-	387,840	6/13	(100)%	405,760	4,501,360	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Condom Provided	-	-	-	-	<b>54,381</b>		<b>(100)%</b>	<b>149,000</b>	<b>255,345</b>	-	-	-
PSI Condom Provided	-	-	-	-	<b>2,195</b>	3/16	(100)%	<b>96,814</b>	<b>203,159</b>	-	-	-
Non-PSI Condom Provided	-	-	-	-	<b>52,186</b>		(100)%	<b>52,186</b>	<b>52,186</b>	-	-	-
Emergency Contraception	<b>(11)</b>	<b>(32)</b>	<b>(106)</b>	-	-		<b>0%</b>	<b>(978)</b>	<b>(1,084)</b>	-	<b>(1)</b>	<b>(1)</b>
PSI Emergency Contraception Distr	<b>(11)</b>	<b>(32)</b>	<b>(106)</b>	-	-		-%	<b>(978)</b>	<b>(1,084)</b>	-	<b>(1)</b>	<b>(1)</b>
Emergency Contraception Provided	<b>11</b>	<b>32</b>	<b>106</b>	-	-		<b>0%</b>	<b>978</b>	<b>1,084</b>	-	<b>1</b>	<b>1</b>
PSI Emergency Contraception Prov	<b>11</b>	<b>32</b>	<b>106</b>	-	-		-%	<b>978</b>	<b>1,084</b>	-	<b>1</b>	<b>1</b>
Female Condom	-	-	-	-	-		<b>0%</b>	<b>(3,436)</b>	<b>(11,660)</b>	-	-	-
PSI Female Condom Distributed Pr	-	-	-	-	-	3/16	-%	<b>(3,436)</b>	<b>(11,660)</b>	-	-	-
Female Condom Provided	-	-	-	-	<b>746</b>		<b>(100)%</b>	<b>4,182</b>	<b>12,406</b>	-	-	-
PSI Female Condom Provided	-	-	-	-	-	3/16	-%	<b>3,436</b>	<b>11,660</b>	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	<b>746</b>		(100)%	<b>746</b>	<b>746</b>	-	-	-
Free Condom	-	-	-	-	<b>56,581</b>		<b>(100)%</b>	<b>167,691</b>	<b>27,352,928</b>	-	-	-
Generic	-	-	-	-	<b>56,581</b>	1/03	(100)%	<b>141,051</b>	<b>26,733,008</b>	-	-	-
No Logo Condom Lubricant Combo	-	-	-	-	-	5/15	-%	<b>26,640</b>	<b>619,920</b>	-	-	-
Free Female Condom	<b>486</b>	<b>928</b>	<b>3,270</b>	-	<b>1,046</b>		<b>213%</b>	<b>4,868</b>	<b>670,026</b>	<b>51</b>	<b>7</b>	<b>58</b>
Female Condom Free	<b>486</b>	<b>928</b>	<b>3,270</b>	-	<b>1,046</b>	8/09	213%	<b>4,868</b>	<b>670,026</b>	<b>51</b>	<b>7</b>	<b>58</b>
HIV Testing Services	-	<b>288</b>	<b>863</b>	-	<b>1,403</b>		<b>(38)%</b>	<b>5,588</b>	<b>906,817</b>	<b>60</b>	-	<b>60</b>
VCT Concordant Couple (HIV-Nega	-	-	-	-	<b>3</b>	12/09	(100)%	<b>62</b>	<b>91,187</b>	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	-	12/09	-%	<b>2</b>	<b>5,455</b>	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	<b>2</b>	12/09	(100)%	<b>12</b>	<b>2,168</b>	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	<b>2</b>	12/09	(100)%	<b>12</b>	<b>2,168</b>	-	-	-
VCT Individual (HIV-Negative)	-	<b>259</b>	<b>776</b>	-	<b>1,318</b>	12/09	(41)%	<b>5,154</b>	<b>757,109</b>	<b>54</b>	-	<b>54</b>
VCT Individual (HIV-Positive)	-	<b>29</b>	<b>87</b>	-	<b>79</b>	12/09	10%	<b>347</b>	<b>48,731</b>	<b>6</b>	-	<b>6</b>
Implant 4	<b>179</b>	<b>206</b>	<b>797</b>	-	<b>1,402</b>		<b>(43)%</b>	<b>3,871</b>	<b>12,283</b>	-	<b>1,867</b>	<b>1,867</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Zarin	179	206	797	-	1,402	2/15	(43)%	3,871	12,283	-	1,867	1,867
Implant 5	(632)	(808)	(3,056)	-	(1,402)		0%	(9,445)	(19,415)	-	(8,404)	(8,404)
PSI Implant 5 Distributed Inserted (	(632)	(808)	(3,056)	-	(1,402)		-%	(9,445)	(19,415)	-	(8,404)	(8,404)
Implant 5 Insertion	632	808	3,056	-	3,063		0%	11,106	21,076	-	9,338	9,338
PSI Implant 5 Inserted	632	808	3,056	-	1,402		118%	9,445	19,415	-	9,338	9,338
Non-PSI Implant 5 Inserted	-	-	-	-	1,661		(100)%	1,661	1,661	-	-	-
Injectable 3	(5,526)	(6,132)	(23,921)	-	(96)		0%	(42,947)	(55,525)	-	(3,206)	(3,206)
PSI Injectable 3 Distributed Provide	(5,964)	(6,978)	(26,897)	-	(8,429)		-%	(59,416)	(128,405)	-	(3,605)	(3,605)
Enaf Injectable	438	846	2,976	-	8,333	6/13	(64)%	16,469	72,880	-	399	399
Injectable 3 Provided	5,964	6,978	26,897	-	18,243		47%	69,230	138,219	-	4,006	4,006
PSI Injectable 3 Provided	5,964	6,978	26,897	-	8,429		219%	59,416	128,405	-	4,006	4,006
Non-PSI Injectable 3 Provided	-	-	-	-	9,814		(100)%	9,814	9,814	-	-	-
IUD 10	(146)	(173)	(666)	-	1,040		(164)%	(318)	(529)	-	(2,256)	(2,256)
PSI IUD 10 Distributed Inserted (1)	(146)	(173)	(666)	-	(127)		-%	(1,754)	(3,419)	-	(2,256)	(2,256)
DIU Copper T 380A	-	-	-	-	1,167	1/15	(100)%	1,436	2,890	-	-	-
IUD 10 Insertion	146	173	666	-	1,323		(50)%	2,950	5,117	-	2,507	2,507
PSI IUD 10 Inserted	146	173	666	-	127		424%	1,754	3,419	-	2,507	2,507
Non-PSI IUD 10 Inserted	-	-	-	-	1,196	3/16	(100)%	1,196	1,698	-	-	-
LLIN	7,732	15,456	54,099	-	8,092		569%	66,603	178,259	-	16,709	16,709
Serena	7,732	15,456	54,099	-	8,092	4/14	569%	66,603	178,259	-	16,709	16,709
Lubricant	1,659	1,261	5,441	-	564		865%	2,742	11,314	-	-	-
J8 (60 ml tube)	1,659	1,261	5,441	-	564	9/14	865%	2,742	11,314	-	-	-
Malaria RDK	13	4	26	-	101		(74)%	218	4,938	-	-	-
Teste Malaria Rapido	13	4	26	-	101	9/14	(74)%	218	4,938	-	-	-
Micronutrient Powder	13,560	151,853	469,120	-	273,100		72%	1,558,480	3,730,660	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Super Bebe	-	-	-	-	1,400	9/13	(100)%	(19,460)	1,683,120	-	-	-
VITA MAIS	13,560	151,853	469,120	-	271,700	11/15	73%	1,577,940	2,047,540	-	-	-
<b>OCs</b>	<b>(5,423)</b>	<b>(7,790)</b>	<b>(28,794)</b>	-	<b>3</b>		<b>(959900)%</b>	<b>(50,442)</b>	<b>(49,433)</b>	-	<b>(1,045)</b>	<b>(1,045)</b>
PSI OCs Distributed Provided	(8,674)	(11,486)	(43,132)	-	(22,213)		-%	(120,944)	(259,541)	-	(1,565)	(1,565)
Microginon Mobiz	-	645	1,935	-	3	5/15	64,400%	2,163	5,628	-	70	70
Microleyn 30 Combined OC	2,472	2,365	9,566	-	14,201	6/13	(33)%	47,700	134,887	-	347	347
Progestyn OC	779	686	2,837	-	8,012	6/13	(65)%	20,639	69,593	-	103	103
<b>OCs Provided</b>	<b>8,674</b>	<b>11,486</b>	<b>43,132</b>	-	<b>30,176</b>		<b>43%</b>	<b>128,907</b>	<b>267,504</b>	-	<b>1,739</b>	<b>1,739</b>
PSI OCs Provided	8,674	11,486	43,132	-	22,213		94%	120,944	259,541	-	1,739	1,739
Non-PSI OCs Provided	-	-	-	-	7,963		(100)%	7,963	7,963	-	-	-
<b>Safe Water Solution</b>	<b>49,902</b>	<b>166,148</b>	<b>548,345</b>	-	<b>489,820</b>		<b>12%</b>	<b>934,564</b>	<b>4,620,155</b>	-	<b>3,925</b>	<b>3,925</b>
Certeza Commercial ISM	36,702	60,254	217,465	-	245,628	9/12	(11)%	428,338	2,454,249	-	1,556	1,556
Certeza Free ISM	13,200	105,893	330,880	-	244,192	9/12	35%	506,226	2,165,906	-	2,368	2,368
<b>Water Treatment Tablets</b>	-	-	-	-	<b>33,130</b>		<b>(100)%</b>	<b>143,520</b>	<b>1,460,370</b>	-	-	-
Certeza Comprimido 20L	-	-	-	-	33,120	2/14	(100)%	90,960	921,360	-	-	-
Certeza Comprimido 5L	-	-	-	-	-	2/14	-%	11,550	303,360	-	-	-
Certeza Free Comprimido 20L	-	-	-	-	10	2/14	(100)%	41,010	235,650	-	-	-
<b>Namibia</b>										<b>180</b>	<b>16</b>	<b>195</b>
<b>Condom</b>	<b>13,824</b>	-	<b>13,824</b>	-	-		<b>0%</b>	<b>69,984</b>	<b>83,808</b>	<b>180</b>	<b>16</b>	<b>195</b>
Lovers Plus	-	-	-	-	-		-%	10,512	10,512	-	-	-
Lovers Plus C&F	3,456	-	3,456	-	-		-%	12,240	15,696	45	4	49
Lovers Plus R&S	-	-	-	-	-		-%	12,240	12,240	-	-	-
Trust	5,184	-	5,184	-	-		-%	17,496	22,680	67	6	73
Trust Studded	5,184	-	5,184	-	-		-%	17,496	22,680	67	6	73

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Condom	-	-	-	-	413,980		(100)%	1,753,718	16,546,045	-	-	-
Smile	-	-	-	-	413,980	1/08	(100)%	1,753,718	16,546,045	-	-	-
Free Female Condom	-	-	-	-	19,158		(100)%	52,311	510,066	-	-	-
Femidom Free	-	-	-	-	19,158	2/07	(100)%	52,311	510,066	-	-	-
Lubricant	-	-	-	-	106,372		(100)%	306,588	1,964,530	-	-	-
Condom Lubricant (Water Based)	-	-	-	-	106,372	8/11	(100)%	306,588	1,964,530	-	-	-
Referral to HIV Testing Services	-	-	-	-	201		(100)%	201	4,492	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	201	12/14	(100)%	201	4,492	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	11		(100)%	11	363	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	11	12/14	(100)%	11	363	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	17		(100)%	17	67	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	17		(100)%	17	67	-	-	-
<b>South Africa</b>										507,473	20,855	528,328
CD4 Tests Provided to HIV+ Clients	19	763	2,308	-	-		0%	59	2,367	-	-	-
CD4 Tests Provided to HIV+ Clients	19	763	2,308	-	-		-%	59	2,367	-	-	-
Condom	2,587,334	2,531,168	10,180,839	-	15,630,654		(35)%	48,943,658	664,702,726	205,217	9,294	214,511
Lovers Plus	427,184	299,834	1,326,686	-	1,483,896	10/92	(11)%	5,140,551	163,361,066	26,742	1,211	27,953
Lovers Plus C&F	220,425	226,977	901,356	-	1,245,330	1/08	(28)%	4,117,957	53,745,367	18,169	823	18,992
Lovers Plus Extra Play	42,563	21,972	108,478	-	191,451	9/13	(43)%	458,103	2,339,740	2,187	99	2,286
Lovers Plus R&S	177,502	171,478	691,935	-	940,752	4/07	(26)%	2,915,143	36,198,459	13,947	632	14,579
Trust	571,860	692,922	2,650,627	-	6,356,610	5/01	(58)%	19,643,191	209,557,259	53,429	2,420	55,849
Trust Studed	1,147,800	1,117,986	4,501,757	-	5,412,615	4/04	(17)%	16,668,713	199,500,835	90,743	4,110	94,852
Female Condom	-	(960)	(2,880)	-	(8,100)		0%	(35,316)	974,999	(58)	(2)	(60)
LP Condom - Inner Condom	-	(960)	(2,880)	-	(8,100)	9/13	-%	(35,316)	974,999	(58)	(2)	(60)
Free Condom	-	4,206,667	12,620,000	-	24,250,400		(48)%	67,505,600	1,016,121,776	254,384	11,520	265,904

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Military Condom	-	1,666,667	5,000,000	-	5,000,000	3/13	-%	5,000,000	20,800,016	100,786	4,564	105,350
Public Distribution	-	2,540,000	7,620,000	-	19,250,400	1/04	(60)%	62,505,600	995,321,760	153,598	6,956	160,554
Free Female Condom	-	20,400	61,200	-	216,400		(72)%	555,800	3,414,300	1,234	43	1,277
Female Condom GOSA	-	20,400	61,200	-	216,400	10/13	(72)%	555,800	3,414,300	1,234	43	1,277
HIV Testing Services	33,296	29,072	120,511	-	81,361		48%	262,513	1,460,073	8,540	-	8,540
VCT Concordant Couple (HIV-Nega	-	-	-	-	11,406	12/09	(100)%	20,004	89,520	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	276	12/09	(100)%	895	3,545	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	295	12/09	(100)%	1,306	2,989	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	295	12/09	(100)%	1,306	2,989	-	-	-
VCT Individual (HIV-Negative)	28,969	25,752	106,224	-	64,851	12/09	64%	217,903	1,250,257	7,528	-	7,528
VCT Individual (HIV-Positive)	4,327	3,320	14,287	-	4,238	12/09	237%	21,100	110,774	1,012	-	1,012
Lubricant	229	1,433	4,528	-	87,036		(95)%	118,584	536,664	-	-	-
Lovers Plus Lube Natural (100mL)	229	1,845	5,764	-	2,100	1/13	174%	4,512	83,128	-	-	-
Lovers Plus Lube Natural (50mL)	-	(412)	(1,236)	-	(17,064)	1/13	-%	(32,928)	46,536	-	-	-
Lovers Plus Lube Natural (5mL)	-	-	-	-	102,000	3/13	(100)%	147,000	407,000	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	392		(100)%	1,521	6,118	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	392	3/16	(100)%	1,521	6,118	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	396		(100)%	1,960	3,364	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	396	12/14	(100)%	1,960	3,364	-	-	-
Referral to Clinical Staging	-	-	-	-	396		(100)%	1,960	3,364	-	-	-
Referral to Clinical Staging	-	-	-	-	396	12/14	(100)%	1,960	3,364	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	475		(100)%	890	1,690	-	-	-
Referral to STI Treatment (unknown	-	-	-	-	475	12/14	(100)%	890	1,690	-	-	-
Referral to Voluntary Medical Male Cir	-	-	-	-	443		(100)%	1,153	3,382	-	-	-
Referral to Voluntary Medical Male C	-	-	-	-	443		(100)%	1,153	3,382	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Voluntary Medical Male Circumcision	2,167	1,083	5,417	-	4,308		26%	19,672	162,841	38,156	-	38,156
Bepelopele (MC HIV-Negative)	-	-	-	-	3,827	3/09	(100)%	14,726	146,696	-	-	-
Bepelopele (MC HIV-Unknown)	-	-	-	-	481	3/09	(100)%	2,227	8,009	-	-	-
Voluntary Medical Male Circumcision	2,167	1,083	5,417	-	-		-%	2,719	8,136	38,156	-	38,156
<b>Swaziland</b>										248,808	11,683	260,491
Antiretroviral Treatment (Currently Enrolled)	105	26	182	-	-		0%	-	182	37	-	37
Antiretroviral Treatment (Currently Enrolled)	105	26	182	-	-		-%	-	182	37	-	37
Antiretroviral Treatment (Newly Enrolled)	60	31	153	-	-		0%	-	153	-	-	-
Antiretroviral Treatment (Newly Enrolled)	60	31	153	-	-		-%	-	153	-	-	-
CD4 Tests Provided to HIV+ Clients	132	68	337	-	-		0%	80	417	-	-	-
CD4 Tests Provided to HIV+ Clients	132	68	337	-	-		-%	80	417	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	1	-	-		-%	-	1	-	-	-
Cervical Cancer-Pap Smear Screening	-	1	2	-	-		0%	-	2	-	-	-
Cervical Cancer-Pap Smear Screening	-	1	2	-	-		-%	-	2	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		0%	-	1	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	1	-	-		-%	-	1	-	-	-
Condom	208,008	215,672	855,024	-	1,631,668		(48)%	2,173,060	26,650,476	34,542	1,804	36,345
Lovers Plus	1,728	2,736	9,936	-	12,096	2/01	(18)%	31,104	1,624,642	401	21	422
Lovers Plus C&F	-	2,304	6,912	-	15,552	1/05	(56)%	43,200	409,360	279	15	294
Lovers Plus Extra Play	-	-	-	-	-		-%	1,728	3,456	-	-	-
Lovers Plus R&S	-	2,304	6,912	-	6,912	5/10	-%	31,680	281,736	279	15	294
Trust	17,280	5,616	34,128	-	76,032	5/01	(55)%	118,800	6,723,577	1,379	72	1,451
Trust Studded	-	35,712	107,136	-	288,576	1/05	(63)%	546,048	8,917,924	4,328	226	4,554
Trust Workplace	189,000	167,000	690,000	-	1,232,500	2/06	(44)%	1,400,500	8,689,781	27,875	1,455	29,331

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Condom Provided	-	-	-	-	-		0%	28,574	28,574	-	-	-
Non-PSI Condom Provided	-	-	-	-	-		-%	28,574	28,574	-	-	-
Emergency Contraception Provided	-	-	1	-	-		0%	4	5	-	-	-
Non-PSI Emergency Contraception I	-	-	1	-	-		-%	4	5	-	-	-
Female Condom	-	667	2,000	-	48,000		(96)%	140,000	805,227	81	3	84
Female Condom	-	667	2,000	-	48,000	7/06	(96)%	140,000	805,227	81	3	84
Free Condom	1,314,000	1,094,000	4,596,000	-	4,257,000		8%	11,475,600	43,925,544	185,672	9,695	195,367
Generic	1,314,000	1,094,000	4,596,000	-	4,257,000	4/05	8%	11,475,600	43,925,544	185,672	9,695	195,367
HIV Testing Services	6,548	6,631	26,440	-	16,354		62%	52,093	536,554	3,595	-	3,595
VCT Concordant Couple (HIV-Negai	-	-	-	-	336	12/09	(100)%	898	9,516	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	72	12/09	(100)%	126	1,050	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	46	12/09	(100)%	97	768	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	46	12/09	(100)%	97	768	-	-	-
VCT Individual (HIV-Negative)	6,166	6,111	24,498	-	13,076	12/09	87%	44,213	480,628	3,331	-	3,331
VCT Individual (HIV-Positive)	382	520	1,942	-	2,778	12/09	(30)%	6,662	43,824	264	-	264
Hypertension Diagnosis	-	3	9	-	-		0%	-	9	-	-	-
Hypertension Diagnosis	-	3	9	-	-		-%	-	9	-	-	-
Hypertension Screening	277	476	1,705	-	-		0%	-	1,705	-	-	-
Hypertension Screening	277	476	1,705	-	-		-%	-	1,705	-	-	-
Injectable 1 Provided	47	24	118	-	-		0%	135	253	-	4	4
Non-PSI Injectable 1 Provided	47	24	118	-	-		-%	135	253	-	4	4
Injectable 3 Provided	68	79	305	-	-		0%	460	765	-	34	34
Non-PSI Injectable 3 Provided	68	79	305	-	-		-%	460	765	-	34	34
Lubricant	13,000	50,333	164,000	-	58,000		183%	190,000	965,557	-	-	-
Assegai Branded (5 mL)	-	-	-	-	58,000	8/11	(100)%	58,000	668,557	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lifestyles Liquid Personal Lubricant	<b>13,000</b>	<b>50,333</b>	<b>164,000</b>	-	-	8/11	-%	<b>132,000</b>	<b>297,000</b>	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	<b>75</b>		<b>(100)%</b>	<b>117</b>	<b>230</b>	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	<b>75</b>	3/16	(100)%	<b>117</b>	<b>230</b>	-	-	-
OCs Provided	<b>58</b>	<b>84</b>	<b>310</b>	-	-		<b>0%</b>	<b>632</b>	<b>942</b>	-	<b>9</b>	<b>9</b>
Non-PSI OCs Provided	<b>58</b>	<b>84</b>	<b>310</b>	-	-		-%	<b>632</b>	<b>942</b>	-	<b>9</b>	<b>9</b>
Referral to HIV Testing Services	-	-	-	-	<b>2,269</b>		<b>(100)%</b>	<b>5,736</b>	<b>9,948</b>	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	<b>2,269</b>	12/14	(100)%	<b>5,736</b>	<b>9,948</b>	-	-	-
Referral to Hypertension Management	<b>1</b>	<b>2</b>	<b>6</b>	-	-		<b>0%</b>	<b>3</b>	<b>9</b>	-	-	-
Referral to Hypertension Management	<b>1</b>	<b>2</b>	<b>6</b>	-	-		-%	<b>3</b>	<b>9</b>	-	-	-
Referral to Injectable 1	<b>9</b>	-	<b>9</b>	-	-		<b>0%</b>	<b>16</b>	<b>25</b>	-	-	-
Referral to Injectable 1	<b>9</b>	-	<b>9</b>	-	-		-%	<b>16</b>	<b>25</b>	-	-	-
Referral to Injectable 3	<b>56</b>	<b>1</b>	<b>59</b>	-	-		<b>0%</b>	<b>45</b>	<b>104</b>	-	<b>3</b>	<b>3</b>
Referral to Injectable 3	<b>56</b>	<b>1</b>	<b>59</b>	-	-		-%	<b>45</b>	<b>104</b>	-	<b>3</b>	<b>3</b>
Referral to Linkage to HIV Care	<b>293</b>	<b>430</b>	<b>1,584</b>	-	-		<b>0%</b>	<b>430</b>	<b>2,014</b>	<b>1,035</b>	-	<b>1,035</b>
Referral to Linkage to HIV Care	<b>293</b>	<b>430</b>	<b>1,584</b>	-	-		-%	<b>430</b>	<b>2,014</b>	<b>1,035</b>	-	<b>1,035</b>
Referral to OCs	<b>31</b>	<b>16</b>	<b>78</b>	-	-		<b>0%</b>	<b>75</b>	<b>153</b>	-	<b>1</b>	<b>1</b>
Referral to OCs	<b>31</b>	<b>16</b>	<b>78</b>	-	-		-%	<b>75</b>	<b>153</b>	-	<b>1</b>	<b>1</b>
Referral to STI Screening (syndromic)	-	-	-	-	-		<b>0%</b>	<b>3</b>	<b>3</b>	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	-		-%	<b>3</b>	<b>3</b>	-	-	-
Referral to STI Treatment (unknown)	<b>3</b>	<b>5</b>	<b>18</b>	-	-		<b>0%</b>	<b>22</b>	<b>191</b>	-	-	-
Referral to STI Treatment (unknown)	<b>3</b>	<b>5</b>	<b>18</b>	-	-	12/14	-%	<b>22</b>	<b>191</b>	-	-	-
Referral to TB Diagnosis	-	<b>3</b>	<b>9</b>	-	-		<b>0%</b>	-	<b>3,629</b>	-	-	-
Referral to TB Diagnosis	-	<b>3</b>	<b>9</b>	-	-	12/14	-%	-	<b>3,629</b>	-	-	-
Referral to TB Screening	<b>293</b>	<b>430</b>	<b>1,584</b>	-	-		<b>0%</b>	<b>433</b>	<b>2,017</b>	-	-	-
Referrals to TB Screening	<b>293</b>	<b>430</b>	<b>1,584</b>	-	-		-%	<b>433</b>	<b>2,017</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Treatment for Genital Herpes	-	-	-	-	-		0%	3	3	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-		-%	3	3	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	-		0%	4	4	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	-		-%	4	4	-	-	-
Referral to Voluntary Medical Male Circumcision	28	25	103	-	127		(19)%	171	4,699	719	-	719
Referral to Voluntary Medical Male Circumcision	28	25	103	-	127	12/14	(19)%	171	4,699	719	-	719
STI Kit (Non-Ulcerative)	63	59	239	-	156		53%	797	4,051	-	43	43
Inguinal Bubo	-	-	-	-	-	4/10	-%	2	2	-	-	-
Urethral Discharge	18	15	64	-	69	3/10	(7)%	298	1,641	-	9	9
Vaginal Discharge	45	43	175	-	87	3/10	101%	497	2,408	-	33	33
STI Kit (Ulcerative)	7	11	40	-	12		233%	127	492	-	16	16
Genital Ulcer Syndrome	7	11	40	-	12	3/10	233%	127	492	-	16	16
STI Screening	4,183	4,050	16,333	-	-		0%	9,589	25,922	-	-	-
STI Screening	4,183	4,050	16,333	-	-		-%	9,589	25,922	-	-	-
TB Screening	4,183	4,079	16,421	-	-		0%	484	16,905	-	-	-
TB Screening	4,183	4,079	16,421	-	-		-%	484	16,905	-	-	-
Treatment for Genital Herpes	1	5	15	-	-		0%	2	17	-	1	1
Treatment for Genital Herpes	1	5	15	-	-		-%	2	17	-	1	1
Treatment for Lower Abdominal Pain	-	-	-	-	-		0%	1	1	-	-	-
Treatment for Lower Abdominal Pain	-	-	-	-	-		-%	1	1	-	-	-
Treatment for Nonherpetic Genital Ulcers	7	10	38	-	-		0%	6	44	-	15	15
Treatment for Nonherpetic Genital Ulcers	7	10	38	-	-		-%	6	44	-	15	15
Treatment for Urethral Discharge (Merck)	18	14	61	-	-		0%	25	86	-	9	9
Treatment for Urethral Discharge (Merck)	18	14	61	-	-		-%	25	86	-	9	9
Treatment for Urethral Discharge (Worthington)	-	-	-	-	-		0%	1	1	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Urethral Discharge (W	-	-	-	-	-		-%	1	1	-	-	-
Treatment for Vaginitis	45	43	175	-	-		0%	23	198	-	46	46
Treatment for Vaginitis	45	43	175	-	-		-%	23	198	-	46	46
Type 2 Diabetes Screening	9	28	93	-	-		0%	-	93	-	-	-
Type 2 Diabetes Screening	9	28	93	-	-		-%	-	93	-	-	-
Voluntary Medical Male Circumcision	780	292	1,656	-	1,598		4%	4,240	60,170	23,127	-	23,127
Male Circumcision (HIV-Negative)	-	-	-	-	1,598	6/09	(100)%	4,062	58,336	-	-	-
Voluntary Medical Male Circumcisi	780	292	1,656	-	-		-%	178	1,834	23,127	-	23,127
<b>Zambia</b>										317,849	3,450	321,299
Condom	-	-	-	-	-		0%	836,352	1,739,520	-	-	-
Trust	-	-	-	-	-	8/16	-%	418,176	418,176	-	-	-
Trust Studded	-	-	-	-	-	1/08	-%	418,176	1,321,344	-	-	-
Early Infant Male Circumcision	-	-	-	-	1		(100)%	5	5	-	-	-
Early Infant MC (HIV-Negative)	-	-	-	-	-		-%	3	3	-	-	-
Early Infant MC (HIV-Positive)	-	-	-	-	1		(100)%	1	1	-	-	-
Early Infant MC (HIV-Unknown)	-	-	-	-	-		-%	1	1	-	-	-
HIV Testing Services	7,344	3,709	18,472	-	-		0%	23,148	968,761	1,060	-	1,060
VCT Individual (HIV-Negative)	7,060	3,472	17,475	-	-	12/09	-%	23,075	877,055	1,003	-	1,003
VCT Individual (HIV-Positive)	284	238	997	-	-	12/09	-%	73	91,706	57	-	57
Implant 3 Insertion	-	-	-	-	-		0%	1	1	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	-		-%	1	1	-	-	-
Implant 4 Insertion	-	-	-	-	-		0%	116	116	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	-		-%	116	116	-	-	-
Implant 5	-	-	-	-	(310)		0%	(310)	(178,192)	-	-	-
PSI Implant 5 Distributed Inserted (	-	-	-	-	(310)		-%	(310)	(178,192)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	221	201	823	-	310		165%	2,731	181,436	-	2,207	2,207
PSI Implant 5 Inserted	-	-	-	-	310		(100)%	310	178,192	-	-	-
Non-PSI Implant 5 Inserted	221	201	823	-	-		-%	2,421	3,244	-	2,207	2,207
Injectable 3 Provided	912	910	3,643	-	-		0%	1,592	5,235	-	474	474
Non-PSI Injectable 3 Provided	912	910	3,643	-	-		-%	1,592	5,235	-	474	474
IUD 10	-	-	-	-	(49)		0%	(49)	(78,096)	-	-	-
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	(49)		-%	(49)	(78,096)	-	-	-
IUD 10 Insertion	3	7	23	-	49		(53)%	135	78,205	-	76	76
PSI IUD 10 Inserted	-	-	-	-	49		(100)%	49	78,096	-	-	-
Non-PSI IUD 10 Inserted	3	7	23	-	-		-%	86	109	-	76	76
IUD 5 Insertion	-	-	-	-	-		0%	241	241	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	241	241	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	96		(100)%	143	297	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	96		(100)%	143	297	-	-	-
OCs Provided	201	169	708	-	-		0%	90	798	-	25	25
Non-PSI OCs Provided	201	169	708	-	-		-%	90	798	-	25	25
Safe Water Solution	49,824	38,344	164,856	-	274,956		(40)%	754,608	34,275,359	-	659	659
Clorin	49,824	38,344	164,856	-	274,956	11/98	(40)%	754,608	34,275,359	-	659	659
Voluntary Medical Male Circumcision	13,098	9,786	42,456	-	38,409		11%	80,719	608,911	316,703	-	316,703
Male Circumcision (HIV-Negative)	-	-	-	-	33,872	4/07	(100)%	67,572	353,786	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	4,537	4/07	(100)%	8,989	208,511	-	-	-
Voluntary Medical Male Circumcision	13,098	9,786	42,456	-	-		-%	4,158	46,614	316,703	-	316,703
Woman Condom	1,152	1,320	5,112	-	336		1421%	9,600	14,712	86	10	96
MAXIMUM DIVA	1,152	1,320	5,112	-	336	4/16	1,421%	9,600	14,712	86	10	96
<b>Zimbabwe</b>										<b>490,009</b>	<b>12,671</b>	<b>502,680</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Antiretroviral Treatment (Currently Enr	<b>6,361</b>	<b>5,750</b>	<b>23,612</b>	-	-		<b>0%</b>	<b>5,010</b>	<b>28,622</b>	<b>4,115</b>	-	<b>4,115</b>
Antiretroviral Treatment (Currently E	<b>6,361</b>	<b>5,750</b>	<b>23,612</b>	-	-		<b>-%</b>	<b>5,010</b>	<b>28,622</b>	<b>4,115</b>	-	<b>4,115</b>
Antiretroviral Treatment (Newly Enrolle	<b>694</b>	<b>875</b>	<b>3,319</b>	-	-		<b>0%</b>	<b>5,283</b>	<b>8,602</b>	-	-	-
Antiretroviral Treatment (Newly Enrc	<b>694</b>	<b>875</b>	<b>3,319</b>	-	-		<b>-%</b>	<b>5,283</b>	<b>8,602</b>	-	-	-
CD4 Tests Provided to HIV+ Clients	<b>541</b>	<b>771</b>	<b>2,854</b>	-	-		<b>0%</b>	<b>639</b>	<b>3,493</b>	-	-	-
CD4 Tests Provided to HIV+ Clients	<b>541</b>	<b>771</b>	<b>2,854</b>	-	-		<b>-%</b>	<b>639</b>	<b>3,493</b>	-	-	-
Cervical Cancer-Pap and Refer to any	-	-	-	-	-		<b>0%</b>	<b>1</b>	<b>1</b>	-	-	-
Cervical Cancer-Pap and Refer to ai	-	-	-	-	-		<b>-%</b>	<b>1</b>	<b>1</b>	-	-	-
Cervical Cancer-Pap and Refer to Con	-	-	-	-	-		<b>0%</b>	<b>7</b>	<b>9</b>	-	-	-
Cervical Cancer-Pap and Refer to C	-	-	-	-	-		<b>-%</b>	<b>7</b>	<b>9</b>	-	-	-
Cervical Cancer-Pap Smear Screeningç	-	-	-	-	-		<b>0%</b>	<b>116</b>	<b>116</b>	-	-	-
Cervical Cancer-Pap Smear Screeni	-	-	-	-	-		<b>-%</b>	<b>116</b>	<b>116</b>	-	-	-
Cervical Cancer-VIA and Conization	<b>23</b>	<b>22</b>	<b>90</b>	-	-		<b>0%</b>	<b>10</b>	<b>100</b>	-	<b>26</b>	<b>26</b>
Cervical Cancer-VIA and Conization	<b>23</b>	<b>22</b>	<b>90</b>	-	-		<b>-%</b>	<b>10</b>	<b>100</b>	-	<b>26</b>	<b>26</b>
Cervical Cancer-VIA and Cryotherapy	<b>41</b>	<b>62</b>	<b>226</b>	-	<b>249</b>		<b>(9)%</b>	<b>1,181</b>	<b>3,284</b>	-	<b>63</b>	<b>63</b>
Cervical Cancer-VIA and Cryotheraç	<b>41</b>	<b>62</b>	<b>226</b>	-	<b>249</b>	11/13	<b>(9)%</b>	<b>1,181</b>	<b>3,284</b>	-	<b>63</b>	<b>63</b>
Cervical Cancer-VIA and Refer to any	<b>1</b>	<b>2</b>	<b>6</b>	-	-		<b>0%</b>	<b>17</b>	<b>254</b>	-	<b>1</b>	<b>1</b>
Cervical Cancer-VIA and Refer to ar	<b>1</b>	<b>2</b>	<b>6</b>	-	-	1/15	<b>-%</b>	<b>17</b>	<b>254</b>	-	<b>1</b>	<b>1</b>
Cervical Cancer-VIA and Refer to Con	<b>14</b>	<b>15</b>	<b>60</b>	-	<b>302</b>		<b>(80)%</b>	<b>402</b>	<b>1,927</b>	-	<b>9</b>	<b>9</b>
Cervical Cancer-VIA and Refer to Cç	<b>14</b>	<b>15</b>	<b>60</b>	-	<b>302</b>	12/14	<b>(80)%</b>	<b>402</b>	<b>1,927</b>	-	<b>9</b>	<b>9</b>
Cervical Cancer-VIA and Refer to Cryc	-	<b>5</b>	<b>16</b>	-	<b>31</b>		<b>(48)%</b>	<b>33</b>	<b>449</b>	-	<b>2</b>	<b>2</b>
Cervical Cancer-VIA and Refer to Cç	-	<b>5</b>	<b>16</b>	-	<b>31</b>	12/14	<b>(48)%</b>	<b>33</b>	<b>449</b>	-	<b>2</b>	<b>2</b>
Cervical Cancer-VIA/VILI Screening	<b>1,215</b>	<b>1,614</b>	<b>6,057</b>	-	<b>11,437</b>		<b>(47)%</b>	<b>26,594</b>	<b>57,392</b>	-	-	-
Cervical Cancer-VIA/VILI Screening	<b>1,215</b>	<b>1,614</b>	<b>6,057</b>	-	<b>11,437</b>		<b>(47)%</b>	<b>26,594</b>	<b>57,392</b>	-	-	-
Condom	<b>94,920</b>	<b>812,160</b>	<b>2,531,400</b>	-	<b>10,631,231</b>		<b>(76)%</b>	<b>25,178,622</b>	<b>296,112,745</b>	<b>54,303</b>	<b>3,454</b>	<b>57,757</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Country**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Condom Distributed Provided	-	-	-	-	(31,529)		-%	(43,698)	(61,465)	-	-	-
Protector Plus	(18,480)	701,960	2,087,400	-	2,749,560	1/08	(24)%	11,649,920	269,443,090	44,778	2,848	47,627
Protector Plus Flavors	113,400	110,200	444,000	-	7,913,200	3/14	(94)%	13,572,400	26,731,120	9,525	606	10,130
Condom Provided	-	-	-	-	91,674		(100)%	167,928	235,493	-	-	-
PSI Condom Provided	-	-	-	-	31,529		(100)%	43,698	61,465	-	-	-
Non-PSI Condom Provided	-	-	-	-	60,145		(100)%	124,230	174,028	-	-	-
Emergency Contraception	2,546	15,438	48,860	-	54,408		(10)%	197,597	776,227	-	251	251
PSI Emergency Contraception Distr	(4)	(7)	(25)	-	(99)		-%	(219)	(408)	-	-	-
Pregnon	2,550	15,445	48,885	-	1,651	9/10	2,861%	124,037	693,335	-	251	251
Revoke-72	-	-	-	-	52,856	12/15	(100)%	73,779	83,300	-	-	-
Emergency Contraception Provided	15	9	42	-	120		(65)%	313	578	-	-	-
PSI Emergency Contraception Prov	4	7	25	-	99		(75)%	219	408	-	-	-
Non-PSI Emergency Contraception I	11	2	17	-	21		(19)%	94	170	-	-	-
Female Condom	30,780	57,633	203,680	-	347,367		(41)%	1,017,642	23,650,168	4,369	214	4,583
PSI Female Condom Distributed Pr	-	-	-	-	(6,513)		-%	(11,058)	(16,366)	-	-	-
Care	30,780	57,633	203,680	-	353,880	6/97	(42)%	1,028,700	23,666,534	4,369	214	4,583
Female Condom Provided	-	-	-	-	9,684		(100)%	21,730	30,088	-	-	-
PSI Female Condom Provided	-	-	-	-	6,513		(100)%	11,058	16,366	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	3,171		(100)%	10,672	13,722	-	-	-
Free Female Condom	-	-	-	-	-		0%	14,000	338,000	-	-	-
Care (Free Distribution)	-	-	-	-	-	12/11	-%	14,000	338,000	-	-	-
HIV Testing Services	20,373	29,945	110,207	-	113,069		(3)%	316,961	2,779,747	7,305	-	7,305
VCT Concordant Couple (HIV-Nega	-	-	-	-	14,516	12/09	(100)%	34,800	334,640	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	578	12/09	(100)%	1,364	24,938	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	666	12/09	(100)%	1,549	14,482	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
VCT Discordant Couple (HIV-Positiv	-	-	-	-	666	12/09	(100)%	1,549	14,482	-	-	-
VCT Individual (HIV-Negative)	18,918	28,086	103,177	-	86,633	12/09	19%	251,984	2,131,784	6,839	-	6,839
VCT Individual (HIV-Positive)	1,455	1,858	7,030	-	10,010	12/09	(30)%	25,715	259,421	466	-	466
Hypertension Diagnosis	62	7	83	-	-		0%	4	87	-	-	-
Hypertension Diagnosis	62	7	83	-	-		-%	4	87	-	-	-
Hypertension Screening	11,760	68,566	217,458	-	-		0%	12,961	230,419	-	-	-
Hypertension Screening	11,760	68,566	217,458	-	-		-%	12,961	230,419	-	-	-
Hypertension_Controlled Condition	-	6	19	-	-		0%	3	22	-	-	-
Hypertension_Controlled Condition	-	6	19	-	-		-%	3	22	-	-	-
Implant 3	(29)	(8)	(54)	-	246		(122)%	(122)	319	-	(49)	(49)
PSI Implant 3 Distributed Inserted (	(29)	(42)	(154)	-	(354)		-%	(622)	(2,085)	-	(139)	(139)
Implanon	-	33	100	-	600	9/15	(83)%	500	2,404	-	90	90
Implant 3 Insertion	74	142	501	-	1,562		(68)%	3,480	8,098	-	503	503
PSI Implant 3 Inserted	29	42	154	-	354		(56)%	622	2,085	-	154	154
Non-PSI Implant 3 Inserted	45	101	347	-	1,208	3/16	(71)%	2,858	6,013	-	348	348
Implant 5	(159)	(291)	(1,032)	-	(386)		0%	(667)	(28,026)	-	(1,372)	(1,372)
PSI Implant 5 Distributed Inserted (	(159)	(291)	(1,032)	-	(386)		-%	(667)	(28,026)	-	(1,372)	(1,372)
Implant 5 Insertion	486	975	3,411	-	7,306		(53)%	17,413	77,924	-	5,040	5,040
PSI Implant 5 Inserted	159	291	1,032	-	386		167%	667	28,026	-	1,525	1,525
Non-PSI Implant 5 Inserted	327	684	2,379	-	6,920	1/14	(66)%	16,746	49,898	-	3,515	3,515
Injectable 3	(252)	1,199	3,345	-	6,938		(52)%	19,378	873,800	-	215	215
PSI Injectable 3 Distributed Provide	(852)	(919)	(3,610)	-	(358)		-%	(1,158)	(34,066)	-	(232)	(232)
Depo-Provera	600	2,118	6,955	-	-	9/00	-%	2,575	677,731	-	447	447
Petogen	-	-	-	-	7,296	9/09	(100)%	17,961	230,135	-	-	-
Injectable 3 Provided	4,047	5,365	20,141	-	22,796		(12)%	68,505	146,794	-	1,439	1,439

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Provided	852	919	3,610	-	358		908%	1,158	34,066	-	258	258
Non-PSI Injectable 3 Provided	3,195	4,445	16,531	-	22,438		(26)%	67,347	112,728	-	1,181	1,181
IUD 10	(73)	83	177	-	(607)		0%	(281)	2,411	-	292	292
PSI IUD 10 Distributed Inserted (1)	(73)	(150)	(523)	-	(757)	3/16	-%	(2,031)	(6,530)	-	(862)	(862)
TCU 380A IUCD Copper T	-	233	700	-	150	4/12	367%	1,750	8,941	-	1,154	1,154
IUD 10 Insertion	77	151	531	-	759		(30)%	2,033	6,718	-	972	972
PSI IUD 10 Inserted	73	150	523	-	757	3/16	(31)%	2,031	6,530	-	958	958
Non-PSI IUD 10 Inserted	4	1	8	-	2		300%	2	188	-	15	15
IUS 5	(38)	-	(38)	-	-		0%	-	(38)	-	(46)	(46)
PSI IUS 5 Distributed Inserted (1)	(38)	-	(38)	-	-		-%	-	(38)	-	(46)	(46)
IUS 5 Insertion	38	-	38	-	-		0%	-	38	-	52	52
PSI IUS 5 Inserted	38	-	38	-	-		-%	-	38	-	52	52
LLIN	-	-	-	-	-		0%	863,993	5,332,182	-	-	-
Interceptor	-	-	-	-	-	10/10	-%	863,993	5,332,182	-	-	-
Lubricant	38,250	11,167	71,750	-	-		0%	-	71,750	-	-	-
Personal lubricants water based 4.5	38,250	11,167	71,750	-	-	2/17	-%	-	71,750	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	377		(100)%	1,227	3,214	-	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	377		(100)%	1,227	3,214	-	-	-
OCs	(1,163)	(1,046)	(4,301)	-	(6,234)		0%	(9,514)	3,671,682	-	(75)	(75)
PSI OCs Distributed Provided	(1,163)	(1,046)	(4,301)	-	(9,114)		-%	(17,254)	(225,110)	-	(75)	(75)
Control Combined OC	-	-	-	-	2,880	4/12	(100)%	2,880	561,777	-	-	-
Marvelon	-	-	-	-	-	2/99	-%	4,860	3,335,015	-	-	-
OCs Provided	15,725	19,542	74,351	-	161,350		(54)%	390,702	838,745	-	1,438	1,438
PSI OCs Provided	1,163	1,046	4,301	-	9,114		(53)%	17,254	225,110	-	83	83
Non-PSI OCs Provided	14,562	18,496	70,050	-	152,236		(54)%	373,448	613,635	-	1,355	1,355

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PrEP	231	207	852	-	-		0%	403	1,255	28	-	28
PrEP (Person months)	231	207	852	-	-		-%	403	1,255	28	-	28
Referral to Advanced Cervical Cancer	2	6	19	-	66		(71)%	142	362	-	-	-
Referral to Advanced Cervical Canc	2	6	19	-	66	12/14	(71)%	142	362	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	734		(100)%	2,373	4,459	-	-	-
Referral to CD4/Clinical Staging	-	-	-	-	734		(100)%	2,373	4,459	-	-	-
Referral to Clinical Staging	-	-	-	-	322		(100)%	497	671	-	-	-
Referral to Clinical Staging	-	-	-	-	322	3/16	(100)%	497	671	-	-	-
Referral to Early Infant Male Circumcis	-	-	-	-	-		0%	8	66	-	-	-
Referral to Early Infant Male Circum	-	-	-	-	-		-%	8	66	-	-	-
Referral to Emergency Contraception	-	-	-	-	-		0%	6	8	-	-	-
Referral to Emergency Contraceptio	-	-	-	-	-		-%	6	8	-	-	-
Referral to HIV Testing Services	-	-	-	-	337		(100)%	718	1,180	-	-	-
Referral to HIV Testing & Counselin	-	-	-	-	337		(100)%	718	1,180	-	-	-
Referral to Hypertension Management	4	1	6	-	-		0%	24	30	-	-	-
Referral to Hypertension Manageme	4	1	6	-	-		-%	24	30	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		0%	1	1	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		-%	1	1	-	-	-
Referral to Injectable 1	-	-	-	-	-		0%	16	16	-	-	-
Referral to Injectable 1	-	-	-	-	-		-%	16	16	-	-	-
Referral to IUD 10 Insertion	8	6	27	-	2		1250%	7	191	-	25	25
Referral to IUD 10 Insertion	8	6	27	-	2	12/13	1,250%	7	191	-	25	25
Referral to IUD Insertion (duration unk	-	-	-	-	-		0%	2	2	-	-	-
Referral to IUD Insertion (duration ui	-	-	-	-	-		-%	2	2	-	-	-
Referral to Linkage to HIV Care	546	662	2,533	-	-		0%	2,082	4,615	1,402	-	1,402

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Linkage to HIV Care	546	662	2,533	-	-		-%	2,082	4,615	1,402	-	1,402
Referral to OCs	-	-	-	-	1		(100)%	4	851	-	-	-
Referral to OCs	-	-	-	-	1	1/15	(100)%	4	851	-	-	-
Referral to Pre-Exposure Prophylaxis (	34	18	87	-	-		0%	-	87	1	-	1
Referral to Pre-Exposure Prophylaxi	34	18	87	-	-		-%	-	87	1	-	1
Referral to STI Screening (syndromic)	7	9	35	-	-		0%	5	40	-	-	-
Referrals to STI Screening (syndronr	7	9	35	-	-		-%	5	40	-	-	-
Referral to STI Treatment (unknown)	4	-	4	-	5		(20)%	12	2,241	-	-	-
Referral to STI Treatment (unknown	4	-	4	-	5	1/15	(20)%	12	2,241	-	-	-
Referral to TB Diagnosis	6	20	65	-	-		0%	11	76	-	-	-
Referral to TB Diagnosis	6	20	65	-	-		-%	11	76	-	-	-
Referral to TB DOTS (completion confi	-	-	1	-	-		0%	2	17	-	1	1
Referral to TB DOTS (completion co	-	-	1	-	-		-%	2	17	-	1	1
Referral to TB DOTS (completion unkr	12	16	59	-	196		(70)%	467	2,445	-	33	33
Referral to TB DOTS (completion un	12	16	59	-	196	12/13	(70)%	467	2,445	-	33	33
Referral to TB Screening	4	2,208	6,628	-	-		0%	1	6,629	-	-	-
Referrals to TB Screening	4	2,208	6,628	-	-		-%	1	6,629	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	4		(100)%	4	23	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	4	1/15	(100)%	4	23	-	-	-
Referral to Treatment for Lower Abdon	-	1	2	-	-		0%	8	25	-	-	-
Referral to Treatment for Lower Abd	-	1	2	-	-		-%	8	25	-	-	-
Referral to Treatment for Urethral Disc	-	-	-	-	7		(100)%	32	56	-	-	-
Referral to Treatment for Urethral Di	-	-	-	-	7		(100)%	32	56	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	1		(100)%	3	8	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	1	1/15	(100)%	3	8	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Tubal Ligation	-	-	1	-	-		0%	-	1	-	2	2
Referral to Tubal Ligation	-	-	1	-	-		-%	-	1	-	2	2
Referral to Tx for Nonherpetic Genital	-	-	-	-	-		0%	13	22	-	-	-
Referral to Tx for Nonherpetic Genit:	-	-	-	-	-		-%	13	22	-	-	-
Referral to Tx for Urethral Discharge (\	10	17	60	-	72		(17)%	156	459	-	6	6
Referral to Tx for Urethral Discharge	10	17	60	-	72		(17)%	156	459	-	6	6
Referral to Voluntary Medical Male Cir	19	37	130	-	1,300		(90)%	2,351	10,485	440	-	440
Referral to Voluntary Medical Male C	19	37	130	-	1,300	12/14	(90)%	2,351	10,485	440	-	440
Safe Water Solution	-	-	-	-	20,410		(100)%	120,121	514,788	-	-	-
WaterGuard Solution 150mL SI	-	-	-	-	20,410	4/14	(100)%	120,121	514,788	-	-	-
STI Screening	264	316	1,211	-	1,187		2%	3,655	6,632	-	-	-
STI Screening	264	316	1,211	-	1,187		2%	3,655	6,632	-	-	-
TB Diagnosis	29	28	112	-	121		(7)%	336	847	-	-	-
TB Diagnosis	29	28	112	-	121		(7)%	336	847	-	-	-
TB DOTS	-	-	-	-	3		(100)%	11	42	-	-	-
TB DOTS	-	-	-	-	3	7/14	(100)%	11	42	-	-	-
TB Screening	17,748	25,235	93,452	-	104,913		(11)%	283,969	625,772	-	-	-
TB Screening	17,748	25,235	93,452	-	104,913		(11)%	283,969	625,772	-	-	-
Treatment for Cervicitis	27	48	170	-	-		0%	20	190	-	16	16
Treatment for Cervicitis	27	48	170	-	-		-%	20	190	-	16	16
Treatment for Genital Herpes	6	4	18	-	-		0%	3	21	-	-	-
Treatment for Genital Herpes	6	4	18	-	-		-%	3	21	-	-	-
Treatment for Inguinal Bubo	-	1	2	-	-		0%	5	7	-	-	-
Treatment for Inguinal Bubo	-	1	2	-	-		-%	5	7	-	-	-
Treatment for Lower Abdominal Pain	2	1	4	-	-		0%	2	6	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Lower Abdominal Pain	2	1	4	-	-		-%	2	6	-	-	-
Treatment for Nonherpetic Genital Ulcers	29	45	165	-	-		0%	45	210	-	59	59
Treatment for Nonherpetic Genital Ulcers	29	45	165	-	-		-%	45	210	-	59	59
Treatment for Urethral Discharge (Meropenem)	25	36	134	-	-		0%	25	159	-	17	17
Treatment for Urethral Discharge (Meropenem)	25	36	134	-	-		-%	25	159	-	17	17
Treatment for Urethral Discharge (Workshop)	103	122	468	-	-		0%	83	551	-	86	86
Treatment for Urethral Discharge (Workshop)	103	122	468	-	-		-%	83	551	-	86	86
Treatment for Vaginitis	-	-	1	-	-		0%	-	1	-	-	-
Treatment for Vaginitis	-	-	1	-	-		-%	-	1	-	-	-
Type 2 Diabetes Screening	150	342	1,177	-	-		0%	-	1,177	-	-	-
Type 2 Diabetes Screening	150	342	1,177	-	-		-%	-	1,177	-	-	-
Type 2 Diabetes_C Controlled Condition	-	-	1	-	-		0%	-	1	-	-	-
Type 2 Diabetes_C Controlled Condition	-	-	1	-	-		-%	-	1	-	-	-
Voluntary Medical Male Circumcision	12,259	16,479	61,696	-	38,462		60%	139,719	750,309	418,045	-	418,045
Male Circumcision (HIV-Negative)	-	-	-	-	38,450	1/09	(100)%	128,675	674,924	-	-	-
Male Circumcision (HIV-Unknown)	-	-	-	-	12	1/09	(100)%	93	2,738	-	-	-
Voluntary Medical Male Circumcision	12,259	16,479	61,696	-	-		-%	10,951	72,647	418,045	-	418,045

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Southern Africa</b>														
<b>Angola</b>							\$0		\$0	\$0	NA			
<b>Medicines &amp; Supplies</b>														
MVA Kit	04/2017	0	0	130	130	NA	\$0	NA	\$0	\$0	NA	82	0	NA
<b>Condom</b>														
Sensual Chocolate	04/2017	0	44,028	0	44,028	100%	\$0	NA	\$0	\$0	NA	370,800	54,000	6.87
Sensual Maracuja	04/2017	0	75,672	0	75,672	100%	\$0	NA	\$0	\$0	NA	507,744	70,752	7.18
Sensual Menta	04/2017	0	80,640	0	80,640	100%	\$0	NA	\$0	\$0	NA	372,824	57,372	6.50
Sensual Morango	04/2017	0	47,232	0	47,232	100%	\$0	NA	\$0	\$0	NA	553,788	56,556	9.79
<b>LLIN</b>														
Generic LLINs	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	63	0	NA
Joia	04/2017	0	5,205	0	5,205	100%	\$0	NA	\$0	\$0	NA	4,795	1,735	2.76
<b>Malaria PPT (ACT)</b>														
Coartem B12 (15-25 kg)	04/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	0	0	NA
Coartem B18 (25-35 kg)	04/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	0	0	NA
Coartem B24 (> 35 kg)	04/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	0	0	NA
Coartem B6 (5-15kg)	04/2017	0	0	30,000	30,000	NA	\$0	NA	\$0	\$0	NA	0	0	NA
<b>Malaria RDK</b>														
Bioline (RDT)	04/2017	0	34,625	0	34,625	100%	\$0	NA	\$0	\$0	NA	144,325	35,092	4.11
<b>Misoprostol for PAC (Sublingual)</b>														
ACE Miso (Misoprostol 200mcg ta	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	25,000	0	NA
<b>Water Treatment Tablets</b>														
Certeza Water Tabs	04/2017	0	1,371,800	0	1,371,800	100%	\$0	NA	\$0	\$0	NA	4,826,788	827,404	5.83
<b>IUD 10</b>														
Coper T 380 A – ENOVA	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,028	0	NA
<b>Lesotho</b>							\$0		\$460	\$0	NA			
<b>Condom</b>														
Lovers Plus C&F	04/2017	0	0	0	0	NA	\$0	NA	\$106	\$0	NA	0	0	NA
Trust	04/2017	0	0	0	0	NA	\$0	NA	\$83	\$0	NA	0	0	NA
Trust Studded	04/2017	0	0	0	0	NA	\$0	NA	\$271	\$0	NA	0	0	NA
<b>Female Condom</b>														
Generic	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	107	1	107.00

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Lesotho</b>							\$0		\$460	\$0	NA				
<b>Free Condom</b>															
Camouflage Free	04/2017	0	60,000	0	60,000	100%	\$0	NA	\$0	\$0	NA	1,293,000	153,000	8.45	
Vibe Condom	04/2017	0	351,741	0	351,741	100%	\$0	NA	\$0	\$0	NA	16,448,014	348,633	47.18	
<b>Madagascar</b>							\$30,054		\$136,149	\$53,144	2.56				
<b>Medicines &amp; Supplies</b>															
Sulfadoxine 500mg/ Pyrimethamin	04/2017	0	843,000	0	843,000	100%	\$0	NA	\$0	\$0	NA	284,000	284,333	1.00	
Syringe IPAS MVA Plus Aspirator	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	40	NA	NA	
<b>Condom</b>															
Protector Plus	04/2017	480	0	0	480	0%	\$5	0%	\$0	\$351	NA	305,569	47,400	6.45	
YES	04/2017	220,440	90	0	220,530	0%	\$9,699	9%	\$861	\$9,932	0.09	666,720	227,270	2.93	
<b>Female Condom</b>															
Feeling	04/2017	600	0	0	600	0%	\$6	0%	\$0	\$8	NA	14,634	778	18.81	
<b>Free Condom</b>															
Generic	04/2017	0	4,600	0	4,600	100%	\$0	NA	\$0	\$0	NA	22,749	6,317	3.60	
Generic Condom	04/2017	0	1,969,472	0	1,969,472	100%	\$0	NA	\$0	\$0	NA	1,968,009	1,695,301	1.16	
<b>Lubricant A</b>															
Gel Lubricant 5 mL	04/2017	0	900	0	900	100%	\$0	NA	\$0	\$0	NA	16,790	38,303	0.44	
<b>LLIN</b>															
Generic net "PERMANET WHITE"	04/2017	0	110,300	0	110,300	100%	\$0	NA	\$0	\$0	NA	50,022	151,817	0.33	
Global Fund Free Nets	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	19,378	0	NA	
Net Protect	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,403	167	8.38	
Olyset Net Blue	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	90	0	NA	
PermaNet-White	04/2017	0	141,755	0	141,755	100%	\$0	NA	\$0	\$0	NA	349,627	53,802	6.50	
Permanet Blue	04/2017	0	103,555	0	103,555	100%	\$0	NA	\$0	\$0	NA	66,790	34,518	1.93	
Super Moustiquaire-Blue	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$184	NA	10,496	400	26.24	
Super Moustiquaire-White	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$366	NA	22,646	802	28.25	
Yorkool Blue (Generic Net)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	20	1	30.00	
<b>Malaria PPT (ACT)</b>															
ACT 100 mg (1x3's)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	15,493	0	NA	
ACT 100 mg (1x6's)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	21,350	0	NA	
ACT 25 mg (1x3's)	04/2017	0	1,400	0	1,400	100%	\$7	0%	\$0	\$10	NA	27,494	2,275	12.09	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$30,054		\$136,149	\$53,144	2.56				
<b><u>Malaria PPT (ACT)</u></b>															
ACT 50 mg (1x3's)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2	0	NA	
Artesunate Amodiaquine 25 mg	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
Artesunate Amodiaquine combo 5	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	50	0	NA	
<b><u>Malaria RDK</u></b>															
RDT Malaria	04/2017	0	1,723,673	0	1,723,673	100%	\$0	NA	\$36,146	\$197	183.49	507,600	592,942	0.86	
<b><u>Chlorhexidine</u></b>															
Arofoitra	04/2017	554	225	0	779	29%	\$91	0%	\$0	\$181	NA	140,026	2,033	68.87	
<b><u>Diarrhea Treatment Kit</u></b>															
Hydrazinc	04/2017	0	0	0	0	NA	\$0	NA	\$47,835	\$1,293	36.99	64,767	2,823	22.94	
ORS-Zinc	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	36,281	0	NA	
Viasur	04/2017	10,856	20,770	0	31,626	66%	\$895	0%	\$0	\$1,400	NA	87,378	27,355	3.19	
<b><u>Micronutrient Powder</u></b>															
ZAZATOMADY (ZZT)	04/2017	387,120	513,270	0	900,390	57%	\$330	0%	\$0	\$348	NA	6,924,360	691,890	10.01	
<b><u>Safe Water Solution</u></b>															
Sur Eau 40 mL	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	33,847	0	NA	
Sur Eau Vaovao	04/2017	109,552	57,533	0	167,085	34%	\$13,848	0%	\$0	\$23,803	NA	2,456,718	251,550	9.77	
<b><u>Water Treatment Tablets</u></b>															
SUR'EAU PILINA (67mg tablet)	04/2017	620,400	475,280	0	1,095,680	43%	\$439	0%	\$0	\$628	NA	3,252,570	1,235,213	2.63	
<b><u>Emergency Contraception</u></b>															
Norlevo	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	600	0	NA	
<b><u>Implant 3</u></b>															
Implanon	04/2017	420	2	0	422	0%	\$66	0%	\$0	\$117	NA	2,520	765	3.30	
<b><u>Implant 4</u></b>															
Implant Zarin	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	34	6	6.00	
<b><u>Implant 5</u></b>															
Jadelle	04/2017	10	0	0	10	0%	\$2	0%	\$0	\$6	NA	409	39	10.40	
<b><u>Injectable 3</u></b>															
Confiance Injectable	04/2017	126,760	0	0	126,760	0%	\$1,195	0%	\$23,131	\$5,953	3.89	428,514	175,299	2.44	
Sayana Press	04/2017	24,614	134	0	24,748	1%	\$284	0%	\$0	\$470	NA	166,161	33,401	4.97	
<b><u>IUD 10</u></b>															
Copper T	04/2017	1,486	100	0	1,586	6%	\$233	0%	\$0	\$270	NA	3,729	1,958	1.90	
IUD 1 x 5	04/2017	120	5	0	125	4%	\$19	0%	\$0	\$6	NA	1,595	45	35.44	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Madagascar</b>							\$30,054		\$136,149	\$53,144	2.56				
<b>OCs</b>															
Pilplan	04/2017	224,502	400	0	224,902	0%	\$1,058	0%	\$28,176	\$5,810	4.85	2,661,749	373,700	7.12	
<b>SDM (Cycle Beads)</b>															
Rojo	04/2017	331	519	0	850	61%	\$4	0%	\$0	\$5	NA	25,823	683	37.79	
<b>Pneumonia PPT</b>															
PneumoStop Tablet (6 x 480 mg)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	14,670	24	619.86	
Pneumox 250 (10's) for Children u	04/2017	37,257	30,946	0	68,203	45%	\$1,873	0%	\$0	\$1,804	NA	205,572	48,652	4.23	
<b>Mozambique</b>							\$51,133		\$137,201	\$75,519	1.82				
<b>LLIC</b>															
Serena Curtina	04/2017	0	1,194	0	1,194	100%	\$0	NA	-\$120	\$32	-3.75	15,584	3,345	4.66	
<b>Medicines &amp; Supplies</b>															
JV (Finger Vibes)	04/2017	0	0	0	0	NA	\$0	NA	\$532	\$0	NA	9,287	0	NA	
Teste Glicemia	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,324	0	NA	
<b>Condom</b>															
J1	04/2017	450,648	0	0	450,648	0%	\$9,496	47%	\$15,640	\$10,157	1.54	722,904	487,680	1.48	
J14	04/2017	0	0	0	0	NA	\$0	NA	-\$346	\$0	NA	6,552	0	NA	
J2	04/2017	335,160	0	0	335,160	0%	\$10,853	84%	\$29,535	\$8,547	3.46	901,944	264,984	3.40	
J3	04/2017	288,000	0	0	288,000	0%	\$9,802	55%	\$37,638	\$9,627	3.91	434,520	293,808	1.48	
Jeito 4	04/2017	89,352	0	0	89,352	0%	\$2,973	62%	\$12,965	\$3,254	3.98	327,312	105,024	3.12	
Jeito 5	04/2017	1,944	0	0	1,944	0%	\$150	0%	\$7,269	\$746	9.74	14,076	10,632	1.32	
Jzero	04/2017	0	0	0	0	NA	\$0	NA	-\$12	\$0	NA	0	0	NA	
<b>Free Condom</b>															
No Logo Condom Lubricant Comb	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	103,968	0	NA	
<b>Free Female Condom</b>															
Female Condom Free	04/2017	0	486	0	486	100%	\$0	NA	-\$3,484	\$0	NA	11	953	0.01	
<b>Lubricant E</b>															
J8 (60 ml tube)	04/2017	0	1,659	0	1,659	100%	\$0	NA	\$1,612	\$365	4.41	8,618	1,805	4.77	
<b>LLIN</b>															
Serena	04/2017	7,732	0	0	7,732	0%	\$5,639	81%	\$20,981	\$10,413	2.01	21,573	14,616	1.48	
<b>Malaria RDK</b>															
Teste Malaria Rapido	04/2017	0	13	0	13	100%	\$0	NA	\$0	\$0	NA	1,062	9	122.54	
<b>Micronutrient Powder</b>															
Super Bebe	04/2017	0	0	0	0	NA	\$0	NA	\$553	\$0	NA	0	0	NA	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Mozambique</b>							\$51,133		\$137,201	\$75,519	1.82				
<u>Micronutrient Powder</u>															
VITA MAIS	04/2017	13,280	280	0	13,560	2%	\$49	0%	\$6,682	\$222	30.15	1,953,260	138,293	14.12	
<u>Safe Water Solution</u>															
Certeza Commercial ISM	04/2017	36,606	96	0	36,702	0%	\$8,734	33%	-\$3,654	\$12,200	-0.30	25,915	53,927	0.48	
Certeza Free ISM	04/2017	12,200	1,000	0	13,200	8%	\$3,437	0%	\$10,207	\$19,875	0.51	16,483	91,483	0.18	
<u>Water Treatment Tablets</u>															
Certeza Comprimido 20L	04/2017	0	0	0	0	NA	\$0	NA	\$181	\$0	NA	90,720	0	NA	
Certeza Comprimido 5L	04/2017	0	0	0	0	NA	\$0	NA	\$817	\$0	NA	1,680	0	NA	
Certeza Free Comprimido 20L	04/2017	0	0	0	0	NA	\$0	NA	-\$120	\$0	NA	246,000	0	NA	
<u>Implant 4</u>															
Zarin	04/2017	0	179	0	179	100%	\$0	NA	\$0	\$0	NA	26,434	183	144.19	
<u>Injectable 3</u>															
Enaf Injectable	04/2017	0	438	0	438	100%	\$0	NA	\$0	\$0	NA	52,388	661	79.26	
<u>IUD 10</u>															
DIU Copper T 380A	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,871	0	NA	
<u>OCs</u>															
Microginon Mobiz	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$81	NA	24,372	645	37.79	
Microlyn 30 Combined OC	04/2017	0	2,472	0	2,472	100%	\$0	NA	\$0	\$0	NA	256,082	2,063	124.13	
Progestyn OC	04/2017	0	779	0	779	100%	\$0	NA	\$0	\$0	NA	46,511	628	74.10	
<u>SDM (Cycle Beads)</u>															
Missangas Ciclo	04/2017	0	0	0	0	NA	\$0	NA	\$328	\$0	NA	7,660	0	NA	
<b>Namibia</b>							\$0		\$0	\$0	NA				
<u>Free Condom</u>															
Smile	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	164,035	0	NA	
<u>Free Female Condom</u>															
Femidom Free	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	55,455	0	NA	
<u>Lubricant A</u>															
Condom Lubricant (Water Based)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,809,869	0	NA	
<b>Swaziland</b>							\$0		-\$2,100	\$0	NA				
<u>Other Revenues</u>															
VCT Fees	04/2017	0	6,549	0	6,549	100%	\$0	NA	\$0	\$0	NA	0	6,796	NA	
<u>Condom</u>															
Lovers Plus	04/2017	0	0	0	0	NA	\$0	NA	-\$766	\$0	NA	0	0	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Swaziland</b>							\$0		-\$2,100	\$0	NA				
<b>Condom</b>															
Lovers Plus C&F	04/2017	0	0	0	0	NA	\$0	NA	\$1,597	\$0	NA	0	0	NA	
Lovers Plus R&S	04/2017	0	0	0	0	NA	\$0	NA	-\$111	\$0	NA	0	0	NA	
Trust	04/2017	0	0	0	0	NA	\$0	NA	-\$940	\$0	NA	0	0	NA	
Trust Studded	04/2017	0	0	0	0	NA	\$0	NA	-\$1,966	\$0	NA	0	0	NA	
Trust Workplace	04/2017	0	189,000	0	189,000	100%	\$0	NA	\$18	\$0	NA	144,000	212,000	0.68	
<b>Female Condom</b>															
Care	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
Female Condom	04/2017	0	0	0	0	NA	\$0	NA	\$70	\$0	NA	20,000	0	NA	
<b>Free Condom</b>															
Generic	04/2017	0	1,314,000	0	1,314,000	100%	\$0	NA	\$0	\$0	NA	771,000	1,156,000	0.67	
<b>Lubricant A</b>															
Lifestyles Liquid Personal Lubrica	04/2017	0	13,000	0	13,000	100%	\$0	NA	\$0	\$0	NA	203,000	46,667	4.35	
<b>STI Kit (Non-Ulcerative)</b>															
Urethral Discharge	04/2017	0	18	0	18	100%	\$0	NA	\$0	\$0	NA	0	18	NA	
Vaginal Discharge	04/2017	0	45	0	45	100%	\$0	NA	\$0	\$0	NA	0	41	NA	
<b>STI Kit (Ulcerative)</b>															
Genital Ulcer Syndrome	04/2017	0	7	0	7	100%	\$0	NA	\$0	\$0	NA	0	11	NA	



# Latin America & the Caribbean

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 4/2017**

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Americas	821	7	-	189	176,400	16	35,731	-	112	-	-	311
Caribbean	-	-	-	-	35	-	5	-	-	-	-	-
Costa Rica	14	-	-	-	3,825	-	548	-	-	-	-	-
Dominican Republic	160	-	-	-	38,942	3	5,613	-	-	-	-	-
El Salvador	50	-	-	-	19,075	1	4,267	-	-	-	-	-
Guatemala	103	-	-	-	62,124	6	16,023	-	-	-	-	1
Haiti	225	7	-	189	115	-	36	-	112	-	-	308
Honduras	144	-	-	-	13,097	1	1,882	-	-	-	-	-
Nicaragua	54	-	-	-	22,475	3	4,705	-	-	-	-	1
Panama	46	-	-	-	10,046	1	1,439	-	-	-	-	-
Paraguay	24	-	-	-	6,666	1	1,213	-	-	-	-	-

\* Using USAID CYP conversion factors

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>									<b>13</b>	<b>3</b>	<b>16</b>
<b>Free Condom</b>	-	<b>1,412</b>	<b>4,236</b>	-	<b>7,736</b>	<b>(45)%</b>	<b>11,779</b>	<b>398,418</b>	<b>12</b>	<b>3</b>	<b>15</b>
<b>HIV Testing Services</b>	-	<b>79</b>	<b>238</b>	-	<b>408</b>	<b>(42)%</b>	<b>636</b>	<b>6,951</b>	<b>2</b>	-	<b>2</b>
<b>Lubricant</b>	-	<b>703</b>	<b>2,108</b>	-	<b>413</b>	<b>410%</b>	<b>939</b>	<b>93,173</b>	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>									<b>16,867</b>	<b>9,207</b>	<b>26,074</b>
Condom	2,002,974	2,484,628	9,456,857	31,715,405	8,979,021	5%	27,549,084	326,747,076	16,854	3,180	20,034
Condom Provided	-	-	-	-	26,913	(100)%	466,816	612,770	-	-	-
Emergency Contraception	-	-	1	-	-	-%	6	7	-	-	-
Family Planning Counseli	-	-	-	-	-	-%	3,787	3,787	-	-	-
Female Condom Provided	-	-	-	-	1	(100)%	1	1	-	-	-
Free Condom	-	-	-	-	4,887,179	(100)%	6,917,715	6,983,994	-	-	-
Free Female Condom	-	-	-	-	118,200	(100)%	167,978	183,380	-	-	-
HIV Testing Services	1,541	1,570	6,252	12,485	5,817	7%	16,648	124,514	13	-	13
Implant 3	-	(19)	(56)	100	138	(141)%	333	620	-	(14)	(14)
Implant 3 Insertion	1	41	125	311	189	(34)%	797	1,101	-	34	34
Implant 5	37	(338)	(977)	558	641	(252)%	(333)	12,455	-	(473)	(473)
Implant 5 Insertion	392	567	2,093	2,372	926	126%	4,862	28,478	-	1,009	1,009
Injectable 1	179	3,286	10,038	54,269	13,292	(24)%	30,791	206,815	-	72	72
Injectable 1 Provided	1,416	992	4,393	42	3,822	15%	11,222	21,670	-	35	35
Injectable 2 Provided	489	450	1,838	-	3,383	(46)%	6,869	16,438	-	29	29
Injectable 3	(4)	-	(4)	-	-	-%	(7)	(11)	-	-	-
Injectable 3 Provided	5,806	3,971	17,720	58	9,495	87%	37,200	83,232	-	426	426
IUD 10	368	(122)	1	2,083	1,914	(100)%	4,538	93,664	-	(234)	(234)
IUD 10 Insertion	938	1,778	6,272	25,173	4,512	39%	18,956	173,061	-	3,430	3,430
IUD 5	3	24	75	50	-	-%	591	666	-	28	28
IUD 5 Insertion	-	-	-	800	-	-%	154	154	-	-	-



**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Lubricant	68,136	58,156	242,604	-	192,118	26%	641,646	4,259,094	-	-	-
Manual Vacuum Aspiratio	352	795	2,736	780	-	-%	5,421	8,157	-	61	61
Micronutrient Powder	-	-	-	-	20,460	(100)%	395,910	546,420	-	-	-
Misoprostol for PAC (Oral	1,088	787	3,449	118,920	300	1,050%	2,054	21,013	-	29	29
Misoprostol for PAC (oral)	561	1,142	3,987	600	-	-%	36	4,023	-	31	31
Misoprostol for PPH	-	293	880	-	76	1,058%	79,680	181,252	-	2	2
OCs	7,371	18,969	64,279	173,120	49,667	29%	152,685	689,636	-	294	294
OCs Provided	1,345	1,063	4,533	40	4,229	7%	12,463	31,825	-	29	29
Referral to HIV Testing Se	-	-	-	-	-	-%	27	27	-	-	-
Referral to Linkage to HIV	-	-	-	-	-	-%	292	292	-	-	-
Repellant	-	-	-	-	-	-%	1,835	1,835	-	-	-
SDM (Cycle Beads) Provic	2	3	10	-	15	(33)%	39	114	-	2	2
Tubal Ligation	246	176	775	-	358	116%	1,982	11,385	-	1,215	1,215
Vasectomy	4	3	12	-	4	200%	14	283	-	19	19
Zika Prevention Kit	63	-	63	-	-	-%	112,890	112,953	-	1	1

POPULATION SERVICES INTERNATIONAL  
Monthly Distribution by Region and Product  
Period: 4  
Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>									<b>20,448</b>	<b>23,441</b>	<b>43,888</b>
Antiretroviral Treatment (C)	12,926	20,491	74,400	8,000	-	-%	-	74,400	12,629	-	12,629
Antiretroviral Treatment (I)	445	290	1,315	-	-	-%	-	1,315	-	-	-
CD4 Tests Provided to HIV	113	-	113	-	-	-%	118	231	-	-	-
Condom	324,300	1,344,146	4,356,737	12,981,520	4,324,189	1%	11,295,344	348,171,096	6,557	1,621	8,179
Diarrhea Treatment Kit	-	-	-	40,000	-	-%	-	-	-	-	-
Emergency Contraception	-	7,735	23,206	336,500	99,707	(77)%	308,976	2,236,396	-	32	32
Fever Cases Attended	1,279	8,476	26,707	-	-	-%	1,187	27,894	-	-	-
Fever Cases Tested with I	6,000	24,436	79,308	-	-	-%	4,934	84,242	-	-	-
Fever Cases Tested with F	17,884	111,947	353,724	-	-	-%	23,956	377,680	-	-	-
Free Condom	42,000	155,000	507,000	7,684,000	540,000	(6)%	1,150,000	7,873,472	668	189	857
HIV Testing Services	34,730	16,719	84,888	155,000	-	-%	337,775	464,320	594	-	594
Implant 3	-	-	-	350	-	-%	-	-	-	-	-
Implant 3 Insertion	21	9	49	-	-	-%	-	3,678	-	13	13
Injectable 2 Provided	6	10	36	-	-	-%	-	112	-	-	-
Injectable 3	-	-	-	57,500	-	-%	-	-	-	-	-
Injectable 3 Provided	9	6	28	-	-	-%	-	296	-	1	1
IUD 10	-	8	25	100	50	(50)%	88	1,399	-	44	44
IUD 10 Insertion	2	2	7	-	-	-%	-	263	-	4	4
LLIN	-	-	-	375,000	-	-%	-	2,987,900	-	-	-
Lubricant	9,000	11,667	44,000	-	208,000	(79)%	360,000	1,348,972	-	-	-
Malaria PPT (Non-ACT)	-	-	-	11,000	-	-%	-	316,240	-	-	-

**POPULATION SERVICES INTERNATIONAL**  
**Monthly Distribution by Region and Product**  
**Period: 4**  
**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Multivitamin</b>	-	<b>70,850</b>	<b>212,550</b>	<b>2,476,080</b>	<b>644,400</b>	<b>(67)%</b>	<b>1,789,770</b>	<b>33,052,800</b>	-	<b>16</b>	<b>16</b>
<b>OCs</b>	-	<b>18,739</b>	<b>56,217</b>	<b>927,500</b>	<b>290,881</b>	<b>(81)%</b>	<b>749,197</b>	<b>7,032,502</b>	-	<b>263</b>	<b>263</b>
<b>OCs Provided</b>	<b>10</b>	<b>1</b>	<b>13</b>	-	-	<b>-%</b>	-	<b>2,492</b>	-	-	-
<b>ORS</b>	<b>150,000</b>	<b>50,000</b>	<b>300,000</b>	<b>330,000</b>	-	<b>-%</b>	<b>300,000</b>	<b>10,047,338</b>	-	<b>10,285</b>	<b>10,285</b>
<b>Positive RDTs</b>	<b>1,246</b>	<b>7,863</b>	<b>24,834</b>	-	-	<b>-%</b>	<b>1,069</b>	<b>25,903</b>	-	-	-
<b>Referral to Linkage to HIV</b>	-	-	-	-	-	<b>-%</b>	<b>41</b>	<b>41</b>	-	-	-
<b>STI Screening</b>	<b>17,560</b>	<b>13,625</b>	<b>58,436</b>	-	<b>75,310</b>	<b>(22)%</b>	<b>222,184</b>	<b>280,620</b>	-	-	-
<b>TB Diagnosis</b>	-	<b>1,135</b>	<b>3,405</b>	-	-	<b>-%</b>	<b>11,406</b>	<b>14,811</b>	-	-	-
<b>TB DOTS</b>	-	<b>1,037</b>	<b>3,110</b>	<b>10,000</b>	-	<b>-%</b>	<b>9,997</b>	<b>13,107</b>	-	<b>10,645</b>	<b>10,645</b>
<b>TB Screening</b>	-	<b>1,188</b>	<b>3,564</b>	-	-	<b>-%</b>	<b>12,026</b>	<b>15,590</b>	-	-	-
<b>Treatment for Nonherpetic</b>	<b>520</b>	<b>483</b>	<b>1,968</b>	-	-	<b>-%</b>	<b>1,290</b>	<b>3,258</b>	-	<b>328</b>	<b>328</b>

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Caribbean</b>										<b>13</b>	<b>3</b>	<b>16</b>
<b>Caribbean</b>										<b>13</b>	<b>3</b>	<b>16</b>
Free Condom	-	<b>1,412</b>	<b>4,236</b>	-	<b>7,736</b>		<b>(45)%</b>	<b>11,779</b>	<b>398,418</b>	<b>12</b>	<b>3</b>	<b>15</b>
GIGI (Got it? Get it!) Free Condom	-	<b>1,412</b>	<b>4,236</b>	-	<b>7,736</b>	10/09	<b>(45)%</b>	<b>11,779</b>	<b>398,418</b>	<b>12</b>	<b>3</b>	<b>15</b>
HIV Testing Services	-	<b>79</b>	<b>238</b>	-	<b>408</b>		<b>(42)%</b>	<b>636</b>	<b>6,951</b>	<b>2</b>	-	<b>2</b>
VCT Individual (HIV-Negative)	-	<b>77</b>	<b>230</b>	-	<b>363</b>	12/10	<b>(37)%</b>	<b>584</b>	<b>6,834</b>	<b>2</b>	-	<b>2</b>
VCT Individual (HIV-Positive)	-	<b>3</b>	<b>8</b>	-	<b>45</b>	12/10	<b>(82)%</b>	<b>52</b>	<b>117</b>	-	-	-
Lubricant	-	<b>703</b>	<b>2,108</b>	-	<b>413</b>		<b>410%</b>	<b>939</b>	<b>93,173</b>	-	-	-
GIGI (Got it? Get it!) Lube Sachet	-	<b>703</b>	<b>2,108</b>	-	<b>413</b>	10/09	<b>410%</b>	<b>939</b>	<b>93,173</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Central America</b>										<b>16,867</b>	<b>9,207</b>	<b>26,074</b>
<b>Belize</b>										-	-	-
Condom	-	-	-	-	-		0%	2,325	994,749	-	-	-
GIGI (Got it? Get it!) Condom	-	-	-	-	-	3/10	-%	2,325	994,749	-	-	-
Free Condom	-	-	-	-	1,076		(100)%	2,606	68,885	-	-	-
GIGI (Got it? Get it!) Free Condom	-	-	-	-	1,076	3/10	(100)%	2,606	68,885	-	-	-
Free Female Condom	-	-	-	-	104		(100)%	104	15,506	-	-	-
GIGI (Got it? Get it!) Free Female C	-	-	-	-	104	3/10	(100)%	104	15,506	-	-	-
HIV Testing Services	-	-	-	-	323		(100)%	481	8,061	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	316	12/10	(100)%	455	7,962	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	7	12/10	(100)%	26	99	-	-	-
Lubricant	-	-	-	-	785		(100)%	868	8,715	-	-	-
GIGI (Got it? Get it!) Lube Sachet	-	-	-	-	785	3/10	(100)%	868	8,715	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	8	8	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	8	8	-	-	-
<b>Costa Rica</b>										<b>490</b>	<b>35</b>	<b>525</b>
Condom	120,342	112,878	458,977	1,405,851	452,503		1%	1,518,375	16,285,472	490	35	525
Combo Pack	-	-	-	2,695	3,142	5/05	(100)%	13,354	53,757	-	-	-
Combo-Mix Lub Fresa	326	259	1,104	2,695	1,689	6/12	(35)%	4,556	16,176	1	-	1
Combo-Mix Lub Natural	-	-	-	2,282	92	6/12	(100)%	1,112	5,342	-	-	-
Combo-Pack Lub Fresa	1,092	157	1,564	-	1,037	10/10	51%	10,212	42,673	2	-	2
Tira Multilinea	23,019	20,916	85,767	-	-	8/16	-%	173,439	259,206	92	6	98
Vive	13,545	12,210	50,175	203,664	140,852	12/97	(64)%	257,825	4,450,044	54	4	57
Vive Amor	49,192	58,915	225,936	525,667	155,523	6/04	45%	633,204	6,900,377	241	17	258
Vive Colors/Mas Colors	17,076	11,517	51,627	370,049	86,652	5/03	(40)%	239,085	2,944,338	55	4	59

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Mas Fuerte /Retardante	4,503	2,450	11,853	134,182	26,637	6/04	(56)%	73,401	599,583	13	1	14
Vive Mas Natural /Sensitivo	9,912	4,932	24,708	131,936	30,204	6/04	(18)%	94,586	714,097	26	2	28
Vive Mas/Texturizado	1,677	1,522	6,243	32,681	6,675	6/04	(6)%	17,601	299,879	7	-	7
Lubricant	1,669	1,978	7,604	-	5,434		40%	18,606	116,835	-	-	-
Vive Lub Natural (sachet)	450	450	1,800	-	1,474	5/11	22%	5,235	42,932	-	-	-
Vive Lub Natural (tube)	454	527	2,035	-	1,432	5/11	42%	4,540	14,208	-	-	-
Vive Lub Sachet Fresa 5 mL	175	300	1,075	-	1,274	5/12	(16)%	3,879	47,525	-	-	-
Vive Lub Tubo Fresa 120 mL	590	701	2,694	-	1,254	1/12	115%	4,952	12,170	-	-	-
<b>El Salvador</b>										1,815	750	2,566
Condom	180,488	351,040	1,233,608	3,244,205	748,504		65%	2,668,520	35,014,155	1,813	255	2,068
Combo-Mix Lub Fresa	816	123	1,184	9,861	(200)	10/10	-%	3,424	26,008	2	-	2
Combo-Mix Lub Natural	800	277	1,632	9,861	(1,440)	10/10	-%	784	18,232	2	-	3
Vive	32,688	108,688	358,752	879,791	217,872	4/98	65%	747,792	13,942,828	527	74	601
Vive Amor	73,392	150,560	525,072	991,402	316,128	7/04	66%	1,086,000	12,049,249	772	108	880
Vive Colors/Mas Colors	52,656	53,912	214,392	826,840	144,552	10/03	48%	539,424	6,329,826	315	44	359
Vive Mas Fuerte /Retardante	13,224	19,664	72,216	254,193	38,856	7/04	86%	156,312	1,229,732	106	15	121
Vive Mas Natural /Sensitivo	1,728	8,136	26,136	172,952	15,192	7/04	72%	62,784	648,128	38	5	44
Vive Mas/Texturizado	5,184	9,680	34,224	99,305	17,544	7/04	95%	72,000	770,152	50	7	57
Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Non-PSI Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Family Planning Counseling	-	-	-	-	-		0%	3,787	3,787	-	-	-
Family Planning Counseling	-	-	-	-	-		-%	3,787	3,787	-	-	-
Free Condom	-	-	-	-	4,886,103		(100)%	6,915,109	6,915,109	-	-	-
Free Condom	-	-	-	-	4,886,103	11/15	(100)%	6,915,109	6,915,109	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Free Female Condom	-	-	-	-	118,096		(100)%	167,874	167,874	-	-	-
Free Female Condoms	-	-	-	-	118,096	11/15	(100)%	167,874	167,874	-	-	-
HIV Testing Services	410	330	1,399	2,551	179		682%	1,283	38,589	2	-	2
VCT Individual (HIV-Negative)	402	317	1,354	2,412	160	12/09	746%	1,207	38,155	2	-	2
VCT Individual (HIV-Positive)	8	12	45	139	19	12/09	137%	76	434	-	-	-
Implant 3 Insertion	-	-	-	-	-		0%	169	169	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	-		-%	169	169	-	-	-
Implant 5	21	18	75	550	(11)		0%	126	3,687	-	15	15
PSI Implant 5 Distributed Inserted (	(10)	(15)	(54)	-	(11)		-%	(74)	(762)	-	(11)	(11)
Jadelle	31	33	129	550	-	12/08	-%	200	4,449	-	26	26
Implant 5 Insertion	10	15	54	-	14		286%	77	765	-	12	12
PSI Implant 5 Inserted	10	15	54	-	11		391%	74	762	-	12	12
Non-PSI Implant 5 Inserted	-	-	-	-	3		(100)%	3	3	-	-	-
Injectable 1	-	(2)	(7)	-	-		0%	(2)	(9)	-	-	-
PSI Injectable 1 Distributed Provide	-	(2)	(7)	-	-		-%	(2)	(9)	-	-	-
Injectable 1 Provided	6	7	26	-	1		2500%	20	46	-	-	-
PSI Injectable 1 Provided	-	2	7	-	-		-%	2	9	-	-	-
Non-PSI Injectable 1 Provided	6	4	19	-	1		1,800%	18	37	-	-	-
IUD 10	93	164	585	816	(335)		0%	902	30,137	-	145	145
PSI IUD 10 Distributed Inserted (1)	(95)	(115)	(441)	(6,932)	(639)		-%	(1,850)	(23,211)	-	(109)	(109)
Copper T 380	188	279	1,026	7,748	304	12/08	238%	2,752	53,348	-	254	254
IUD 10 Insertion	183	247	925	6,932	1,182		(22)%	3,266	32,953	-	255	255
PSI IUD 10 Inserted	95	115	441	6,932	639		(31)%	1,850	23,211	-	122	122
Non-PSI IUD 10 Inserted	88	132	484	-	543	11/13	(11)%	1,416	9,742	-	133	133
Lubricant	29,048	21,982	94,995	-	43,907		116%	173,765	978,622	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Lub (sachet)	18,900	7,667	41,900	-	22,650	12/06	85%	73,750	579,690	-	-	-
Vive Lub (tube)	80	971	2,992	-	2,057	12/06	45%	7,105	48,741	-	-	-
Vive Lub Natural (sachet)	9,050	12,683	47,100	-	18,150	1/10	160%	88,705	332,162	-	-	-
Vive Lub Natural (tube)	1,018	662	3,003	-	1,050	1/10	186%	4,205	18,029	-	-	-
Manual Vacuum Aspiration for PAC	167	122	532	155	-		0%	1,280	1,812	-	8	8
MVA for PAC	167	122	532	155	-	8/16	-%	1,280	1,812	-	8	8
Micronutrient Powder	-	-	-	-	20,460		(100)%	395,910	546,420	-	-	-
VitalDia Kids	-	-	-	-	20,460	10/14	(100)%	395,910	546,420	-	-	-
Misoprostol for PAC (Oral)	748	159	1,226	30,200	300		309%	738	17,474	-	5	5
PSI Misoprostol for PAC Oral Dist F	-	-	-	-	-		-%	(12)	(12)	-	-	-
Misoprostol for PAC (oral)	748	159	1,226	30,200	300	10/13	309%	750	17,486	-	5	5
Misoprostol for PAC (oral) Provided	21	39	138	-	-		0%	12	150	-	1	1
PSI Misoprostol for PAC (oral) Prov	-	-	-	-	-		-%	12	12	-	-	-
Non-PSI Misoprostol for PAC (oral) I	21	39	138	-	-		-%	-	138	-	1	1
OCs	4,036	5,442	20,361	42,360	717		2740%	15,361	131,141	-	54	54
PSI OCs Distributed Provided	-	(1)	(3)	-	-		-%	(4)	(7)	-	-	-
Segura Plus	4,036	5,443	20,364	42,360	717	2/12	2,740%	15,365	131,148	-	54	54
OCs Provided	-	1	3	-	2		50%	7	10	-	-	-
PSI OCs Provided	-	1	3	-	-		-%	4	7	-	-	-
Non-PSI OCs Provided	-	-	-	-	2		(100)%	3	3	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	42	42	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	42	42	-	-	-
Zika Prevention Kit	63	-	63	-	-		0%	930	993	-	1	1
Zika Prevention Kit	63	-	63	-	-	7/16	-%	930	993	-	1	1
<b>Guatemala</b>										<b>4,290</b>	<b>6,191</b>	<b>10,481</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Condom</b>	<b>613,728</b>	<b>895,643</b>	<b>3,300,656</b>	<b>12,755,737</b>	<b>3,589,022</b>		<b>(8)%</b>	<b>10,980,589</b>	<b>125,241,009</b>	<b>4,284</b>	<b>1,517</b>	<b>5,801</b>
PSI Condom Distributed Provided	-	-	-	-	(186)		-%	(11,755)	(11,804)	-	-	-
Bodyguard	-	-	-	-	59,616	10/15	(100)%	77,328	259,488	-	-	-
Combo Pack	-	5,067	15,200	34,548	13,040	4/05	17%	32,960	380,776	20	7	27
Vive	222,672	231,408	916,896	3,628,203	1,291,632	4/98	(29)%	3,856,224	50,968,365	1,190	421	1,611
Vive Amor	271,152	544,224	1,903,824	3,839,268	1,746,480	7/04	9%	5,796,576	56,684,847	2,471	875	3,346
Vive Colors/Mas Colors	84,240	73,648	305,184	3,472,854	307,056	4/02	(1)%	778,296	12,722,086	396	140	536
Vive Mas Fuerte /Retardante	22,008	-	22,008	1,382,019	120,984	7/04	(82)%	312,576	2,415,680	29	10	39
Vive Mas Natural /Sensitivo	8,640	-	8,640	368,803	23,976	7/04	(64)%	76,080	900,517	11	4	15
Vive Mas/Texturizado	5,016	41,296	128,904	30,042	26,424	7/04	388%	62,304	921,054	167	59	227
<b>Condom Provided</b>	-	-	-	-	<b>26,912</b>		<b>(100)%</b>	<b>466,815</b>	<b>612,769</b>	-	-	-
PSI Condom Provided	-	-	-	-	186		(100)%	11,755	11,804	-	-	-
Non-PSI Condom Provided	-	-	-	-	26,726		(100)%	455,060	600,965	-	-	-
<b>Emergency Contraception Provided</b>	-	-	<b>1</b>	-	-		<b>0%</b>	<b>6</b>	<b>7</b>	-	-	-
Non-PSI Emergency Contraception I	-	-	1	-	-		-%	6	7	-	-	-
<b>Female Condom Provided</b>	-	-	-	-	<b>1</b>		<b>(100)%</b>	<b>1</b>	<b>1</b>	-	-	-
Non-PSI Female Condom Provided	-	-	-	-	1		(100)%	1	1	-	-	-
<b>HIV Testing Services</b>	<b>568</b>	<b>641</b>	<b>2,491</b>	<b>4,672</b>	<b>3,733</b>		<b>(33)%</b>	<b>8,883</b>	<b>45,751</b>	<b>6</b>	-	<b>6</b>
VCT Individual (HIV-Negative)	544	621	2,407	4,433	3,689	12/09	(35)%	8,640	45,194	6	-	6
VCT Individual (HIV-Positive)	24	20	84	239	44	12/09	91%	243	557	-	-	-
<b>Implant 3 Insertion</b>	-	-	-	-	-		<b>0%</b>	<b>11</b>	<b>33</b>	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	-		-%	11	33	-	-	-
<b>Implant 5</b>	<b>(82)</b>	<b>(397)</b>	<b>(1,272)</b>	<b>108</b>	<b>515</b>		<b>(347)%</b>	<b>(723)</b>	<b>7,512</b>	-	<b>(566)</b>	<b>(566)</b>
PSI Implant 5 Distributed Inserted (	(170)	(475)	(1,595)	(972)	(390)		-%	(2,859)	(10,309)	-	(710)	(710)
Jadelle	88	78	323	1,080	905	12/08	(64)%	2,136	17,821	-	144	144

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Implant 5 Insertion	351	522	1,916	972	857		124%	4,553	25,549	-	948	948
PSI Implant 5 Inserted	170	475	1,595	972	390		309%	2,859	10,309	-	789	789
Non-PSI Implant 5 Inserted	181	47	321	-	467		(31)%	1,694	15,240	-	159	159
Injectable 1	180	3,289	10,046	54,269	13,292		(24)%	30,798	206,830	-	73	73
PSI Injectable 1 Distributed Provide	(470)	(89)	(738)	-	(843)		-%	(1,826)	(3,161)	-	(5)	(5)
Cyclofem	650	3,378	10,784	54,269	14,135	5/11	(24)%	32,624	209,991	-	78	78
Injectable 1 Provided	1,401	978	4,335	-	3,821		13%	11,103	21,493	-	35	35
PSI Injectable 1 Provided	470	89	738	-	843		(12)%	1,826	3,161	-	6	6
Non-PSI Injectable 1 Provided	931	889	3,597	-	2,978		21%	9,277	18,332	-	29	29
Injectable 2	-	-	-	-	(7)		0%	(7)	(7)	-	-	-
PSI Injectable 2 Distributed Provide	-	-	-	-	(7)		-%	(7)	(7)	-	-	-
Injectable 2 Provided	489	450	1,838	-	3,383		(46)%	6,869	16,438	-	29	29
PSI Injectable 2 Provided	-	-	-	-	7		(100)%	7	7	-	-	-
Non-PSI Injectable 2 Provided	489	450	1,838	-	3,376		(46)%	6,862	16,431	-	29	29
Injectable 3	-	-	-	-	(407)		0%	(407)	(593)	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	(407)		-%	(407)	(593)	-	-	-
Injectable 3 Provided	5,798	3,967	17,698	-	9,495		86%	37,157	83,167	-	426	426
PSI Injectable 3 Provided	-	-	-	-	407		(100)%	407	593	-	-	-
Non-PSI Injectable 3 Provided	5,798	3,967	17,698	-	9,088		95%	36,750	82,574	-	426	426
IUD 10	296	(471)	(1,116)	517	1,164		(196)%	(618)	27,654	-	(613)	(613)
PSI IUD 10 Distributed Inserted (1)	(567)	(1,264)	(4,358)	(12,226)	(1,817)		-%	(11,625)	(79,736)	-	(2,395)	(2,395)
Copper T 380	863	776	3,191	12,743	2,981	12/08	7%	11,007	107,339	-	1,754	1,754
Copper T 380 Postpartum	-	17	51	-	-	1/17	-%	-	51	-	28	28
IUD 10 Insertion	635	1,323	4,603	12,226	2,572		79%	13,400	99,431	-	2,811	2,811
PSI IUD 10 Inserted	567	1,264	4,358	12,226	1,817		140%	11,625	79,736	-	2,661	2,661

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI IUD 10 Inserted	68	59	245	-	755		(68)%	1,775	19,695	-	150	150
IUD 5	-	14	43	-	-		0%	530	573	-	18	18
IUD Sleek	-	14	43	-	-	5/16	-%	530	573	-	18	18
IUD 5 Insertion	-	-	-	-	-		0%	147	147	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	147	147	-	-	-
Lubricant	4,381	4,906	19,098	-	74,231		(74)%	192,313	1,281,003	-	-	-
Vive Lub (sachet)	425	743	2,655	-	49,402	4/05	(95)%	107,228	877,134	-	-	-
Vive Lub (tube)	1,654	894	4,335	-	5,598	4/05	(23)%	19,302	118,173	-	-	-
Vive Lub Natural (sachet)	924	1,957	6,794	-	13,386	1/10	(49)%	46,983	217,428	-	-	-
Vive Lub Natural (tube)	1,378	1,312	5,314	-	5,845	1/10	(9)%	18,800	68,268	-	-	-
Manual Vacuum Aspiration for PAC	161	635	2,066	300	-		0%	3,716	5,782	-	48	48
MVA for PAC	161	635	2,066	300	-	5/16	-%	3,716	5,782	-	48	48
Misoprostol for PAC (Oral)	343	(253)	(416)	59,720	-		0%	(24)	(440)	-	(3)	(3)
PSI Misoprostol for PAC Oral Dist F	(537)	(1,093)	(3,816)	(600)	-		-%	(24)	(3,840)	-	(27)	(27)
Misoprostol for PAC (oral)	880	840	3,400	60,320	-	7/13	-%	-	3,400	-	24	24
Misoprostol for PAC (oral) Provided	537	1,093	3,816	600	-		0%	24	3,840	-	30	30
PSI Misoprostol for PAC (oral) Prov	537	1,093	3,816	600	-		-%	24	3,840	-	30	30
Misoprostol for PPH	-	293	880	-	76		1058%	79,680	181,252	-	2	2
Misoprostol for PPH	-	293	880	-	76	7/13	1,058%	79,680	181,252	-	2	2
OCs	3,336	8,717	29,488	39,760	26,673		11%	60,581	453,537	-	173	173
PSI OCs Distributed Provided	(418)	(127)	(799)	-	(262)		-%	(906)	(1,849)	-	(5)	(5)
Oralcon-F (28 tablets Blister)	-	-	-	-	22,693	8/10	(100)%	40,212	366,801	-	-	-
Segura Plus	3,754	8,844	30,287	39,760	4,242	5/14	614%	21,275	88,585	-	178	178
OCs Provided	1,343	1,057	4,514	-	4,227		7%	12,390	31,733	-	29	29
PSI OCs Provided	418	127	799	-	262		205%	906	1,849	-	5	5

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI OCs Provided	925	930	3,715	-	3,965		(6)%	11,484	29,884	-	24	24
Referral to Linkage to HIV Care	-	-	-	-	-		0%	90	90	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	90	90	-	-	-
Repellant	-	-	-	-	-		0%	1,835	1,835	-	-	-
Repellant	-	-	-	-	-	12/16	-%	1,835	1,835	-	-	-
SDM (Cycle Beads)	-	-	-	-	(2)		0%	(2)	(2)	-	-	-
PSI SDM (Cycle Beads) Distributed	-	-	-	-	(2)		-%	(2)	(2)	-	-	-
SDM (Cycle Beads) Provided	2	3	10	-	15		(33)%	39	114	-	2	2
PSI SDM (Cycle Beads) Provided	-	-	-	-	2		(100)%	2	2	-	-	-
Non-PSI SDM (Cycle Beads) Provid	2	3	10	-	13		(23)%	37	112	-	2	2
Tubal Ligation	246	176	775	-	358		116%	1,982	11,385	-	1,215	1,215
Tubal Ligation	246	176	775	-	358	7/12	116%	1,982	11,385	-	1,215	1,215
Vasectomy	4	3	12	-	4		200%	14	283	-	19	19
Vasectomy	4	3	12	-	4	7/12	200%	14	283	-	19	19
<b>Honduras</b>										6,051	476	6,527
Condom	449,864	372,736	1,568,072	4,290,217	1,385,688		13%	4,121,656	44,208,288	6,048	474	6,522
Bodyguard	-	736	2,208	-	-	7/16	-%	98,592	100,800	9	1	9
Combo Pack	-	-	-	-	848	4/05	(100)%	(256)	153,800	-	-	-
Combo-Mix Lub Fresa	-	-	-	1,259	160	10/10	(100)%	848	10,864	-	-	-
Combo-Mix Lub Natural	-	-	-	1,111	152	10/10	(100)%	1,216	9,984	-	-	-
Combo-Pack Lub Fresa	-	-	-	4,852	-	2/16	-%	-	-	-	-	-
Combo-Pack Lub Natural	80	-	80	6,219	424	10/10	(81)%	4,160	25,776	-	-	-
Vive	69,888	96,320	358,848	720,013	246,192	9/00	46%	657,168	13,715,155	1,384	108	1,492
Vive Amor	292,560	185,072	847,776	2,760,149	927,696	8/04	(9)%	2,619,312	20,725,832	3,270	256	3,526

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Colors/Mas Colors	61,392	67,280	263,232	589,161	149,856	4/02	76%	537,168	7,719,766	1,015	80	1,095
Vive Mas Fuerte /Retardante	9,216	15,208	54,840	117,089	35,472	8/04	55%	131,064	890,208	212	17	228
Vive Mas Natural /Sensitivo	1,008	3,400	11,208	35,859	11,112	8/04	1%	38,448	415,706	43	3	47
Vive Mas/Texturizado	15,720	4,720	29,880	54,505	13,776	8/04	117%	33,936	440,397	115	9	124
HIV Testing Services	387	358	1,462	2,725	370		295%	3,717	9,026	3	-	3
VCT Individual (HIV-Negative)	382	347	1,424	2,589	369	4/12	286%	3,659	8,926	3	-	3
VCT Individual (HIV-Positive)	5	11	38	136	1	4/14	3,700%	58	100	-	-	-
Implant 3 Insertion	-	2	5	11	-		0%	5	10	-	1	1
Non-PSI Implant 3 Inserted	-	2	5	11	-		-%	5	10	-	1	1
Injectable 1	(1)	-	(1)	-	-		0%	(5)	(6)	-	-	-
PSI Injectable 1 Distributed Provide	(1)	-	(1)	-	-		-%	(5)	(6)	-	-	-
Injectable 1 Provided	1	3	11	42	-		0%	24	35	-	-	-
PSI Injectable 1 Provided	1	-	1	-	-		-%	5	6	-	-	-
Non-PSI Injectable 1 Provided	-	3	10	42	-		-%	19	29	-	-	-
Injectable 3	(4)	-	(4)	-	-		0%	(7)	(11)	-	-	-
PSI Injectable 3 Distributed Provide	(4)	-	(4)	-	-		-%	(7)	(11)	-	-	-
Injectable 3 Provided	4	3	14	58	-		0%	26	40	-	-	-
PSI Injectable 3 Provided	4	-	4	-	-		-%	7	11	-	-	-
Non-PSI Injectable 3 Provided	-	3	10	58	-		-%	19	29	-	-	-
IUD 10	-	-	-	-	-		0%	(1)	(1)	-	-	-
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	-		-%	(1)	(1)	-	-	-
IUD 10 Insertion	-	1	3	15	-		0%	7	10	-	1	1
PSI IUD 10 Inserted	-	-	-	-	-		-%	1	1	-	-	-
Non-PSI IUD 10 Inserted	-	1	3	15	-		-%	6	9	-	1	1
IUD 5	-	-	-	-	-		0%	(4)	(4)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI IUD 5 Distributed Inserted (1)	-	-	-	-	-		-%	(4)	(4)	-	-	-
IUD 5 Insertion	-	-	-	-	-		0%	7	7	-	-	-
PSI IUD 5 Inserted	-	-	-	-	-		-%	4	4	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	3	3	-	-	-
Lubricant	12,880	10,322	43,845	-	16,547		165%	67,107	696,786	-	-	-
Vive Lub (sachet)	12,500	8,917	39,250	-	7,890	3/05	397%	27,717	476,557	-	-	-
Vive Lub (tube)	115	292	990	-	2,961	3/05	(67)%	14,698	74,719	-	-	-
Vive Lub Natural (sachet)	-	200	600	-	4,620	1/10	(87)%	16,191	110,376	-	-	-
Vive Lub Natural (tube)	265	913	3,005	-	1,076	1/10	179%	8,501	35,134	-	-	-
OCs	(1)	-	(1)	-	-		0%	(20)	(21)	-	-	-
PSI OCs Distributed Provided	(1)	-	(1)	-	-		-%	(20)	(21)	-	-	-
OCs Provided	1	1	3	40	-		0%	26	29	-	-	-
PSI OCs Provided	1	-	1	-	-		-%	20	21	-	-	-
Non-PSI OCs Provided	-	1	2	40	-		-%	6	8	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	27	27	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	-		-%	27	27	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	24	24	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	24	24	-	-	-
<b>Nicaragua</b>										2,413	1,478	3,890
Condom	301,880	462,707	1,690,000	5,632,395	1,526,902		11%	4,590,438	67,792,662	2,412	623	3,036
Bodyguard	3,600	26,896	84,288	30,000	49,552	2/04	70%	111,568	11,101,840	120	31	151
Combo-Pack Lub Fresa	1,392	779	3,728	14,041	5,136	5/11	(27)%	9,152	45,992	5	1	7
Combo-Pack Lub Natural	464	160	944	6,797	3,744	10/10	(75)%	5,904	22,784	1	-	2
Vive	185,904	328,656	1,171,872	4,182,330	1,036,608	4/98	13%	2,984,352	43,394,384	1,673	432	2,105

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Vive Colors/Mas Colors	105,744	52,776	264,072	916,570	270,876	4/02	(3)%	998,172	10,094,012	377	97	474
Vive Mas Fuerte /Retardante	-	32,728	98,184	308,902	101,664	6/04	(3)%	333,384	1,608,566	140	36	176
Vive Mas Natural /Sensitivo	120	13,624	40,992	126,853	32,988	6/04	24%	95,868	830,891	59	15	74
Vive Mas/Texturizado	4,656	7,088	25,920	46,902	26,334	6/04	(2)%	52,038	694,193	37	10	47
HIV Testing Services	-	16	47	-	281		(83)%	616	6,985	-	-	-
VCT Individual (HIV-Negative)	-	14	43	-	264	12/09	(84)%	567	6,896	-	-	-
VCT Individual (HIV-Positive)	-	1	4	-	17	12/09	(76)%	49	89	-	-	-
Implant 3	-	(19)	(56)	100	138		(141)%	333	620	-	(14)	(14)
PSI Implant 3 Distributed Inserted (	(1)	(40)	(120)	(300)	(189)	3/16	-%	(612)	(889)	-	(29)	(29)
Implanon	1	21	64	400	327	7/15	(80)%	945	1,509	-	16	16
Implant 3 Insertion	1	40	120	300	189		(37)%	612	889	-	32	32
PSI Implant 3 Inserted	1	40	120	300	189	3/16	(37)%	612	889	-	32	32
Implant 5	98	41	220	(100)	137		61%	264	1,256	-	79	79
PSI Implant 5 Distributed Inserted (	(31)	(31)	(123)	(1,400)	(55)		-%	(232)	(2,164)	-	(44)	(44)
Jadelle	129	71	343	1,300	192	12/08	79%	496	3,420	-	123	123
Implant 5 Insertion	31	31	123	1,400	55		124%	232	2,164	-	49	49
PSI Implant 5 Inserted	31	31	123	1,400	55		124%	232	2,164	-	49	49
Injectable 1 Provided	8	4	21	-	-		0%	75	96	-	-	-
Non-PSI Injectable 1 Provided	8	4	21	-	-		-%	75	96	-	-	-
Injectable 3 Provided	4	1	8	-	-		0%	17	25	-	-	-
Non-PSI Injectable 3 Provided	4	1	8	-	-		-%	17	25	-	-	-
IUD 10	(21)	184	532	750	1,085		(51)%	4,254	35,873	-	235	235
PSI IUD 10 Distributed Inserted (1)	(120)	(207)	(741)	(6,000)	(758)		-%	(2,283)	(40,667)	-	(327)	(327)
Copper T 380	99	391	1,273	6,750	1,843	12/08	(31)%	6,485	76,488	-	562	562
Copper-T 380-A IUD	-	-	-	-	-	3/16	-%	52	52	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
IUD 10 Insertion	120	207	741	6,000	758		(2)%	2,283	40,667	-	363	363
PSI IUD 10 Inserted	120	207	741	6,000	758		(2)%	2,283	40,667	-	363	363
IUD 5	3	10	32	50	-		0%	61	93	-	11	11
PSI IUD 5 Distributed Inserted (1)	-	-	-	(800)	-		-%	-	-	-	-	-
Copper T375 Sleek	3	10	32	850	-	3/16	-%	61	93	-	11	11
IUD 5 Insertion	-	-	-	800	-		0%	-	-	-	-	-
PSI IUD 5 Inserted	-	-	-	800	-		-%	-	-	-	-	-
Lubricant	16,958	14,571	60,672	-	40,276		51%	141,496	779,539	-	-	-
Vive Lub (sachet)	6,177	4,568	19,880	-	16,806	3/05	18%	60,504	364,419	-	-	-
Vive Lub (tube)	1,317	1,976	7,245	-	5,135	3/05	41%	16,332	93,329	-	-	-
Vive Lub Natural (sachet)	8,700	6,425	27,975	-	15,506	1/10	80%	52,175	266,760	-	-	-
Vive Lub Natural (tube)	764	1,603	5,572	-	2,829	1/10	97%	12,485	55,031	-	-	-
Manual Vacuum Aspiration for PAC	24	38	138	325	-		0%	425	563	-	5	5
MVA for PAC	24	38	138	325	-	5/16	-%	425	563	-	5	5
Misoprostol for PAC (Oral)	(3)	881	2,639	29,000	-		0%	1,328	3,967	-	27	27
PSI Misoprostol for PAC Oral Dist F	(3)	(10)	(33)	-	-		-%	-	(33)	-	-	-
Misoprostol for PAC (oral)	-	891	2,672	29,000	-	10/16	-%	1,328	4,000	-	27	27
Misoprostol for PAC (oral) Provided	3	10	33	-	-		0%	-	33	-	-	-
PSI Misoprostol for PAC (oral) Prov	3	10	33	-	-		-%	-	33	-	-	-
OCs	-	4,810	14,431	91,000	22,277		(35)%	76,754	104,970	-	68	68
PSI OCs Distributed Provided	-	-	-	-	-		-%	(9)	(9)	-	-	-
Segura Plus	-	4,810	14,431	91,000	22,277	7/15	(35)%	76,763	104,979	-	68	68
OCs Provided	1	4	13	-	-		0%	40	53	-	-	-
PSI OCs Provided	-	-	-	-	-		-%	9	9	-	-	-
Non-PSI OCs Provided	1	4	13	-	-		-%	31	44	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Linkage to HIV Care	-	-	-	-	-		0%	35	35	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	35	35	-	-	-
<b>Panama</b>										<b>1,808</b>	<b>277</b>	<b>2,085</b>
Condom	<b>336,672</b>	<b>289,624</b>	<b>1,205,544</b>	<b>4,387,000</b>	<b>1,277,064</b>		<b>(6)%</b>	<b>3,655,170</b>	<b>37,352,737</b>	<b>1,806</b>	<b>277</b>	<b>2,083</b>
Bodyguard	-	-	-	-	3,456	12/14	(100)%	3,700	27,460	-	-	-
Vive	294,240	215,728	941,424	3,552,285	1,033,728	7/00	(9)%	3,056,256	31,049,921	1,411	216	1,627
Vive Colors/Mas Colors	17,088	32,529	114,675	470,962	111,480	3/05	3%	270,696	3,556,956	172	26	198
Vive Mas Fuerte /Retardante	15,600	25,600	92,400	207,076	82,800	3/05	12%	201,110	1,405,375	138	21	160
Vive Mas Natural /Sensitivo	6,000	10,536	37,608	94,353	28,800	3/05	31%	73,632	712,160	56	9	65
Vive Mas/Texturizado	3,744	5,231	19,437	62,324	16,800	3/05	16%	49,776	600,865	29	4	34
HIV Testing Services	176	226	853	2,537	931		<b>(8)%</b>	<b>1,668</b>	<b>16,102</b>	<b>2</b>	<b>-</b>	<b>2</b>
VCT Individual (HIV-Negative)	164	219	821	2,417	858	12/11	(4)%	1,502	15,637	2	-	2
VCT Individual (HIV-Positive)	12	7	32	120	73	12/11	(56)%	166	465	-	-	-
Lubricant	3,200	4,397	16,390	-	10,938		<b>50%</b>	<b>47,491</b>	<b>397,594</b>	<b>-</b>	<b>-</b>	<b>-</b>
Vive Lub (sachet)	-	1,667	5,000	-	5,000	2/09	-%	22,573	247,776	-	-	-
Vive Lub (tube)	1,250	900	3,950	-	3,245	2/09	22%	8,965	56,892	-	-	-
Vive Lub Natural (sachet)	50	217	700	-	600	5/11	17%	5,400	43,305	-	-	-
Vive Lub Natural (tube)	1,900	1,613	6,740	-	2,093	5/11	222%	10,553	49,621	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	93	93	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	93	93	-	-	-
Zika Prevention Kit	-	-	-	-	-		0%	111,960	111,960	-	-	-
Zika Prevention Kit	-	-	-	-	-	7/16	-%	111,960	111,960	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Americas - Other</b>										<b>20,448</b>	<b>23,441</b>	<b>43,888</b>
<b>Dominican Republic</b>										<b>6,171</b>	<b>1,751</b>	<b>7,921</b>
CD4 Tests Provided to HIV+ Clients	113	-	113	-	-		0%	118	231	-	-	-
CD4 Tests Provided to HIV+ Clients	113	-	113	-	-		-%	118	231	-	-	-
Condom	324,300	1,273,818	4,145,753	8,669,760	3,430,050		21%	8,230,724	176,200,070	5,463	1,544	7,007
Pante	324,300	1,273,818	4,145,753	8,669,760	3,430,050	9/03	21%	8,230,724	176,200,070	5,463	1,544	7,007
Free Condom	42,000	155,000	507,000	684,000	540,000		(6)%	1,150,000	7,873,472	668	189	857
No Logo	42,000	155,000	507,000	684,000	540,000	4/10	(6)%	1,150,000	7,873,472	668	189	857
HIV Testing Services	16,136	-	16,136	-	-		0%	24,360	54,919	39	-	39
VCT Individual (HIV-Negative)	15,804	-	15,804	-	-	9/13	-%	23,751	53,734	38	-	38
VCT Individual (HIV-Positive)	332	-	332	-	-	9/13	-%	609	1,185	1	-	1
Implant 3 Insertion	21	9	49	-	-		0%	-	3,678	-	13	13
Non-PSI Implant 3 Inserted	21	9	49	-	-	11/13	-%	-	3,678	-	13	13
Injectable 2 Provided	6	10	36	-	-		0%	-	112	-	-	-
Non-PSI Injectable 2 Provided	6	10	36	-	-		-%	-	112	-	-	-
Injectable 3 Provided	9	6	28	-	-		0%	-	296	-	1	1
Non-PSI Injectable 3 Provided	9	6	28	-	-	3/16	-%	-	296	-	1	1
IUD 10 Insertion	2	2	7	-	-		0%	-	263	-	4	4
Non-PSI IUD 10 Inserted	2	2	7	-	-	11/13	-%	-	263	-	4	4
Lubricant	9,000	11,667	44,000	-	208,000		(79)%	360,000	1,348,972	-	-	-
No Logo Lubricant (4.5 gram sachet	9,000	11,667	44,000	-	208,000	3/13	(79)%	360,000	1,348,972	-	-	-
OCs Provided	10	1	13	-	-		0%	-	2,492	-	-	-
Non-PSI OCs Provided	10	1	13	-	-	3/16	-%	-	2,492	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		0%	41	41	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	-		-%	41	41	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Haiti</b>										<b>13,183</b>	<b>21,302</b>	<b>34,485</b>
Antiretroviral Treatment (Currently Enr <b>12,926</b>		<b>20,491</b>	<b>74,400</b>	<b>8,000</b>	-		<b>0%</b>	-	<b>74,400</b>	<b>12,629</b>	-	<b>12,629</b>
Antiretroviral Treatment (Currently E <b>12,926</b>		<b>20,491</b>	<b>74,400</b>	<b>8,000</b>	-		<b>-%</b>	-	<b>74,400</b>	<b>12,629</b>	-	<b>12,629</b>
Antiretroviral Treatment (Newly Enrolle <b>445</b>		<b>290</b>	<b>1,315</b>	-	-		<b>0%</b>	-	<b>1,315</b>	-	-	-
Antiretroviral Treatment (Newly Enrc <b>445</b>		<b>290</b>	<b>1,315</b>	-	-		<b>-%</b>	-	<b>1,315</b>	-	-	-
Condom	-	-	-	<b>250,000</b>	-		<b>0%</b>	-	<b>135,350,664</b>	-	-	-
Pante	-	-	-	<b>250,000</b>	-	11/90	<b>-%</b>	-	<b>135,350,664</b>	-	-	-
Diarrhea Treatment Kit	-	-	-	<b>40,000</b>	-		<b>0%</b>	-	-	-	-	-
Saluzinc	-	-	-	<b>40,000</b>	-	3/17	<b>-%</b>	-	-	-	-	-
Emergency Contraception	-	-	-	<b>17,500</b>	-		<b>0%</b>	-	-	-	-	-
Pronta1	-	-	-	<b>17,500</b>	-	3/17	<b>-%</b>	-	-	-	-	-
Fever Cases Attended	<b>1,279</b>	<b>8,476</b>	<b>26,707</b>	-	-		<b>0%</b>	<b>1,187</b>	<b>27,894</b>	-	-	-
Fever Cases Attended	<b>1,279</b>	<b>8,476</b>	<b>26,707</b>	-	-		<b>-%</b>	<b>1,187</b>	<b>27,894</b>	-	-	-
Fever Cases Tested with Microscopy	<b>6,000</b>	<b>24,436</b>	<b>79,308</b>	-	-		<b>0%</b>	<b>4,934</b>	<b>84,242</b>	-	-	-
Fever Cases Tested with Microscopy	<b>6,000</b>	<b>24,436</b>	<b>79,308</b>	-	-		<b>-%</b>	<b>4,934</b>	<b>84,242</b>	-	-	-
Fever Cases Tested with RDTs	<b>17,884</b>	<b>111,947</b>	<b>353,724</b>	-	-		<b>0%</b>	<b>23,956</b>	<b>377,680</b>	-	-	-
Fever Cases Tested with RDTs	<b>17,884</b>	<b>111,947</b>	<b>353,724</b>	-	-		<b>-%</b>	<b>23,956</b>	<b>377,680</b>	-	-	-
Free Condom	-	-	-	<b>7,000,000</b>	-		<b>0%</b>	-	-	-	-	-
Generic Condom	-	-	-	<b>7,000,000</b>	-	3/17	<b>-%</b>	-	-	-	-	-
HIV Testing Services	<b>18,594</b>	<b>16,719</b>	<b>68,752</b>	<b>155,000</b>	-		<b>0%</b>	<b>313,415</b>	<b>409,401</b>	<b>554</b>	-	<b>554</b>
VCT Individual (HIV-Negative)	<b>18,058</b>	<b>16,196</b>	<b>66,647</b>	<b>150,000</b>	-	4/10	<b>-%</b>	<b>306,390</b>	<b>399,663</b>	<b>537</b>	-	<b>537</b>
VCT Individual (HIV-Positive)	<b>536</b>	<b>523</b>	<b>2,105</b>	<b>5,000</b>	-	4/10	<b>-%</b>	<b>7,025</b>	<b>9,738</b>	<b>17</b>	-	<b>17</b>
Implant 3	-	-	-	<b>350</b>	-		<b>0%</b>	-	-	-	-	-
Implanon	-	-	-	<b>350</b>	-	3/17	<b>-%</b>	-	-	-	-	-
Injectable 3	-	-	-	<b>57,500</b>	-		<b>0%</b>	-	-	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Saluplan Piki	-	-	-	50,000	-	3/17	-%	-	-	-	-	-
Sayana Press	-	-	-	7,500	-	3/17	-%	-	-	-	-	-
IUD 10	-	8	25	100	50		(50)%	88	1,399	-	44	44
Confiance Plus IUD	-	8	25	100	50	12/13	(50)%	88	1,399	-	44	44
LLIN	-	-	-	375,000	-		0%	-	2,987,900	-	-	-
LLIN Free	-	-	-	375,000	-	1/08	-%	-	2,987,900	-	-	-
Malaria PPT (Non-ACT)	-	-	-	11,000	-		0%	-	316,240	-	-	-
Chloroquine	-	-	-	11,000	-	3/12	-%	-	316,240	-	-	-
OCs	-	-	-	117,500	-		0%	-	-	-	-	-
MEURI	-	-	-	17,500	-	3/17	-%	-	-	-	-	-
Saluplan Gren	-	-	-	100,000	-	3/17	-%	-	-	-	-	-
ORS	150,000	50,000	300,000	330,000	-		0%	300,000	10,047,338	-	10,285	10,285
Salusel	-	-	-	80,000	-	3/17	-%	-	-	-	-	-
Sel Lavi	150,000	50,000	300,000	250,000	-	10/99	-%	300,000	10,047,338	-	10,285	10,285
Positive RDTs	1,246	7,863	24,834	-	-		0%	1,069	25,903	-	-	-
Positive RDTs	1,246	7,863	24,834	-	-		-%	1,069	25,903	-	-	-
STI Screening	17,560	13,625	58,436	-	75,310		(22)%	222,184	280,620	-	-	-
STI Screening	17,560	13,625	58,436	-	75,310		(22)%	222,184	280,620	-	-	-
TB Diagnosis	-	1,135	3,405	-	-		0%	11,406	14,811	-	-	-
TB Diagnosis	-	1,135	3,405	-	-		-%	11,406	14,811	-	-	-
TB DOTS	-	1,037	3,110	10,000	-		0%	9,997	13,107	-	10,645	10,645
TB DOTS	-	1,037	3,110	10,000	-		-%	9,997	13,107	-	10,645	10,645
TB Screening	-	1,188	3,564	-	-		0%	12,026	15,590	-	-	-
TB Screening	-	1,188	3,564	-	-		-%	12,026	15,590	-	-	-
Treatment for Nonherpetic Genital Ulc	520	483	1,968	-	-		0%	1,290	3,258	-	328	328

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Treatment for Nonherpetic Genital U	520	483	1,968	-	-		-%	1,290	3,258	-	328	328
<b>Paraguay</b>										1,094	388	1,482
Condom	-	70,328	210,984	4,061,760	894,139		(76)%	3,064,620	36,620,362	1,094	77	1,171
Pantera	-	40,476	121,428	1,982,400	530,078	8/98	(77)%	1,649,108	33,497,313	630	45	674
Pantera Banana	-	3,284	9,853	240,000	-	9/16	-%	69,557	79,410	51	4	55
Pantera Chocolate	-	3,827	11,480	278,400	73,096	2/14	(84)%	234,083	568,458	60	4	64
Pantera Frutilla	-	-	-	326,400	-		-%	-	-	-	-	-
Pantera Retardant	-	7,327	21,980	598,560	141,914	2/14	(85)%	528,012	1,168,777	114	8	122
Pantera Ribbed	-	3,014	9,043	180,000	51,852	2/14	(83)%	169,989	467,346	47	3	50
Pantera Strawberry	-	5,547	16,641	-	97,199	2/14	(83)%	280,297	684,925	86	6	92
Pantera Tachas	-	3,287	9,860	216,000	-	9/16	-%	61,081	70,941	51	4	55
Pantera Tutti Frutti	-	3,566	10,699	240,000	-	9/16	-%	72,493	83,192	55	4	59
Emergency Contraception	-	7,735	23,206	319,000	99,707		(77)%	308,976	2,236,396	-	32	32
Pronta	-	7,735	23,206	319,000	99,707	2/04	(77)%	308,976	2,236,396	-	32	32
Multivitamin	-	70,850	212,550	2,476,080	644,400		(67)%	1,789,770	33,052,800	-	16	16
VitalDia	-	70,850	212,550	2,476,080	644,400	11/00	(67)%	1,789,770	33,052,800	-	16	16
OCs	-	18,739	56,217	810,000	290,881		(81)%	749,197	7,032,502	-	263	263
Segura	-	18,110	54,331	750,000	269,638	4/01	(80)%	706,380	6,860,769	-	254	254
Segura Plus	-	629	1,886	60,000	21,243	3/11	(91)%	42,817	171,733	-	9	9

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Americas - Central America</b>															
<b>Belize</b>							\$0		\$109	\$0	NA				
<u>Condom</u>															
GIGI (Got it? Get it!) Condom	04/2017	0	0	0	0	NA	\$0	NA	\$109	\$0	NA	0	0	NA	
<u>Free Female Condom</u>															
GIGI (Got it? Get it!) Free Female	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4	0	NA	
<u>Lubricant A</u>															
GIGI (Got it? Get it!) Lube Sachet	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	70	0	NA	
<b>Costa Rica</b>							\$0		\$35,363	\$18,740	1.89				
<u>Condom</u>															
Combo Pack	04/2017	0	0	0	0	NA	\$0	NA	\$42	\$0	NA	0	0	NA	
Combo-Mix Lub Fresa	04/2017	326	0	0	326	0%	\$0	NA	\$181	\$128	1.42	542	310	1.75	
Combo-Pack Lub Fresa	04/2017	1,056	36	0	1,092	3%	\$0	NA	\$85	\$66	1.29	2,644	490	5.40	
Tira Multilinea	04/2017	23,019	0	0	23,019	0%	\$0	NA	\$9,862	\$6,687	1.47	45,525	25,095	1.81	
Vive	04/2017	12,729	816	6,000	19,545	6%	\$0	NA	\$4,366	\$1,478	2.95	131,563	9,986	13.17	
Vive Amor	04/2017	48,816	376	0	49,192	1%	\$0	NA	\$0	\$3,832	NA	148,944	63,216	2.36	
Vive Colors/Mas Colors	04/2017	16,644	432	13,800	30,876	3%	\$0	NA	\$6,903	\$2,434	2.84	114,018	12,229	9.32	
Vive Mas Fuerte /Retardante	04/2017	4,455	48	6,000	10,503	1%	\$0	NA	\$2,218	\$567	3.91	6,654	3,052	2.18	
Vive Mas Natural /Sensitivo	04/2017	9,864	48	8,400	18,312	0%	\$0	NA	\$5,856	\$1,013	5.78	47,880	6,097	7.85	
Vive Mas/Texturizado	04/2017	1,629	48	4,200	5,877	3%	\$0	NA	\$529	\$142	3.74	8,547	1,670	5.12	
<u>Lubricant A</u>															
Vive Lub Natural (sachet)	04/2017	375	75	0	450	17%	\$0	NA	\$75	\$76	0.98	10,182	533	19.09	
Vive Lub Sachet Fresa 5 mL	04/2017	100	75	0	175	43%	\$0	NA	\$109	\$42	2.59	13,804	292	47.33	
<u>Lubricant E</u>															
Vive Lub Natural (tube)	04/2017	454	0	0	454	0%	\$0	NA	\$1,462	\$803	1.82	11,574	426	27.19	
Vive Lub Tubo Fresa 120 mL	04/2017	590	0	0	590	0%	\$0	NA	\$3,676	\$1,472	2.50	10,430	707	14.75	
<b>El Salvador</b>							\$46,780		\$106,104	\$65,596	1.62				
<u>Medicines &amp; Supplies</u>															
Intrauterine Vacuum cleaner for p	04/2017	44	0	0	44	0%	\$2,726	5%	\$558	\$1,322	0.42	177	21	8.30	
Accessories for the vacuum cleane	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	46	0	NA	
<u>Condom</u>															
Combo-Mix Lub Fresa	04/2017	816	0	0	816	0%	\$305	97%	\$353	\$123	2.86	704	331	2.13	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>El Salvador</b>							\$46,780		\$106,104	\$65,596	1.62				
<u>Condom</u>															
Combo-Mix Lub Natural	04/2017	800	0	0	800	0%	\$295	100%	\$442	\$149	2.96	1,280	405	3.16	
Vive	04/2017	32,688	0	0	32,688	0%	\$5,174	92%	\$26,069	\$14,312	1.82	342,816	84,160	4.07	
Vive Amor	04/2017	72,336	1,056	0	73,392	1%	\$9,494	88%	\$25,820	\$18,126	1.42	665,904	137,728	4.83	
Vive Colors/Mas Colors	04/2017	50,640	2,016	0	52,656	4%	\$12,497	93%	\$20,687	\$12,663	1.63	671,736	51,976	12.92	
Vive Mas Fuerte /Retardante	04/2017	13,224	0	0	13,224	0%	\$3,287	86%	\$6,656	\$3,980	1.67	32,760	16,048	2.04	
Vive Mas Natural /Sensitivo	04/2017	1,728	0	0	1,728	0%	\$439	67%	\$830	\$1,170	0.71	191,984	5,008	38.34	
Vive Mas/Texturizado	04/2017	5,184	0	0	5,184	0%	\$1,303	68%	\$1,838	\$1,680	1.09	79,920	6,744	11.85	
<u>Lubricant A</u>															
Vive Lub (sachet)	04/2017	18,750	150	0	18,900	1%	\$2,487	97%	\$3,524	\$1,566	2.25	54,050	11,750	4.60	
Vive Lub Natural (sachet)	04/2017	8,900	150	0	9,050	2%	\$1,217	81%	\$3,135	\$1,568	2.00	46,290	11,717	3.95	
<u>Lubricant E</u>															
Vive Lub (tube)	04/2017	55	25	0	80	31%	\$147	30%	\$2,774	\$1,442	1.92	21	687	0.03	
Vive Lub Natural (tube)	04/2017	993	25	0	1,018	2%	\$2,126	94%	\$3,098	\$1,581	1.96	4,584	742	6.18	
<u>Micronutrient Powder</u>															
VitalDia Kids	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	30	0	NA	
<u>Misoprostol for PAC (Oral)</u>															
Misoprostol for PAC (oral)	04/2017	738	10	0	748	1%	\$294	75%	\$220	\$100	2.20	2,424	285	8.50	
<u>Zika Prevention Kit</u>															
Zika Prevention Kit	04/2017	0	63	0	63	100%	\$0	NA	\$0	\$0	NA	175	21	8.33	
<u>Implant 5</u>															
Jadelle	04/2017	29	2	0	31	6%	\$538	0%	\$0	\$419	NA	1,171	28	42.33	
<u>IUD 10</u>															
Copper T 380	04/2017	187	1	0	188	1%	\$354	0%	\$0	\$494	NA	18,638	284	65.63	
<u>OCs</u>															
Segura Plus	04/2017	4,036	0	0	4,036	0%	\$4,098	99%	\$10,100	\$4,870	2.07	116	4,788	0.02	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<u>HIV Test Kit</u>															
Determine	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,800	733	2.45	
<u>Condom</u>															
Bodyguard	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	88,272	0	NA	
Vive	04/2017	222,576	96	0	222,672	0%	\$0	NA	\$0	\$0	NA	1,668,720	220,528	7.57	
Vive Amor	04/2017	271,056	96	4,800	275,952	0%	\$0	NA	\$0	\$0	NA	3,245,328	440,224	7.37	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Guatemala</b>							\$0		\$0	\$0	NA				
<b>Condom</b>															
Vive Colors/Mas Colors	04/2017	82,224	2,016	0	84,240	2%	\$0	NA	\$0	\$0	NA	916,536	81,280	11.28	
Vive Mas Fuerte /Retardante	04/2017	21,960	48	-220,176	-198,168	0%	\$0	NA	\$0	NA	NA	202,968	NA	NA	
Vive Mas Natural /Sensitivo	04/2017	8,640	0	-36,216	-27,576	0%	\$0	NA	\$0	NA	NA	27,576	NA	NA	
Vive Mas/Texturizado	04/2017	4,920	96	256,392	261,408	2%	\$0	NA	\$0	\$0	NA	51,432	25,008	2.06	
<b>Lubricant A</b>															
Vive Lub (sachet)	04/2017	375	50	0	425	12%	\$0	NA	\$0	\$0	NA	164,224	566	289.98	
Vive Lub Natural (sachet)	04/2017	874	50	0	924	5%	\$0	NA	\$0	\$0	NA	49,449	1,471	33.62	
<b>Lubricant E</b>															
Vive Lub (tube)	04/2017	1,649	5	4	1,658	0%	\$0	NA	\$0	\$0	NA	4,975	1,321	3.77	
Vive Lub Natural (tube)	04/2017	1,342	36	0	1,378	3%	\$0	NA	\$0	\$0	NA	894	1,193	0.75	
<b>Repellant</b>															
Repellant	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	9,325	0	NA	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	04/2017	880	0	0	880	0%	\$0	NA	\$0	NA	NA	11,736	NA	NA	
<b>Implant 5</b>															
Jadelle	04/2017	88	0	0	88	0%	\$0	NA	\$0	\$0	NA	1,729	89	19.43	
<b>Injectable 1</b>															
Cyclofem	04/2017	647	3	0	650	0%	\$0	NA	\$0	\$0	NA	98,228	2,108	46.60	
<b>IUD 10</b>															
Copper T 380	04/2017	863	0	0	863	0%	\$0	NA	\$0	\$0	NA	36,156	835	43.30	
Copper T 380 Postpartum	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,820	16	176.25	
<b>IUD 5</b>															
IUD Sleek	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	1,427	7	214.05	
<b>OCs</b>															
Oralcon-F (28 tablets Blister)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	5	0	NA	
Segura Plus	04/2017	3,754	0	0	3,754	0%	\$0	NA	\$0	\$0	NA	15,576	6,478	2.40	
<b>Honduras</b>							\$69,409		\$18,391	\$69,525	0.26				
<b>Condom</b>															
Combo-Mix Lub Fresa	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	288	0	NA	
Combo-Mix Lub Natural	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	320	0	NA	
Combo-Pack Lub Natural	04/2017	80	0	4,560	4,640	0%	\$43	0%	\$0	\$14	NA	304	27	11.40	
Vive	04/2017	69,888	0	4,896	74,784	0%	\$11,053	4%	\$3,700	\$14,671	0.25	427,104	88,992	4.80	



Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Honduras</b>							\$69,409		\$18,391	\$69,525	0.26				
<b>Condom</b>															
Vive Amor	04/2017	292,320	240	0	292,560	0%	\$43,583	2%	\$3,659	\$30,996	0.12	182,880	207,072	0.88	
Vive Colors/Mas Colors	04/2017	32,856	28,536	0	61,392	46%	\$9,832	28%	\$6,538	\$13,415	0.49	272,208	81,080	3.36	
Vive Mas Fuerte /Retardante	04/2017	9,216	0	0	9,216	0%	\$3,055	20%	\$2,346	\$5,019	0.47	10,296	15,080	0.68	
Vive Mas Natural /Sensitivo	04/2017	1,008	0	0	1,008	0%	\$362	70%	\$1,031	\$1,175	0.88	15,600	3,440	4.53	
Vive Mas/Texturizado	04/2017	1,464	14,256	0	15,720	91%	\$391	51%	\$911	\$1,023	0.89	77,304	8,568	9.02	
<b>Lubricant A</b>															
Vive Lub (sachet)	04/2017	1,500	11,000	2,448	14,948	88%	\$320	0%	\$0	\$107	NA	33,672	13,083	2.57	
Vive Lub Natural (sachet)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	16,902	0	NA	
<b>Lubricant E</b>															
Vive Lub (tube)	04/2017	35	80	0	115	70%	\$99	51%	\$69	\$716	0.10	85	318	0.27	
Vive Lub Natural (tube)	04/2017	265	0	0	265	0%	\$671	1%	\$136	\$2,389	0.06	2,071	981	2.11	
<b>Nicaragua</b>							\$0		\$0	\$25,125	NA				
<b>Condom</b>															
Bodyguard	04/2017	3,600	0	0	3,600	0%	\$0	NA	\$0	\$202	NA	91,016	13,680	6.65	
Combo-Pack Lub Fresa	04/2017	1,392	0	0	1,392	0%	\$0	NA	\$0	\$0	NA	3,120	619	5.04	
Combo-Pack Lub Natural	04/2017	464	0	0	464	0%	\$0	NA	\$0	\$43	NA	6,000	309	19.40	
Vive	04/2017	185,904	0	0	185,904	0%	\$0	NA	\$0	\$18,260	NA	747,507	298,256	2.51	
Vive Colors/Mas Colors	04/2017	101,616	4,128	0	105,744	4%	\$0	NA	\$0	\$1,975	NA	570,036	73,984	7.70	
Vive Mas Fuerte /Retardante	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$1,276	NA	52,128	27,376	1.90	
Vive Mas Natural /Sensitivo	04/2017	0	120	0	120	100%	\$0	NA	\$0	\$153	NA	62,881	10,416	6.04	
Vive Mas/Texturizado	04/2017	4,176	480	0	4,656	10%	\$0	NA	\$0	\$715	NA	57,127	8,640	6.61	
<b>Lubricant A</b>															
Vive Lub (sachet)	04/2017	6,177	0	0	6,177	0%	\$0	NA	\$0	\$361	NA	13,312	6,264	2.13	
Vive Lub Natural (sachet)	04/2017	8,700	0	0	8,700	0%	\$0	NA	\$0	\$632	NA	3,636	7,875	0.46	
<b>Lubricant E</b>															
Vive Lub (tube)	04/2017	1,305	12	0	1,317	1%	\$0	NA	\$0	\$479	NA	1,601	1,772	0.90	
Vive Lub Natural (tube)	04/2017	754	10	0	764	1%	\$0	NA	\$0	\$406	NA	1,499	1,235	1.21	
<b>Implant 3</b>															
Implanon	04/2017	1	0	0	1	0%	\$0	NA	\$0	\$9	NA	0	2	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Nicaragua</b>							\$0		\$0	\$25,125	NA				
<u>Implant 5</u>															
Jadelle	04/2017	129	0	1	130	0%	\$0	NA	\$0	\$449	NA	2,660	100	26.69	
<u>IUD 10</u>															
Copper T 380	04/2017	99	0	0	99	0%	\$0	NA	\$0	\$113	NA	3,071	283	10.84	
Copper-T 380-A IUD	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,948	0	NA	
<u>IUD 5</u>															
Copper T375 Sleek	04/2017	3	0	0	3	0%	\$0	NA	\$0	\$2	NA	4,907	9	545.22	
<u>OCs</u>															
Segura Plus	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	20	0	60.00	
<b>Panama</b>							\$0		\$0	\$52,910	NA				
<u>HIV Test Kit</u>															
Uni Gold Kit	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	153	87	1.77	
<u>Condom</u>															
Bodyguard	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	44,640	0	NA	
Vive	04/2017	294,240	0	48	294,288	0%	\$0	NA	\$0	\$30,919	NA	728,832	260,560	2.80	
Vive Colors/Mas Colors	04/2017	16,800	288	0	17,088	2%	\$0	NA	\$0	\$6,571	NA	516,552	29,851	17.30	
Vive Mas Fuerte /Retardante	04/2017	15,600	0	0	15,600	0%	\$0	NA	\$0	\$6,272	NA	96,048	22,000	4.37	
Vive Mas Natural /Sensitivo	04/2017	6,000	0	0	6,000	0%	\$0	NA	\$0	\$2,389	NA	59,433	10,616	5.60	
Vive Mas/Texturizado	04/2017	3,600	144	0	3,744	4%	\$0	NA	\$0	\$1,643	NA	109,992	5,679	19.37	
<u>Lubricant A</u>															
Vive Lub (sachet)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$597	NA	20,450	1,667	12.27	
Vive Lub Natural (sachet)	04/2017	50	0	0	50	0%	\$0	NA	\$0	\$72	NA	33,750	200	168.75	
<u>Lubricant E</u>															
Vive Lub (tube)	04/2017	1,250	0	0	1,250	0%	\$0	NA	\$0	\$1,467	NA	19,432	1,083	17.94	
Vive Lub Natural (tube)	04/2017	1,900	0	0	1,900	0%	\$0	NA	\$0	\$2,981	NA	13,978	1,963	7.12	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Americas - Other</b>														
<b>Haiti</b>							\$22,703		\$0	\$15,264	NA			
<b><u>Malaria PPT (Non-ACT) P</u></b>														
Primaquine Tablet	04/2017	0	0	20,917	20,917	NA	\$0	NA	\$0	NA	NA	28,817	NA	NA
<b><u>Malaria PPT (Non-ACT)</u></b>														
Chloroquine	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	670	NA	NA
<b><u>ORS</u></b>														
Sel Lavi	04/2017	150,000	0	0	150,000	0%	\$22,703	0%	\$0	\$15,229	NA	0	100,000	NA
<b><u>IUD 10</u></b>														
Confiance Plus IUD	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$35	NA	1,325	8	159.00
Copper-T 380-A IUD	04/2017	0	0	0	0	NA	\$0	NA	\$0	NA	NA	993	NA	NA
<b>Paraguay</b>							\$0		\$372,938	\$0	NA			
<b><u>Condom</u></b>														
Pantera	04/2017	0	0	0	0	NA	\$0	NA	\$25,063	\$0	NA	1,719,804	0	NA
Pantera Banana	04/2017	0	0	0	0	NA	\$0	NA	\$1,996	\$0	NA	208,560	0	NA
Pantera Chocolate	04/2017	0	0	0	0	NA	\$0	NA	\$3,889	\$0	NA	295,582	0	NA
Pantera Retardant	04/2017	0	0	0	0	NA	\$0	NA	\$8,390	\$0	NA	271,005	0	NA
Pantera Ribbed	04/2017	0	0	0	0	NA	\$0	NA	\$2,233	\$0	NA	108,681	0	NA
Pantera Strawberry	04/2017	0	0	0	0	NA	\$0	NA	\$3,770	\$0	NA	323,038	0	NA
Pantera Tachas	04/2017	0	0	0	0	NA	\$0	NA	\$1,734	\$0	NA	217,062	0	NA
Pantera Tutti Frutti	04/2017	0	0	0	0	NA	\$0	NA	\$2,496	\$0	NA	204,762	0	NA
<b><u>Multivitamin</u></b>														
VitalDia	04/2017	0	0	0	0	NA	\$0	NA	\$41,159	\$0	NA	255,660	0	NA
<b><u>Emergency Contraception</u></b>														
Pronta	04/2017	0	0	0	0	NA	\$0	NA	\$144,899	\$0	NA	128,620	0	NA
<b><u>OCs</u></b>														
Segura	04/2017	0	0	0	0	NA	\$0	NA	\$133,289	\$0	NA	604,743	0	NA
Segura Plus	04/2017	0	0	0	0	NA	\$0	NA	\$4,020	\$0	NA	73,992	0	NA
<b>SFH Dominican Republic</b>							\$10,161		\$0	\$19,861	NA			
<b><u>Condom</u></b>														
Pante	04/2017	209,280	115,020	0	324,300	35%	\$10,161	0%	\$0	\$19,861	NA	27,558,182	1,081,629	25.48
<b><u>Free Condom</u></b>														
No Logo	04/2017	0	42,000	0	42,000	100%	\$0	NA	\$0	\$0	NA	6,026,528	157,000	38.39

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>SFH Dominican Republic</b>							\$10,161		\$0	\$19,861	NA				
<u>Lubricant A</u>															
No Logo Lubricant (4.5 gram sach	04/2017	0	9,000	0	9,000	100%	\$0	NA	\$0	\$0	NA	1,354,193	14,000	96.73	



# Asia & Eastern Europe

**POPULATION SERVICES INTERNATIONAL**  
**CYPs, Cases, and Deaths by Country**  
**1/2017 - 4/2017**

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Asia and Eastern Eur	2,825	-	1	1,352	2,379,853	558	653,352	179	83	-	-	2,003
Cambodia	546	-	-	-	211,870	34	52,015	11	3	-	-	133
India	-	-	-	426	228,695	62	97,447	-	41	-	-	465
India LLC	1,357	-	-	-	507,651	104	110,889	-	22	-	-	234
Kazakhstan	4	-	-	-	83	-	11	-	-	-	-	-
Kyrgyzstan	7	-	-	-	-	-	-	-	-	-	-	-
Laos	7	-	-	2	28,361	5	9,540	-	-	-	-	8
Myanmar	708	-	-	515	206,003	35	45,352	168	9	-	-	691
Nepal	30	-	-	-	45,666	16	14,394	-	-	-	-	43
Pakistan	151	-	-	410	1,150,034	302	323,474	-	-	-	-	419
Papua New Guinea	7	-	-	-	882	-	122	-	7	-	-	7
Tajikistan	9	-	1	-	484	-	69	-	-	-	-	1
Viet Nam	-	-	-	-	123	-	38	-	-	-	-	-
<b>Total</b>	<b>70,551</b>	<b>17</b>	<b>1</b>	<b>1,542</b>	<b>6,693,305</b>	<b>3,911</b>	<b>1,686,113</b>	<b>33,036</b>	<b>1,487</b>	<b>1,362</b>	<b>-</b>	<b>38,742</b>

\* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>									<b>136,001</b>	<b>591,330</b>	<b>727,331</b>
Antiretroviral Treatment (C	3,274	2,791	11,646	-	-	-%	1,661	13,307	2,034	-	2,034
Antiretroviral Treatment (I	214	227	895	-	-	-%	1,042	1,937	-	-	-
Cervical Cancer-Pap Sme:	-	101	304	-	-	-%	4,743	5,047	-	-	-
Cervical Cancer-VIA and C	1	140	420	-	21	1,900%	2,718	4,013	-	115	115
Cervical Cancer-VIA and F	-	26	79	-	-	-%	48	127	-	11	11
Cervical Cancer-VIA and F	-	140	419	-	-	-%	446	865	-	57	57
Cervical Cancer-VIA/VILI	2	1,854	5,563	-	528	954%	98,040	107,288	-	-	-
Clean Delivery Kit	-	-	-	-	300	(100)%	400	260,026	-	-	-
Condom	12,465,898	16,863,892	63,057,574	-	68,061,397	(7)%	232,147,502	6,223,732,395	113,740	55,374	169,114
Condom Provided	-	-	-	-	2,932	(100)%	63,111	85,090	-	-	-
Diarrhea Treatment Kit	3,217	9,665	32,213	-	169,756	(81)%	443,466	5,892,950	-	1,188	1,188
Emergency Contraception	55,657	198,323	650,627	-	857,091	(24)%	2,360,728	5,839,329	-	2,643	2,643
Emergency Contraception	746	881	3,390	-	3,639	(7)%	9,101	24,006	-	16	16
Fecal Sludge Managemen	44	63	232	-	-	-%	921	1,153	-	-	-
Fecal Sludge Managemen	172,000	294,667	1,056,000	-	-	-%	3,021,000	4,077,000	-	58	58
Female Condom	19,226	6,006	37,243	-	33,571	11%	108,934	1,632,213	144	23	167
Fever Cases Attended	56,836	57,438	229,151	-	-	-%	657,831	886,982	-	-	-
Fever Cases Tested with F	56,836	57,438	229,151	-	-	-%	657,831	886,982	-	-	-
Free Condom	22,630	190,533	594,230	-	41,688	1,325%	681,034	1,275,264	1,410	404	1,814
Free Female Condom	-	1,333	4,000	-	-	-%	20,000	24,000	4	1	5
HIV Testing Services	8,647	7,252	30,403	-	22,160	37%	70,109	320,417	40	-	40

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Hypertension Diagnosis	150	-	150	-	-	-%	-	150	-	-	-
Hypertension Screening	170	-	170	-	-	-%	-	170	-	-	-
Hypertension_Controlled	129	-	129	-	-	-%	-	129	-	-	-
Implant 3	71	2,047	6,211	-	199	3,021%	2,657	8,868	-	1,882	1,882
Implant 3 Insertion	820	856	3,388	-	403	741%	4,155	7,819	-	1,599	1,599
Implant 5	218	406	1,436	-	1,203	19%	21,275	43,165	-	1,131	1,131
Implant 5 Insertion	175	339	1,191	-	1,058	13%	3,146	29,236	-	831	831
Injectable 1	8,048	7,049	29,195	-	23,937	22%	85,224	1,547,852	-	504	504
Injectable 1 Provided	3,152	3,684	14,205	-	10,863	31%	30,476	69,361	-	272	272
Injectable 2	(2,048)	43,971	129,866	-	94,053	38%	299,852	6,803,119	-	4,480	4,480
Injectable 2 Provided	2,048	2,269	8,854	-	7,867	13%	22,868	54,985	-	339	339
Injectable 3	141,877	124,861	516,460	-	474,645	9%	1,598,682	16,770,713	-	19,491	19,491
Injectable 3 Provided	33,251	30,157	123,723	-	8,150	1,418%	39,569	181,630	-	6,984	6,984
IUD 10	16,796	15,045	61,930	-	56,534	10%	161,290	308,856	-	77,783	77,783
IUD 10 Insertion	15,212	14,046	57,351	-	8,099	608%	47,793	352,097	-	72,858	72,858
IUD 5	25,116	20,308	86,041	-	6,331	1,259%	34,252	4,192,441	-	71,301	71,301
IUD 5 Insertion	18,859	16,793	69,237	-	74,065	(7)%	202,186	897,295	-	71,273	71,273
LLIN	-	-	-	-	-	-%	22,280	22,280	-	-	-
Lubricant	51,106	79,835	290,611	-	270,057	8%	712,089	8,899,581	-	-	-
Malaria PPT (ACT)	26,359	30,578	118,094	-	127,129	(7)%	466,511	3,274,129	-	16,285	16,285
Malaria PPT (Non-ACT)	132	128	515	-	2,587	(80)%	3,078	105,480	-	72	72
Malaria RDK	104,600	86,847	365,140	-	321,397	14%	1,231,291	4,532,184	-	-	-



POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Manual Vacuum Aspiratio	2,444	2,663	10,432	-	-	-%	31,135	41,567	-	535	535
Medical Abortion	55,351	59,558	234,026	-	160,548	46%	390,924	3,021,487	-	21,032	21,032
Medical Abortion Provider	403	659	2,381	-	-	-%	-	2,381	-	203	203
Micronutrient Powder	64,070	146,763	504,360	-	-	-%	97,980	602,340	-	-	-
Misoprostol for PAC (Oral	-	6,667	20,000	-	2,500	700%	124,500	289,900	-	347	347
Naloxone	60	-	60	-	-	-%	-	10,692	82	-	82
Needle & Syringe	486,000	602,970	2,294,911	-	1,240,200	85%	4,903,605	17,044,328	17,706	-	17,706
OCs	1,092,965	1,186,989	4,653,932	-	2,045,895	127%	9,152,550	122,312,587	-	40,244	40,244
OCs Provided	78,360	57,895	252,045	-	22,291	1,031%	91,978	398,303	-	3,867	3,867
ORS	(55,275)	49,767	94,025	-	347,850	(73)%	568,984	25,779,160	-	1,762	1,762
Pneumonia PPT	-	-	-	-	56,197	(100)%	127,866	1,057,411	-	-	-
Positive RDTs	442	813	2,882	-	-	-%	13,201	16,083	-	-	-
Positive RDTs Given First	428	574	2,149	-	-	-%	10,870	13,019	-	-	-
PUR	4,687	23,159	74,165	-	319,959	(77)%	2,080,716	15,687,727	-	2	2
QAACTs Provided after C	191	492	1,668	-	-	-%	7,361	9,029	-	274	274
Referral to HIV Testing Se	774	1,413	5,012	-	-	-%	10,424	34,747	7	-	7
Referral to Implant 3 Inser	-	-	-	-	-	-%	636	636	-	-	-
Referral to Implant 5 Inser	16	19	72	-	44	64%	114	659	-	25	25
Referral to Injectable 3	17	12	54	-	97	(44)%	1,248	2,132	-	1	1
Referral to IUD 10 Insertio	46	62	231	-	423	(45)%	2,010	10,446	-	99	99
Referral to Linkage to HIV	172	247	912	-	-	-%	834	1,746	833	-	833
Referral to Manual Vacuur	-	-	-	-	-	-%	46	46	-	-	-

POPULATION SERVICES INTERNATIONAL  
 Monthly Distribution by Region and Product  
 Period: 4  
 Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE SALES	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Medication Abi	-	-	-	-	-	-%	24	24	-	-	-
Referral to OCs	8	12	45	-	40	13%	1,280	1,678	-	-	-
Referral to Opioid Treatme	13	17	63	-	-	-%	136	199	-	-	-
Referral to PAC Service (u	-	-	-	-	-	-%	488	488	-	-	-
Referral to TB Diagnosis	413	317	1,364	-	-	-%	1,435	13,513	-	-	-
Referral to TB DOTS (com	196	78	430	-	-	-%	771	1,201	-	721	721
Referral to TB DOTS (com	327	244	1,060	-	-	-%	1,268	2,328	-	1,600	1,600
Referral to TB Screening	12,259	5,641	29,181	-	-	-%	35,261	64,442	-	-	-
Safe Water Solution	-	-	-	-	5,000	(100)%	6,973	655,267	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	23,108	(100)%	43,388	548,483	-	-	-
STI Kit (Ulcerative)	-	-	-	-	1,336	(100)%	3,679	60,473	-	-	-
STI Screening	2,558	2,913	11,297	-	-	-%	221	12,101	-	-	-
TB Diagnosis	6,448	4,817	20,899	-	9,259	126%	40,546	85,047	-	-	-
TB DOTS	3,350	2,297	10,242	-	7,558	36%	23,790	272,174	-	51,730	51,730
TB Screening	21,463	18,345	76,499	-	17,696	332%	109,755	250,982	-	-	-
Toilets Constructed	-	4,267	12,802	-	-	-%	-	12,802	-	1,719	1,719
Toilets Sold	40,294	15,264	86,087	-	-	-%	73,282	159,369	-	-	-
Tubal Ligation	2,406	4,296	15,293	-	649	2,256%	18,281	248,373	-	55,423	55,423
Vasectomy	176	304	1,089	-	-	-%	1,870	2,959	-	4,084	4,084
Vivax Treatment after Con	129	162	615	-	-	-%	3,796	4,411	-	101	101
Water Treatment Tablets	2,700	933	5,500	-	242,500	(98)%	268,130	3,631,123	-	-	-
Zinc	-	28,300	84,900	-	2,500	3,296%	50,500	328,442	-	585	585

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Asia and Eastern Europe - Asia</b>										<b>136,001</b>	<b>591,330</b>	<b>727,331</b>
<b>Cambodia</b>										<b>21,773</b>	<b>36,026</b>	<b>57,799</b>
Condom	751,878	890,120	3,422,238	-	3,638,120		(6)%	10,681,429	367,246,264	21,773	2,218	23,991
PSI Condom Distributed Provided	-	-	-	-	(346)		-%	(2,117)	(3,043)	-	-	-
Number One	267,048	310,560	1,198,728	-	1,209,456	12/94	(1)%	3,632,976	261,552,085	7,626	777	8,403
OK Condom	484,830	579,560	2,223,510	-	2,429,010	2/04	(8)%	7,050,570	105,697,222	14,146	1,441	15,588
Condom Provided	-	-	-	-	346		(100)%	2,117	3,043	-	-	-
PSI Condom Provided	-	-	-	-	346		(100)%	2,117	3,043	-	-	-
Diarrhea Treatment Kit	2,590	3,930	14,380	-	50,960		(72)%	115,160	830,140	-	283	283
Orasel Kit	2,590	3,930	14,380	-	50,960	3/09	(72)%	115,160	830,140	-	283	283
Emergency Contraception	3,880	4,315	16,826	-	18,029		(7)%	51,970	179,694	-	41	41
PSI Emergency Contraception Distr	-	(1)	(4)	-	(1)		-%	(10)	(26)	-	-	-
NEXT 72 EC	3,880	4,317	16,830	-	18,030	8/13	(7)%	51,980	179,720	-	41	41
Emergency Contraception Provided	-	1	4	-	1		300%	10	26	-	-	-
PSI Emergency Contraception Prov	-	1	4	-	1		300%	10	26	-	-	-
Implant 5	220	231	914	-	1,129		(19)%	2,801	11,101	-	573	573
PSI Implant 5 Distributed Inserted (	(167)	(323)	(1,136)	-	(1,057)		-%	(3,061)	(26,546)	-	(712)	(712)
Implant 5	387	554	2,050	-	2,186	5/09	(6)%	5,862	37,647	-	1,285	1,285
Implant 5 Insertion	167	323	1,136	-	1,058		7%	3,064	26,573	-	791	791
PSI Implant 5 Inserted	167	323	1,136	-	1,057		7%	3,061	26,546	-	791	791
Non-PSI Implant 5 Inserted	-	-	-	-	1		(100)%	3	27	-	-	-
Injectable 3	25,672	21,019	88,728	-	143,760		(38)%	349,694	4,979,180	-	2,710	2,710
PSI Injectable 3 Distributed Provide	(178)	(431)	(1,472)	-	(1,255)		-%	(3,446)	(8,204)	-	(45)	(45)
OK Injection-3	25,850	21,450	90,200	-	145,015	2/02	(38)%	353,140	4,987,384	-	2,755	2,755
Injectable 3 Provided	178	431	1,472	-	1,257		17%	3,448	8,206	-	50	50

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 3 Provided	178	431	1,472	-	1,255		17%	3,446	8,204	-	50	50
Non-PSI Injectable 3 Provided	-	-	-	-	2		(100)%	2	2	-	-	-
IUD 10	941	1,125	4,315	-	4,475		(4)%	12,935	64,326	-	3,335	3,335
PSI IUD 10 Distributed Inserted (1)	(1,214)	(1,829)	(6,700)	-	(5,075)		-%	(15,805)	(109,654)	-	(5,178)	(5,178)
IUD Copper T	2,155	2,953	11,015	-	9,550	1/10	15%	28,740	173,980	-	8,513	8,513
IUD 10 Insertion	1,214	1,829	6,700	-	5,075		32%	15,819	110,018	-	5,753	5,753
PSI IUD 10 Inserted	1,214	1,829	6,700	-	5,075		32%	15,805	109,654	-	5,753	5,753
Non-PSI IUD 10 Inserted	-	-	-	-	-		-%	14	364	-	-	-
Lubricant	50,400	79,220	288,060	-	249,480		15%	676,860	8,127,440	-	-	-
OK Plus Lubricant	50,400	79,220	288,060	-	249,480	6/09	15%	676,860	8,127,440	-	-	-
Malaria PPT (ACT)	2,590	2,179	9,126	-	22,452		(59)%	70,406	408,365	-	1,046	1,046
ASMQ for Adult	1,390	739	3,606	-	-	5/16	-%	17,673	21,279	-	413	413
ASMQ for Children	-	67	201	-	-	10/16	-%	357	558	-	23	23
DHA-PIP For Adolescent	15	134	416	-	1,961	8/12	(79)%	6,049	40,697	-	48	48
DHA-PIP For Adult	1,175	1,108	4,499	-	18,794	8/12	(76)%	41,229	310,915	-	516	516
DHA-PIP For Children	10	131	404	-	1,697	8/12	(76)%	5,098	34,916	-	46	46
Malaria RDK	15,525	25,392	91,700	-	131,225		(30)%	401,875	1,390,475	-	-	-
Malaria RDT (Diagnosis)	15,525	25,392	91,700	-	131,225	6/15	(30)%	401,875	1,390,475	-	-	-
Medical Abortion	17,027	22,013	83,067	-	93,656		(11)%	250,187	1,210,697	-	6,389	6,389
PSI Medical Abortion Distributed Pr	(403)	(659)	(2,381)	-	-		-%	-	(2,381)	-	(183)	(183)
Medabon	17,430	22,673	85,448	-	93,656	11/09	(9)%	250,187	1,213,078	-	6,572	6,572
Medical Abortion Provided	403	659	2,381	-	-		0%	-	2,381	-	203	203
PSI Medical Abortion Provided	403	659	2,381	-	-		-%	-	2,381	-	203	203
OCs	392,717	372,788	1,511,082	-	1,371,307		10%	4,871,331	50,959,048	-	12,495	12,495
PSI OCs Distributed Provided	(276)	(339)	(1,292)	-	(966)		-%	(2,648)	(5,897)	-	(11)	(11)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Marvelon	66,725	30,615	158,570	-	181,705	12/12	(13)%	419,255	968,905	-	1,311	1,311
OK Pills	326,268	342,512	1,353,804	-	1,190,568	9/97	14%	4,454,724	49,996,040	-	11,195	11,195
OCs Provided	276	339	1,292	-	967		34%	2,649	5,898	-	12	12
PSI OCs Provided	276	339	1,292	-	966		34%	2,648	5,897	-	12	12
Non-PSI OCs Provided	-	-	-	-	1		(100)%	1	1	-	-	-
Referral to Implant 5 Insertion	16	19	72	-	44		64%	114	659	-	25	25
Referral to Implant 5 Insertion	16	19	72	-	44		64%	114	659	-	25	25
Referral to Injectable 3	17	12	54	-	97		(44)%	250	1,134	-	1	1
Referral to Injectable 3	17	12	54	-	97		(44)%	250	1,134	-	1	1
Referral to IUD 10 Insertion	46	62	231	-	423		(45)%	825	8,516	-	99	99
Referral to IUD 10 Insertion	46	62	231	-	423	12/11	(45)%	825	8,516	-	99	99
Referral to OCs	8	12	45	-	40		13%	105	503	-	-	-
Referral to OCs	8	12	45	-	40		13%	105	503	-	-	-
<b>India</b>										(2)	70,653	70,651
Cervical Cancer-Pap Smear Screening	-	101	304	-	-		0%	4,743	5,047	-	-	-
Cervical Cancer-Pap Smear Screeni	-	101	304	-	-		-%	4,743	5,047	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	140	419	-	-		0%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Cryotherap	-	140	419	-	-		-%	2,696	3,115	-	114	114
Cervical Cancer-VIA and Refer to any	-	26	79	-	-		0%	48	127	-	11	11
Cervical Cancer-VIA and Refer to ar	-	26	79	-	-		-%	48	127	-	11	11
Cervical Cancer-VIA and Refer to Cryc	-	140	419	-	-		0%	446	865	-	57	57
Cervical Cancer-VIA and Refer to Ci	-	140	419	-	-		-%	446	865	-	57	57
Cervical Cancer-VIA/VILI Screening	-	1,835	5,504	-	-		0%	97,406	102,910	-	-	-
Cervical Cancer-VIA/VILI Screening	-	1,835	5,504	-	-		-%	97,406	102,910	-	-	-
Clean Delivery Kit	-	-	-	-	300		(100)%	400	260,026	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
NewBorn	-	-	-	-	300	7/02	(100)%	400	260,026	-	-	-
Condom	-	(300)	(900)	-	16,355,520		(100)%	17,665,520	2,907,664,828	(2)	(1)	(2)
Masti	-	(300)	(900)	-	16,355,520	9/88	(100)%	17,655,020	1,966,656,606	(2)	(1)	(2)
Nirodh	-	-	-	-	-	5/88	-%	10,500	941,008,222	-	-	-
Condom Provided	-	-	-	-	-		0%	50,644	50,644	-	-	-
Non-PSI Condom Provided	-	-	-	-	-		-%	50,644	50,644	-	-	-
Diarrhea Treatment Kit	-	-	-	-	-		0%	(4,574)	546,681	-	-	-
Neotral Zinc Kit	-	-	-	-	-	7/13	-%	(3,611)	267,989	-	-	-
ORS + Zinc (Generic)	-	-	-	-	-	9/12	-%	(963)	278,692	-	-	-
Fecal Sludge Management (Household)	44	63	232	-	-		0%	921	1,153	-	-	-
Fecal Sludge Management (Household)	44	63	232	-	-		-%	921	1,153	-	-	-
Fecal Sludge Management (Liters)	172,000	294,667	1,056,000	-	-		0%	3,021,000	4,077,000	-	58	58
Fecal Sludge Management (Liters)	172,000	294,667	1,056,000	-	-		-%	3,021,000	4,077,000	-	58	58
Injectable 3	-	(138)	(414)	-	14,580		(103)%	37,194	266,201	-	(16)	(16)
Freedom Inject (3-month)	-	(138)	(414)	-	14,580	7/13	(103)%	37,478	152,577	-	(16)	(16)
Procosteron 150	-	-	-	-	-	6/10	-%	(284)	113,624	-	-	-
Injectable 3 Provided	1,283	1,474	5,706	-	-		0%	16,188	21,894	-	239	239
Non-PSI Injectable 3 Provided	1,283	1,474	5,706	-	-		-%	16,188	21,894	-	239	239
Iron Folic Acid Tablet	-	-	-	-	-		0%	(5,412)	48,228,558	-	-	-
Vitalet-Preg	-	-	-	-	-	8/02	-%	(5,412)	48,228,558	-	-	-
IUD 10	-	-	-	-	-		0%	4,370	4,370	-	-	-
Freedom 10	-	-	-	-	-	7/16	-%	4,370	4,370	-	-	-
IUD 10 Insertion	107	97	397	-	-		0%	1,608	2,005	-	421	421
Non-PSI IUD 10 Inserted	107	97	397	-	-		-%	1,608	2,005	-	421	421
IUD 5	-	(377)	(1,131)	-	21,460		(105)%	20,146	998,525	-	(805)	(805)

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Freedom 5	-	(377)	(1,131)	-	21,460	7/08	(105)%	20,146	998,525	-	(805)	(805)
IUD 5 Insertion	3,200	3,176	12,729	-	-		0%	26,529	39,258	-	10,071	10,071
Non-PSI IUD 5 Inserted	3,200	3,176	12,729	-	-		-%	26,529	39,258	-	10,071	10,071
Medical Abortion	-	(419)	(1,258)	-	49,352		(103)%	72,708	1,482,093	-	(117)	(117)
Safe Abort kit	-	(419)	(1,258)	-	49,352	11/09	(103)%	72,708	1,482,093	-	(117)	(117)
OCs	-	(3,750)	(11,250)	-	1,286		(975)%	(642,408)	115,515,319	-	(115)	(115)
Mala-D	-	-	-	-	900	5/97	(100)%	(33,833)	67,283,904	-	-	-
Pearl 3	-	(3,750)	(11,250)	-	386	1/02	(3,015)%	(608,575)	48,231,415	-	(115)	(115)
OCs Provided	2,976	2,702	11,082	-	-		0%	28,714	39,796	-	126	126
Non-PSI OCs Provided	2,976	2,702	11,082	-	-		-%	28,714	39,796	-	126	126
ORS	(152,025)	46,467	(12,625)	-	347,850		(104)%	306,053	25,409,579	-	(237)	(237)
Neutral Orange 1000ml	(152,025)	46,467	(12,625)	-	347,850	7/98	(104)%	306,053	25,409,579	-	(237)	(237)
Referral to TB Diagnosis	389	277	1,221	-	-		0%	1,393	2,614	-	-	-
Referral to TB Diagnosis	389	277	1,221	-	-		-%	1,393	2,614	-	-	-
Referral to TB DOTS (completion confi	196	78	430	-	-		0%	437	867	-	721	721
Referral to TB DOTS (completion co	196	78	430	-	-		-%	437	867	-	721	721
Referral to TB DOTS (completion unkr	327	244	1,060	-	-		0%	1,268	2,328	-	1,600	1,600
Referral to TB DOTS (completion un	327	244	1,060	-	-		-%	1,268	2,328	-	1,600	1,600
Referral to TB Screening	12,259	5,641	29,181	-	-		0%	35,095	64,276	-	-	-
Referrals to TB Screening	12,259	5,641	29,181	-	-		-%	35,095	64,276	-	-	-
TB Diagnosis	3,105	1,899	8,801	-	-		0%	6,769	15,570	-	-	-
TB Diagnosis	3,105	1,899	8,801	-	-		-%	6,769	15,570	-	-	-
TB DOTS	496	180	1,035	-	-		0%	880	1,915	-	3,471	3,471
TB DOTS	496	180	1,035	-	-		-%	880	1,915	-	3,471	3,471
TB Screening	12,377	7,292	34,253	-	-		0%	44,185	78,438	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
TB Screening	12,377	7,292	34,253	-	-		-%	44,185	78,438	-	-	-
Toilets Constructed	-	4,267	12,802	-	-		0%	-	12,802	-	1,719	1,719
Toilet Type 1	-	1,022	3,067	-	-	10/16	-%	-	3,067	-	671	671
Toilet Type 2	-	2,436	7,308	-	-	10/16	-%	-	7,308	-	899	899
Toilet Type 3	-	809	2,427	-	-	10/16	-%	-	2,427	-	149	149
Toilets Sold	40,177	15,179	85,714	-	-		0%	73,282	158,996	-	-	-
Toilet Type 1, Direct Sales	12,299	4,248	25,042	-	-		-%	17,812	42,854	-	-	-
Toilet Type 2, Direct Sales	20,994	8,522	46,559	-	-		-%	30,789	77,348	-	-	-
Toilet Type 3, Direct Sales	1,434	954	4,295	-	-		-%	7,307	11,602	-	-	-
Toilet Type 3, Microfinance	5,450	1,456	9,818	-	-		-%	17,374	27,192	-	-	-
Tubal Ligation	2,060	3,753	13,318	-	-		0%	16,209	29,527	-	49,250	49,250
Tubal Ligation	2,060	3,753	13,318	-	-		-%	16,209	29,527	-	49,250	49,250
Vasectomy	176	304	1,089	-	-		0%	1,870	2,959	-	4,084	4,084
Vasectomy	176	304	1,089	-	-		-%	1,870	2,959	-	4,084	4,084
Zinc	-	-	-	-	-		0%	(3,758)	478,970	-	-	-
BIBZinC	-	-	-	-	-	11/09	-%	(1,000)	420,928	-	-	-
NeoZinc (50ml zinc acetate syrup)	-	-	-	-	-	7/13	-%	(2,758)	58,042	-	-	-
<b>India LLC</b>										56,229	88,351	144,580
Condom	6,969,600	7,350,308	29,020,525	-	-		0%	48,873,945	77,894,470	56,229	23,237	79,466
Masti Classic 3's	2,617,200	3,786,175	13,975,725	-	-	12/16	-%	29,023,320	42,999,045	27,079	11,190	38,269
Masti Classic 6's	2,538,000	2,145,600	8,974,800	-	-	12/16	-%	17,442,120	26,416,920	17,389	7,186	24,575
Masti Premium 3's	1,814,400	1,418,533	6,070,000	-	-	12/16	-%	2,408,505	8,478,505	11,761	4,860	16,621
Injectable 3	4,180	-	4,180	-	-		0%	-	4,180	-	158	158
Freedom Inject (3-month)	4,180	-	4,180	-	-	12/16	-%	-	4,180	-	158	158
IUD 5	15,025	11,353	49,085	-	-		0%	-	49,085	-	34,953	34,953

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Freedom 5	15,025	11,353	49,085	-	-	12/16	-%	-	49,085	-	34,953	34,953
Medical Abortion	30,610	33,813	132,050	-	-		0%	-	132,050	-	12,256	12,256
Safe Abort kit	30,610	33,813	132,050	-	-	12/16	-%	-	132,050	-	12,256	12,256
OCs	286,000	418,607	1,541,820	-	-		0%	431,100	1,972,920	-	15,750	15,750
Pearl	286,000	418,607	1,541,820	-	-	12/16	-%	431,100	1,972,920	-	15,750	15,750
ORS	96,750	3,300	106,650	-	-		0%	-	106,650	-	1,998	1,998
Neotral Orange 1000ml	96,750	3,300	106,650	-	-	12/16	-%	-	106,650	-	1,998	1,998
<b>Kazakhstan</b>										212	3	215
Free Condom	-	2,000	6,000	-	-		0%	619,800	625,800	5	2	7
Generic Male Condom	-	2,000	6,000	-	-	8/16	-%	619,800	625,800	5	2	7
Free Female Condom	-	1,333	4,000	-	-		0%	20,000	24,000	4	1	5
Generic Female Condom	-	1,333	4,000	-	-	8/16	-%	20,000	24,000	4	1	5
HIV Testing Services	93	-	93	-	-		0%	367	1,171	-	-	-
VCT Individual (HIV-Negative)	90	-	90	-	-		-%	367	1,168	-	-	-
VCT Individual (HIV-Positive)	3	-	3	-	-		-%	-	3	-	-	-
Referral to HIV Testing Services	129	229	817	-	-		0%	1,273	5,072	1	-	1
Referral to HIV Testing & Counseling	129	229	817	-	-	12/13	-%	1,273	5,072	1	-	1
Referral to Linkage to HIV Care	27	66	224	-	-		0%	281	505	203	-	203
Referral to Linkage to HIV Care	27	66	224	-	-		-%	281	505	203	-	203
Referral to Opioid Treatment	2	3	10	-	-		0%	-	10	-	-	-
Referral to Opioid Treatment	2	3	10	-	-		-%	-	10	-	-	-
Referral to TB Diagnosis	12	13	50	-	-		0%	-	1,312	-	-	-
Referral to TB Diagnosis	12	13	50	-	-	12/14	-%	-	1,312	-	-	-
TB Screening	137	144	570	-	-		0%	447	1,535	-	-	-
TB Screening	137	144	570	-	-		-%	447	1,535	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Kyrgyzstan</b>										<b>349</b>	<b>-</b>	<b>349</b>
HIV Testing Services	809	656	2,777	-	-		0%	1,502	5,174	5	-	5
VCT Individual (HIV-Negative)	796	640	2,716	-	-		-%	1,502	5,113	5	-	5
VCT Individual (HIV-Positive)	13	16	61	-	-		-%	-	61	-	-	-
Referral to HIV Testing Services	2	1	5	-	-		0%	7,517	14,516	-	-	-
Referral to HIV Testing & Counseling	2	1	5	-	-	12/13	-%	7,517	14,516	-	-	-
Referral to Linkage to HIV Care	68	87	328	-	-		0%	473	801	344	-	344
Referral to Linkage to HIV Care	68	87	328	-	-		-%	473	801	344	-	344
Referral to Opioid Treatment	3	-	3	-	-		0%	131	134	-	-	-
Referral to Opioid Treatment	3	-	3	-	-		-%	131	134	-	-	-
Referral to TB Diagnosis	6	18	59	-	-		0%	-	4,359	-	-	-
Referral to TB Diagnosis	6	18	59	-	-	12/14	-%	-	4,359	-	-	-
TB Screening	112	113	451	-	-		0%	1,868	4,053	-	-	-
TB Screening	112	113	451	-	-		-%	1,868	4,053	-	-	-
<b>Laos</b>										<b>215</b>	<b>5,908</b>	<b>6,124</b>
Condom	-	70,132	210,396	-	-		0%	2,935,872	25,524,843	214	147	361
No 1 Condom Grp	-	14,915	44,745	-	-	11/10	-%	452,736	3,971,647	46	31	77
No 1 Condom Strw	-	54,711	164,133	-	-	8/08	-%	1,410,048	13,285,794	167	114	281
Number One Rose	-	506	1,518	-	-	4/08	-%	1,073,088	8,267,402	2	1	3
HIV Testing Services	211	623	2,080	-	-		0%	195	11,102	1	-	1
VCT Individual (HIV-Negative)	207	621	2,069	-	-	2/10	-%	192	10,983	1	-	1
VCT Individual (HIV-Positive)	4	2	11	-	-	4/10	-%	3	119	-	-	-
Implant 3 Insertion	570	617	2,420	-	403		500%	4,152	6,848	-	1,229	1,229
Non-PSI Implant 3 Inserted	570	617	2,420	-	403	3/16	500%	4,152	6,848	-	1,229	1,229
IUD 10 Insertion	1,061	1,136	4,469	-	3,024		48%	10,848	24,838	-	4,063	4,063

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Non-PSI IUD 10 Inserted	<b>1,061</b>	<b>1,136</b>	<b>4,469</b>	-	<b>3,024</b>		48%	<b>10,848</b>	<b>24,838</b>	-	<b>4,063</b>	<b>4,063</b>
Lubricant	-	-	-	-	-		0%	<b>6,024</b>	<b>38,836</b>	-	-	-
Number One Lubricant (20 cc)	-	-	-	-	-	7/12	-%	<b>6,024</b>	<b>38,836</b>	-	-	-
Misoprostol for PAC (Oral)	-	<b>6,667</b>	<b>20,000</b>	-	<b>2,500</b>		700%	<b>124,500</b>	<b>289,900</b>	-	<b>347</b>	<b>347</b>
Misoprostol for PAC (oral)	-	<b>6,667</b>	<b>20,000</b>	-	<b>2,500</b>	8/13	700%	<b>124,500</b>	<b>289,900</b>	-	<b>347</b>	<b>347</b>
Referral to HIV Testing Services	-	-	-	-	-		0%	<b>195</b>	<b>195</b>	-	-	-
Referral to HIV Testing & Counseling	-	-	-	-	-		-%	<b>195</b>	<b>195</b>	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		0%	<b>636</b>	<b>636</b>	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	-		-%	<b>636</b>	<b>636</b>	-	-	-
Referral to Injectable 3	-	-	-	-	-		0%	<b>998</b>	<b>998</b>	-	-	-
Referral to Injectable 3	-	-	-	-	-		-%	<b>998</b>	<b>998</b>	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-		0%	<b>1,185</b>	<b>1,930</b>	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	-	12/11	-%	<b>1,185</b>	<b>1,930</b>	-	-	-
Referral to Manual Vacuum Aspiration	-	-	-	-	-		0%	<b>46</b>	<b>46</b>	-	-	-
Referral to Manual Vacuum Aspiratic	-	-	-	-	-		-%	<b>46</b>	<b>46</b>	-	-	-
Referral to Medication Abortion	-	-	-	-	-		0%	<b>24</b>	<b>24</b>	-	-	-
Referral to Medication Abortion	-	-	-	-	-		-%	<b>24</b>	<b>24</b>	-	-	-
Referral to OCs	-	-	-	-	-		0%	<b>1,175</b>	<b>1,175</b>	-	-	-
Referral to OCs	-	-	-	-	-		-%	<b>1,175</b>	<b>1,175</b>	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	-		0%	<b>488</b>	<b>488</b>	-	-	-
Referral to PAC Service (unknown)	-	-	-	-	-		-%	<b>488</b>	<b>488</b>	-	-	-
Referral to TB Diagnosis	-	-	-	-	-		0%	<b>42</b>	<b>42</b>	-	-	-
Referral to TB Diagnosis	-	-	-	-	-		-%	<b>42</b>	<b>42</b>	-	-	-
Referral to TB DOTS (completion conf	-	-	-	-	-		0%	<b>41</b>	<b>41</b>	-	-	-
Referral to TB DOTS (completion co	-	-	-	-	-	3/16	-%	<b>41</b>	<b>41</b>	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to TB Screening	-	-	-	-	-		0%	166	166	-	-	-
Referrals to TB Screening	-	-	-	-	-		-%	166	166	-	-	-
TB Diagnosis	64	20	123	-	52		137%	218	503	-	-	-
TB Diagnosis	64	20	123	-	52		137%	218	503	-	-	-
TB DOTS	110	22	177	-	-		0%	121	408	-	122	122
TB DOTS	110	22	177	-	-	11/11	-%	121	408	-	122	122
TB Screening	197	60	378	-	206		83%	782	1,909	-	-	-
TB Screening	197	60	378	-	206		83%	782	1,909	-	-	-
<b>Myanmar</b>										32,628	60,307	92,935
Antiretroviral Treatment (Currently Enr	3,274	2,791	11,646	-	-		0%	1,661	13,307	2,034	-	2,034
Antiretroviral Treatment (Currently E	3,274	2,791	11,646	-	-		-%	1,661	13,307	2,034	-	2,034
Antiretroviral Treatment (Newly Enrolle	214	227	895	-	-		0%	1,042	1,937	-	-	-
Antiretroviral Treatment (Newly Enrc	214	227	895	-	-		-%	1,042	1,937	-	-	-
Cervical Cancer-VIA and Cryotherapy	1	-	1	-	21		(95)%	22	898	-	-	-
Cervical Cancer-VIA and Cryotherap	1	-	1	-	21	11/12	(95)%	22	898	-	-	-
Cervical Cancer-VIA/VILI Screening	2	19	59	-	528		(89)%	634	4,378	-	-	-
Cervical Cancer-VIA/VILI Screening	2	19	59	-	528		(89)%	634	4,378	-	-	-
Condom	1,343,580	1,481,837	5,789,092	-	5,432,524		7%	21,386,624	388,984,377	27,396	2,716	30,112
Aphaw	192,560	165,920	690,320	-	2,687,215	7/96	(74)%	6,364,593	186,678,411	3,267	324	3,591
Aphaw - Natural Touch	198,180	322,400	1,165,380	-	783,000	8/12	49%	2,680,116	12,105,633	5,515	547	6,062
Aphaw Flavors	542,890	625,013	2,417,930	-	1,167,123	10/01	107%	4,981,175	165,553,889	11,442	1,135	12,577
Aphaw Studded	401,010	359,360	1,479,090	-	778,050	7/12	90%	3,666,879	15,836,127	7,000	694	7,694
Generic Male Condom	-	-	-	-	-	1/08	-%	3,551,661	3,754,529	-	-	-
OK Condom	8,940	9,144	36,372	-	17,136	5/03	112%	142,200	5,055,788	172	17	189
Diarrhea Treatment Kit	548	5,014	15,590	-	117,788		(87)%	322,860	5,044,574	-	838	838

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
OraSrel DTK	548	5,014	15,590	-	117,788	2/09	(87)%	322,860	5,044,574	-	838	838
Emergency Contraception	2	7	22	-	820		(97)%	1,084	177,844	-	-	-
OK EC	2	7	22	-	820	8/07	(97)%	1,084	177,844	-	-	-
Female Condom	5,546	5,826	23,023	-	29,971		(23)%	89,174	1,342,614	109	8	117
Generic Female Condom	5,546	5,826	23,023	-	29,971	5/08	(23)%	89,174	1,342,614	109	8	117
Fever Cases Attended	56,836	57,438	229,151	-	-		0%	657,831	886,982	-	-	-
Fever Cases Attended	56,836	57,438	229,151	-	-		-%	657,831	886,982	-	-	-
Fever Cases Tested with RDTs	56,836	57,438	229,151	-	-		0%	657,831	886,982	-	-	-
Fever Cases Tested with RDTs	56,836	57,438	229,151	-	-		-%	657,831	886,982	-	-	-
HIV Testing Services	5,900	5,878	23,535	-	22,160		6%	68,045	300,211	28	-	28
VCT Concordant Couple (HIV-Negati	-	-	-	-	22	12/09	(100)%	42	2,090	-	-	-
VCT Concordant Couple (HIV-Positi	-	-	-	-	28	12/09	(100)%	94	1,800	-	-	-
VCT Discordant Couple (HIV-Negati	-	-	-	-	5	12/09	(100)%	27	752	-	-	-
VCT Discordant Couple (HIV-Positiv	-	-	-	-	5	12/09	(100)%	27	752	-	-	-
VCT Individual (HIV-Negative)	5,489	5,506	22,007	-	21,280	12/09	3%	64,256	273,286	26	-	26
VCT Individual (HIV-Positive)	411	372	1,528	-	820	12/09	86%	3,599	21,531	2	-	2
Implant 3	68	2,072	6,283	-	199		3057%	2,660	8,943	-	1,944	1,944
PSI Implant 3 Distributed Inserted (	(248)	(207)	(870)	-	-		-%	-	(870)	-	(269)	(269)
Implanon NXT	316	2,279	7,153	-	199	12/15	3,494%	2,660	9,813	-	2,213	2,213
Implant 3 Insertion	248	207	870	-	-		0%	-	870	-	299	299
PSI Implant 3 Inserted	248	207	870	-	-		-%	-	870	-	299	299
Implant 5	(2)	-	(2)	-	-		0%	107	(998)	-	(1)	(1)
PSI Implant 5 Distributed Inserted (	(2)	-	(2)	-	-		-%	-	(1,105)	-	(1)	(1)
Jadelle	-	-	-	-	-	5/16	-%	107	107	-	-	-
Implant 5 Insertion	2	-	2	-	-		0%	-	1,105	-	1	1

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Implant 5 Inserted	2	-	2	-	-		-%	-	1,105	-	1	1
Injectable 3	43,047	45,227	178,727	-	193,548		(8)%	584,852	8,980,175	-	3,951	3,951
OK-3 Injection	43,047	45,227	178,727	-	193,548	9/01	(8)%	584,852	8,980,175	-	3,951	3,951
IUD 10	(45)	517	1,505	-	30		4917%	50	3,152	-	843	843
PSI IUD 10 Distributed Inserted (1)	(45)	-	(45)	-	-		-%	-	(45)	-	(25)	(25)
OK IUD (Copper T Cu 380A)	-	517	1,550	-	30	10/14	5,067%	50	3,197	-	868	868
IUD 10 Insertion	45	-	45	-	-		0%	-	45	-	28	28
PSI IUD 10 Inserted	45	-	45	-	-		-%	-	45	-	28	28
IUD 5	(310)	202	297	-	733		(59)%	6,528	140,332	-	124	124
PSI IUD 5 Distributed Inserted (1)	(516)	-	(516)	-	-		-%	-	(55,743)	-	(216)	(216)
OK IUD	206	202	813	-	733	5/03	11%	6,528	196,075	-	340	340
IUD 5 Insertion	516	-	516	-	-		0%	-	55,743	-	239	239
PSI IUD 5 Inserted	516	-	516	-	-		-%	-	55,743	-	239	239
LLIN	-	-	-	-	-		0%	22,280	22,280	-	-	-
LLIN	-	-	-	-	-	11/16	-%	22,280	22,280	-	-	-
Lubricant	706	615	2,551	-	20,577		(88)%	29,205	733,305	-	-	-
Aphaw Gel - Tube 20 cc	706	405	1,921	-	-	10/06	-%	-	610,607	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	-	210	630	-	20,577	10/14	(97)%	29,205	122,698	-	-	-
Malaria PPT (ACT)	23,769	28,400	108,968	-	101,311		8%	392,739	2,850,177	-	15,239	15,239
PSI QAACts Distributed Provided ε	(189)	(492)	(1,666)	-	-		-%	(7,361)	(9,027)	-	(233)	(233)
AL 1	82	81	324	-	873	7/12	(63)%	1,386	12,707	-	45	45
AL 2	82	81	324	-	759	7/12	(57)%	1,285	13,356	-	45	45
AL 3	75	86	334	-	1,233	1/11	(73)%	2,304	47,396	-	47	47
AL 4	302	557	1,973	-	3,962	1/11	(50)%	11,892	256,520	-	276	276
Arte+1	1,440	12	1,477	-	-	8/14	-%	2,762	21,490	-	207	207

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Arte+2	1,440	12	1,477	-	900	8/14	64%	3,660	22,389	-	207	207
Arte+3	1,440	312	2,377	-	900	8/14	164%	3,630	25,058	-	332	332
Arte+4	-	14,367	43,102	-	50,147	8/14	(14)%	143,957	432,754	-	6,028	6,028
Supa Arte 1	182	598	1,977	-	3,974	9/12	(50)%	14,120	119,231	-	276	276
Supa Arte 2	140	216	788	-	3,175	9/12	(75)%	16,436	115,000	-	110	110
Supa Arte 3	605	1,191	4,179	-	3,189	9/12	31%	15,611	194,839	-	584	584
Supa Arte 4	18,170	11,377	52,302	-	32,199	9/12	62%	183,057	1,598,464	-	7,314	7,314
Malaria PPT (Non-ACT)	132	128	515	-	2,587		(80)%	3,078	105,480	-	72	72
PSI Vivax Tx Distributed Provided a	(129)	(162)	(615)	-	-		-%	(3,796)	(4,411)	-	(86)	(86)
Vivax Treatment Kit	261	290	1,130	-	2,587	6/11	(56)%	6,874	109,891	-	158	158
Malaria RDK	89,075	61,455	273,440	-	190,172		44%	829,416	3,141,709	-	-	-
Malaria RDT (Diagnosis)	89,075	61,455	273,440	-	190,172	3/11	44%	829,416	3,141,709	-	-	-
Micronutrient Powder	64,070	146,763	504,360	-	-		0%	97,980	602,340	-	-	-
Happy Kid (Micronutrient powder)	64,070	146,763	504,360	-	-	9/16	-%	97,980	602,340	-	-	-
Needle & Syringe	75,400	99,133	372,800	-	85,200		338%	303,605	753,405	3,061	-	3,061
Needle & Syringe (LDS)	75,400	99,133	372,800	-	85,200	10/15	338%	303,605	753,405	3,061	-	3,061
OCs	301,412	325,483	1,277,862	-	431,054		196%	3,337,534	17,955,803	-	7,649	7,649
OK Pills	301,412	325,483	1,277,862	-	431,054	9/01	196%	3,337,534	17,955,803	-	7,649	7,649
ORS	-	-	-	-	-		0%	262,931	262,931	-	-	-
ORS	-	-	-	-	-	1/08	-%	262,931	262,931	-	-	-
Pneumonia PPT	-	-	-	-	56,197		(100)%	127,866	1,057,411	-	-	-
Pneumox 125 mg (15 tabs)	-	-	-	-	18,873	2/11	(100)%	75,684	431,561	-	-	-
Pneumox 250 mg (15 tabs)	-	-	-	-	37,324	2/11	(100)%	52,182	625,850	-	-	-
Positive RDTs	435	813	2,875	-	-		0%	13,201	16,076	-	-	-
Positive RDTs	435	813	2,875	-	-		-%	13,201	16,076	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Positive RDTs Given First Line Treatm	425	574	2,146	-	-		0%	10,870	13,016	-	-	-
Positive RDTs Given First Line Trea	425	574	2,146	-	-		-%	10,870	13,016	-	-	-
PUR	4,687	23,159	74,165	-	319,959		(77)%	1,502,076	14,451,915	-	2	2
Purifier of Water	4,687	23,159	74,165	-	319,959	4/14	(77)%	1,502,076	14,451,915	-	2	2
QAActs Provided after Confirmatory I	189	492	1,666	-	-		0%	7,361	9,027	-	274	274
PSI QAActs Provided after Confirm	189	492	1,666	-	-		-%	7,361	9,027	-	274	274
Referral to TB DOTS (completion confi	-	-	-	-	-		0%	293	293	-	-	-
Referral to TB DOTS (completion co	-	-	-	-	-		-%	293	293	-	-	-
STI Kit (Non-Ulcerative)	-	-	-	-	23,108		(100)%	43,388	548,483	-	-	-
Cure U for Urethritis & Cervicitis	-	-	-	-	19,898	8/09	(100)%	38,888	514,283	-	-	-
Cure U Vaginitis	-	-	-	-	3,210	5/11	(100)%	4,500	34,200	-	-	-
STI Kit (Ulcerative)	-	-	-	-	1,336		(100)%	3,679	60,473	-	-	-
Cure U for Non-Herpetic Ulcer	-	-	-	-	1,336	8/09	(100)%	3,679	60,473	-	-	-
STI Screening	2,528	2,896	11,216	-	-		0%	-	11,216	-	-	-
STI Screening	2,528	2,896	11,216	-	-		-%	-	11,216	-	-	-
TB Diagnosis	884	850	3,434	-	3,726		(8)%	15,499	33,926	-	-	-
TB Diagnosis	884	850	3,434	-	3,726		(8)%	15,499	33,926	-	-	-
TB DOTS	1,084	1,035	4,188	-	4,867		(14)%	15,133	194,513	-	25,977	25,977
TB DOTS	1,084	1,035	4,188	-	4,867	12/04	(14)%	15,133	194,513	-	25,977	25,977
TB Screening	4,180	4,878	18,815	-	17,490		8%	60,830	140,233	-	-	-
TB Screening	4,180	4,878	18,815	-	17,490		8%	60,830	140,233	-	-	-
Vivax Treatment after Confirmatory Di	129	162	615	-	-		0%	3,796	4,411	-	101	101
PSI Vivax Treatment after Confirme	129	162	615	-	-		-%	3,796	4,411	-	101	101
<b>Nepal</b>										1,183	10,582	11,765
Emergency Contraception	-	4,821	14,464	-	-		0%	15	14,479	-	38	38

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Emergency Contraception	-	4,821	14,464	-	-	9/16	-%	15	14,479	-	38	38
Free Condom	-	176,733	530,200	-	41,688		1172%	41,934	572,134	1,183	367	1,550
Generic Condom	-	176,733	530,200	-	41,688	1/16	1,172%	41,934	572,134	1,183	367	1,550
Implant 5	-	-	(1)	-	-		0%	18,088	19,376	-	(1)	(1)
PSI Implant 5 Distributed Inserted (	-	-	(1)	-	-		-%	(7)	(1,338)	-	(1)	(1)
Jadelle	-	-	-	-	-	8/09	-%	18,095	20,714	-	-	-
Implant 5 Insertion	6	16	53	-	-		0%	82	1,558	-	39	39
PSI Implant 5 Inserted	-	-	1	-	-		-%	7	1,338	-	1	1
Non-PSI Implant 5 Inserted	6	15	52	-	-		-%	75	220	-	38	38
Injectable 3	-	-	-	-	-		0%	61,975	62,000	-	-	-
Depo-Provera	-	-	-	-	-	6/16	-%	61,975	62,000	-	-	-
IUD 10	900	(124)	529	-	4,102		(87)%	1,190	10,242	-	427	427
PSI IUD 10 Distributed Inserted (1)	(1,820)	(1,798)	(7,214)	-	-		-%	(18,982)	(167,535)	-	(5,821)	(5,821)
IUD	2,720	1,674	7,743	-	4,102	8/03	89%	20,172	177,777	-	6,248	6,248
IUD 10 Insertion	1,925	1,898	7,620	-	-		0%	19,489	177,042	-	6,832	6,832
PSI IUD 10 Inserted	1,820	1,798	7,214	-	-		-%	18,982	167,535	-	6,468	6,468
Non-PSI IUD 10 Inserted	105	100	406	-	-		-%	507	9,506	-	364	364
Medical Abortion	7,714	4,151	20,167	-	17,540		15%	68,029	196,647	-	2,503	2,503
Medabon	7,714	4,151	20,167	-	17,540	12/08	15%	68,029	196,647	-	2,503	2,503
OCs	-	14,208	42,624	-	-		0%	8	143,172	-	376	376
Zinnia	-	14,208	42,624	-	-	8/15	-%	8	143,172	-	376	376
PUR	-	-	-	-	-		0%	578,640	1,235,812	-	-	-
PuR	-	-	-	-	-	6/15	-%	578,640	1,235,812	-	-	-
STI Screening	30	17	81	-	-		0%	221	885	-	-	-
STI Screening	30	17	81	-	-		-%	221	885	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>Pakistan</b>										<b>7,904</b>	<b>318,672</b>	<b>326,576</b>
Condom	<b>3,335,076</b>	<b>7,063,166</b>	<b>24,524,575</b>	-	<b>42,586,925</b>		<b>(42)%</b>	<b>129,964,527</b>	<b>2,448,922,734</b>	<b>7,904</b>	<b>26,934</b>	<b>34,837</b>
PSI Condom Distributed Provided	-	-	-	-	<b>(2,586)</b>		-%	<b>(10,350)</b>	<b>(31,403)</b>	-	-	-
Generic Male Condom	<b>260,421</b>	<b>210,572</b>	<b>892,137</b>	-	<b>89,411</b>		898%	<b>1,710,632</b>	<b>2,602,769</b>	<b>288</b>	<b>980</b>	<b>1,267</b>
Sathi	<b>2,271,675</b>	<b>6,142,496</b>	<b>20,699,163</b>	-	<b>36,906,240</b>	1/87	(44)%	<b>113,482,837</b>	<b>2,215,182,704</b>	<b>6,671</b>	<b>22,732</b>	<b>29,403</b>
Touch	<b>802,980</b>	<b>710,098</b>	<b>2,933,275</b>	-	<b>5,593,860</b>	4/96	(48)%	<b>14,781,408</b>	<b>231,168,664</b>	<b>945</b>	<b>3,221</b>	<b>4,167</b>
Condom Provided	-	-	-	-	<b>2,586</b>		<b>(100)%</b>	<b>10,350</b>	<b>31,403</b>	-	-	-
PSI Condom Provided	-	-	-	-	<b>2,586</b>		(100)%	<b>10,350</b>	<b>31,403</b>	-	-	-
Emergency Contraception	<b>51,775</b>	<b>189,180</b>	<b>619,315</b>	-	<b>838,242</b>		<b>(26)%</b>	<b>2,307,659</b>	<b>5,467,312</b>	-	<b>2,564</b>	<b>2,564</b>
PSI Emergency Contraception Distr	<b>(745)</b>	<b>(880)</b>	<b>(3,385)</b>	-	<b>(3,638)</b>		-%	<b>(9,091)</b>	<b>(23,979)</b>	-	<b>(14)</b>	<b>(14)</b>
ECP	<b>52,520</b>	<b>190,060</b>	<b>622,700</b>	-	<b>841,880</b>	9/14	(26)%	<b>2,316,750</b>	<b>5,491,291</b>	-	<b>2,578</b>	<b>2,578</b>
Emergency Contraception Provided	<b>745</b>	<b>880</b>	<b>3,385</b>	-	<b>3,638</b>		<b>(7)%</b>	<b>9,091</b>	<b>23,979</b>	-	<b>16</b>	<b>16</b>
PSI Emergency Contraception Prov	<b>745</b>	<b>880</b>	<b>3,385</b>	-	<b>3,638</b>		(7)%	<b>9,091</b>	<b>23,979</b>	-	<b>16</b>	<b>16</b>
Implant 3	-	<b>(29)</b>	<b>(87)</b>	-	-		<b>0%</b>	-	<b>(87)</b>	-	<b>(63)</b>	<b>(63)</b>
PSI Implant 3 Distributed Inserted (	-	<b>(29)</b>	<b>(87)</b>	-	-		-%	-	<b>(87)</b>	-	<b>(63)</b>	<b>(63)</b>
Implant 3 Insertion	-	<b>29</b>	<b>87</b>	-	-		<b>0%</b>	-	<b>87</b>	-	<b>70</b>	<b>70</b>
PSI Implant 3 Inserted	-	<b>29</b>	<b>87</b>	-	-		-%	-	<b>87</b>	-	<b>70</b>	<b>70</b>
Implant 5	-	<b>175</b>	<b>525</b>	-	<b>74</b>		<b>609%</b>	<b>279</b>	<b>13,686</b>	-	<b>560</b>	<b>560</b>
Jadelle	-	<b>175</b>	<b>525</b>	-	<b>74</b>	12/11	609%	<b>279</b>	<b>13,686</b>	-	<b>560</b>	<b>560</b>
Injectable 1	<b>8,048</b>	<b>7,049</b>	<b>29,195</b>	-	<b>23,937</b>		<b>22%</b>	<b>85,224</b>	<b>1,547,852</b>	-	<b>504</b>	<b>504</b>
PSI Injectable 1 Distributed Provide	<b>(3,152)</b>	<b>(3,684)</b>	<b>(14,205)</b>	-	<b>(10,863)</b>		-%	<b>(30,476)</b>	<b>(69,361)</b>	-	<b>(245)</b>	<b>(245)</b>
Femi-ject	<b>11,200</b>	<b>10,733</b>	<b>43,400</b>	-	<b>34,800</b>	6/03	25%	<b>115,700</b>	<b>1,617,213</b>	-	<b>749</b>	<b>749</b>
Injectable 1 Provided	<b>3,152</b>	<b>3,684</b>	<b>14,205</b>	-	<b>10,863</b>		<b>31%</b>	<b>30,476</b>	<b>69,361</b>	-	<b>272</b>	<b>272</b>
PSI Injectable 1 Provided	<b>3,152</b>	<b>3,684</b>	<b>14,205</b>	-	<b>10,863</b>		31%	<b>30,476</b>	<b>69,361</b>	-	<b>272</b>	<b>272</b>
Injectable 2	<b>(2,048)</b>	<b>43,971</b>	<b>129,866</b>	-	<b>94,053</b>		<b>38%</b>	<b>299,852</b>	<b>6,803,119</b>	-	<b>4,480</b>	<b>4,480</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
PSI Injectable 2 Distributed Provide (2,048)		(2,269)	(8,854)	-	(7,867)		-%	(22,868)	(54,985)	-	(305)	(305)
Novaject	-	46,240	138,720	-	101,920	12/96	36%	322,720	6,858,104	-	4,785	4,785
<b>Injectable 2 Provided</b>	<b>2,048</b>	<b>2,269</b>	<b>8,854</b>	<b>-</b>	<b>7,867</b>		<b>13%</b>	<b>22,868</b>	<b>54,985</b>	<b>-</b>	<b>339</b>	<b>339</b>
PSI Injectable 2 Provided	2,048	2,269	8,854	-	7,867		13%	22,868	54,985	-	339	339
<b>Injectable 3</b>	<b>68,973</b>	<b>58,747</b>	<b>245,214</b>	<b>-</b>	<b>122,757</b>		<b>100%</b>	<b>564,683</b>	<b>2,592,576</b>	<b>-</b>	<b>12,688</b>	<b>12,688</b>
PSI Injectable 3 Distributed Provide (1,669)		(1,981)	(7,612)	-	(6,893)		-%	(19,928)	(42,592)	-	(394)	(394)
Depo-Provera	40,560	34,480	144,000	-	110,160	7/11	31%	372,600	2,314,331	-	7,451	7,451
Generic 3-month Injactable	30,082	26,248	108,826	-	19,490		458%	212,011	320,837	-	5,631	5,631
<b>Injectable 3 Provided</b>	<b>31,751</b>	<b>28,229</b>	<b>116,438</b>	<b>-</b>	<b>6,893</b>		<b>1589%</b>	<b>19,928</b>	<b>151,418</b>	<b>-</b>	<b>6,694</b>	<b>6,694</b>
PSI Injectable 3 Provided	1,669	1,981	7,612	-	6,893		10%	19,928	42,592	-	438	438
Non-PSI Injectable 3 Provided	30,082	26,248	108,826	-	-		-%	-	108,826	-	6,257	6,257
<b>IUD 10</b>	<b>15,000</b>	<b>13,527</b>	<b>55,581</b>	<b>-</b>	<b>47,927</b>		<b>16%</b>	<b>142,645</b>	<b>226,666</b>	<b>-</b>	<b>73,178</b>	<b>73,178</b>
Generic IUD 10	10,860	8,367	35,961	-	20,067		79%	81,552	117,513	-	47,346	47,346
Safeload	4,140	5,160	19,620	-	27,860	8/14	(30)%	61,093	109,153	-	25,832	25,832
<b>IUD 10 Insertion</b>	<b>10,860</b>	<b>9,085</b>	<b>38,116</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>-</b>	<b>38,116</b>	<b>-</b>	<b>55,760</b>	<b>55,760</b>
Non-PSI IUD 10 Inserted	10,860	9,085	38,116	-	-		-%	-	38,116	-	55,760	55,760
<b>IUD 5</b>	<b>10,401</b>	<b>9,130</b>	<b>37,790</b>	<b>-</b>	<b>(15,862)</b>		<b>0%</b>	<b>7,578</b>	<b>3,004,499</b>	<b>-</b>	<b>37,030</b>	<b>37,030</b>
PSI IUD 5 Distributed Inserted (1) (14,321)		(12,696)	(52,410)	-	(74,065)		-%	(175,657)	(798,712)	-	(51,356)	(51,356)
Generic IUD 5	822	3,193	10,400	-	3		346,567%	15,035	25,435	-	10,191	10,191
Multiload	23,900	18,633	79,800	-	58,200	12/95	37%	168,200	3,777,776	-	78,195	78,195
<b>IUD 5 Insertion</b>	<b>15,143</b>	<b>13,616</b>	<b>55,992</b>	<b>-</b>	<b>74,065</b>		<b>(24)%</b>	<b>175,657</b>	<b>802,294</b>	<b>-</b>	<b>60,962</b>	<b>60,962</b>
PSI IUD 5 Inserted	14,321	12,696	52,410	-	74,065		(29)%	175,657	798,712	-	57,062	57,062
Non-PSI IUD 5 Inserted	822	920	3,582	-	-		-%	-	3,582	-	3,900	3,900
<b>Manual Vacuum Aspiration for PAC</b>	<b>2,444</b>	<b>2,663</b>	<b>10,432</b>	<b>-</b>	<b>-</b>		<b>0%</b>	<b>31,135</b>	<b>41,567</b>	<b>-</b>	<b>535</b>	<b>535</b>
MVA for PAC	2,444	2,663	10,432	-	-		-%	31,135	41,567	-	535	535

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
<b>OCs</b>	<b>112,836</b>	<b>59,653</b>	<b>291,794</b>	-	<b>243,148</b>		<b>20%</b>	<b>1,121,152</b>	<b>3,050,229</b>	-	<b>4,088</b>	<b>4,088</b>
PSI OCs Distributed Provided	(4,158)	(5,871)	(21,771)	-	(21,324)		-%	(60,615)	(134,709)	-	(305)	(305)
Generic OC	70,914	48,964	217,805	-	36,232		501%	364,567	582,372	-	3,052	3,052
Novadol	46,080	16,560	95,760	-	228,240	1/08	(58)%	817,200	2,602,566	-	1,342	1,342
<b>OCs Provided</b>	<b>75,072</b>	<b>54,835</b>	<b>239,576</b>	-	<b>21,324</b>		<b>1024%</b>	<b>60,615</b>	<b>352,514</b>	-	<b>3,730</b>	<b>3,730</b>
PSI OCs Provided	4,158	5,871	21,771	-	21,324		2%	60,615	134,709	-	339	339
Non-PSI OCs Provided	70,914	48,964	217,805	-	-		-%	-	217,805	-	3,391	3,391
<b>TB Diagnosis</b>	<b>2,344</b>	<b>1,989</b>	<b>8,310</b>	-	<b>4,855</b>		<b>71%</b>	<b>15,666</b>	<b>30,627</b>	-	-	-
TB Diagnosis	2,344	1,989	8,310	-	4,855		71%	15,666	30,627	-	-	-
<b>TB DOTS</b>	<b>1,660</b>	<b>1,061</b>	<b>4,842</b>	-	<b>2,691</b>		<b>80%</b>	<b>7,656</b>	<b>75,338</b>	-	<b>22,159</b>	<b>22,159</b>
TB DOTS	1,660	1,061	4,842	-	2,691	4/05	80%	7,656	75,338	-	22,159	22,159
<b>TB Screening</b>	<b>4,222</b>	<b>5,684</b>	<b>21,275</b>	-	-		<b>0%</b>	-	<b>21,275</b>	-	-	-
TB Screening	4,222	5,684	21,275	-	-		-%	-	21,275	-	-	-
<b>Tubal Ligation</b>	<b>346</b>	<b>543</b>	<b>1,975</b>	-	<b>649</b>		<b>204%</b>	<b>2,072</b>	<b>218,846</b>	-	<b>6,174</b>	<b>6,174</b>
VSC	346	543	1,975	-	649	6/01	204%	2,072	218,846	-	6,174	6,174
<b>Water Treatment Tablets</b>	-	-	-	-	<b>241,500</b>		<b>(100)%</b>	<b>241,500</b>	<b>2,754,300</b>	-	-	-
Aquatabs 33 mg (10 L)	-	-	-	-	167,380	2/12	(100)%	167,380	2,166,780	-	-	-
Aquatabs 67 mg (20 L)	-	-	-	-	74,120	2/12	(100)%	74,120	587,520	-	-	-
<b>Papua New Guinea</b>										<b>261</b>	<b>790</b>	<b>1,051</b>
<b>Condom</b>	<b>65,764</b>	<b>8,628</b>	<b>91,648</b>	-	<b>45,376</b>		<b>102%</b>	<b>627,118</b>	<b>7,460,433</b>	<b>226</b>	<b>123</b>	<b>349</b>
Seif Raida	8,944	5,848	26,488	-	37,696	1/08	(30)%	427,780	6,822,725	65	36	101
Seif Raida Orange Plus	56,820	2,780	65,160	-	7,680	8/13	748%	199,338	637,708	161	88	248
<b>Diarrhea Treatment Kit</b>	<b>79</b>	<b>721</b>	<b>2,243</b>	-	<b>1,008</b>		<b>123%</b>	<b>5,446</b>	<b>18,236</b>	-	<b>67</b>	<b>67</b>
DTK	79	721	2,243	-	1,008	2/15	123%	5,446	18,236	-	67	67
<b>Female Condom</b>	<b>13,680</b>	<b>180</b>	<b>14,220</b>	-	<b>3,600</b>		<b>295%</b>	<b>19,760</b>	<b>289,599</b>	<b>35</b>	<b>15</b>	<b>50</b>

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

Period: 4

Year: 2017

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Stap Seif	13,680	180	14,220	-	3,600	2/09	295%	19,760	289,599	35	15	50
Malaria PPT (ACT)	-	-	-	-	3,366		(100)%	3,366	15,587	-	-	-
Coartem 1x12's for 1-5 years old	-	-	-	-	660	8/15	(100)%	660	3,453	-	-	-
Coartem 1x18's for 6-13 years old	-	-	-	-	338	8/15	(100)%	338	1,530	-	-	-
Coartem 1x24's for 14+ years old	-	-	-	-	1,590	8/15	(100)%	1,590	5,972	-	-	-
Coartem 1x6's for 2-11 months	-	-	-	-	778	8/15	(100)%	778	4,632	-	-	-
Water Treatment Tablets	2,700	933	5,500	-	1,000		450%	26,630	876,823	-	-	-
Aquatab	2,700	933	5,500	-	1,000	12/11	450%	26,630	876,823	-	-	-
Zinc	-	28,300	84,900	-	2,500		3296%	50,500	328,442	-	585	585
Zinc 20 mg	-	28,300	84,900	-	2,500	12/11	3,296%	50,500	328,442	-	585	585
<b>Tajikistan</b>										3,153	35	3,188
Free Condom	22,630	11,800	58,030	-	-		0%	19,300	77,330	222	35	257
Generic Male Condom	22,630	11,800	58,030	-	-	8/16	-%	19,300	77,330	222	35	257
HIV Testing Services	1,145	-	1,145	-	-		0%	-	1,986	4	-	4
VCT Individual (HIV-Negative)	1,100	-	1,100	-	-		-%	-	1,941	4	-	4
VCT Individual (HIV-Positive)	45	-	45	-	-		-%	-	45	-	-	-
Naloxone	60	-	60	-	-		0%	-	10,692	82	-	82
Naloxone	60	-	60	-	-	1/11	-%	-	10,692	82	-	82
Needle & Syringe	30,300	57,687	203,361	-	-		0%	-	1,112,633	2,552	-	2,552
Needle/Syringe	30,300	57,687	203,361	-	-	1/11	-%	-	1,112,633	2,552	-	2,552
Referral to HIV Testing Services	643	1,182	4,190	-	-		0%	1,439	14,964	7	-	7
Referral to HIV Testing & Counseling	643	1,182	4,190	-	-	12/13	-%	1,439	14,964	7	-	7
Referral to Linkage to HIV Care	77	94	360	-	-		0%	80	440	286	-	286
Referral to Linkage to HIV Care	77	94	360	-	-		-%	80	440	286	-	286
Referral to Opioid Treatment	8	14	50	-	-		0%	5	55	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Referral to Opioid Treatment	8	14	50	-	-		-%	5	55	-	-	-
Referral to TB Diagnosis	6	9	34	-	-		0%	-	5,186	-	-	-
Referral to TB Diagnosis	6	9	34	-	-	12/14	-%	-	5,186	-	-	-
TB Screening	238	173	757	-	-		0%	1,643	3,539	-	-	-
TB Screening	238	173	757	-	-		-%	1,643	3,539	-	-	-
<b>Viet Nam</b>										12,095	4	12,098
Emergency Contraception Provided	1	-	1	-	-		0%	-	1	-	-	-
Non-PSI Emergency Contraception I	1	-	1	-	-		-%	-	1	-	-	-
HIV Testing Services	489	95	773	-	-		0%	-	773	1	-	1
VCT Individual (HIV-Negative)	442	78	675	-	-		-%	-	675	1	-	1
VCT Individual (HIV-Positive)	47	17	98	-	-		-%	-	98	-	-	-
Hypertension Diagnosis	150	-	150	-	-		0%	-	150	-	-	-
Hypertension Diagnosis	150	-	150	-	-		-%	-	150	-	-	-
Hypertension Screening	170	-	170	-	-		0%	-	170	-	-	-
Hypertension Screening	170	-	170	-	-		-%	-	170	-	-	-
Hypertension_Controlled Condition	129	-	129	-	-		0%	-	129	-	-	-
Hypertension_Controlled Condition	129	-	129	-	-		-%	-	129	-	-	-
Implant 3	3	4	15	-	-		0%	(3)	12	-	1	1
PSI Implant 3 Distributed Inserted ('	-	(2)	(5)	-	-		-%	(3)	(8)	-	-	-
Implanon NXT	3	6	20	-	-	2/17	-%	-	20	-	1	1
Implant 3 Insertion	2	3	11	-	-		0%	3	14	-	1	1
PSI Implant 3 Inserted	-	2	5	-	-		-%	3	8	-	-	-
Non-PSI Implant 3 Inserted	2	1	6	-	-		-%	-	6	-	-	-
Injectable 3	5	7	25	-	-		0%	(5)	20	-	-	-
PSI Injectable 3 Distributed Provide	-	-	-	-	-		-%	(5)	(5)	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Depoteron	5	7	25	-	-	2/17	-%	-	25	-	-	-
<b>Injectable 3 Provided</b>	<b>39</b>	<b>23</b>	<b>107</b>	-	-		<b>0%</b>	<b>5</b>	<b>112</b>	-	<b>1</b>	<b>1</b>
PSI Injectable 3 Provided	-	-	-	-	-		-%	5	5	-	-	-
Non-PSI Injectable 3 Provided	39	23	107	-	-		-%	-	107	-	1	1
<b>IUD 10</b>	-	-	-	-	-		<b>0%</b>	<b>71</b>	<b>71</b>	-	-	-
PSI IUD 10 Distributed Inserted (1)	-	-	-	-	-		-%	(29)	(29)	-	-	-
Copper-T 380-A IUD	-	-	-	-	-	9/16	-%	100	100	-	-	-
<b>IUD 10 Insertion</b>	-	<b>1</b>	<b>4</b>	-	-		<b>0%</b>	<b>29</b>	<b>33</b>	-	<b>1</b>	<b>1</b>
PSI IUD 10 Inserted	-	-	-	-	-		-%	29	29	-	-	-
Non-PSI IUD 10 Inserted	-	1	4	-	-		-%	-	4	-	1	1
<b>Needle &amp; Syringe</b>	<b>380,300</b>	<b>446,150</b>	<b>1,718,750</b>	-	<b>1,155,000</b>		<b>49%</b>	<b>4,600,000</b>	<b>15,178,290</b>	<b>12,093</b>	-	<b>12,093</b>
B-braun Omnican 40 (U-40 Insulin)	380,300	446,150	1,718,750	-	1,152,000	9/13	49%	4,584,000	15,155,800	12,093	-	12,093
Needle & Syringe (LDS)	-	-	-	-	3,000	4/13	(100)%	16,000	22,490	-	-	-
<b>OCs Provided</b>	<b>36</b>	<b>20</b>	<b>95</b>	-	-		<b>0%</b>	-	<b>95</b>	-	-	-
Non-PSI OCs Provided	36	20	95	-	-		-%	-	95	-	-	-
<b>Positive RDTs</b>	<b>7</b>	-	<b>7</b>	-	-		<b>0%</b>	-	<b>7</b>	-	-	-
Positive RDTs	7	-	7	-	-		-%	-	7	-	-	-
<b>Positive RDTs Given First Line Treatm</b>	<b>3</b>	-	<b>3</b>	-	-		<b>0%</b>	-	<b>3</b>	-	-	-
Positive RDTs Given First Line Trea	3	-	3	-	-		-%	-	3	-	-	-
<b>QAACTs Provided after Confirmatory I</b>	<b>2</b>	-	<b>2</b>	-	-		<b>0%</b>	-	<b>2</b>	-	-	-
Non-PSI QAACTs Provided after Co	2	-	2	-	-		-%	-	2	-	-	-
<b>Safe Water Solution</b>	-	-	-	-	<b>5,000</b>		<b>(100)%</b>	<b>6,973</b>	<b>655,267</b>	-	-	-
SafeWat	-	-	-	-	5,000	11/05	(100)%	6,973	655,267	-	-	-
<b>TB Diagnosis</b>	<b>51</b>	<b>60</b>	<b>231</b>	-	<b>626</b>		<b>(63)%</b>	<b>2,394</b>	<b>4,421</b>	-	-	-
TB Diagnosis	51	60	231	-	626		(63)%	2,394	4,421	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

**POPULATION SERVICES INTERNATIONAL**

**Monthly Distribution by Country**

**Period: 4**

**Year: 2017**

	DISTRIBUTION 4/2017	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2017	DISTRIBUTION TARGET 2017	YTD DISTRIBUTION 2016	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2016	CUMULATIVE DISTRIBUTION	YTD DALY HIV2017	YTD DALY Non-HIV 2017	YTD DALY 2017
Toilets Sold	117	85	373	-	-		0%	-	373	-	-	-
Toilet Type 1, Direct Sales	117	85	373	-	-		-%	-	373	-	-	-

(1) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.



Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>Asia and Eastern Europe - Asia</b>														
<b>Cambodia</b>							\$0		\$0	\$0	NA			
<u>Condom</u>														
Number One	04/2017	267,048	0	0	267,048	0%	\$0	NA	\$0	NA	NA	168,912	NA	NA
OK Condom	04/2017	484,680	150	0	484,830	0%	\$0	NA	\$0	NA	NA	4,537,113	NA	NA
<u>Lubricant A</u>														
OK Plus Lubricant	04/2017	50,340	60	0	50,400	0%	\$0	NA	\$0	NA	NA	35,080	NA	NA
<u>Malaria PPT (ACT)</u>														
ASMQ For Adult	04/2017	1,390	0	0	1,390	0%	\$0	NA	\$0	NA	NA	2,281	NA	NA
DHA-PIP For Adolescent	04/2017	15	0	0	15	0%	\$0	NA	\$0	NA	NA	3,353	NA	NA
DHA-PIP For Adult	04/2017	975	200	0	1,175	17%	\$0	NA	\$0	NA	NA	33,186	NA	NA
DHA-PIP For Children	04/2017	10	0	0	10	0%	\$0	NA	\$0	NA	NA	2,435	NA	NA
<u>Malaria RDK</u>														
Malaria RDT (Diagnosis)	04/2017	14,925	600	0	15,525	4%	\$0	NA	\$0	NA	NA	505,825	NA	NA
<u>Diarrhea Treatment Kit</u>														
Orasel Kit	04/2017	2,110	480	0	2,590	19%	\$0	NA	\$0	NA	NA	38,320	NA	NA
<u>Medical Abortion</u>														
Medabon	04/2017	17,430	0	0	17,430	0%	\$0	NA	\$0	NA	NA	112,704	NA	NA
<u>Emergency Contraception</u>														
NEXT 72 EC	04/2017	3,880	0	0	3,880	0%	\$0	NA	\$0	NA	NA	20,169	NA	NA
<u>Implant 5</u>														
Implant 5	04/2017	387	0	0	387	0%	\$0	NA	\$0	NA	NA	3,733	NA	NA
<u>Injectable 3</u>														
OK Injection-3	04/2017	25,850	0	0	25,850	0%	\$0	NA	\$0	NA	NA	144,850	NA	NA
<u>IUD 10</u>														
IUD Copper T	04/2017	2,155	0	0	2,155	0%	\$0	NA	\$0	NA	NA	4,590	NA	NA
<u>OCs</u>														
Marvelon	04/2017	66,725	0	0	66,725	0%	\$0	NA	\$0	NA	NA	69,836	NA	NA
OK Pills	04/2017	326,268	0	0	326,268	0%	\$0	NA	\$0	NA	NA	3,718,452	NA	NA
<b>India</b>							\$0		\$5,886	\$1,928	3.05			
<u>Condom</u>														
Masti	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	6,960	0	NA
<u>Clean Delivery Kit</u>														
NewBorn	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	60	0	NA

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock
<b>India</b>														
<u>ORS</u>														
Neotral Orange 1000ml	04/2017	-152,025	0	152,025	0	0%	\$0	NA	\$5,886	\$1,928	3.05	15,205	0	NA
<u>Injectable 3</u>														
Freedom Inject (3-month)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	68	0	NA
<u>IUD 10</u>														
Freedom 10	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	65,560	0	NA
<b>India LLC</b>														
<u>Condom</u>														
Masti Classic 3's	04/2017	2,617,200	0	0	2,617,200	0%	\$0	NA	\$0	\$30,298	NA	7,062,249	3,312,160	2.13
Masti Classic 6's	04/2017	2,538,000	0	0	2,538,000	0%	\$0	NA	\$0	\$17,159	NA	673,920	2,290,800	0.29
Masti Premium 3's	04/2017	1,814,400	0	0	1,814,400	0%	\$0	NA	\$0	\$19,207	NA	495,376	1,496,533	0.33
<u>Medical Abortion</u>														
Safe Abort kit	04/2017	30,510	100	0	30,610	0%	\$0	NA	\$0	\$21,070	NA	60,810	44,017	1.38
<u>ORS</u>														
Neotral Orange 1000ml	04/2017	96,750	0	0	96,750	0%	\$0	NA	\$0	NA	NA	45,375	NA	NA
<u>Injectable 3</u>														
Freedom Inject (3-month)	04/2017	4,080	100	0	4,180	2%	\$0	NA	\$0	NA	NA	45,720	NA	NA
<u>IUD 5</u>														
Freedom 5	04/2017	14,925	100	0	15,025	1%	\$0	NA	\$0	\$3,769	NA	715	11,162	0.06
<u>OCs</u>														
Pearl	04/2017	284,400	1,600	0	286,000	1%	\$0	NA	\$0	\$15,796	NA	310,580	340,240	0.91
<b>Kazakhstan</b>														
<u>HIV Test Kit</u>														
OraQuick	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	4,950	683	7.24
<u>Free Condom</u>														
Generic Male Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	475,200	2,000	237.60
<u>Free Female Condom</u>														
Generic Female Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	26,000	1,333	19.50
<b>Kyrgyzstan</b>														
<u>HIV Test Kit</u>														
Alere Determine	04/2017	0	900	0	900	100%	\$0	NA	\$0	\$0	NA	900	900	1.00
<b>Laos</b>														
<u>Condom</u>														
No 1 Condom Grp	04/2017	0	0	0	0	NA	\$0	NA	\$15,128	\$5,044	3.00	604,683	14,915	40.54

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Laos</b>							\$0		\$15,128	\$5,044	3.00				
<b>Condom</b>															
No 1 Condom Strw	04/2017	0	0	0	0	NA	\$0	NA	\$8,342	\$2,781	3.00	1,770,519	54,711	32.36	
Number One Rose	04/2017	0	0	0	0	NA	\$0	NA	\$77	\$26	3.01	750,447	506	1,483.10	
<b>Misoprostol for PAC (Oral)</b>															
Misoprostol for PAC (oral)	04/2017	0	0	0	0	NA	\$0	NA	\$4,435	\$1,480	3.00	129,070	6,667	19.36	
<b>IUD 5</b>															
IUD Cu375	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	8,000	0	NA	
<b>Myanmar</b>							\$121,414		\$2,622	\$145,230	0.02				
<b>Condom</b>															
Aphaw	04/2017	182,580	9,980	5	192,565	5%	\$6,683	0%	\$0	\$6,419	NA	7,421,158	183,447	40.45	
Aphaw - Natural Touch	04/2017	191,160	7,020	2	198,182	4%	\$6,997	0%	\$0	\$10,966	NA	3,488,151	311,800	11.19	
Aphaw Flavors	04/2017	243,030	299,860	19	542,909	55%	\$8,894	0%	\$0	\$12,363	NA	10,915,386	648,997	16.82	
Aphaw Studded	04/2017	386,250	14,760	0	401,010	4%	\$14,137	0%	\$0	\$14,325	NA	1,556,460	408,710	3.81	
Generic Male Condom	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	2,721,000	0	NA	
OK Condom	04/2017	8,640	300	0	8,940	3%	\$53	0%	\$0	\$54	NA	179,024	9,004	19.88	
<b>Female Condom</b>															
Generic Female Condom	04/2017	0	5,546	0	5,546	100%	\$0	NA	\$0	\$0	NA	208,964	5,993	34.87	
<b>Lubricant B</b>															
Aphaw Gel - Tube 20 cc	04/2017	646	60	0	706	8%	\$189	0%	\$0	\$182	NA	91,919	640	143.55	
Aphaw Gel - Tube 20 cc - Flavors	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$7	NA	5,484	25	222.32	
<b>Needle &amp; Syringe</b>															
Needle & Syringe (LDS)	04/2017	0	75,400	0	75,400	100%	\$0	NA	\$0	\$0	NA	842,664	79,433	10.61	
<b>Malaria PPT (ACT)</b>															
AL 1	04/2017	0	82	0	82	100%	\$0	NA	\$0	\$0	NA	16,221	107	151.60	
AL 2	04/2017	0	82	0	82	100%	\$0	NA	\$0	\$0	NA	16,340	107	152.71	
AL 3	04/2017	0	75	0	75	100%	\$0	NA	\$0	\$0	NA	32,429	105	308.85	
AL 4	04/2017	0	302	24,001	24,303	100%	\$0	NA	\$0	\$0	NA	74,730	388	192.60	
Arte+1	04/2017	0	1,440	0	1,440	100%	\$0	NA	\$0	\$0	NA	2,345	492	4.76	
Arte+2	04/2017	0	1,440	0	1,440	100%	\$0	NA	\$0	\$0	NA	1,710	492	3.47	
Arte+3	04/2017	0	1,440	0	1,440	100%	\$0	NA	\$0	\$35	NA	5,353	792	6.76	
Arte+4	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$2,033	NA	19,032	14,367	1.32	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Myanmar</b>							\$121,414		\$2,622	\$145,230	0.02				
<b><u>Malaria PPT (ACT)</u></b>															
Supa Arte 1	04/2017	0	182	0	182	100%	\$0	NA	\$0	\$0	NA	12,805	397	32.25	
Supa Arte 2	04/2017	0	140	0	140	100%	\$0	NA	\$0	\$0	NA	10,518	207	50.81	
Supa Arte 3	04/2017	0	605	0	605	100%	\$0	NA	\$0	\$0	NA	6,681	1,064	6.28	
Supa Arte 4	04/2017	18,000	170	0	18,170	1%	\$2,622	100%	\$2,622	\$2,479	1.06	1,048	17,309	0.06	
<b><u>Malaria PPT (Non-ACT)</u></b>															
Vivax Treatment Kit	04/2017	0	261	0	261	100%	\$0	NA	\$0	\$0	NA	4,141	269	15.39	
<b><u>Malaria RDK</u></b>															
Malaria RDT (Diagnosis)	04/2017	0	89,075	0	89,075	100%	\$0	NA	\$0	\$0	NA	389,785	68,453	5.69	
<b><u>Diarrhea Treatment Kit</u></b>															
Orasel DTK	04/2017	400	148	0	548	27%	\$73	0%	\$0	\$112	NA	1,881	743	2.53	
<b><u>Micronutrient Powder</u></b>															
Happy Kid (Micronutrient powder)	04/2017	34,010	30,060	0	64,070	47%	\$996	0%	\$0	\$4,265	NA	6,897,530	165,727	41.62	
<b><u>PUR</u></b>															
Purifier of Water	04/2017	4,687	0	0	4,687	0%	\$136	0%	\$0	\$680	NA	1,419,658	22,618	62.77	
<b><u>Emergency Contraception</u></b>															
OK EC	04/2017	0	2	0	2	100%	\$0	NA	\$0	\$1	NA	25	6	4.41	
<b><u>Implant 3</u></b>															
Implanon NXT	04/2017	316	0	0	316	0%	\$3,470	0%	\$0	\$3,278	NA	12,187	2,307	5.28	
<b><u>Implant 5</u></b>															
Jadelle	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	93	0	NA	
<b><u>Injectable 3</u></b>															
OK-3 Injection	04/2017	42,975	72	0	43,047	0%	\$12,584	0%	\$0	\$12,860	NA	337,253	43,938	7.68	
<b><u>IUD 10</u></b>															
OK IUD (Copper T Cu 380A)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	302	500	0.60	
<b><u>IUD 5</u></b>															
OK IUD	04/2017	206	0	0	206	0%	\$75	0%	\$0	\$61	NA	15,639	168	93.27	
<b><u>OCs</u></b>															
OK Pills	04/2017	299,737	1,675	5	301,417	1%	\$64,505	0%	\$0	\$75,109	NA	356,097	349,714	1.02	
<b>Pakistan</b>							\$171,981		\$150,624	\$271,510	0.55				
<b><u>Condom</u></b>															
Sathi	04/2017	2,271,675	0	0	2,271,675	0%	\$39,007	100%	\$100,429	\$121,164	0.83	133,227,591	5,728,353	23.26	
Touch	04/2017	802,980	0	0	802,980	0%	\$63,730	100%	\$34,716	\$60,850	0.57	7,939,119	780,478	10.17	

Brand Name/Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>Pakistan</b>							\$171,981		\$150,624	\$271,510	0.55				
<u>Water Treatment Tablets</u>															
Aquatabs 33 mg (10 L)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,016	0	NA	
Aquatabs 67 mg (20 L)	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	3,246	0	NA	
<u>Emergency Contraception</u>															
ECP	04/2017	52,520	0	0	52,520	0%	\$5,685	100%	\$3,251	\$16,356	0.20	105,136	151,060	0.70	
<u>Implant 5</u>															
Jadelle	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$235	NA	18,861	123	153.34	
<u>Injectable 1</u>															
Femi-ject	04/2017	11,200	0	0	11,200	0%	\$4,122	100%	\$1,811	\$4,049	0.45	198,340	11,000	18.03	
<u>Injectable 2</u>															
Novaject	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$16,614	NA	165,254	33,840	4.88	
<u>Injectable 3</u>															
Depo-Provera	04/2017	40,560	0	0	40,560	0%	\$28,978	100%	\$3,847	\$25,210	0.15	476,091	35,280	13.49	
<u>IUD 10</u>															
Safeload	04/2017	4,140	0	0	4,140	0%	\$3,515	100%	\$3,973	\$5,554	0.72	135,368	6,540	20.70	
<u>IUD 5</u>															
Multiload	04/2017	23,900	0	0	23,900	0%	\$20,292	100%	\$1,401	\$16,870	0.08	608,129	19,867	30.61	
<u>OCs</u>															
Novadol	04/2017	46,080	0	0	46,080	0%	\$6,651	100%	\$1,195	\$4,608	0.26	197,011	31,920	6.17	
<b>Papua New Guinea</b>							\$1,734		\$9,045	\$1,623	5.57				
<u>Condom</u>															
Seif Raida	04/2017	6,312	2,632	0	8,944	29%	\$830	100%	\$2,140	\$956	2.24	146,328	8,829	16.57	
Seif Raida Orange Plus	04/2017	5,490	51,330	0	56,820	90%	\$821	100%	\$1,908	\$625	3.05	444,402	21,720	20.46	
<u>Female Condom</u>															
Stap Seif	04/2017	360	13,320	0	13,680	97%	\$83	100%	\$83	\$28	3.00	48,980	4,740	10.33	
<u>Lubricant A</u>															
Glide Lubricant	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	256	0	NA	
<u>Diarrhea Treatment Kit</u>															
DTK	04/2017	0	79	0	79	100%	\$0	NA	\$2,662	\$0	NA	291	748	0.39	
<u>Water Treatment Tablets</u>															
Aquatab	04/2017	0	2,700	0	2,700	100%	\$0	NA	\$2,252	\$15	147.58	487,770	1,833	266.06	
<b>PSI Pakistan</b>							\$0		\$0	\$0	NA				
<u>Condom</u>															
Generic Male Condom	04/2017	260,421	0	0	260,421	0%	\$0	NA	\$0	\$0	NA	0	297,379	NA	

Brand Name\Var.	Date	Qty Sales	Qty Out Samples	Qty Out Other	Total Qty Out	% Sample	Total Value Sales	% Credit Sales	Outstanding Credit	Monthly Sales Avg	Outst Credit/ Mo. Sales Avg	Inventory Ending Bal	Monthly Sales Avg (Qty)	Mos. Inv in Stock	
<b>PSI Pakistan</b>							\$0		\$0	\$0	NA				
<u><b>Injectable 3</b></u>															
Generic 3-month Injectable	04/2017	30,082	0	0	30,082	0%	\$0	NA	\$0	\$0	NA	0	36,275	NA	
<u><b>IUD 10</b></u>															
Generic IUD 10	04/2017	10,860	0	0	10,860	0%	\$0	NA	\$0	\$0	NA	0	11,987	NA	
<u><b>IUD 5</b></u>															
Generic IUD 5	04/2017	822	0	0	822	0%	\$0	NA	\$0	\$0	NA	0	3,467	NA	
<u><b>OCs</b></u>															
Generic OC	04/2017	70,914	0	0	70,914	0%	\$0	NA	\$0	\$0	NA	0	72,602	NA	
<b>Tajikistan</b>							\$0		\$0	\$0	NA				
<u><b>HIV Test Kit</b></u>															
HIV Test Kit	04/2017	0	6,356	0	6,356	100%	\$0	NA	\$0	\$0	NA	12,647	2,455	5.15	
<u><b>Free Condom</b></u>															
Generic Male Condom	04/2017	0	22,630	0	22,630	100%	\$0	NA	\$0	\$0	NA	924,670	17,777	52.02	
<u><b>Needle &amp; Syringe</b></u>															
Needle/Syringe-1 ml (0.3x13mm)	04/2017	0	5,100	0	5,100	100%	\$0	NA	\$0	\$0	NA	0	8,045	NA	
Needle/Syringe-5 ml (0.6x32mm)	04/2017	0	25,200	0	25,200	100%	\$0	NA	\$0	NA	NA	0	NA	NA	
<u><b>Naloxone</b></u>															
Naloxone	04/2017	0	60	0	60	100%	\$0	NA	\$0	NA	NA	0	NA	NA	
<b>Viet Nam</b>							\$0		\$0	\$0	NA				
<u><b>Needle &amp; Syringe</b></u>															
B-braun Omnican 40 (U-40 Insulin/	04/2017	0	380,300	-380,300	0	100%	\$0	NA	\$0	\$0	NA	1,150	491,050	0.00	
Needle & Syringe (LDS)	04/2017	0	0	12,960	12,960	NA	\$0	NA	\$0	\$0	NA	0	0	NA	
<u><b>Implant 3</b></u>															
Implanon NXT	04/2017	0	3	-3	0	100%	\$0	NA	\$0	\$0	NA	0	7	NA	
<u><b>Injectable 3</b></u>															
Depoteron	04/2017	0	5	-5	0	100%	\$0	NA	\$0	\$0	NA	0	8	NA	
<u><b>IUD 10</b></u>															
Copper-T 380-A IUD	04/2017	0	0	0	0	NA	\$0	NA	\$0	\$0	NA	544	0	NA	